Recombinant poxvirus-cytomegalovirus, compositions and uses

FIELD OF THE INVENTION
The present invention relates to a modified poxvirus and to methods of making and using the same; for instance, a vaccinia virus or avipox (e.g. canarypox or fowlpox), e.g., modified recombinant poxvirus-cytomegalovirus (CMV), e.g., human cytomegalovirus (HCMV) such as an attenuated recombinant, especially a NYVAC or ALVAC CMV or HCMV recombinant. More in particular, the invention relates to improved vectors for the insertion and expression of foreign genes for use as safe immunization vehicles to elicit an immune response against CMV or HCMV virus. Thus, the invention relates to a recombinant poxvirus, which virus expresses gene products of CMV or HCMV and to immunogenic compositions which induce an immunological response against CMV or HCMV infections when administered to a host, or in vitro (e.g., ex vivo modalities) as well as to the products of expression of the poxvirus which by themselves are useful for eliciting an immune response e.g., raising antibodies, which antibodies are useful against CMV or HCMV infection, in either seropositive or seronegative individuals, or which expression products or antibodies elicited thereby, isolated from an animal or human or cell culture as the case may be, are useful for preparing a diagnostic kit, test or assay for the detection of the virus, or of infected cells, or, of the expression of the antigens or products in other systems. The isolated expression products are especially useful in kits, tests or assays for detection of antibodies in a system, host, serum or sample, or for generation of antibodies. The poxvirus recombinants preferably contain DNA coding for any or all of CMV or HCMVgB, gH, gL, pp150, pp65 and IE1, including recombinants expressing truncated versions of IE1; and, the recombinant poxvirus DNA is useful for probes for CMV or HCMV or for preparing PCR primers for detecting the presence or absence of CMV or HCMV or antigens thereof.
Several publications are referenced in this application. Full citation to these references is found at the end of the specification immediately preceding the claims or where the publication is mentioned; and each of these publications is hereby incorporated herein by reference.
BACKGROUND OF THE INVENTION
Vaccinia virus and more recently other poxviruses have been used for the insertion and expression of foreign genes. The basic technique of inserting foreign genes into live infectious poxvirus involves recombination between pox DNA sequences flanking a foreign genetic element in a donor plasmid and homologous sequences present in the rescuing poxvirus (Piccini et al., 1987).
Specifically, the recombinant poxviruses are constructed in two steps known in the art and analogous to the methods for creating synthetic recombinants of poxviruses such as the vaccinia virus and avipox virus described in U.S. Pat. Nos. 4,769,330, 4,722,848, 4,603,112, 5,110,587, and 5,174,993, the disclosures of which are incorporated herein by reference.
First, the DNA gene sequence to be inserted into the virus, particularly an open reading frame from a non-pox source, is placed into an E. coli plasmid construct into which DNA homologous to a section of DNA of the poxvirus has been inserted. Separately, the DNA gene sequence to be inserted is ligated to a promoter. The promoter-gene linkage is positioned in the plasmid construct so that the promoter-gene linkage is flanked on both ends by DNA homologous to a DNA sequence flanking a region of pox DNA containing a nonessential locus. The resulting plasmid construct is then amplified by growth within E. coli bacteria (Clewell, 1972) and isolated (Clewell et al., 1969; Maniatis et al., 1982).
Second, the isolated plasmid containing the DNA gene sequence to be inserted is transfected into a cell culture, e.g. chick embryo fibroblasts, along with the poxvirus. Recombination between homologous pox DNA in the plasmid and the viral genome respectively gives a poxvirus modified by the presence, in a nonessential region of its genome, of foreign DNA sequences. The term "foreign" DNA designates exogenous DNA, particularly DNA from a non-pox source, that codes for gene products not ordinarily produced by the genome into which the exogenous DNA is placed.
Genetic recombination is in general the exchange of homologous sections of DNA between two strands of DNA. In certain viruses RNA may replace DNA. Homologous sections of nucleic acid are sections of nucleic acid (DNA or RNA) which have the same sequence of nucleotide bases.
Genetic recombination may take place naturally during the replication or manufacture of new viral genomes within the infected host cell. Thus, genetic recombination between viral genes may occur during the viral replication cycle that takes place in a host cell which is co-infected with two or more different viruses or other genetic constructs. A section of DNA from a first genome is used interchangeably in constructing the section of the genome of a second co-infecting virus in which the DNA is homologous with that of the first viral genome.
However, recombination can also take place between sections of DNA in different genomes that are not perfectly homologous. If one such section is from a first genome homologous with a section of another genome except for the presence within the first section of, for example, a genetic marker or a gene coding for an antigenic determinant inserted into a portion of the homologous DNA, recombination can still take place and the products of that recombination are then detectable by the presence of that genetic marker or gene in the recombinant viral genome. Additional strategies have recently been reported for generating recombinant vaccinia virus.
Successful expression of the inserted DNA genetic sequence by the modified infectious virus requires two conditions. First, the insertion must be into a nonessential region of the virus in order that the modified virus remain viable. The second condition for expression of inserted DNA is the presence of a promoter in the proper relationship to the inserted DNA. The promoter must be placed so that it is located upstream from the DNA sequence to be expressed.
Vaccinia virus has been used successfully to immunize against smallpox, culminating in the worldwide eradication of smallpox in 1980. In the course of its history, many strains of vaccinia have arisen. These different strains demonstrate varying immunogenicity and are implicated to varying degrees with potential complications, the most serious of which are post-vaccinial encephalitis and generalized vaccinia (Behbehani, 1983).
With the eradication of smallpox, a new role for vaccinia became important, that of a genetically engineered vector for the expression of foreign genes. Genes encoding a vast number of heterologous antigens have been expressed in vaccinia, often resulting in protective immunity against challenge by the corresponding pathogen (reviewed in Tartaglia et al., 1990a).
The genetic background of the vaccinia vector has been shown to affect the protective efficacy of the expressed foreign immunogen. For example, expression of Epstein Barr Virus (EBV) gp340 in the Wyeth vaccine strain of vaccinia virus did not protect cottontop tamarins against EBV virus induced lymphoma, while expression of the same gene in the WR laboratory strain of vaccinia virus was protective (Morgan et al., 1988).
A fine balance between the efficacy and the safety of a vaccinia virus-based recombinant vaccine candidate is extremely important. The recombinant virus must present the immunogen(s) in a manner that elicits a protective immune response in the vaccinated animal but lacks any significant pathogenic properties. Therefore attenuation of the vector strain would be a highly desirable advance over the current state of technology.
A number of vaccinia genes have been identified which are non-essential for growth of the virus in tissue culture and whose deletion or inactivation reduces virulence in a variety of animal systems.
The gene encoding the vaccinia virus thymidine kinase (TK) has been mapped (Hruby et al., 1982) and sequenced (Hruby et al., 1983; Weir et al., 1983). Inactivation or complete deletion of the thymidine kinase gene does not prevent growth of vaccinia virus in a wide variety of cells in tissue culture. TK.sup.- vaccinia virus is also capable of replication in vivo at the site of inoculation in a variety of hosts by a variety of routes.
It has been shown for herpes simplex virus type 2 that intravaginal inoculation of guinea pigs with TK.sup.- virus resulted in significantly lower virus titers in the spinal cord than did inoculation with TK.sup.+ virus (Stanberry et al., 1985). It has been demonstrated that herpesvirus encoded TK activity in vitro was not important for virus growth in actively metabolizing cells, but was required for virus growth in quiescent cells (Jamieson et al., 1974).
Attenuation of TK.sup.- vaccinia has been shown in mice inoculated by the intracerebral and intraperitoneal routes (Buller et al., 1985). Attenuation was observed both for the WR neurovirulent laboratory strain and for the Wyeth vaccine strain. In mice inoculated by the intradermal route, TK.sup.- recombinant vaccinia generated equivalent anti-vaccinia neutralizing antibodies as compared with the parental TK.sup.+ vaccinia virus, indicating that in this test system the loss of TK function does not significantly decrease immunogenicity of the vaccinia virus vector. Following intranasal inoculation of mice with TK.sup.- and TK.sup.+ recombinant vaccinia virus (WR strain), significantly less dissemination of virus to other locations, including the brain, has been found (Taylor et al., 1991a).
Another enzyme involved with nucleotide metabolism is ribonucleotide reductase. Loss of virally encoded ribonucleotide reductase activity in herpes simplex virus (HSV) by deletion of the gene encoding the large subunit was shown to have no effect on viral growth and DNA synthesis in dividing cells in vitro, but severely compromised the ability of the virus to grow on serum starved cells (Goldstein et al., 1988). Using a mouse model for acute HSV infection of the eye and reactivatable latent infection in the trigeminal ganglia, reduced virulence was demonstrated for HSV deleted of the large subunit of ribonucleotide reductase, compared to the virulence exhibited by wild type HSV (Jacobson et al., 1989).
Both the small (Slabaugh et al., 1988) and large (Schmidtt et al., 1988) subunits of ribonucleotide reductase have been identified in vaccinia virus. Insertional inactivation of the large subunit of ribonucleotide reductase in the WR strain of vaccinia virus leads to attenuation of the virus as measured by intracranial inoculation of mice (Child et al., 1990).
The vaccinia virus hemagglutinin gene (HA) has been mapped and sequenced (Shida, 1986). The HA gene of vaccinia virus is nonessential for growth in tissue culture (Ichihashi et al., 1971). Inactivation of the HA gene of vaccinia virus results in reduced neurovirulence in rabbits inoculated by the intracranial route and smaller lesions in rabbits at the site of intradermal inoculation (Shida et al., 1988). The HA locus was used for the insertion of foreign genes in the WR strain (Shida et al., 1987), derivatives of the Lister strain (Shida et al., 1988) and the Copenhagen strain (Guo et al., 1989) of vaccinia virus. Recombinant HA.sup.- vaccinia virus expressing foreign genes have been shown to be immunogenic (Guo et al., 1989; Itamura et al., 1990; Shida et al., 1988; Shida et al., 1987) and protective against challenge by the relevant pathogen (Guo et al., 1989; Shida et al., 1987).
Cowpox virus (Brighton red strain) produces red (hemorrhagic) pocks on the chorioallantoic membrane of chicken eggs. Spontaneous deletions within the cowpox genome generate mutants which produce white pocks (Pickup et al., 1984). The hemorrhagic function (u) maps to a 38 kDa protein encoded by an early gene (Pickup et al., 1986). This gene, which has homology to serine protease inhibitors, has been shown to inhibit the host inflammatory response to cowpox virus (Palumbo et al., 1989) and is an inhibitor of blood coagulation.
The u gene is present in WR strain of vaccinia virus (Kotwal et al., 1989b). Mice inoculated with a WR vaccinia virus recombinant in which the u region has been inactivated by insertion of a foreign gene produce higher antibody levels to the foreign gene product compared to mice inoculated with a similar recombinant vaccinia virus in which the u gene is intact (Zhou et al., 1990). The u region is present in a defective nonfunctional form in Copenhagen strain of vaccinia virus (open reading frames B13 and B14 by the terminology reported in Goebel et al., 1990a,b).
Cowpox virus is localized in infected cells in cytoplasmic A type inclusion bodies (ATI) (Kato et al., 1959). The function of ATI is thought to be the protection of cowpox virus virions during dissemination from animal to animal (Bergoin et al., 1971). The ATI region of the cowpox genome encodes a 160 kDa protein which forms the matrix of the ATI bodies (Funahashi et al., 1988; Patel et al., 1987). Vaccinia virus, though containing a homologous region in its genome, generally does not produce ATI. In WR strain of vaccinia, the ATI region of the genome is translated as a 94 kDa protein (Patel et al., 1988). In Copenhagen strain of vaccinia virus, most of the DNA sequences corresponding to the ATI region are deleted, with the remaining 3' end of the region fused with sequences upstream from the ATI region to form open reading frame (ORF) A26L (Goebel et al., 1990a,b).
A variety of spontaneous (Altenburger et al., 1989; Drillien et al., 1981; Lai et al., 1989; Moss et al., 1981; Paez et al., 1985; Panicali et al., 1981) and engineered (Perkus et al., 1991; Perkus et al., 1989; Perkus et al., 1986) deletions have been reported near the left end of the vaccinia virus genome. A WR strain of vaccinia virus with a 10 kb spontaneous deletion (Moss et al., 1981; Panicali et al., 1981) was shown to be attenuated by intracranial inoculation in mice (Buller et al., 1985). This deletion was later shown to include 17 potential ORFs (Kotwal et al., 1988b). Specific genes within the deleted region include the virokine N1L and a 35 kDa protein (C3L, by the terminology reported in Goebel et al., 1990a,b). Insertional inactivation of NIL reduces virulence by intracranial inoculation for both normal and nude mice (Kotwal et al., 1989a). The 35 kDa protein is secreted like N1L into the medium of vaccinia virus infected cells. The protein contains homology to the family of complement control proteins, particularly the complement 4B binding protein (C4bp) (Kotwal et al., 1988a). Like the cellular C4bp, the vaccinia 35 kDa protein binds the fourth component of complement and inhibits the classical complement cascade (Kotwal et al., 1990). Thus the vaccinia 35 kDa protein appears to be involved in aiding the virus in evading host defense mechanisms.
The left end of the vaccinia genome includes two genes which have been identified as host range genes, K1L (Gillard et al., 1986) and C7L (Perkus et al., 1990). Deletion of both of these genes reduces the ability of vaccinia virus to grow on a variety of human cell lines (Perkus et al., 1990).
Two additional vaccine vector systems involve the use of naturally host-restricted poxviruses, avipox viruses. Both fowlpoxvirus (FPV) and canarypoxvirus (CPV) have been engineered to express foreign gene products. Fowlpox virus (FPV) is the prototypic virus of the Avipox genus of the Poxvirus family. The virus causes an economically important disease of poultry which has been well controlled since the 1920's by the use of live attenuated vaccines. Replication of the avipox viruses is limited to avian species (Matthews, 1982) and there are no reports in the literature of avipoxvirus causing a productive infection in any non-avian species including man. This host restriction provides an inherent safety barrier to transmission of the virus to other species and makes use of avipoxvirus based vaccine vectors in veterinary and human applications an attractive proposition.
FPV has been used advantageously as a vector expressing antigens from poultry pathogens. The hemagglutinin protein of a virulent avian influenza virus was expressed in an FPV recombinant (Taylor et al., 1988a). After inoculation of the recombinant into chickens and turkeys, an immune response was induced which was protective against either a homologous or a heterologous virulent influenza virus challenge (Taylor et al., 1988a). FPV recombinants expressing the surface glycoproteins of Newcastle Disease Virus have also been developed (Taylor et al., 1990; Edbauer et al., 1990).
Despite the host-restriction for replication of FPV and CPV to avian systems, recombinants derived from these viruses were found to express extrinsic proteins in cells of nonavian origin. Further, such recombinant viruses were shown to elicit immunological responses directed towards the foreign gene product and where appropriate were shown to afford protection from challenge against the corresponding pathogen (Tartaglia et al., 1993a,b; Taylor et al., 1992; 1991b; 1988b).
Human cytomegalovirus (HCMV) is a member of the betaherpesviridae subfamily (family Herpesviridae). HCMV is ubiquitous in humans, with usually mild or inapparent acute infection followed by persistence or latency. However, HCMV is a significant cause of morbidity and mortality in infants infected in-utero (Stagno et al., 1983). HCMV is the most common infectious complication of organ transplantation (Glenn et al., 1981) and in immunocompromised hosts (Weller et al., 1971). In AIDS patients, CMV retinitis is the leading cause of blindness (Roarty et al., 1993; Gallant et al., 1992; Gross et al., 1990) A potential role of HCMV in coronary restinosis has recently been described (Speir et al., 1994). The live attenuated Towne strain of HCMV has been shown to protect seronegative renal transplant recipients from severe clinical symptoms of HCMV infection (Plotkin et al., 1976, 1984 and 1989) and to protect initially seronegative healthy individuals from infection and clinical symptoms after subcutaneous challenge with a wild-type strain of HCMV (Plotkin et al., 1989). Concerns remain about the use of a live HCMV vaccine because of the latency reactivation phenomenon characteristic of herpesvirus infections in humans and because of the capability of certain strains of HCMV to transform cells malignantly in vitro (Albrecht and Rapp, 1973; Galloway et al., 1986). For these reasons, a recombinant subunit CMV vaccine may be more acceptable for human immunization.
The role of individual HCMV proteins in protective immunity is unclear. Three immunologically distinct families of glycoproteins associated with the HCMV envelope have been described (Gretch et al., 1988b); gCI (gp55 and gp93-130); gCII (gp47-52); and gCIII (gp85-p145). Neutralization of HCMV has been demonstrated in vitro with antibodies specific for each of these glycoprotein families (Pachl et al., 1989; Rasmussen et al., 1988; Kari et al., 1986).
The gene coding for gCI is homologous to HSV I gB (Cranage et al., 1986). HCMVgB is synthesized as a glycosylated uncleaved precursor of apparent molecular weight 130-140 kDa which is processed by cellular proteinase into N-terminal 90-110 kDa and C-terminal 55-58 kDa products which remain associated in a disulfide linked complex (Britt and Auger, 1986; Britt and Vugler, 1989; Reis et al., 1993). Monoclonal antibodies capable of neutralizing HCMV have been obtained from mice immunized with lysates of HCMV infected cells or HCMV virions, these monoclonals were predominantly reactive with the C-terminal 55-58 kDa fragment (Britt, 1984; Kari et al., 1986; Pereira et al., 1984; Rasmussen et al., 1988). However, immunization with biochemically purified gP93 resulted in the development of gp93-specific neutralizing mAbs (Kari et al., 1990).
HCMV-gB may serve to elicit protective immunity in humans: immunization with the purified gB protein induces neutralizing antibody (Gonczol et al., 1990) and human antigB monoclonal antibodies neutralize the virus (Masuho et al., 1987). Following natural infection neutralizing antibody specific for HCMV-gB is observed. When gB specific antibody is absorbed from human sera, HCMV neutralizing antibody titer is reduced significantly (50-88%, Gonczol et al., 1991; 0-98% median 48%, Marshall et al., 1992). There is also evidence for activation of helper T cells by the gB protein in naturally seropositive humans (Liu et al., 1991) and gB specific CTL has been detected in humans in some studies (Borysiewicz et al., 1988; Liu et al., 1991; Riddell, et al., 1991).
The gCII glycoproteins are encoded by a gene or genes in the US6 gene family (US6 through US11, Gretch et al., 1988a). These glycoproteins are recognized by human anti-HCMV antibody in sera from convalescent adults. However, sera from congenitally infected infants with persistent infection failed to react with gCII glycoproteins (Kari and Gehrz, 1990), suggesting that gCII may be important to human protective immune responses to HCMV.
The gP86 component of the gCIII complex is encoded by a gene that is homologous to HSV-I gH (Cranage et al., 1988; Pachl et al., 1989). The HCMV gH protein is capable of inducing a neutralizing immune response in humans (10% of HCMV infected individuals have a detectable level of circulating gH specific antibody (Rasmussen et al., 1991) as well as in laboratory animals (Baboonian et al., 1989; Cranage et al., 1988; Ehrlich et al., 1988; Rasmussen et al., 1984). Murine gH-specific monoclonal antibodies neutralize virus infectivity in a complement-independent manner (Baboonian et al., 1989; Cranage et al., 1988; Rasmussen et al., 1984) and inhibit viral spread (Pachl et al., 1989) suggesting that gH may be responsible for virus attachment, penetration and or spread.
Although gH is found on the surface of HCMV infected cells (Cranage et al., 1988), when expressed by a variety of recombinant systems it is restricted to the endoplasmic reticulum (Spaete et al., 1991). Coexpression of the HCMV UL115 gene product (glycoprotein gL) results in the formation of a stable complex of these two proteins and the transport of gH to the cell surface (Spaete et al., 1993; Kaye et al., 1992).
HCMV synthesizes a number of matrix tegument phosphoproteins. The pp150 phosphoprotein is highly immunogenic apparently more so than any other of the HCMV structural proteins (Jahn et al., 1987). A second matrix phosphoprotein, pp65, elicits a variable humoral response in humans (Jahn et al., 1987; Plachter et al., 1990). This protein can stimulate lymphoproliferation, IL-2 and interferon production, B-cell stimulation of antibody and natural killer cell activity (Forman et al., 1985). It also serves as a target antigen for HCMV-specific, HLA-restricted cytotoxic T cells (CTLs) (Pande et al., 1991; Gilbert et al., 1993).
Additional structural proteins may be required for eliciting a protective immune response to HCMV. The major capsid protein (UL86) is known to induce specific antibodies during natural infection and has been considered as the CMV-group common antigen (Spaete et al., 1994). The tegument phosphoprotein, pp28 (UL99), is also known to elicit persistent antibody responses during a natural infection. Further, this protein has also been implicated as a CTL target immunogen (Charpentier et al., 1986). The immune response to the upper tegument phosphoprotein, pp71 (UL82), is not as well characterized as the other tegument phosphoproteins (pp28, pp65), but as a known tegument protein requires further attention.
In addition to these structural proteins, some nonstructural proteins may also be candidates for inclusion in a recombinant subunit vaccine. Immunization of mice with a recombinant vaccinia virus expressing murine cytomegalovirus (MCMV) pp89 (functional homolog of HCMV IE 1) induces CD8.sup.+ T-cell responses that mediate protective immunity from challenge with MCMV (Jonjic et al., 1988). The human CMV major immediate early protein (IE 1) has been shown to be a target for CTLs isolated from HCMV seropositive individuals (Borysiewicz et al., 1988). Since IE 1 is among the initial viral proteins expressed and is necessary for inducing the expression of other CMV genes and initiating the viral life cycle in latently infected cells (Blanton and Tevethia, 1981; Cameron and Preston, 1981; DeMarchi et al., 1980: McDonough and Spector, 1983; Wathen et al., 1981), CTL responses directed against IE 1 may be important for controlling and/or eliminating HCMV infection. Recently Gilbert et al., (1993) have suggested that HCMV has evolved a mechanism by which other viral encoded proteins selectively interfere with the presentation of IE-derived peptides in association with Class I major histocompatibility complex (MHC) molecules.
Some additional nonstructural proteins may also be candidates for inclusion in a recombinant subunit HCMV vaccine candidate. The immediate early protein, IE2 (UL122), and the regulatory protein UL69 are known to contain human T-helper epitopes (Beninga et al., 1995).
One approach to the development of a subunit HCMV vaccine is the use of live viral vectors to express relevant HCMV gene products.
It can thus be appreciated that provision of a CMV or an HCMV recombinant poxvirus, and of compositions and products therefrom particularly NYVAC or ALVAC based CMV or HCMV recombinants and compositions and products therefrom, especially such recombinants containing coding for any or all of HCMVgB, gH, gL, pp150, pp65 and IE1, including recombinants expressing altered or truncated versions of IE1 and/or gB and compositions and products therefrom would be a highly desirable advance over the current state of technology.
OBJECTS AND SUMMARY OF THE INVENTION
It is therefore an object of this invention to provide modified recombinant viruses, which viruses have enhanced safety, and to provide a method of making such recombinant viruses.
It is an additional object of this invention to provide a recombinant poxvirus antigenic vaccine or immunological composition having an increased level of safety compared to known recombinant poxvirus vaccines.
It is a further object of this invention to provide a modified vector for expressing a gene product in a host, wherein the vector is modified so that it has attenuated virulence in the host.
It is another object of this invention to provide a method for expressing a gene product in a cell cultured in vitro using a modified recombinant virus or modified vector having an increased level of safety.
These and other objects and advantages of the present invention will become more readily apparent after consideration of the following.
In one aspect, the present invention relates to a modified recombinant virus having inactivated virus-encoded genetic functions so that the recombinant virus has attenuated virulence and enhanced safety. The functions can be non-essential, or associated with virulence. The virus is advantageously a poxvirus, particularly a vaccinia virus or an avipox virus, such as fowlpox virus or canarypox virus. The modified recombinant virus can include, within a non-essential region of the virus genome, a heterologous DNA sequence which encodes an antigen or epitope derived from HCMV, such as any or all of HCMVgB, gH, gL, pp150, pp65, IE1, including altered or truncated versions of IE1, and/or gB.
In another aspect, the present invention relates to an antigenic, immunological or vaccine composition or a therapeutic composition for inducing an antigenic or immunological response in a host animal inoculated with the composition, said vaccine including a carrier and a modified recombinant virus having inactivated nonessential virus-encoded genetic functions so that the recombinant virus has attenuated virulence and enhanced safety. The virus used in the composition according to the present invention is advantageously a poxvirus, particularly a vaccinia virus or an avipox virus, such as fowlpox virus and canarypox virus. The modified recombinant virus can include, within a nonessential region of the virus genome, a heterologous DNA sequence which encodes an antigenic protein, e.g., derived from HCMV, such as any or all of HCMVgB, gH, gL, pp150, pp65, IE1, including altered or truncated versions of IE1, and/or gB.
In yet another aspect, the present invention relates to an immunogenic composition containing a modified recombinant virus having inactivated nonessential virus-encoded genetic functions so that the recombinant virus has attenuated virulence and enhanced safety. The modified recombinant virus includes, within a non-essential region of the virus genome, a heterologous DNA sequence which encodes an antigenic protein (e.g., derived from HCMV, such as any or all of HCMVgB, gH, gL, pp150, pp65, IE1, including altered or truncated versions of IE1, and/or gB) wherein the composition, when administered to a host, is capable of inducing an immunological response specific to the antigen.
In a further aspect, the present invention relates to a method for expressing a gene product in a cell in vitro by introducing into the cell a modified recombinant virus having attenuated virulence and enhanced safety. The modified recombinant virus can include, within a nonessential region of the virus genome, a heterologous DNA sequence which encodes an antigenic protein, e.g. derived from HCMV such as any or all of HCMVgB, gH, gL, pp150, pp65, IE1, including altered or truncated versions of IE1, and/or gB. The cells can then be reinfused directly into the individual or used to amplify specific reactivities for reinfusion (Ex vivo therapy).
In a further aspect, the present invention relates to a method for expressing a gene product in a cell cultured in vitro by introducing into the cell a modified recombinant virus having attenuated virulence and enhanced safety. The modified recombinant virus can include, within a nonessential region of the virus genome, a heterologous DNA sequence which encodes an antigenic protein, e.g., derived from HCMV such as any or all of HCMVgB, gH, gL, pp150, pp65, IE1, including altered or truncated versions of IE1, and/or gB. The product can then be administered to individuals or animals to stimulate an immune response. The antibodies raised can be useful in individuals for the prevention or treatment of HCMV and, the antibodies from individuals or animals or the isolated in vitro expression products can be used in diagnostic kits, assays or tests to determine the presence or absence in a sample such as sera of HCMV or antigens therefrom or antibodies thereto (and therefore the absence or presence of the virus or of the products, or of an immune response to the virus or antigens).
In a still further aspect, the present invention relates to a modified recombinant virus having nonessential virus-encoded genetic functions inactivated therein so that the virus has attenuated virulence, and wherein the modified recombinant virus further contains DNA from a heterologous source in a nonessential region of the virus genome. The DNA can code for HCMV such as any or all of HCMVgB, gH, gL, pp150, pp65, IE1, including altered or truncated versions of IE1, and/or gB. In particular, the genetic functions are inactivated by deleting an open reading frame encoding a virulence factor or by utilizing naturally host restricted viruses. The virus used according to the present invention is advantageously a poxvirus, particularly a vaccinia virus or an avipox virus, such as fowlpox virus or canarypox virus. Advantageously, the open reading frame is selected from the group consisting of J2R, B13R+B14R, A26L, A56R, C7L-K1L, and I4L (by the terminology reported in Goebel et al., 1990a,b); and, the combination thereof. In this respect, the open reading frame comprises a thymidine kinase gene, a hemorrhagic region, an A type inclusion body region, a hemagglutinin gene, a host range gene region or a large subunit, ribonucleotide reductase; or, the combination thereof. A suitable modified Copenhagen strain of vaccinia virus is identified as NYVAC (Tartaglia et al., 1992), or a vaccinia virus from which has been deleted J2R, B13R+B14R, A26L, A56R, C7L-K1l and I4L or a thymidine kinase gene, a hemorrhagic region, an A type inclusion body region, a hemagglutinin gene, a host range region, and a large subunit, ribonucleotide reductase (See also U.S. Pat. No. 5,364,773). Alternatively, a suitable poxvirus is an ALVAC or, a canarypox virus (Rentschler vaccine strain) which was attenuated, for instance, through more than 200 serial passages on chick embryo fibroblasts, a master seed therefrom was subjected to four successive plaque purifications under agar from which a plaque clone was amplified through five additional passages.
The invention in yet a further aspect relates to the product of expression of the inventive recombinant poxvirus and uses therefor, such as to form antigenic, immunological or vaccine compositions for treatment, prevention, diagnosis or testing; and, to DNA from the recombinant poxvirus which is useful in constructing DNA probes and PCR primers.
These and other embodiments are disclosed or are obvious from and encompassed by the following detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS
The following detailed description, given by way of example, but not intended to limit the invention solely to the specific embodiments described, may best be understood in conjunction with the accompanying drawings, in which:
FIG. 1 schematically shows a method for the construction of plasmid pSD460 for deletion of thymidine kinase gene and generation of recombinant vaccinia virus vP410;
FIG. 2 schematically shows a method for the construction of plasmid pSD486 for deletion of hemorrhagic region and generation of recombinant vaccinia virus vP553;
FIG. 3 schematically shows a method for the construction of plasmid pMP494.DELTA. for deletion of ATI region and generation of recombinant vaccinia virus vP618;
FIG. 4 schematically shows a method for the construction of plasmid pSD467 for deletion of hemagglutinin gene and generation of recombinant vaccinia virus vP723;
FIG. 5 schematically shows a method for the construction of plasmid pMPCK1.DELTA. for deletion of gene cluster [C7L-K1L] and generation of recombinant vaccinia virus vP804;
FIG. 6 schematically shows a method for the construction of plasmid pSD548 for deletion of large subunit, ribonucleotide reductase and generation of recombinant vaccinia virus vP866 (NYVAC);
FIG. 7 schematically shows a method for the construction of plasmid pRW842 for insertion of rabies glycoprotein G gene into the TK deletion locus and generation of recombinant vaccinia virus vP879;
FIG. 8 shows the DNA sequence of a 3209 base pair fragment of canarypox DNA containing the C5 ORF (SEQ ID NO:27) (the C5 ORF initiates at position 1537 and terminates at position 1857);
FIGS. 9A and 9B schematically show a method for the construction of recombinant canarypox virus vCP65 (ALVACRG);
FIG. 10 shows schematically the ORFs deleted to generate NYVAC;
FIGS. 11A to 11D show graphs of rabies neutralizing antibody titers (RFFIT, IU/ml), booster effect of HDC and vCP65 (10.sup.5.5 TCID.sub.50) in volunteers previously immunized with either the same or the alternate vaccine (vaccines given at days 0, 28 and 180, antibody titers measured at days 0, 7, 28, 35, 56, 173, 187 and 208);
FIG. 12 shows the DNA sequence of HCMVgB (Towne strain) (SEQ ID NO:37);
FIGS. 13A and B show the DNA sequence of the H6 promoted HCMVgB and NYVAC sequences flanking the TK locus (SEQ ID NO:38) (the 5'end of the H6 promoted CMVgB is at position 3447; the CMVgB coding sequence is from position 3324 through position 606);
FIGS. 14A to C show the DNA sequence of a 7351 base pair fragment of canarypox DNA containing the C3 ORF (SEQ ID NO:39) (the C3 ORF is initiated at position 1458 and terminates at position 2897);
FIGS. 15A to C show the DNA sequence of the H6 promoted HCMVgB and ALVAC sequences flanking the C3 locus (SEQ ID NO:40) (the 5' end of the H6 promoted CMVgB is at position 4425; the CMVgB coding sequence is from position 4301 through position 1581);
FIGS. 16A and B show the DNA sequence of the H6 promoted HCMVgB and NYVAC sequences flanking the ATI locus (SEQ ID NO:41) (the 5'end of the H6 promoted CMVgB is at position 3348; the CMVgB coding sequence is from position 3224 through position 504);
FIG. 17 shows the DNA sequence of HCMVgB (Towne strain) deleted of its transmembrane region (SEQ ID NO:42);
FIGS. 18A and B show the DNA sequence of the H6 promoted HCMVgB lacking its transmembrane region and NYVAC sequences flanking the ATI locus (SEQ ID NO:43) (the 5' end of the H6 promoted CMVgB is at position 3173; the CMVgB coding sequence is from position 3050 through position 504);
FIG. 19 shows the DNA sequence of HCMVgB (Towne strain) deleted of its transmembrane region and containing an altered cleavage site (SEQ ID NO:44);
FIGS. 20A and B show the DNA sequence of the H6 promoted HCMVgB lacking its transmembrane region and containing an altered cleavage site plus NYVAC sequences flanking the ATI locus (SEQ ID NO:45) (the 5' end of the H6 promoted CMVgB is at position 3173; the CMVgB coding sequence is from position 3050 through position 504);
FIG. 21 shows the DNA sequence of HCMVgH (Towne strain) (SEQ ID NO:46);
FIGS. 22A and B show the DNA sequence of the 42K promoted HCMVgH plus NYVAC sequences flanking the I4L locus (SEQ ID NO:47) (the 5' end of the 42K promoted CMVgH is at position 641; the CMVgH coding sequence is from position 708 through position 2933);
FIGS. 23A and B show the DNA sequence of the 42K promoted CMVgH and ALVAC sequences flanking the C5 locus (SEQ ID NO:48) (the 5' end of the 42K promoted CMVgH is at position 1664; the CMVgH coding sequence is from position 1730 through position 3955);
FIG. 24 shows the DNA sequence of the 42K promoted CMVgH and WR flanking sequences (SEQ ID NO:49) (the 5' end of the 42K promoted CMVgH is at position 2457; the CMVgH coding sequence is from position 2391 through 166);
FIG. 25 shows the DNA sequence of HCMV IE1 (AD169 strain) (SEQ ID NO:50);
FIG. 26 shows the DNA sequence of the H6 promoted CMVIE1 and WR flanking sequences (SEQ ID NO:51) (the 5' end of the H6 promoted CMVIE1 is at position 1796; the CMVIE1 coding sequence is from position 1673 through 201);
FIGS. 27A and B show the DNA sequence of the H6 promoted CMVIE1 and NYVAC sequences flanking the ATI locus (SEQ ID NO:52) (the 5' end of the H6 promoted CMVIE1 is at position 2030; the CMVIE1 coding sequence is from position 1906 through position 434); FIG. 28 shows the DNA sequence of HCMVIE1 (AD169 strain) lacking amino acids 292-319 (SEQ ID NO:53);
FIGS. 29A and B show the DNA sequence of the H6 promoted CMVIE1 lacking amino acids 292-319 and NYVAC sequences flanking the ATI locus (SEQ ID NO:54) (the 5' end of the H6 promoted CMVIE1 is at position 1940; the CMVIE1 coding sequence is from position 1816 through position 434);
FIG. 30 shows the DNA sequence of the Exon 4 segment of HCMVIE1 (AD169 strain) (SEQ ID NO:55);
FIG. 31 shows the DNA sequence of the H6 promoted CMVIE1 Exon 4 segment and NYVAC sequences flanking the I4L locus (SEQ ID NO:56) (the 5' end of the H6 promoted IE1 Exon 4 is at position 630; the CMVIE1 Exon 4 coding sequence is from position 754 through position 1971).
FIG. 32A and B show the DNA sequence of the H6 promoted CMVIE1 Exon 4 segment and ALVAC sequences flanking the C5 locus (SEQ ID NO:57) (the 5' end of the H6 promoted IE1 Exon 4 is at position 1647; the CMVIE1 Exon 4 coding sequence is from position 1771 through position 2988).
FIG. 33 shows the DNA sequence of HCMVIE1 (AD169 strain) lacking amino acids 2-32 (SEQ ID NO:58);
FIG. 34 shows the DNA sequence of the H6 promoted CMVIE1 lacking amino acids 2-32 and NYVAC sequences flanking the I4L locus (SEQ ID NO:59) (the 5' end of the H6 promoted IE1 lacking amino acids 2-32 is at position 630; the coding sequence for CMVIE1 lacking amino acids 2-32 is from position 754 through position 2133);
FIGS. 35A and B show the DNA sequence of the H6 promoted CMVIE1 lacking amino acids 2-32 and ALVAC sequences flanking the C5 locus (SEQ ID NO:60) (the 5' end of the H6 promoted IE1 lacking amino acids 2-32 is at position 1647; the CMVIE1 coding sequence for CMVIE1 lacking amino acids 2-32 is from position 1771 through position 3150);
FIG. 36 shows the DNA sequence of HCMV pp65 (Towne strain) (SEQ ID NO:61);
FIG. 37 shows the DNA sequence of the H6 promoted CMVpp65 and NYVAC sequences flanking the HA locus (SEQ ID NO:62) (the 5' end of the H6 promoted pp65 is at position 476; the CMVpp65 coding sequence is from position 600 through 2282);
FIGS. 38A and B show the DNA sequence of a 3706 base pair fragment of canarypox DNA containing the C6 ORF (SEQ ID NO:63) (the C6 ORF is initiated at position 377 and terminated at position 2254);
FIGS. 39A and B show the DNA sequence of the H6 promoted CMVpp65 and ALVAC sequences flanking the C6 locus (SEQ ID NO:64) (the 5' end of the H6 promoted pp65 is at position 496; the CMVpp65 coding sequence is from position 620 through 2302);
FIG. 40 shows the DNA sequence of the H6 promoted CMVpp65 and WR flanking sequences (SEQ ID NO:65) (the 5' end of the H6 promoted pp65 is at position 168; the CMVpp65 coding sequence is from position 292 through 1974);
FIG. 41 shows the DNA sequence of HCMVpp150 (Towne strain) (SEQ ID NO:66);
FIGS. 42A and B show the DNA sequence of the 42K promoted CMVpp150 and NYVAC sequences flanking the ATI locus (SEQ ID NO:67) (the 5' end of the 42K promoted pp150 is at position 3645; the CMVpp150 coding sequence is from position 3580 through 443);
FIGS. 43A and B show the DNA sequence of the 42K promoted CMVpp150 and ALVAC sequences flanking the C6 locus (SEQ ID NO:68) (the 5' end of the 42K promoted pp150 is at position 3714; the CMVpp150 coding sequence is from position 3649 through 512);
FIGS. 44A and B show the DNA sequence of the 42K promoted CMVpp150 gene and WR flanking sequences (SEQ ID NO:69) (the 5' end of the H6 promoted pp150 is at position 3377; the CMVpp150 coding sequence is from position 3312 through 175); FIGS. 45A and B show the DNA sequence of the 42K promoted HCMVgH and H6 promoted HCMVIE Exon 4 and NYVAC sequences flanking the I4L locus (SEQ ID NO:70) (the 5' end of the 42K promoted CMVgH is at position 2935; the CMVgH coding sequence is from position 2869 through 644; the 5' end of the H6 promoted CMVIE Exon 4 is at position 2946; the CMVIE Exon 4 coding sequence is from position 3070 through position 4287);
FIGS. 46A to C show the DNA sequence of the H6 promoted HCMV pp65 and 42K promoted HCMVpp150 and ALVAC sequences flanking the C6 locus (SEQ ID NO:71) (the 5' end of the H6 promoted CMVpp65 is at position 496; the CMVpp65 coding sequence is from position 620 through 2302; the 5' end of the 42K promoted CMVpp150 is at position 5554; the CMVpp150 coding sequence is from position 5489 through position 2352);
FIG. 47 shows the DNA sequence of HCMVgL (Towne strain) (SEQ ID NO:72);
FIGS. 48A and B show the DNA sequence of the H6 promoted HCMVgB and H6 promoted HCMVgL and NYVAC sequences flanking the TK locus (SEQ ID NO:73) (the 5' end of the H6 promoted CMVgB is at position 3447; the CMVgB coding sequence is from position 3324 through position 606; the 5' end of the H6 promoted CMVgL is at position 3500; the CMVgL coding sequence is from position 3624 through position 4460);
FIG. 49 shows the results of HCMV IE1 CTL stimulation by ALVAC-IE1 (vCP256) (percent cytotoxicity; white bars=WR, black bars=WRIE1, striped bars=nonautologous);
FIG. 50 shows the results of stimulation of HCMV pp65-CTLs by ALVAC-pp65 (vCP260) (human CTLs stimulated in vitro and assayed for HCMV pp65 CTLs using methodology similar to that used for FIG. 49; percent cytotoxity; white bars=WR, black bars=WR-pp65, striped bars=nonautologous);
FIG. 51 shows the results of stimulation of HCMV IE1 CTLs by ALVAC-IE1 (vCP256) (methodology similar to that used for FIG. 49, except that following 6 days incubation for restimulation, the responder mononuclear cells were incubated with immunomagnetic beads coupled to monoclonal anti-human CD3, CD4 or CD8; percent cytotoxicity; white bars=WR, black bars=WR-IE1, striped bars=HLA mismatch);
FIGS. 52A to D show expression of CMV gB by COPAK recombinants in Vero and HeLa cells (cell and medium fractions from infected cells radiolabeled with [S 35] methionine were immune precipitated with guinea pig anti-CMV gB; Vero medium (A), HeLa medium (B), Vero cell (C), and HeLa cell (D) fractions derived from infections by vP993 COPAK parent (lanes 1), vP1126 expressing the entire gB (lanes 2), vP1128 expressing gB without the transmembrane site (lanes 3), and vP1145 expressing the gB without transmembrane and with altered cleavage sites (lanes 4) are shown; far right lane contains molecular weight markers);
FIGS. 53A and B show vaccinia infection of Vero and HeLa cells detected by expression of vaccinia early protein E3L (cell fractions from infected cells radiolabeled with [35 S] methionine were immune precipitated with rabbit anti-p25 (E3L); Vero (A) and HeLa (B) cell fractions derived from infections by vP993 (lanes 1), vP1126 (lanes 2), vP1128 (lanes 3), and vP1145 (lanes 4) are shown; far right lane contains molecular weight markers);
FIG. 54 shows comparison of CMV gB production by Vero, HeLa and MRC-5 cells (SDS-PAGE and western blot analysis were performed on the medium from MRC-5 cells (lanes 1, 4), Vero cells (lanes 2, 5), or HeLa cells (lanes 3, 6) after infection with vP1145 (lanes 1, 2, 3) or vP993 (lanes 4, 5, 6); CMV gB was detected with monoclonal CH380; molecular weight markers are present in lane M);
FIG. 55 shows immunoprecipitation of CMV gB by a panel of monoclonal antibodies and guinea pig anti-gB (radiolabeled medium fractions from Vero cells infected with vP993 (lanes 1), vP1126 (lanes 2), vP1128 (lanes 3), and vP1145 (lanes 4) were immune precipitated with guinea pig anti-CMV gB or with monoclonals 13-127, 13-128, CH380, HCMV 34, or HCMV 37; far left lane contains molecular weight markers);
FIG. 56 shows western blot analysis of fractions and bed material from CMV gB immunoaffinity chromatography columns (column 19 fractions representing eluted gB (lane 5), flow through material (lane 6), and crude gB material applied to the column (lane 7) were analyzed by SDS-PAGE and western blot using monoclonal CH380; included in the assay was bed material from column 19 (lane 2) and column 11 (lane 3), as well as gB purified on column 7 (lane 4); molecular weight markers are present in lane 1);
FIG. 57 shows SDS-PAGE analysis of CMV gB eluted from an immunoaffinity chromatography column (fractions 8.16 through 8.22, eluted from column 8, were electrophoretically separated on a 10% gel under reducing conditions, and stained with silver);
FIG. 58 shows SDS-PAGE analysis of five batches of immunoaffinity purified CMV gB (samples of batches 1 through 5 (lanes 1-5) were electrophoretically separated on a 10% gel under reducing conditions and stained with Coomassie Blue; Lane M contains molecular weight markers);
FIGS. 59, 59A shows characterization of immunoaffinity purified CMV gB (batch 5, analyzed by SDS-PAGE, as shown in FIGS. 58A and B, was scanned with a densitometer, and bands were defined (lane 7, labels 1 through 8) with FIG. 59A showing a densitometer tracing through lane 7);
FIGS. 60A and B show immunoblot analysis of immunoaffinity purified CMV gB (purified HIV env (lanes 1), affinity purified CMV gB (lanes 2), crude CMV gB (lane (B3), or monoclonal CH380 (lane A3) were electrophoretically separated on a 10% gel, blotted onto nitrocellulose paper and probed for the presence of mouse IgG H and L chains or CMVgB using goat anti-mouse IgG (A) or monoclonal CH380 (B), respectively; molecular weight markers are present in lanes 4);
FIGS. 61A and B show immunoprecipitation/immunoblot analysis of affinity purified gB (Batch 1 immunoaffinity purified gB(1) or crude gB (B) was immunoprecipitated with monoclonals CH380 (lanes 1), 13-127 (lanes 2), 13-128 (lanes 3), HCMV 37 (lanes 4), or HCMV 34 (lanes 5); the immunoprecipitates were electrophoretically separated on a 10% gel under reducing conditions, blotted onto nitrocellulose and probed for the presence of gB, using guinea pig anti-CMB gB; far left lanes are molecular weight markers);
FIGS. 62A and B show immunoblot analysis of affinity purified CMV gB (Vero cells lysates (lanes A3, B2), CEF lysates (lane A2), vaccinia-infected Vero cells (lane B3), crude CMV gB (lanes 4), affinity purified CMV gB (lanes 5), or purified HIV env (lanes 6) were electrophoretically separated on a 10% gel under reducing conditions, blotted onto nitrocellulose, and probed for the presence of Vero cell proteins using rabbit anti-Vero cells (A), or vaccinia proteins using rabbit anti-vaccinia (B); molecular weight markers are present in lanes 1);
FIGS. 63A-C show the DNA sequence of the H6 promoted HCMVpp65 and 42K promoted HCMVpp150 and ALVAC sequences flanking the C6 locus (SEQ ID NO: 188) (The 5' end of the H6 promoted CMVpp65 is at position 496. The CMVpp65 coding sequence is from position 620 through 2302. The 5' end of the 42K promoted CMVpp150 is at position 2341. The CMVpp150 coding sequence is from position 2406 through 5543);.
FIGS. 64A and B show the DNA sequence of a 5798bp fragment of canarypox DNA containing the C.sub.7 ORF (tk) (SEQ ID NO: 189) (The C.sub.7 ORF is initiated at position 4412 and terminated at position 4951);
FIG. 65A and B show the DNA sequence of the H6 promoted HCMVgL gene and ALVAC sequences flanking the C.sub.7 locus (The 5' end of the H6 promoted CMVgL gene is at position 2136. The CMVgL coding sequence is from position 2260 through 3093);
FIGS. 66A and B show the DNA sequence of the H6 promoted HCMVgL gene and H6 promoted HCMV IE1-exon4 gene and ALVAC sequences flanking the C.sub.7 locus (SEQ ID NO: 190) (The 5' end of the H6 promoted CMVgL gene is at position 3476. The CMVgL coding region is from position 3600 through 4433. The 5' end of the H6 promoted IE1-exon4 is at position 3469. The CMV IE1-exon4 coding region is from position 3345 through 2128);
FIG. 67 shows the DNA sequence of HCMVgH (SEQ ID NO: 191)(Towne strain) deleted of its transmembrane region and cytoplasmic tail; and
FIGS. 68A and B show the DNA sequence of the H6 promoted HCMVgL gene and 42K promoted truncated HCMVgH gene and NYVAC sequences flanking the ATI locus (SEQ ID NO: 191) (The 5' end of the H6 promoted CMVgL gene is at position 2669. The CMVgL coding region is from position 2793 through 3626. The 5' end of the 42K promoted truncated CMVgH gene is at position 2650. The truncated CMVgH coding sequence is from position 2584 through 434).

DETAILED DESCRIPTION OF THE INVENTION
To develop a new vaccinia vaccine strain, NYVAC (vP866), the Copenhagen vaccine strain of vaccinia virus was modified by the deletion of six nonessential regions of the genome encoding known or potential virulence factors. The sequential deletions are detailed below (See U.S. Pat. No. 5,364,773). All designations of vaccinia restriction fragments, open reading frames and nucleotide positions are based on the terminology reported in Goebel et al., 1990a,b.
The deletion loci were also engineered as recipient loci for the insertion of foreign genes.
The regions deleted in NYVAC are listed below. Also listed are the abbreviations and open reading frame designations for the deleted regions (Goebel et al., 1990a,b) and the designation of the vaccinia recombinant (vP) containing all deletions through the deletion specified:
(1) thymidine kinase gene (TK; J2R) vP410;
(2) hemorrhagic region (u; B13R+B14R) vP553;
(3) A type inclusion body region (ATI; A26L) vP618;
(4) hemagglutinin gene (HA; A56R) vP723;
(5) host range gene region (C7L-K1L) vP804; and
(6) large subunit, ribonucleotide reductase (I4L) vP866 (NYVAC).
NYVAC is a genetically engineered vaccinia virus strain that was generated by the specific deletion of eighteen open reading frames encoding gene products some of which associated with virulence and host range (Tartaglia et al., 1992; Goebel et al., 1990a,b). The deletion of host range genes diminishes the ability of the virus to replicate in tissue culture cell derived from certain species such as swine and humans (Tartaglia et al., 1992; Perkus et al., 1990). In addition to reduced replication competency, NYVAC was shown to be highly attenuated by a number of criteria including (a) lack of induration or ulceration on rabbit skin, (b) rapid clearance from the site of inoculation, (c) high avirulence by intracranial inoculation into newborn mice when compared with other vaccinia strains including WYETH, and (d) failure to cause death, secondary lesions or disseminated infection when inoculated intraperitoneally in immunocompromised animals (Tartaglia et al., 1992). In spite of the highly attenuated characteristics of NYVAC, NYVAC based recombinants were effective in protecting mice from rabies challenge (Tartaglia et al., 1992), swine from challenge with Japanese encephalitis virus and pseudorabies virus challenge (Brockmeier et al., 1993; Konishi et al., 1992) and horses from equine influenza virus challenge (Taylor et al., 1993).
NYVAC is also highly attenuated by a number of criteria including i) decreased virulence after intracerebral inoculation in newborn mice, ii) inocuity in genetically (nu.sup.+ /nu.sup.+) or chemically (cyclophosphamide) immunocompromised mice, iii) failure to cause disseminated infection in immunocompromised mice, iv) lack of significant induration and ulceration on rabbit skin, v) rapid clearance from the site of inoculation, and vi) greatly reduced replication competency on a number of tissue culture cell lines including those of human origin. Nevertheless, NYVAC based vectors induce excellent responses to extrinsic immunogens and provided protective immunity.
Avipoxvirus-based recombinants as live vectors provide an additional approach to develop recombinant subunit vaccines. These viruses are naturally restricted by their ability to replicate only in avian species. TROVAC refers to an attenuated fowlpox that was a plaque-cloned isolate derived from the FP-1 vaccine strain of fowlpoxvirus which is licensed for vaccination of 1 day old chicks.
ALVAC is an attenuated canarypox virus-based vector that was a plaque-cloned derivative of the licensed canarypox vaccine, Kanapox (Tartaglia et al., 1992). ALVAC has some general properties which are the same as some general properties of Kanapox. ALVAC-based recombinant viruses expressing extrinsic immunogens have also been demonstrated efficacious as vaccine vectors (Tartaglia et al., 1993 a,b). For instance, mice immunized with an ALVAC recombinant expressing the rabies virus glycoprotein were protected from lethal challenge with rabies virus (Tartaglia et al., 1992) demonstrating the potential for ALVAC as a vaccine vector. ALVAC-based recombinants have also proven efficacious in dogs challenged with canine distemper virus (Taylor et al., 1992) and rabies virus (Perkus et al., 1994), in cats challenged with feline leukemia virus (Tartaglia et al., 1993b), and in horses challenged with equine influenza virus (Taylor et al., 1993).
This avipox vector is restricted to avian species for productive replication. On human cell cultures, canarypox virus replication is aborted early in the viral replication cycle prior to viral DNA synthesis. Nevertheless, when engineered to express extrinsic immunogens, authentic expression and processing is observed in vitro in mammalian cells and inoculation into numerous mammalian species induces antibody and cellular immune responses to the extrinsic immunogen and provides protection against challenge with the cognate pathogen (Taylor et al., 1992; Taylor et al., 1991b). Recent Phase I clinical trials in both Europe and the United States of a canarypox/rabies glycoprotein recombinant (ALVAC-RG; vCP65) demonstrated that the experimental vaccine was well tolerated and induced protective levels of rabiesvirus neutralizing antibody titers (Cadoz et al., 1992; Fries et al., 1992). Indeed, reactogenicity in volunteers following administration of ALVAC-RG was minimal; and following two administrations of ALVAC-RG at a dose of 10.sup.5.5 TCID.sub.50, all vaccinees developed rabies neutralizing antibody. Additionally, peripheral blood mononuclear cells (PBMCs) derived from the ALVAC-RG vaccinates demonstrated significant levels of lymphocyte proliferation when stimulated with purified rabies virus (Fries et al., 1992).
An ALVAC recombinant expressing the HIV envelope glycoprotein gp160 (ALVAC-HIV; vCP125) has been tested in phase I human clinical trial in a prime/boost protocol with recombinant gp160 (Pialoux et al., 1995). Reactogenicity in volunteers following administration of ALVAC-HIV was minimal and this vaccine candidate primed both HIV-I envelope-specific humoral and cell-mediated immune responses.
Recent studies have indicated that a prime/boost protocol, whereby immunization with a poxvirus recombinant expressing a foreign gene product is followed by a boost using a purified subunit preparation form of that gene product, elicits an enhanced immune response relative to the response elicited with either product alone. Human volunteers immunized with a vaccinia recombinant expressing the HIV-1 envelope glycoprotein and boosted with purified HIV-1 envelope glycoprotein subunit preparation exhibit higher HIV-1 neutralizing antibody titers than individuals immunized with just the vaccinia recombinant or purified envelope glycoprotein alone (Graham et al., 1993; Cooney et al., 1993). Humans immunized with two injections of an ALVAC-HIV-1 env recombinant (vCP125) failed to develop HIV specific antibodies. Boosting with purified rgp160 from a vaccinia virus recombinant resulted in detectable HIV-1 neutralizing antibodies. Furthermore, specific lymphocyte T cell proliferation to rgp160 was clearly increased by the boost with rgp160. Envelope specific cytotoxic lymphocyte activity was also detected with this vaccination regimen (Pialoux et al., 1995). Macaques immunized with a vaccinia recombinant expressing the simian immunodeficiency virus (SIV) envelope glycoprotein and boosted with SIV envelope glycoprotein from a baculovirus recombinant are protected against a SIV challenge (Hu et al., 1991; 1992). In the same fashion, purified HCMvgB protein can be used in prime/boost protocols with NYVAC or ALVAC-gB recombinants.
NYVAC, ALVAC and TROVAC have also been recognized as unique among all poxviruses in that the National Institutes of Health ("NIH")(U.S. Public Health Service), Recombinant DNA Advisory Committee, which issues guidelines for the physical containment of genetic material such as viruses and vectors, i.e., guidelines for safety procedures for the use of such viruses and vectors which are based upon the pathogenicity of the particular virus or vector, granted a reduction in physical containment level: from BSL2 to BSL1. No other poxvirus has a BSL1 physical containment level. Even the Copenhagen strain of vaccinia virus--the common smallpox vaccine--has a higher physical containment level; namely, BSL2. Accordingly, the art has recognized that NYVAC, ALVAC and TROVAC have a lower pathogenicity than any other poxvirus.
ALVAC, TROVAC, and NYVAC were deposited under the terms of the Budapest Treaty with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Md., 20852, USA:
NYVAC under ATCC accession number VR-2559 on Mar. 6, 1997;
TROVAC under ATCC accession number VR-2553 on Feb. 6, 1997
And, ALVAC under ATCC accession number VR-2547 on Nov. 14, 1996.
CMV is a frequent cause of morbidity and mortality in AIDS patients, bone marrow transplant recipients, and patients undergoing immunosuppressive therapies for neoplastic diseases. There is no effective, well-tolerated, pharmaceutical therapy for CMV infection. One approach might be the ex vivo stimulation of donor CMV-specific CTLs for the treatment and control of the often fatal pneumonia caused by CMV infection in the bone marrow transplant recipient. In fact, the treatment and control of CMV infection in man by adoptive transfer of CMV CTL clones has been successfully demonstrated (Riddell et al., 1992). However, in this instance, CMV was used to stimulate and maintain the CMV-specific CTL clones used in this therapeutic protocol. The use of CMV for the purpose of ex vivo stimulation of CTL clones has its drawbacks, the most obvious being the possibility of introducing additional CMV into an immunosuppressed patient. The availability of immunotherapeutic agents that provide a safe and acceptable means for stimulating antigen-specific cellular immune effector activities seems to be a major shortcoming in the field of adoptive immunotherapy. Protein subunits, although potentially safe, are notoriously poor at stimulating CTLS. Peptides, generally considered safe yet effective at stimulating a CTL response, are highly restrictive in their abilities to stimulate CTL responses. Peptides are typically capable of inducing a CTL response to only one CTL epitope of many possible CTL epitopes contained within a single protein. Furthermore, peptides typically stimulate CTL responses from only a restricted portion of the population, being restricted to only those individuals expressing a particular allele of the human major histocompatibility complex (MHC). Recombinant virus vectors are considered excellent inducers of CTL reactivities since they are capable of expressing the entire antigen, thus not restricted to a single epitope for a single segment of the population. However, most of these virus vectors, such as adenovirus, are capable of replication and are not considered safe for use in this type of protocol. Since ALVAC recombinants do not replicate in mammalian cells, yet are capable of stimulating antigen-specific CTL responses, as demonstrated by data contained within this application, ALVAC recombinants represent a uniquely safe and effective method for the ex vivo stimulation of virus-specific CTL clones for utilization in immunotherapeutic applications.
This invention pertains to NYVAC, ALVAC and vaccinia (WR strain) recombinants containing the HCMV genes encoding for gB, gH, gL, pp150, pp65 and IE 1, including truncated versions thereof, which are further described in the Examples below.
Clearly based on the attenuation profiles of the NYVAC, ALVAC, and TROVAC vectors and their demonstrated ability to elicit both humoral and cellular immunological responses to extrinsic immunogens (Tartaglia et al., 1993a,b; Taylor et al., 1992; Konishi et al., 1992) such recombinant viruses offer a distinct advantage over previously described vaccinia-based recombinant viruses.
The administration procedure for recombinant virus or expression product thereof, compositions of the invention such as immunological, antigenic or vaccine compositions or therapeutic compositions can be via a parenteral route (intradermal, intramuscular or subcutaneous). Such an administration enables a systemic immune response.
More generally, the inventive antigenic, immunological or vaccine compositions or therapeutic compositions (compositions containing the poxvirus recombinants of the invention) can be prepared in accordance with standard techniques well known to those skilled in the pharmaceutical art. Such compositions can be administered in dosages and by techniques well known to those skilled in the medical arts taking into consideration such factors as the age, sex, weight, and condition of the particular patient, and the route of administration. The compositions can be administered alone, or can be co-administered or sequentially administered with compositions of the invention or with other immunological, antigenic or vaccine or therapeutic compositions in seropositive individuals. The compositions can be administered alone, or can be co-administered or sequentially administered with compositions of the invention or with other antigenic, immunological, vaccine or therapeutic compositions in seronegative individuals. Such other compositions can include purified antigens from HCMV or from the expression of such antigens by a recombinant poxvirus or other vector system or, such other compositions can include a recombinant poxvirus which expresses other HCMV antigens or biological response modifiers again taking into consideration such factors as the age, sex, weight, and condition of the particular patient, and, the route of administration.
Examples of compositions of the invention include liquid preparations for orifice, e.g., oral, nasal, anal, vaginal, etc., administration such as suspensions, syrups or elixirs; and, preparations for parenteral, subcutaneous, intradermal, intramuscular or intravenous administration (e.g., injectable administration) such as sterile suspensions or emulsions. In such compositions the recombinant poxvirus may be in admixture with a suitable carrier, diluent, or excipient such as sterile water, physiological saline, glucose or the like.
Further, the products of expression of the inventive recombinant poxviruses can be used directly to stimulate an immune response in either seronegative or seropositive individuals or in animals. Thus, the expression products can be used in compositions of the invention instead or in addition to the inventive recombinant poxvirus in the aforementioned compositions.
Additionally, the inventive recombinant poxvirus and the expression products therefrom stimulate an immune or antibody response in humans and animals and therefore those products are antigens. From those antibodies or antigens, by techniques well-known in the art, monoclonal antibodies can be prepared and, those monoclonal antibodies or the antigens, can be employed in well known antibody binding assays, diagnostic kits or tests to determine the presence or absence of particular HCMV antigen(s) and therefore the presence or absence of the virus or expression of the antigen(s) (in HCMV or other systems), or to determine whether an immune response to the virus or antigen(s) has simply been stimulated. Those monoclonal antibodies or the antigens can also be employed in immunoadsorption chromatography to recover or isolate HCMV or expression products of the inventive recombinant poxvirus.
More in particular, the inventive recombinants and compositions have numerous utilities, including:
(i) inducing an immunological response in seronegative individuals (use as or as part of a vaccine regimen);
(ii) therapy in seropositive individuals; and
(iii) a means for generating HCMV protein in vitro without the risk of virus infection.
The products of expression of the inventive recombinant poxvirus can be used directly to stimulate an immune response in either seronegative or seropositive individuals or in animals. Thus, the expression products can be used in compositions of the invention instead of or in addition to the inventive recombinant poxvirus.
Additionally, the inventive recombinant poxvirus and the expression products therefrom stimulate an immune or antibody response in humans and animals. From those antibodies, by techniques well-known in the art, monoclonal antibodies can be prepared and, those monoclonal antibodies or the expression products of the inventive poxvirus and composition can be employed in well known antibody binding assays, diagnostic kits or tests to determine the presence or absence of particular HCMV antigen(s) or antibody(ies) and therefore the presence or absence of the virus, or to determine whether an immune response to the virus or antigen(s) has simply been stimulated. Those monoclonal antibodies can also be employed in immunoadsorption chromatography to recover, isolate or detect HCMV or expression products of the inventive recombinant poxvirus. Methods for producing monoclonal antibodies and for uses of monoclonal antibodies, and, of uses and methods for HCMV antigens--the expression products of the inventive poxvirus and composition--are well known to those of ordinary skill in the art. They can be used in diagnostic methods, kits, tests or assays, as well as to recover materials by immunoadsorption chromatography or by immunoprecipitation.
Monoclonal antibodies are immunoglobulins produced by hybridoma cells. A monoclonal antibody reacts with a single antigenic determinant and provides greater specificity than a conventional, serum-derived antibody. Furthermore, screening a large number of monoclonal antibodies makes it possible to select an individual antibody with desired specificity, avidity and isotype. Hybridoma cell lines provide a constant, inexpensive source of chemically identical antibodies and preparations of such antibodies can be easily standardized. Methods for producing monoclonal antibodies are well known to those of ordinary skill in the art, e.g., Koprowski, H. et al., U.S. Pat. No. 4,196,265, issued Apr. 1, 1989, incorporated herein by reference.
Uses of monoclonal antibodies are known. One such use is in diagnostic methods, e.g., David, G. and Greene, H. U.S. Pat. No. 4,376,110, issued Mar. 8, 1983; incorporated herein by reference. Monoclonal antibodies have also been used to recover materials by immunoadsorption chromatography, e.g., Milstein, C. 1980, Scientific American 243:66, 70, incorporated herein by reference.
Furthermore, the inventive recombinant poxvirus or expression products therefrom can be used to stimulate a response in cells in vitro or ex vivo for subsequent reinfusion into a patient. If the patient is seronegative, the reinfusion is to stimulate an immune response, e.g., an immunological or antigenic response such as active immunization. In a seropositive individual, the reinfusion is to stimulate or boost the immune system against HCMV.
Accordingly, the inventive recombinant poxvirus has several utilities: In antigenic, immunological or vaccine compositions such as for administration to seronegative individuals. In therapeutic compositions in seropositive individuals in need of therapy to stimulate or boost the immune system against HCMV. In vitro to produce antigens which can be further used in antigenic, immunological or vaccine compositions or in therapeutic compositions. To generate antibodies (either by direct administration or by administration of an expression product of the inventive recombinant poxvirus) or expression products or antigens which can be further used: in diagnosis, tests or kits to ascertain the presence or absence of antigens in a sample such as sera, for instance, to ascertain the presence or absence of HCMV in a sample such as sera or, to determine whether an immune response has elicited to the virus or, to particular antigen(s); or, in immunoadsorption chromatography, immunoprecipitation and the like.
Furthermore, the recombinant poxviruses of the invention are useful for generating DNA for probes or for
PCR primers which can be used to detect the presence or absence of hybridizable DNA or to amplify DNA, e.g., to detect HCMV in a sample or for amplifying HCMV DNA.
Other utilities also exist for embodiments of the invention.
A better understanding of the present invention and of its many advantages will be had from the following examples, given by way of illustration.
EXAMPLES
DNA Cloning and Synthesis. Plasmids were constructed, screened and grown by standard procedures (Maniatis et al., 1982; Perkus et al., 1985; Piccini et al., 1987). Restriction endonucleases were obtained from Bethesda Research Laboratories, Gaithersburg, Md., New England Biolabs, Beverly, Mass.; and Boehringer Mannheim Biochemicals, Indianapolis, Ind. Klenow fragment of E. coli polymerase was obtained from Boehringer Mannheim Biochemicals. BAL-31 exonuclease and phage T4 DNA ligase were obtained from New England Biolabs. The reagents were used as specified by the various suppliers.
Synthetic oligodeoxyribonucleotides were prepared on a Biosearch 8750 or Applied Biosystems 380B DNA synthesizer as previously described (Perkus et al., 1989). DNA sequencing was performed by the dideoxy-chain termination method (Sanger et al., 1977) using Sequenase (Tabor et al., 1987) as previously described (Guo et al., 1989). DNA amplification by polymerase chain reaction (PCR) for sequence verification (Engelke et al., 1988) was performed using custom synthesized oligonucleotide primers and GeneAmp DNA amplification Reagent Kit (Perkin Elmer Cetus, Norwalk, Conn.) in an automated Perkin Elmer Cetus DNA Thermal Cycler. Excess DNA sequences were deleted from plasmids by restriction endonuclease digestion followed by limited digestion by BAL-31 exonuclease and mutagenesis (Mandecki, 1986) using synthetic oligonucleotides.
Cells, Virus, and Transfection. The origins and conditions of cultivation of the Copenhagen strain of vaccinia virus has been previously described (Guo et al., 1989). Generation of recombinant virus by recombination, in situ hybridization of nitrocellulose filters and screening for B-galactosidase activity are as previously described (Piccini et al., 1987).
The origins and conditions of cultivation of the Copenhagen strain of vaccinia virus and NYVAC has been previously described (Guo et al., 1989; Tartaglia et al., 1992). Generation of recombinant virus by recombination, in situ hybridization of nitrocellulose filters and screening for B-galactosidase activity are as previously described (Panicali et al., 1982; Perkus et al., 1989).
The parental canarypox virus (Rentschler strain) is a vaccinal strain for canaries. The vaccine strain was obtained from a wild type isolate and attenuated through more than 200 serial passages on chick embryo fibroblasts. A master viral seed was subjected to four successive plaque purifications under agar and one plaque clone was amplified through five additional passages after which the stock virus was used as the parental virus in in vitro recombination tests. The plaque purified canarypox isolate is designated ALVAC.
The strain of fowlpox virus (FPV) designated FP-1 has been described previously (Taylor et al., 1988a). It is an attenuated vaccine strain useful in vaccination of day old chickens. The parental virus strain Duvette was obtained in France as a fowlpox scab from a chicken. The virus was attenuated by approximately 50 serial passages in chicken embryonated eggs followed by 25 passages on chicken embryo fibroblast cells. The virus was subjected to four successive plaque purifications. One plaque isolate was further amplified in primary CEF cells and a stock virus, designated as TROVAC, established.
NYVAC, ALVAC and TROVAC viral vectors and their derivatives were propagated as described previously (Piccini et al., 1987; Taylor et al., 1988a,b). Vero cells and chick embryo fibroblasts (CEF) were propagated as described previously (Taylor et al., 1988a,b).
As to NYVAC and especially Examples 1 to 6, reference's made to U.S. Pat. No. 5,364,773, incorporated herein by reference.
Example 1
Construction of Plasmid pSD460 for Deletion of Thymidine Kinase Gene (J2R)
Referring now to FIG. 1, plasmid pSD406 contains vaccinia HindIII J (pos. 83359-88377) cloned into pUC8. pSD406 was cut with HindIII and PvuII, and the 1.7 kb fragment from the left side of HindIII J cloned into pUC8 cut with HindIII/SmaI, forming pSD447. pSD447 contains the entire gene for J2R (pos. 83855-84385). The initiation codon is contained within an NlaIII site and the termination codon is contained within an SspI site. Direction of transcription is indicated by an arrow in FIG. 1.
To obtain a left flanking arm, a 0.8 kb HindIII/EcoRI fragment was isolated from pSD447, then digested with NlaIII and a 0.5 kb HindIII/NlaIII fragment isolated. Annealed synthetic oligonucleotides MPSYN43/MPSYN44 (SEQ ID NO:1/SEQ ID NO:2)
SmaIMPSYN43 5' TAATTAACTAGCTACCCGGG 3'MPSYN44 3' GTACATTAATTGATCGATGGGCCCTTAA 5' NlaIII EcoRI
were ligated with the 0.5 kb HindIII/NlaIII fragment into pUC18 vector plasmid cut with HindIII/EcoRI, generating plasmid pSD449.
To obtain a restriction fragment containing a vaccinia right flanking arm and pUC vector sequences, pSD447 was cut with SspI (partial) within vaccinia sequences and HindIII at the pUC/vaccinia junction, and a 2.9 kb vector fragment isolated. This vector fragment was ligated with annealed synthetic oligonucleotides MPSYN45/MPSYN46 (SEQ ID NO:3/SEQ ID NO:4)
HindIII SmaI m m NotI SspIMPSYN45 5' AGCTTCCCGGGTAAGTAATACGTCAAGGAGAAAACGAAACGATCTGTAGTTAGCGGCCGCCTAATTAACTAAT 3' MPSYN45MPSYN46 3' AGGGCCCATTCATTATGCAGTTCCTCTTTTGCTT TGCTAGACATCAATCGCCGGCGGATTAATTGATTA 5' MPSYN46
generating pSD459.
To combine the left and right flanking arms into one plasmid, a 0.5 kb HindIII/SmaI fragment was isolated from pSD449 and ligated with pSD459 vector plasmid cut with HindIII/SmaI, generating plasmid pSD460. pSD460 was used as donor plasmid for recombination with wild type parental vaccinia virus Copenhagen strain VC-2. .sup.32 P labelled probe was synthesized by primer extension using MPSYN45 (SEQ ID NO:3) as template and the complementary 20 mer oligonucleotide MPSYN47 (SEQ ID NO:5) (5' TTAGTTAATTAGGCGGCCGC 3') as primer. Recombinant virus vP410 was identified by plaque hybridization.
Example 2
Construction of Plasmid pSD486 for Deletion of Hemorrhagic Region (B13r+B14r)
Referring now to FIG. 2, plasmid pSD419 contains vaccinia SalI G (pos. 160,744-173,351) cloned into pUC8. pSD422 contains the contiguous vaccinia SalI fragment to the right, SalI J (pos. 173,351-182,746) cloned into pUC8. To construct a plasmid deleted for the hemorrhagic region, u, B13R-B14R (pos. 172,549-173,552), pSD419 was used as the source for the left flanking arm and pSD422 was used as the source of the right flanking arm. The direction of transcription for the u region is indicated by an arrow in FIG. 2.
To remove unwanted sequences from pSD419, sequences to the left of the NcoI site (pos. 172,253) were removed by digestion of pSD419 with NcoI/SmaI followed by blunt ending with Klenow fragment of E. coli polymerase and ligation generating plasmid pSD476. A vaccinia right flanking arm was obtained by digestion of pSD422 with HpaI at the termination codon of B14R and by digestion with NruI 0.3 kb to the right. This 0.3 kb fragment was isolated and ligated with a 3.4 kb HincII vector fragment isolated from pSD476, generating plasmid pSD477. The location of the partial deletion of the vaccinia u region in pSD477 is indicated by a triangle. The remaining B13R coding sequences in pSD477 were removed by digestion with ClaI/HpaI, and the resulting vector fragment was ligated with annealed synthetic oligonucleotides SD22mer/SD20mer (SEQ ID NO:6/SEQ ID NO:7)
ClaI BamHI HpaISD22mer 5' CGATTACTATGAAGGATCCGTT 3'SD20mer 3' TAATGATACTTCCTAGGCAA 5'
generating pSD479. pSD479 contains an initiation codon (underlined) followed by a BamHI site. To place E. coli Beta-galactosidase in the B13-B14 (u) deletion locus under the control of the u promoter, a 3.2 kb BamHI fragment containing the Beta-galactosidase gene (Shapira et al., 1983) was inserted into the BamHI site of pSD479, generating pSD479BG. pSD479BG was used as donor plasmid for recombination with vaccinia virus vP410. Recombinant vaccinia virus vP533 was isolated as a blue plaque in the presence of chromogenic substrate X-gal. In vP533 the B13R-B14R region is deleted and is replaced by Betagalactosidase.
To remove Beta-galactosidase sequences from vP533, plasmid pSD486, a derivative of pSD477 containing a polylinker region but no initiation codon at the u deletion junction, was utilized. First the ClaI/HpaI vector fragment from pSD477 referred to above was ligated with annealed synthetic oligonucleotides SD42mer/SD40mer (SEQ ID NO:8/SEQ ID NO:9)
ClaI SacI XhoI HpaI SD42mer 5' CGATTACTAGATCTGAGCTCCCCGGGCTCGAGGG ATCCGTT 3' SD40mer 3' TAATGATCTAGACTCGAGGGGCCCGAGCTCCC TAGGCAA 5' BglII SmaI BamHI
generating plasmid pSD478. Next the EcoRI site at the pUC/vaccinia junction was destroyed by digestion of pSD478 with EcoRI followed by blunt ending with Klenow fragment of E. coli polymerase and ligation, generating plasmid pSD478E.sup.-. pSD478E.sup.- was digested with BamHI and HpAI and ligated with annealed synthetic oligonucleotides HEM5/HEM6 (SEQ ID NO:10/SEQ ID NO:11)
BamHI EcoRI HpaI HEM5 5' GATCCGAATTCTAGCT 3' HEM6 3' GCTTAAGATCGA 5'
generating plasmid pSD486. pSD486 was used as donor plasmid for recombination with recombinant vaccinia virus vP533, generating vP553, which was isolated as a clear plaque in the presence of X-gal.
Example 3
Construction of Plasmid pMP494.DELTA. for Deletion of ATI Region (A26L)
Referring now to FIG. 3, pSD414 contains SalI B cloned into pUC8. To remove unwanted DNA sequences to the left of the A26L region, pSD414 was cut with XbaI within vaccinia sequences (pos. 137,079) and with HindIII at the pUC/vaccinia junction, then blunt ended with Klenow fragment of E. coli polymerase and ligated, resulting in plasmid pSD483. To remove unwanted vaccinia DNA sequences to the right of the A26L region, pSD483 was cut with EcoRI (pos. 140,665 and at the pUC/vaccinia junction) and ligated, forming plasmid pSD484. To remove the A26L coding region, pSD484 was cut with NdeI (partial) slightly upstream from the A26L ORF (pos. 139,004) and with HpaI (pos. 137,889) slightly downstream from the A26L ORF. The 5.2 kb vector fragment was isolated and ligated with annealed synthetic oligonucleotides ATI3/ATI4 (SEQ ID NO:12/SEQ ID NO:13)
NdeI BglIIEcoRI HpaIATI3 5' TATGAGTAACTTAACTCTTTTGTTAATTAAAAGTATATTCAAAAAATAAGTTATATAAATAGATCTGAATTCGTT 3' ATI3ATI4 3' ACTCATTGAATTGAGAAAACAATTAATTTTCATATAAGTTTTTTATTCAATATATTTATCTAGACTTAAGCAA 5' ATI4
reconstructing the region upstream from A26L and replacing the A26L ORF with a short polylinker region containing the restriction sites BQlII, EcoRI and HpaI, as indicated above. The resulting plasmid was designated pSD485. Since the BqlII and EcoRI sites in the polylinker region of pSD485 are not unique, unwanted BqlII and EcoRI sites were removed from plasmid pSD483 (described above) by digestion with BglII (pos. 140,136) and with EcoRI at the pUc/vaccinia junction, followed by blunt ending with Klenow fragment of E. coli polymerase and ligation. The resulting plasmid was designated pSD489. The 1.8 kb ClaI (pos. 137,198)/EcoRV (pos. 139,048) fragment from pSD489 containing the A26L ORF was replaced with the corresponding 0.7 kb polylinker-containing CaI/EcoRV fragment from pSD485, generating pSD492. The BqlII and EcoRI sites in the polylinker region of pSD492 are unique.
A 3.3 kb BglII cassette containing the E. coli Beta-galactosidase gene (Shapira et al., 1983) under the control of the vaccinia 11 kDa promoter (Bertholet et al., 1985; Perkus et al., 1990) was inserted into the BglII site of pSD492, forming pSD493KBG. Plasmid pSD493KBG was used in recombination with rescuing virus vP553. Recombinant vaccinia virus, vP581, containing Beta-galactosidase in the A26L deletion region, was isolated as a blue plaque in the presence of X-gal.
To generate a plasmid for the removal of Beta-galactosidase sequences from vaccinia recombinant virus vP581, the polylinker region of plasmid pSD492 was deleted by mutagenesis (Mandecki, 1986) using synthetic oligonucleotide MPSYN177 (SEQ ID NO:14)
(5' AAAATGGGCGTGGATTGTTAACTTTATATAACTTATTTTTTGAATATAC 3'). In the resulting plasmid, pMP494.DELTA., vaccinia DNA encompassing positions [137,889-138,937], including the entire A26L ORF is deleted. Recombination between the pMP494.DELTA. and the Beta-galactosidase containing vaccinia recombinant, vP581, resulted in vaccinia deletion mutant vP618, which was isolated as a clear plaque in the presence of X-gal.
Example 4
Construction of Plasmid pSD467 for Deletion of Hemagglutinin Gene (A56R)
Referring now to FIG. 4, vaccinia SalI G restriction fragment (pos. 160,744-173,351) crosses the HindIII A/B junction (pos. 162,539). pSD419 contains vaccinia SalI G cloned into pUC8. The direction of transcription for the hemagglutinin (HA) gene is indicated by an arrow in FIG. 4. Vaccinia sequences derived from HindIII B were removed by digestion of pSD419 with HindIII within vaccinia sequences and at the pUC/vaccinia junction followed by ligation. The resulting plasmid, pSD456, contains the HA gene, A56R, flanked by 0.4 kb of vaccinia sequences to the left and 0.4 kb of vaccinia sequences to the right. A56R coding sequences were removed by cutting pSD456 with RsaI (partial; pos. 161,090) upstream from A56R coding sequences, and with EagI (pos. 162,054) near the end of the gene. The 3.6 kb RsaI/EagI vector fragment from pSD456 was isolated and ligated with annealed synthetic oligonucleotides MPSYN59 (SEQ ID NO:15), MPSYN62 (SEQ ID NO:16), MPSYN60 (SEQ ID NO:17), and MPSYN61 (SEQ ID NO:18)
RsaIMPSYN595'ACACGAATGATTTTCTAAAGTATTTGGAAAGTTTTATAGGT-MPSYN623'TGTGCTTACTAAAAGATTTCATAAACCTTTCAAAATATCCA-MPSYN59 AGTTGATAGAACAAAATACATAATTT 3'MPSYN62 TCAACTATCT 5'MPSYN605' TGTAAAAATAAATCACTTTTTATA-MPSYN613'TGTTTTATGTATTAAAACATTTTTATTTAGTGAAAAATAT- BglII SmaI PstI EagIMPSYN60 CTAAGATCTCCCGGGCTGCAGC 3'MPSYN61 GATTCTAGAGGGCCCGACGTCGCCGG 5'
reconstructing the DNA sequences upstream from the A56R ORF and replacing the A56R ORF with a polylinker region as indicated above. The resulting plasmid is pSD466. The vaccinia deletion in pSD466 encompasses positions [161,185-162,053]. The site of the deletion in pSD466 is indicated by a triangle in FIG. 4.
A 3.2 kb BqlII/BamHI (partial) cassette containing the E. coli Beta-galactosidase gene (Shapira et al., 1983) under the control of the vaccinia 11 kDa promoter (Bertholet et al., 1985; Guo et al., 1989) was inserted into the BglII site of pSD466, forming pSD466KBG. Plasmid pSD466KBG was used in recombination with rescuing virus vP618. Recombinant vaccinia virus, vP708, containing Beta-galactosidase in the A56R deletion, was isolated as a blue plaque in the presence of X-gal.
Beta-galactosidase sequences were deleted from vP708 using donor plasmid pSD467. pSD467 is identical to pSD466, except that EcoRI, SmaI and BamHI sites were removed from the pUC/vaccinia junction by digestion of pSD466 with EcoRI/BamHI followed by blunt ending with Klenow fragment of E. coli polymerase and ligation. Recombination between vP708 and pSD467 resulted in recombinant vaccinia deletion mutant, vP723, which was isolated as a clear plaque in the presence of X-gal.
Example 5
Construction of Plasmid pMPCSK1.DELTA. for Deletion of Open Reading Frames [C7L-K1L]
Referring now to FIG. 5, the following vaccinia clones were utilized in the construction of pMPCSK1.DELTA.. pSD420 is SalI H cloned into pUC8. pSD435 is KpnI F cloned into pUC18. pSD435 was cut with SphI and religated, forming pSD451. In pSD451, DNA sequences to the left of the SphI site (pos. 27,416) in HindIII M are removed (Perkus et al., 1990). pSD409 is HindIII M cloned into pUC8.
To provide a substrate for the deletion of the [C7L-K1L] gene cluster from vaccinia, E. coli Beta-galactosidase was first inserted into the vaccinia M2L deletion locus (Guo et al., 1990) as follows. To eliminate the BglII site in pSD409, the plasmid was cut with BglII in vaccinia sequences (pos. 28,212) and with BamHI at the pUC/vaccinia junction, then ligated to form plasmid pMP409B. pMP409B was cut at the unique SphI site (pos. 27,416). M2L coding sequences were removed by mutagenesis (Guo et al., 1990; Mandecki, 1986) using synthetic oligonucleotide MPSYN82 (SEQ. ID NO:19)
BglII5' TTTCTGTATATTTGCACCAATTTAGATCTTACTCAAAATATGTAACAATA 3'
The resulting plasmid, pMP409D, contains a unique BglII site inserted into the M2L deletion locus as indicated above. A 3.2 kb BamHI (partial)/BglII cassette containing the E. coli Beta-galactosidase gene (Shapira et al., 1983) under the control of the 11 kDa promoter (Bertholet et al., 1985) was inserted into pMP409D cut with BglII. The resulting plasmid, pMP409DBG (Guo et al., 1990), was used as donor plasmid for recombination with rescuing vaccinia virus vP723. Recombinant vaccinia virus, vP784, containing Beta-galactosidase inserted into the M2L deletion locus, was isolated as a blue plaque in the presence of X-gal.
A plasmid deleted for vaccinia genes [C7L-K1L] was assembled in pUC8 cut with SmaI, HindIII and blunt ended with Klenow fragment of E. coli polymerase. The left flanking arm consisting of vaccinia HindIII C sequences was obtained by digestion of pSD420 with XbaI (pos. 18,628) followed by blunt ending with Klenow fragment of E. coli polymerase and digestion with BglII (pos. 19,706). The right flanking arm consisting of vaccinia HindIII K sequences was obtained by digestion of pSD451 with BglII (pos. 29,062) and EcoRV (pos. 29,778). The resulting plasmid, pMP581CK is deleted for vaccinia sequences between the BglII site (pos. 19,706) in HindIII C and the BglII site (pos. 29,062) in HindIII K. The site of the deletion of vaccinia sequences in plasmid pMP581CK is indicated by a triangle in FIG. 5.
To remove excess DNA at the vaccinia deletion junction, plasmid pMP581CK, was cut at the NcoI sites within vaccinia sequences (pos. 18,811; 19,655), treated with Bal-31 exonuclease and subjected to mutagenesis (Mandecki, 1986) using synthetic oligonucleotide MPSYN233 (SEQ ID NO:20) 5'-TGTCATTTAACACTATACTCATATTAATAAAAATAATATTTATT-3'. The resulting plasmid, pMPCSK1.DELTA., is deleted for vaccinia sequences positions 18,805-29,108, encompassing 12 vaccinia open reading frames [C7L-K1L]. Recombination between pMPCSK1.DELTA. and the Beta-galactosidase containing vaccinia recombinant, vP784, resulted in vaccinia deletion mutant, vP804, which was isolated as a clear plaque in the presence of X-gal.
Example 6
Construction of Plasmid pSD548 for Deletion of Large Subunit, Ribonucleotide Reductase (I4L)
Referring now to FIG. 6, plasmid pSD405 contains vaccinia HindIII I (pos. 63,875-70,367) cloned in pUC8. pSD405 was digested with EcoRV within vaccinia sequences (pos. 67,933) and with SmaI at the pUC/vaccinia junction, and ligated, forming plasmid pSD518. pSD518 was used as the source of all the vaccinia restriction fragments used in the construction of pSD548.
The vaccinia I4L gene extends from position 67,371-65,059. Direction of transcription for I4L is indicated by an arrow in FIG. 6. To obtain a vector plasmid fragment deleted for a portion of the I4L coding sequences, pSD518 was digested with BamHI (pos. 65,381) and HpaI (pos. 67,001) and blunt ended using Klenow fragment of E. coli polymerase. This 4.8 kb vector fragment was ligated with a 3.2 kb SmaI cassette containing the E. coli Beta-galactosidase gene (Shapira et al., 1983) under the control of the vaccinia 11 kDa promoter (Bertholet et al., 1985; Perkus et al., 1990), resulting in plasmid pSD524KBG. pSD524KBG was used as donor plasmid for recombination with vaccinia virus vP804. Recombinant vaccinia virus, vP855, containing Beta-galactosidase in a partial deletion of the I4L gene, was isolated as a blue plaque in the presence of X-gal.
To delete Beta-galactosidase and the remainder of the I4L ORF from vP855, deletion plasmid pSD548 was constructed. The left and right vaccinia flanking arms were assembled separately in pUC8 as detailed below and presented schematically in FIG. 6.
To construct a vector plasmid to accept the left vaccinia flanking arm, pUC8 was cut with BamHI/EcoRI and ligated with annealed synthetic oligonucleotides 518A1/518A2 (SEQ ID NO:21/SEQ ID NO:22)
BamHI RsaIBglI EcoRI518A1 5' GATCCTGAGTACTTTGTAATATAATGATATATATTTTCACTTTATCTCATTTGAGAATAAAAAGATCTTAGG 3' 518A1518A2 3' GACTCATGAAACATTATATTACTATATATAAAAGTGAAATAGAGTAAACTCTTATTTTTCTAGAATCCTTAA 5' 518A2
forming plasmid pSD531. pSD531 was cut with RsaI (partial) and BamHI and a 2.7 kb vector fragment isolated. pSD518 was cut with BglII (pos. 64,459)/RsaI (pos. 64,994) and a 0.5 kb fragment isolated. The two fragments were ligated together, forming pSD537, which contains the complete vaccinia flanking arm left of the I4L coding sequences.
To construct a vector plasmid to accept the right vaccinia flanking arm, pUC8 was cut with BamHI/EcoRI and ligated with annealed synthetic oligonucleotides 518B1/518B2 (SEQ ID NO:23/SEQ ID NO:24)
BamHI BglII SmaI RsaI EcoRI518B1 5' GATCCAGATCTCCCGGGAAAAAAATTATTTAACTTTTCATTAATAGGGATTTGACGTATGTAGCGTACTAGG 3' 518B1518B2 3' GTCTAGAGGGCCCTTTTTTTAATAAATTGAAAAGTAATTATCCCTAAACTGCATACTACGCATGATCCTTAA 5' 518B2
forming plasmid pSD532. pSD532 was cut with RsaI (partial)/EcoRI and a 2.7 kb vector fragment isolated. pSD518 was cut with RsaI within vaccinia sequences (pos. 67,436) and EcoRI at the vaccinia/pUC junction, and a 0.6 kb fragment isolated. The two fragments were ligated together, forming pSD538, which contains the complete vaccinia flanking arm to the right of I4L coding sequences.
The right vaccinia flanking arm was isolated as a 0.6 kb EcoRI/BglII fragment from pSD538 and ligated into pSD537 vector plasmid cut with EcoRI/BglII. In the resulting plasmid, pSD539, the I4L ORF (pos. 65,047-67,386) is replaced by a polylinker region, which is flanked by 0.6 kb vaccinia DNA to the left and 0.6 kb vaccinia DNA to the right, all in a pUC background. The site of deletion within vaccinia sequences is indicated by a triangle in FIG. 6. To avoid possible recombination of Beta-galactosidase sequences in the pUC-derived portion of pSD539 with Beta-galactosidase sequences in recombinant vaccinia virus vP855, the vaccinia I4L deletion cassette was moved from pSD539 into pRC11, a pUC derivative from which all Beta-galactosidase sequences have been removed and replaced with a polylinker region (Colinas et al., 1990). pSD539 was cut with EcoRI/PstI and the 1.2 kb fragment isolated. This fragment was ligated into pRC11 cut with EcoRI/PstI (2.35 kb), forming pSD548. Recombination between pSD548 and the Beta-galactosidase containing vaccinia recombinant, vP855, resulted in vaccinia deletion mutant vP866, which was isolated as a clear plaque in the presence of X-gal.
DNA from recombinant vaccinia virus vP866 was analyzed by restriction digests followed by electrophoresis on an agarose gel. The restriction patterns were as expected. Polymerase chain reactions (PCR) (Engelke et al., 1988) using vP866 as template and primers flanking the six deletion loci detailed above produced DNA fragments of the expected sizes. Sequence analysis of the PCR generated fragments around the areas of the deletion junctions confirmed that the junctions were as expected. Recombinant vaccinia virus vP866, containing the six engineered deletions as described above, was designated vaccinia vaccine strain "NYVAC."
Example 7
Insertion of a Rabies Glycoprotein G Gene Into NYVAC
The gene encoding rabies glycoprotein G under the control of the vaccinia H6 promoter (Taylor et al., 1988a,b) was inserted into TK deletion plasmid pSD513. pSD513 is identical to plasmid pSD460 (FIG. 1) except for the presence of a polylinker region.
Referring now to FIG. 7, the polylinker region was inserted by cutting pSD460 with SmaI and ligating the plasmid vector with annealed synthetic oligonucleotides VQ1A/VQ1B (SEQ ID NO:25/SEQ ID NO:26)
SmaI BglII XhoI PstI NarI BamHIVQ1A 5' GGGAGATCTCTCGAGCTGCAGGGCGCCGGATCCTTTTTCT 3'VQ1B 3' CCCTCTAGAGAGCTCGACGTCCCGCGGCCTAGGAAAAAGA 5'
to form vector plasmid pSD513. pSD513 was cut with SmaI and ligated with a SmaI ended 1.8 kb cassette containing the gene encoding the rabies glycoprotein G gene under the control of the vaccinia H6 promoter (Taylor et al., 1988a,b). The resulting plasmid was designated pRW842. pRW842 was used as donor plasmid for recombination with NYVAC rescuing virus (vP866). Recombinant vaccinia virus vP879 was identified by plaque hybridization using .sup.32 P labelled DNA probe to rabies glycoprotein G coding sequences.
The modified recombinant viruses of the present invention provide advantages as recombinant vaccine vectors. The attenuated virulence of the vector advantageously reduces the opportunity for the possibility of a runaway infection due to vaccination in the vaccinated individual and also diminishes transmission from vaccinated to unvaccinated individuals or contamination of the environment.
The modified recombinant viruses are also advantageously used in a method for expressing a gene product in a cell cultured in vitro by introducing into the cell the modified recombinant virus having foreign DNA which codes for and expresses gene products in the cell.
Example 8
Construction of ALVAC Recombinants Expressing Rabies Virus Glycoprotein G
This example describes the development of ALVAC, a canarypox virus vector and, of a canarypox-rabies recombinant designated as ALVAC-RG (vCP65) and its safety and efficacy.
Cells and Viruses. The parental canarypox virus (Rentschler strain) is a vaccinal strain for canaries. The vaccine strain was obtained from a wild type isolate and attenuated through more than 200 serial passages on chick embryo fibroblasts. A master viral seed was subjected to four successive plaque purifications under agar and one plaque clone was amplified through five additional passages after which the stock virus was used as the parental virus in in vitro recombination tests. The plaque purified canarypox isolate is designated ALVAC.
Construction of a Canarypox Insertion Vector. An 880 bp canarypox PvuII fragment was cloned between the PvuII sites of pUC9 to form pRW764.5. The sequence of this fragment is shown in FIG. 8 (SEQ ID NO:27) between positions 1372 and 2251. The limits of an open reading frame designated as C5 were defined. It was determined that the open reading frame was initiated at position 166 within the fragment and terminated at position 487. The C5 deletion was made without interruption of open reading frames. Bases from position 167 through position 455 were replaced with the sequence (SEQ ID NO:28) GCTTCCCGGGAATTCTAGCTAGCTAGTTT. This replacement sequence contains HindIII, SmaI and EcoRI insertion sites followed by translation stops and a transcription termination signal recognized by vaccinia virus RNA polymerase (Yuen et al., 1987). Deletion of the C5 ORF was performed as described below. Plasmid pRW764.5 was partially cut with RsaI and the linear product was isolated. The RsaI linear fragment was recut with BglII and the pRW764.5 fragment now with a RsaI to BglII deletion from position 156 to position 462 was isolated and used as a vector for the following synthetic oligonucleotides:
RW145 (SEQ ID NO:29):
ACTCTCAAAAGCTTCCCGGGAATTCTAGCTAGCTAGTTTTTATAAA
RW146 (SEQ ID NO:30):
GATCTTTATAAAAACTAGCTAGCTAGAATTCCCGGGAAGCTTTTGAGAGT
Oligonucleotides RW145 and RW146 were annealed and inserted into the pRW 764.5 RsaI and BglII vector described above. The resulting plasmid is designated pRW831.
Construction of Insertion Vector Containing the Rabies G Gene. Construction of pRW838 is illustrated below. oligonucleotides A through E, which overlap the translation initiation codon of the H6 promoter with the ATG of rabies G, were cloned into pUC9 as pRW737. Oligonucleotides A through E contain the H6 promoter, starting at NruI, through the HindIII site of rabies G followed by BglII. Sequences of oligonucleotides A through E ((SEQ ID NO:31)-(SEQ ID NO:35)) are:
A (SEQ ID NO:31):CTGAAATTATTTCATTATCGCGATATCCGTTAA GTTTGTATCGTAATGGTTCCTCAGGCTCTCCTGTTTGTB (SEQ ID NO:32):CATTACGATACAAACTTAACGGATATCGCGATAA TGAAATAATTTCAGC (SEQ ID NO:33: ACCCCTTCTGGTTTTTCCGTTGTGTTTTGGGAAA TTCCCTATTTACACGATCCCAGACAAGCTTAGATCTCAGD (SEQ ID NO:34):CTGAGATCTAAGCTTGTCTGGGATCGTGTAAATA GGGAATTTCCCAAAACAE (SEQ ID NO:35):CAACGGAAAAACCAGAAGGGGTACAAACAGGAGA GCCTGAGGAAC
The diagram of annealed oligonucleotides A through E is as follows: ##STR1##
Oligonucleotides A through E were kinased, annealed (95.degree. C. for 5 minutes, then cooled to room temperature), and inserted between the PvuII sites of pUC9. The resulting plasmid, pRW737, was cut with HindIII and BglII and used as a vector for the 1.6 kbp HindIII-BglII fragment of ptg155PRO (Kieny et al., 1984) generating pRW739. The ptg155PRO HindIII site is 86 bp downstream of the rabies G translation initiation codon. BglII is downstream of the rabies G translation stop codon in ptg155PRO. pRW739 was partially cut with NruI, completely cut with BglII, and a 1.7 kbp NruI-BglII fragment, containing the 3' end of the H6 promoter previously described (Taylor et al., 1988a,b; Guo et al., 1989; Perkus et al., 1989) through the entire rabies G gene, was inserted between the NruI and BamHI sites of pRW824. The resulting plasmid is designated pRW832. Insertion into pRW824 added the H6 promoter 5' of NruI. The pRW824 sequence of BamHI followed by SmaI is (SEQ ID NO:36): GGATCCCCGGG. pRW824 is a plasmid that contains a nonpertinent gene linked precisely to the vaccinia virus H6 promoter. Digestion with NruI and BamHI completely excised this nonpertinent gene. The 1.8 kbp pRW832 SmaI fragment, containing H6 promoted rabies G, was inserted into the SmaI of pRW831, to form plasmid pRW838.
Development of ALVAC-RG. Plasmid pRW838 was transfected into ALVAC infected primary CEF cells by using the calcium phosphate precipitation method previously described (Panicali et al., 1982; Piccini et al., 1987). Positive plaques were selected on the basis of hybridization to a specific rabies G probe and subjected to 6 sequential rounds of plaque purification until a pure population was achieved. One representative plaque was then amplified and the resulting ALVAC recombinant was designated ALVAC-RG (vCP65) (see also FIGS. 9A and 9B). The correct insertion of the rabies G gene into the ALVAC genome without subsequent mutation was confirmed by sequence analysis.
Immunofluorescence. During the final stages of assembly of mature rabies virus particles, the glycoprotein component is transported from the golgi apparatus to the plasma membrane where it accumulates with the carboxy terminus extending into the cytoplasm and the bulk of the protein on the external surface of the cell membrane. In order to confirm that the rabies glycoprotein expressed in ALVAC-RG was correctly presented, immunofluorescence was performed on primary CEF cells infected with ALVAC or ALVAC-RG. Immunofluorescence was performed as previously described (Taylor et al., 1990) using a rabies G monoclonal antibody. Strong surface fluorescence was detected on CEF cells infected with ALVAC-RG but not with the parental ALVAC.
Immunoprecipitation. Preformed monolayers of primary CEF, Vero (a line of African Green monkey kidney cells ATCC # CCL81) and MRC-5 cells (a fibroblast-like cell line derived from normal human fetal lung tissue ATCC # CCL171) were inoculated at 10 pfu per cell with parental virus ALVAC and recombinant virus ALVAC-RG in the presence of radiolabelled .sup.35 S-methionine and treated as previously described (Taylor et al., 1990). Immunoprecipitation reactions were performed using a rabies G specific monoclonal antibody. Efficient expression of a rabies specific glycoprotein with a molecular weight of approximately 67 kDa was detected with the recombinant ALVAC-RG. No rabies specific products were detected in uninfected cells or cells infected with the parental ALVAC virus.
Sequential Passaging Experiment. In studies with ALVAC virus in a range of non-avian species no proliferative infection or overt disease was observed (Taylor et al., 1991b). However, in order to establish that neither the parental nor recombinant virus could be adapted to grow in non-avian cells, a sequential passaging experiment was performed.
The two viruses, ALVAC and ALVAC-RG, were inoculated in 10 sequential blind passages in three cell substrates:
(1) Primary chick embryo fibroblast (CEF) cells produced from 11 day old white leghorn embryos;
(2) Vero cells--a continuous line of African Green monkey kidney cells (ATCC # CCL81); and
(3) MRC-5 cells--a diploid cell line derived from human fetal lung tissue (ATCC # CCL171).
The initial inoculation was performed at an m.o.i. of 0.1 pfu per cell using three 60 mm dishes of each cell substrate containing 2.times.10.sup.6 cells per dish. One dish was inoculated in the presence of 40 .mu.g/ml of Cytosine arabinoside (Ara C), an inhibitor of DNA replication. After an absorption period of 1 hour at 37.degree. C., the inoculum was removed and the monolayer washed to remove unabsorbed virus. At this time the medium was replaced with 5 ml of EMEM+2% NBCS on two dishes (samples t0 and t7) and 5ml of EMEM+2% NBCS containing 40 .mu.g/ml Ara C on the third (sample t7A). Sample to was frozen at -70.degree. C. to provide an indication of the residual input virus. Samples t7 and t7A were incubated at 37.degree. C. for 7 days, after which time the contents were harvested and the cells disrupted by indirect sonication.
One ml of sample t7 of each cell substrate was inoculated undiluted onto three dishes of the same cell substrate (to provide samples t0, t7 and t7A) and onto one dish of primary CEF cells. Samples to, t7 and t7A were treated as for passage one. The additional inoculation on CEF cells was included to provide an amplification step for more sensitive detection of virus which might be present in the non-avian cells.
This procedure was repeated for 10 (CEF and MRC-5) or 8 (Vero) sequential blind passages. Samples were then frozen and thawed three times and assayed by titration on primary CEF monolayers.
Virus yield in each sample was then determined by plaque titration on CEF monolayers under agarose. Summarized results of the experiment are shown in Tables 1 and 2.
The results indicate that both the parental ALVAC and the recombinant ALVAC-RG are capable of sustained replication on CEF monolayers with no loss of titer. In Vero cells, levels of virus fell below the level of detection after 2 passages for ALVAC and 1 passage for ALVAC-RG. In MRC-5 cells, a similar result was evident, and no virus was detected after 1 passage. Although the results for only four passages are shown in Tables 1 and 2 the series was continued for 8 (Vero) and 10 (MRC-5) passages with no detectable adaptation of either virus to growth in the non-avian cells.
In passage 1 relatively high levels of virus were present in the t7 sample in MRC-5 and Vero cells. However this level of virus was equivalent to that seen in the to sample and the t7A sample incubated in the presence of Cytosine arabinoside in which no viral replication can occur. This demonstrated that the levels of virus seen at 7 days in non-avian cells represented residual virus and not newly replicated virus.
In order to make the assay more sensitive, a portion of the 7 day harvest from each cell substrate was inoculated onto a permissive CEF monolayer and harvested at cytopathic effect (CPE) or at 7 days if no CPE was evident. The results of this experiment are shown in Table 3. Even after amplification through a permissive cell substrate, virus was only detected in MRC-5 and Vero cells for two additional passages. These results indicated that under the conditions used, there was no adaptation of either virus to growth in Vero or MRC-5 cells.
Inoculation of Macaques. Four HIV seropositive macaques were initially inoculated with ALVAC-RG as described in Table 4. After 100 days these animals were re-inoculated to determine a booster effect, and an additional seven animals were inoculated with a range of doses. Blood was drawn at appropriate intervals and sera analyzed, after heat inactivation at 56.degree. C. for 30 minutes, for the presence of anti-rabies antibody using the Rapid Fluorescent Focus Inhibition Assay (Smith et al., 1973).
Inoculation of Chimpanzees. Two adult male chimpanzees (50 to 65 kg weight range) were inoculated intramuscularly or subcutaneously with 1.times.10.sup.7 pfu of vCP65. Animals were monitored for reactions and bled at regular intervals for analysis for the presence of anti-rabies antibody with the RFFI test (Smith et al., 1973). Animals were re-inoculated with an equivalent dose 13 weeks after the initial inoculation.
Inoculation of Mice. Groups of mice were inoculated with 50 to 100 .mu.l of a range of dilutions of different batches of vCP65. Mice were inoculated in the footpad. On day 14, mice were challenged by intracranial inoculation of from 15 to 43 mouse LD.sub.50 of the virulent CVS strain of rabies virus. Survival of mice was monitored and a protective dose 50% (PD.sub.50) calculated at 28 days post-inoculation.
Inoculation of Dogs and Cats. Ten beagle dogs, 5 months old, and 10 cats, 4 months old, were inoculated subcutaneously with either 6.7 or 7.7 log.sub.10 TCID.sub.50 of ALVAC-RG. Four dogs and four cats were not inoculated. Animals were bled at 14 and 28 days post-inoculation and anti-rabies antibody assessed in an RFFI test. The animals receiving 6.7 log.sub.10 TCID.sub.50 of ALVAC-RG were challenged at 29 days post-vaccination with 3.7 log.sub.10 mouse LDSO (dogs) or 4.3 log.sub.10 mouse LD.sub.50 (cats) of the NYGS rabies virus challenge strain.
Inoculation of Squirrel Monkeys. Three groups of four squirrel monkeys (Saimiri sciureus) were inoculated with one of three viruses (a) ALVAC, the parental canarypox virus, (b) ALVAC-RG, the recombinant expressing the rabies G glycoprotein or (c) vCP37, a canarypox recombinant expressing the envelope glycoprotein of feline leukemia virus. Inoculations were performed under ketamine anaesthesia. Each animal received at the same time: (1) 20 .mu.l instilled on the surface of the right eye without scarification; (2) 100 .mu.l as several droplets in the mouth; (3) 100 .mu.l in each of two intradermal injection sites in the shaven skin of the external face of the right arm; and (4) 100 .mu.l in the anterior muscle of the right thigh.
Four monkeys were inoculated with each virus, two with a total of 5.0 log.sub.10 pfu and two with a total of 7.0 log.sub.10 pfu. Animals were bled at regular intervals and sera analyzed for the presence of antirabies antibody using an RFFI test (Smith et al., 1973). Animals were monitored daily for reactions to vaccination. Six months after the initial inoculation the four monkeys receiving ALVAC-RG, two monkeys initially receiving vCP37, and two monkeys initially receiving ALVAC, as well as one naive monkey were inoculated with 6.5 log.sub.10 pfu of ALVAC-RG subcutaneously. Sera were monitored for the presence of rabies neutralizing antibody in an RFFI test (Smith et al., 1973).
Inoculation of Human Cell Lines with ALVAC-RG. In order to determine whether efficient expression of a foreign gene could be obtained in non-avian cells in which the virus does not productively replicate, five cell types, one avian and four non-avian, were analyzed for virus yield, expression of the foreign rabies G gene and viral specific DNA accumulation. The cells inoculated were:
(a) Vero, African Green monkey kidney cells, ATCC# CCL81;
(b) MRC-5, human embryonic lung, ATCC # CCL 171;
(c) WISH human amnion, ATCC # CCL 25;
(d) Detroit-532, human foreskin, Downs's syndrome, ATCC # CCL 54; and
(e) Primary CEF cells.
Chicken embryo fibroblast cells produced from 11 day old white leghorn embryos were included as a positive control. All inoculations were performed on preformed monolayers of 2.times.10.sup.6 cells as discussed below.
A. Methods for DNA analysis.
Three dishes of each cell line were inoculated at 5 pfu/cell of the virus under test, allowing one extra dish of each cell line un-inoculated. One dish was incubated in the presence of 40 .mu.g/ml of cytosine arabinoside (Ara C). After an adsorption period of 60 minutes at 37.degree. C., the inoculum was removed and the monolayer washed twice to remove unadsorbed virus. Medium (with or without Ara C) was then replaced. Cells from one dish (without Ara C) were harvested as a time zero sample. The remaining dishes were incubated at 37.degree. C. for 72 hours, at which time the cells were harvested and used to analyze DNA accumulation. Each sample of 2.times.10.sup.6 cells was resuspended in 0.5 ml phosphate buffered saline (PBS) containing 40 mM EDTA and incubated for 5 minutes at 37.degree. C. An equal volume of 1.5% agarose prewarmed at 42.degree. C. and containing 120 mM EDTA was added to the cell suspension and gently mixed. The suspension was transferred to an agarose plug mold and allowed to harden for at least 15 min. The agarose plugs were then removed and incubated for 12-16 hours at 50.degree. C. in a volume of lysis buffer (1% sarkosyl, 100 .mu.g/ml proteinase K, 10 mM Tris HCl pH 7.5, 200 mM EDTA) that completely covers the plug. The lysis buffer was then replaced with 5.0 ml sterile 0.5.times.TBE (44.5 mM Tris-borate, 44.5 mM boric acid, 0.5 mM EDTA) and equilibrated at 4.degree. C. for 6 hours with 3 changes of TBE buffer. The viral DNA within the plug was fractionated from cellular RNA and DNA using a pulse field electrophoresis system. Electrophoresis was performed for 20 hours at 180 V with a ramp of 50-90 sec at 15.degree. C. in 0.5.times.TBE. The DNA was run with lambda DNA molecular weight standards. After electrophoresis the viral DNA band was visualized by staining with ethidium bromide. The DNA was then transferred to a nitrocellulose membrane and probed with a radiolabelled probe prepared from purified ALVAC genomic DNA.
B. Estimation of virus yield.
Dishes were inoculated exactly as described above, with the exception that input multiplicity was 0.1 pfu/cell. At 72 hours post infection, cells were lysed by three successive cycles of freezing and thawing. Virus yield was assessed by plaque titration on CEF monolayers.
C. Analysis of expression of Rabies G gene.
Dishes were inoculated with recombinant or parental virus at a multiplicity of 10 pfu/cell, allowing an additional dish as an uninfected virus control. After a one hour absorption period, the medium was removed and replaced with methionine free medium. After a 30 minute period, this medium was replaced with methionine-free medium containing 25 uCi/ml of .sup.35 S-Methionine. Infected cells were labelled overnight (approximately 16 hours), then lysed by the addition of buffer A lysis buffer. Immunoprecipitation was performed as previously described (Taylor et al., 1990) using a rabies G specific monoclonal antibody.
Results: Estimation of Viral Yield. The results of titration for yield at 72 hours after inoculation at 0.1 pfu per cell are shown in Table 5. The results indicate that while a productive infection can be attained in the avian cells, no increase in virus yield can be detected by this method in the four non-avian cell systems.
Analysis of Viral DNA Accumulation. In order to determine whether the block to productive viral replication in the non-avian cells occurred before or after DNA replication, DNA from the cell lysates was fractionated by electrophoresis, transferred to nitrocellulose and probed for the presence of viral specific DNA. DNA from uninfected CEF cells, ALVAC-RG infected CEF cells at time zero, ALVACRG infected CEF cells at 72 hours post-infection and ALVACRG infected CEF cells at 72 hours post-infection in the presence of 40 .mu.g/ml of cytosine arabinoside all showed some background activity, probably due to contaminating CEF cellular DNA in the radiolabelled ALVAC DNA probe preparation. However, ALVAC-RG infected CEF cells at 72 hours post-infection exhibited a strong band in the region of approximately 350 kbp representing ALVAC-specific viral DNA accumulation. No such band is detectable when the culture is incubated in the presence of the DNA synthesis inhibitor, cytosine arabinoside. Equivalent samples produced in Vero cells showed a very faint band at approximately 350 kbp in the ALVAC-RG infected Vero cells at time zero. This level represented residual virus. The intensity of the band was amplified at 72 hours post-infection indicating that some level of viral specific DNA replication had occurred in Vero cells which had not resulted in an increase in viral progeny. Equivalent samples produced in MRC-5 cells indicated that no viral specific DNA accumulation was detected under these conditions in this cell line. This experiment was then extended to include additional human cell lines, specifically WISH and Detroit-532 cells. ALVAC infected CEF cells served as a positive control. No viral specific DNA accumulation was detected in either WISH or Detroit cells inoculated with ALVAC-RG. It should be noted that the limits of detection of this method have not been fully ascertained and viral DNA accumulation may be occurring, but at a level below the sensitivity of the method. Other experiments in which viral DNA replication was measured by .sup.3 H-thymidine incorporation support the results obtained with Vero and MRC-5 cells.
Analysis of Rabies Gene Expression. To determine if any viral gene expression, particularly that of the inserted foreign gene, was occurring in the human cell lines even in the absence of viral DNA replication, immunoprecipitation experiments were performed on .sup.35 S-methionine labelled lysates of avian and non-avian cells infected with ALVAC and ALVAC-RG. The results of immunoprecipitation using a rabies G specific monoclonal antibody illustrated specific immunoprecipitation of a 67 kDa glycoprotein in CEF, Vero and MRC-5, WISH and Detroit cells infected with ALVAC-RG. No such specific rabies gene products were detected in any of the uninfected and parentally infected cell lysates.
The results of this experiment indicated that in the human cell lines analyzed, although the ALVAC-RG recombinant was able to initiate an infection and express a foreign gene product under the transcriptional control of the H6 early/late vaccinia virus promoter, the replication did not proceed through DNA replication, nor was there any detectable viral progeny produced. In the Vero cells, although some level of ALVAC-RG specific DNA accumulation was observed, no viral progeny was detected by these methods. These results would indicate that in the human cell lines analyzed the block to viral replication occurs prior to the onset of DNA replication, while in Vero cells, the block occurs following the onset of viral DNA replication.
In order to determine whether the rabies glycoprotein expressed in ALVAC-RG was immunogenic, a number of animal species were tested by inoculation of the recombinant. The efficacy of current rabies vaccines is evaluated in a mouse model system. A similar test was therefore performed using ALVAC-RG. Nine different preparations of virus (including one vaccine batch (J) produced after 10 serial tissue culture passages of the seed virus) with infectious titers ranging from 6.7 to 8.4 log.sub.10 TCID.sub.50 per ml were serially diluted and 50 to 100 .mu.l of dilutions inoculated into the footpad of four to six week old mice. Mice were challenged 14 days later by the intracranial route with 300 .mu.l of the CVS strain of rabies virus containing from 15 to 43 mouse LD.sub.50 as determined by lethality titration in a control group of mice. Potency, expressed as the PD.sub.50 (Protective dose 50%), was calculated at 14 days post-challenge. The results of the experiment are shown in Table 6. The results indicated that ALVAC-RG was consistently able to protect mice against rabies virus challenge with a PD.sub.50 value ranging from 3.33 to 4.56 with a mean value of 3.73 (STD 0.48). As an extension of this study, male mice were inoculated intracranially with 50 .mu.l of virus containing 6.0 log.sub.10 TCID.sub.50 of ALVAC-RG or with an equivalent volume of an uninfected cell suspension. Mice were sacrificed on days 1, 3 and 6 post-inoculation and their brains removed, fixed and sectioned. Histopathological examination showed no evidence for neurovirulence of ALVAC-RG in mice.
In order to evaluate the safety and efficacy of ALVAC-RG for dogs and cats, a group of 14, 5 month old beagles and 14, 4 month old cats were analyzed. Four animals in each species were not vaccinated. Five animals received 6.7 log.sub.10 TCID.sub.50 subcutaneously and five animals received 7.7 log.sub.10 TCID.sub.50 by the same route. Animals were bled for analysis for anti-rabies antibody. Animals receiving no inoculation or 6.7 log.sub.10 TCID.sub.50 of ALVAC-RG were challenged at 29 days post-vaccination with 3.7 log.sub.10 mouse LD.sub.50 (dogs, in the temporal muscle) or 4.3 log.sub.10 mouse LD.sub.50 (cats, in the neck) of the NYGS rabies virus challenge strain. The results of the experiment are shown in Table 7.
No adverse reactions to inoculation were seen in either cats or dogs with either dose of inoculum virus. Four of 5 dogs immunized with 6.7 log.sub.10 TCID.sub.50 had antibody titers on day 14 post-vaccination and all dogs had titers at 29 days. All dogs were protected from a challenge which killed three out of four controls. In cats, three of five cats receiving 6.7 log.sub.10 TCID.sub.50 had specific antibody titers on day 14 and all cats were positive on day 29 although the mean antibody titer was low at 2.9 IU. Three of five cats survived a challenge which killed all controls. All cats immunized with 7.7 log.sub.10 TCID.sub.50 had antibody titers on day 14 and at day 29 the Geometric Mean Titer was calculated as 8.1 International Units.
The immune response of squirrel monkeys (Saimiri sciureus) to inoculation with ALVAC, ALVAC-RG and an unrelated canarypox virus recombinant was examined. Groups of monkeys were inoculated as described above and sera analyzed for the presence of rabies specific antibody. Apart from minor typical skin reactions to inoculation by the intradermal route, no adverse reactivity was seen in any of the monkeys. Small amounts of residual virus were isolated from skin lesions after intradermal inoculation on days two and four post-inoculation only. All specimens were negative on day seven and later. There was no local reaction to intra-muscular injection. All four monkeys inoculated with ALVAC-RG developed anti-rabies serum neutralizing antibodies as measured in an RFFI test. Approximately six months after the initial inoculation all monkeys and one additional naive monkey were re-inoculated by the subcutaneous route on the external face of the left thigh with 6.5 log.sub.10 TCID.sub.50 of ALVAC-RG. Sera were analyzed for the presence of anti-rabies antibody. The results are shown in Table 8.
Four of the five monkeys naive to rabies developed a serological response by seven days post-inoculation with ALVAC-RG. All five monkeys had detectable antibody by 11 days post-inoculation. Of the four monkeys with previous exposure to the rabies glycoprotein, all showed a significant increase in serum neutralization titer between days 3 and 7 post-vaccination. The results indicate that vaccination of squirrel monkeys with ALVAC-RG does not produce adverse side-effects and a primary neutralizing antibody response can be induced. An anamnestic response is also induced on re-vaccination. Prior exposure to ALVAC or to a canarypox recombinant expressing an unrelated foreign gene does not interfere with induction of an anti-rabies immune response upon re-vaccination.
The immunological response of HIV-2 seropositive macaques to inoculation with ALVAC-RG was assessed. Animals were inoculated as described above and the presence of anti-rabies serum neutralizing antibody assessed in an RFFI test. The results, shown in Table 9, indicated that HIV-2 positive animals inoculated by the subcutaneous route developed anti-rabies antibody by 11 days after one inoculation. An anamnestic response was detected after a booster inoculation given approximately three months after the first inoculation. No response was detected in animals receiving the recombinant by the oral route. In addition, a series of six animals were inoculated with decreasing doses of ALVAC-RG given by either the intra-muscular or subcutaneous routes. Five of the six animals inoculated responded by 14 days post-vaccination with no significant difference in antibody titer.
Two chimpanzees with prior exposure to HIV were inoculated with 7.0 log.sub.10 pfu of ALVAC-RG by the subcutaneous or intra-muscular route. At 3 months post-inoculations both animals were re-vaccinated in an identical fashion. The results are shown in Table 10.
No adverse reactivity to inoculation was noted by either intramuscular or subcutaneous routes. Both chimpanzees responded to primary inoculation by 14 days and a strongly rising response was detected following revaccination.
TABLE 1______________________________________Sequential Passage of ALVAC in Avian and non-Avian Cells. CEF Vero MRC-5______________________________________Pass 1Sample to.sup.a 2.4 3.0 2.6 t7.sup.b 7.0 1.4 0.4 t7A.sup.c 1.2 1.2 0.4Pass 2Sample to 5.0 0.4 .sup. N.D..sup.d t7 7.3 0.4 N.D. t7A 3.9 N.D. N.D.Pass 3Sample to 5.4 0.4 N.D. t7 7.4 N.D. N.D. t7A 3.8 N.D. N.D.Pass 4Sample to 5.2 N.D. N.D. t7 7.1 N.D. N.D. t7A 3.9 N.D. N.D.______________________________________ .sup.a This sample was harvested at zero time and represents the residual input virus. The titer is expressed as log.sub.10 pfu per ml. .sup.b This sample was harvested at 7 days postinfection. .sup.c This sample was inoculated in the presence of 40 .mu.g/ml of Cytosine arabinoside and harvested at 7 days post infection. .sup.d Not detectable
TABLE 2______________________________________Sequential Passage of ALVAC-RG in Avian and non-Avian Cells CEF Vero MRC-5______________________________________Pass 1Sample t0.sup.a 3.0 2.9 2.9 t7.sup.b 7.1 1.0 1.4 t7A.sup.c 1.8 1.4 1.2Pass 2Sample t0 5.1 0.4 0.4 t7 7.1 .sup. N.D..sup.d N.D. t7A 3.8 N.D. N.D.Pass 3Sample t0 5.1 0.4 N.D. t7 7.2 N.D. N.D. t7A 3.6 N.D. N.D.Pass 4Sample t0 5.1 N.D. N.D. t7 7.0 N.D. N.D. t7A 4.0 N.D. N.D______________________________________ .sup.a This sample was harvested at zero time and represents the residual input virus. The titer is expressed as log.sub.10 pfu per ml. .sup.b This sample was harvested at 7 days postinfection. .sup.c This sample was inoculated in the presence of 40 .mu.g/ml of Cytosine arabinoside and harvested at 7 days postinfection. .sup.d Not detectable.
TABLE 3______________________________________Amplification of residual virus by passage in CEF cells CEF Vero MRC-5______________________________________a) ALVACPass 2.sup.a .sup. 7.0.sup.b 6.0 5.2 3 7.5 4.1 4.9 4 7.5 N.D..sup.c N.D. 5 7.1 N.D. N.D.b) ALVAC-RGPass 2.sup.a 7.2 5.5 5.5 3 7.2 5.0 5.1 4 7.2 N.D. N.D. 5 7.2 N.D. N.D.______________________________________ .sup.a Pass 2 represents the amplification in CEF cells of the 7 day sample from Pass 1. .sup.b Titer expressed as log.sub.10 pfu per ml .sup.c Not Detectable
TABLE 4______________________________________Schedule of inoculation of rhesus macaques with ALVAC-RG (vCP65)Animal Inoculation______________________________________176L Primary 1 .times. 10.sup.8 pfu of vCP65 orally in TANG Secondary 1 .times. 10.sup.7 pfu of vCP65 plus 1 .times. 10.sup.7 pfu of vCP82.sup.a by SC route185L Primary 1 .times. 10.sup.8 pfu of vCP65 orally in TANG Secondary 1 .times. 10.sup.7 pfu of vCP65 plus 1 .times. 10.sup.7 pfu of vCP82 by SC route177L Primary 5 .times. 10.sup.7 pfu SC of vCP65 by SC route Secondary 1 .times. 10.sup.7 pfu of vCP65 plus 1 .times. 10.sup.7 pfu of vCP82 by SC route186L Primary 5 .times. 10.sup.7 pfu of vCP65 by SC route Secondary 1 .times. 10.sup.7 pfu of vCP65 plus 1 .times. 10.sup.7 pfu of vCP82 by SC route178L Primary 1 .times. 10.sup.7 pfu of vCP65 by SC route182L Primary 1 .times. 10.sup.7 pfu of vCP65 by IM route179L Primary 1 .times. 10.sup.6 pfu of vCP65 by SC route183L Primary 1 .times. 10.sup.6 pfu of vCP65 by IM route180L Primary 1 .times. 10.sup.6 pfu of vCP65 by SC route184L Primary 1 .times. 10.sup.5 pfu of vCP65 by IM route187L Primary 1 .times. 10.sup.7 pfu of vCP65 orally______________________________________ .sup.a vCP82 is a canarypox virus recombinant expressing the measles viru fusion and hemagglutinin genes.
TABLE 5______________________________________Analysis of yield in avian and non-avian cellsinoculated with ALVAC-RGSample TimeCell Type t0 t72 t72A.sup.b______________________________________Expt 1 CEF 3.3.sup.a 7.4 1.7 Vero 3.0 1.4 1.7 MRC-5 3.4 2.0 1.7Expt 2 CEF 2.9 7.5 <1.7 WISH 3.3 2.2 2.0 Detroit-532 2.8 1.7 <1.7______________________________________ .sup.a Titer expressed as log.sub.10 pfu per ml .sup.b Culture incubated in the presence of 40 .mu.g/ml of Cytosine arabinoside
TABLE 6______________________________________Potency of ALVAC-RG as tested in miceTest Challenge Dose.sup.a PD.sub.50.sup.b______________________________________Initial seed 43 4.56Primary seed 23 3.34Vaccine Batch H 23 4.52Vaccine Batch I 23 3.33Vaccine Batch K 15 3.64Vaccine Batch L 15 4.03Vaccine Batch M 15 3.32Vaccine Batch N 15 3.39Vaccine Batch J 23 3.42______________________________________ .sup.a Expressed as mouse LD.sub.50 .sup.b Expressed as log.sub.10 TCID.sub.50
TABLE 7______________________________________Efficacy of ALVAC-RG in dogs and cats Dogs CatsDose Antibody.sup.a Survival.sup.b Antibody Survival______________________________________6.7 11.9 5/5 2.9 3/57.7 10.1 N.T. 8.1 N.T.______________________________________ .sup.a Antibody at day 29 post inoculation expressed as the geometric mea titer in International Units. .sup.b Expressed as a ratio of survivors over animals challenged
TABLE 8______________________________________Anti-rabies serological response of Squirrel monkeysinoculated with canarypox recombinantsMonkey Previous Rabies serum-neutralizing antibody.sup.a# Exposure -196.sup.b 0 3 7 11 21 28______________________________________22 ALVAC.sup.c NT.sup.g <1.2 <1.2 <1.2 2.1 2.3 2.251 ALVAC.sup.c NT <1.2 <1.2 1.7 2.2 2.2 2.239 vCP37.sup.d NT <1.2 <1.2 1.7 2.1 2.2 N.T..sup.g55 vCP37.sup.d NT <1.2 <1.2 1.7 2.2 2.1 N.T.37 ALVAC- 2.2 <1.2 <1.2 3.2 3.5 3.5 3.2 RG.sup.e53 ALVAC- 2.2 <1.2 <1.2 3.6 3.6 3.6 3.4 RG.sup.e38 ALVAC- 2.7 <1.7 <1.7 3.2 3.8 3.6 N.T. RG.sup.f54 ALVAC- 3.2 <1.7 <1.5 3.6 4.2 4.0 3.6 RG.sup.f57 None NT <1.2 <1.2 1.7 2.7 2.7 2.3______________________________________ .sup.a As determined by RFFI test on days indicated and expressed in International Units .sup.b Day196 represents serum from day 28 after primary vaccination .sup.c Animals received 5.0 log.sub.10 TCID.sub.50 of ALVAC .sup.d Animals received 5.0 log.sub.10 TCID.sub.50 of vCP37 .sup.e Animals received 5.0 log.sub.10 TCID.sub.50 of ALVACRG .sup.f Animals received 7.0 log.sub.10 TCID.sub.50 of ALVACRG .sup.g Not tested.
TABLE 9__________________________________________________________________________Inoculation of rhesus macaques with ALVAC-RG.sup.aRoute of Primary InoculationDays post- or/Tang SC SC SC IM SC IM SC IM ORInoculation 176L.sup.b 185L 177L 186L 178L 182L 179L 183L 180L 184L Y87L.sup.b__________________________________________________________________________-84 -- ---9 -- -- -- -- --3 -- -- -- --6 -- -- .+-. .+-.11 -- -- 16.sup.d 12819 -- -- 32 128 --35 -- -- 32 51259 -- -- 64 25675 -- -- 64 128 --99.sup.c -- -- 64 256 -- -- -- -- -- --2 -- -- 32 256 -- -- -- -- -- -- --6 -- -- 512 512 -- -- -- -- -- -- --15 16 16 512 512 64 32 64 128 32 -- --29 16 32 256 256 64 64 32 128 32 -- --55 32 32 32 16 --57 16 128 128 16 16 --__________________________________________________________________________ .sup.a See Table 9 for schedule of inoculations. .sup.b Animals 176L and 185L received 8.0 log.sub.10 pfu by the oral rout in 5 ml Tang. Animal 187L received 7.0 log.sub.10 pfu by oral route not i Tang. .sup.c Day of revaccination for animals 176L, 185L, 177L and 186L by S.C. route, and primary vaccination for animals 178L, 182L, 179L, 183L, 180L, 184L and 187L. .sup.d Titers expressed as reciprocal of last dilution showing inhibition of fluorescence in an RFFI test.
TABLE 10______________________________________Inoculation of chimpanzees with ALVAC-RGWeeks post- Animal 431 Animal 457Inoculation I.M. S.C.______________________________________0 <8.sup.a <81 <8 <82 8 324 16 328 16 3212.sup.b /0.sup. 16 813/1 128 12815/3 256 51220/8 64 128 26/12 32 128______________________________________ .sup.a Titer expressed as reciprocal of last dilution showing inhibition of fluorescence in an RFFI test .sup.b Day of reinoculation
Example 9
Immunization of Humans Using Canarypox Expressing Rabies Glycoprotein (ALVAC-RG: vCP65)
ALVAC-RG (vCP65) was generated as described in Example 9 and FIGS. 9A and 9B. For scaling-up and vaccine manufacturing ALVAC-RG (vCP65) was grown in primary CEF derived from specified pathogen free eggs. Cells were infected at a multiplicity of 0.1 and incubated at 37.degree. C. for three days.
The vaccine virus suspension was obtained by ultrasonic disruption in serum free medium of the infected cells; cell debris were then removed by centrifugation and filtration. The resulting clarified suspension was supplemented with lyophilization stabilizer (mixture of amino-acids), dispensed in single dose vials and freeze dried. Three batches of decreasing titer were prepared by ten-fold serial dilutions of the virus suspension in a mixture of serum free medium and lyophilization stabilizer, prior to lyophilization.
Quality control tests were applied to the cell substrates, media and virus seeds and final product with emphasis on the search for adventitious agents and inocuity in laboratory rodents. No undesirable trait was found.
Preclinical data. Studies in vitro indicated that VERO or MRC-5 cells do not support the growth of ALVAC-RG (vCP65); a series of eight (VERO) and 10 (MRC) blind serial passages caused no detectable adaptation of the virus to grow in these non avian lines. Analyses of human cell lines (MRC-5, WISH, Detroit 532, HEL, HNK or EBV-transformed lymphoblastoid cells) infected or inoculated with ALVAC-RG (vCP65) showed no accumulation of virus specific DNA suggesting that in these cells the block in replication occurs prior to DNA synthesis. Significantly, however, the expression of the rabies virus glycoprotein gene in all cell lines tested indicating that the abortive step in the canarypox replication cycle occurs prior to viral DNA replication.
The safety and efficacy of ALVAC-RG (vCP65) were documented in a series of experiments in animals. A number of species including canaries, chickens, ducks, geese, laboratory rodents (suckling and adult mice), hamsters, guinea-pigs, rabbits, cats and dogs, squirrel monkeys, rhesus macaques and chimpanzees, were inoculated with doses ranging from 10.sup.5 to 10.sup.8 pfu. A variety of routes were used, most commonly subcutaneous, intramuscular and intradermal but also oral (monkeys and mice) and intracerebral (mice).
In canaries, ALVAC-RG (vCP65) caused a "take" lesion at the site of scarification with no indication of disease or death. Intradermal inoculation of rabbits resulted in a typical poxvirus inoculation reaction which did not spread and healed in seven to ten days. There was no adverse side effects due to canarypox in any of the animal tests. Immunogenicity was documented by the development of anti-rabies antibodies following inoculation of ALVAC-RG (vCP65) in rodents, dogs, cats, and primates, as measured by Rapid Fluorescent Focus Inhibition Test (RFFIT). Protection was also demonstrated by rabies virus challenge experiments in mice, dogs, and cats immunized with ALVAC-RG (vCP65).
Volunteers. Twenty-five healthy adults aged 20-45 with no previous history of rabies immunization were enrolled. Their health status was assessed by complete medical histories, physical examinations, hematological and blood chemistry analyses. Exclusion criteria included pregnancy, allergies, immune depression of any kind, chronic debilitating disease, cancer, injection of immune globins in the past three months, and seropositivity to human immunodeficiency virus (HIV) or to hepatitis B virus surface antigen.
Study design. Participants were randomly allocated to receive either standard Human Diploid Cell Rabies Vaccine (HDC) batch no E0751 (Pasteur Merieux Serums & Vaccine, Lyon, France) or the study vaccine ALVAC-RG (vCP65).
The trial was designated as a dose escalation study. Three batches of experimental ALVAC-RG (vCP65) vaccine were used sequentially in three groups of volunteers (Groups A, B and C) with two week intervals between each step. The concentration of the three batches was 10.sup.3.5, 10.sup.4.5, 10.sup.5.5 Tissue Culture Infectious Dose (TCID.sub.50) per dose, respectively.
Each volunteer received two doses of the same vaccine subcutaneously in the deltoid region at an interval of four weeks. The nature of the injected vaccine was not known by the participants at the time of the first injection but was known by the investigator.
In order to minimize the risk of immediate hypersensitivity at the time of the second injection, the volunteers of Group B allocated to the medium dose of experimental vaccine were injected 1 h previously with the lower dose and those allocated to the higher dose (Group C) received successively the lower and the medium dose at hourly intervals.
Six months later, the recipients of the highest dosage of ALVAC-RG (vCP65) (Group C) and HDC vaccine were offered a third dose of vaccine; they were then randomized to receive either the same vaccine as previously or the alternate vaccine. As a result, four groups were formed corresponding to the following immunization scheme: 1. HDC, HDC-HDC; 2. HDC, HDC-ALVAC-RG (vCP65); 3. ALVAC-RG (vCP65), ALVAC-RG (vCP65)-HDC; 4. ALVAC-RG (vCP65), ALVAC-RG (vCP65), ALVAC-RG (vCP65).
Monitoring of Side Effects. All subjects were monitored for 1 h after injection and re-examined every day for the next five days. They were asked to record local and systemic reactions for the next three weeks and were questioned by telephone two times a week.
Laboratory Investigators. Blood specimens were obtained before enrollment and two, four and six days after each injection. Analysis included complete blood cell count, liver enzymes and creatine kinase assays.
Antibody assays. Antibody assays were performed seven days prior to the first injection and at days 7, 28, 35, 56, 173, 187 and 208 of the study.
The levels of neutralizing antibodies to rabies were determined using the Rapid Fluorescent Focus Inhibition test (RFFIT) (Smith et al., 1973). Canarypox antibodies were measured by direct ELISA. The antigen, a suspension of purified canarypox virus disrupted with 0.1% Triton X100, was coated in microplates. Fixed dilutions of the sera were reacted for two hours at room temperature and reacting antibodies were revealed with a peroxidase labelled antihuman IgG goat serum. The results are expressed as the optical density read at 490 nm.
Analysis. Twenty-five subjects were enrolled and completed the study. There were 10 males and 15 females and the mean age was 31.9 (21 to 48). All but three subjects had evidence of previous smallpox vaccination; the three remaining subjects had no typical scar and vaccination history. Three subjects received each of the lower doses of experimental vaccine (10.sup.3.5 and 10.sup.4.5 TCID.sub.50), nine subjects received 10.sup.5.5 TCID.sub.50 and ten received the HDC vaccine.
Safety (Table 11). During the primary series of immunization, fever greater than 37.7.degree. C. was noted within 24 hours after injection in one HDC recipient (37.8.degree. C.) and in one vCP65 10.sup.5.5 TCID.sub.50 recipient (38.degree. C.). No other systemic reaction attributable to vaccination was observed in any participant.
Local reactions were noted in 9/10 recipients of HDC vaccine injected subcutaneously and in 0/3, 1/3 and 9/9 recipients of vCP65 10.sup.3.5, 10.sup.4.5, 10.sup.5.5 TCID.sub.50, respectively.
Tenderness was the most common symptoms and was always mild. Other local symptoms included redness and induration which were also mild and transient. All symptoms usually subsided within 24 hours and never lasted more than 72 hours.
There was no significant change in blood cell counts, liver enzymes or creatine kinase values.
Immune Responses; Neutralizing Antibodies to Rabies (Table 12). Twenty eight days after the first injection all the HDC recipients had protective titers (.gtoreq.0.5 IU/ml). By contrast none in groups A and B (10.sup.3.5 and 10.sup.4.5 TCID.sub.50) and only 2/9 in group C (10.sup.5.5 TCID.sub.50) ALVAC-RG (vCP65) recipients reached this protective titer.
At day 56 (i.e. 28 days after the second injection) protective titers were achieved in 0/3 of Group A, 2/3 of Group B and 9/9 of Group C recipients of ALVAC-RG (vCP65) vaccine and persisted in all 10 HDC recipients.
At day 56 the geometric mean titers were 0.05, 0.47, 4.4 and 11.5 IU/ml in groups A, B, C and HDC respectively.
At day 180, the rabies antibody titers had substantially decreased in all subjects but remained above the minimum protective titer of 0.5 IU/ml in 5/10 HCD recipients and in 5/9 ALVAC-RG (vCP65) recipients; the geometric mean titers were 0.51 and 0.45 IU/ml in groups HCD and C, respectively.
Antibodies to the Canarypox virus (Table 13). The preimmune titers observed varied widely with titers varying from 0.22 to 1.23 O.D. units despite the absence of any previous contact with canary birds in those subjects with the highest titers. When defined as a greater than two-fold increase between preimmunization and post second injection titers, a seroconversion was obtained in 1/3 subjects in group B and in 9/9 subjects in group C whereas no subject seroconverted in groups A or HDC.
Booster Injection. The vaccine was similarly well tolerated six months later, at the time of the booster injection: fever was noted in 2/9 HDC booster recipients and in 1/10 ALVAC-RG (vCP65) booster recipients. Local reactions were present in 5/9 recipients of HDC booster and in 6/10 recipients of the ALVAC-RG (vCP65) booster.
Observations. FIGS. 11A-11D show graphs of rabies neutralizing antibody titers (Rapid Fluorescent Focus Inhibition Test or RFFIT, IU/ml): Booster effect of HDC and vCP65 (10.sup.5.5 TCID.sub.50) in volunteers previously immunized with either the same or the alternate vaccine. Vaccines were given at days 0, 28 and 180. Antibody titers were measured at days 0, 7, 28, 35, 56, 173, and 187 and 208.
As shown in FIGS. 11A to 11D, the booster dose given resulted in a further increase in rabies antibody titers in every subject whatever the immunization scheme. However, the ALVAC-RG (vCP65) booster globally elicited lower immune responses than the HDC booster and the ALVAC-RG (vCP65), ALVAC-RG (vCP65)-ALVAC-RG (vCP65) group had significantly lower titers than the three other groups. Similarly, the ALVAC-RG (vCP65) booster injection resulted in an increase in canarypox antibody titers in 3/5 subjects who had previously received the HDC vaccine and in all five subjects previously immunized with ALVAC-RG (vCP65).
In general, none of the local side effects from administration of vCP65 was indicative of a local replication of the virus. In particular, lesions of the skin such as those observed after injection of vaccine were absent. In spite of the apparent absence of replication of the virus, the injection resulted in the volunteers generating significant amounts of antibodies to both the canarypox vector and to the expressed rabies glycoprotein.
Rabies neutralizing antibodies were assayed with the Rapid Fluorescent Focus Inhibition Test (RFFIT) which is known to correlate well with the sero neutralization test in mice. Of 9 recipients of 10.sup.5.5 TCID.sub.50, five had low level responses after the first dose. Protective titers of rabies antibodies were obtained after the second injection in all recipients of the highest dose tested and even in 2 of the 3 recipients of the medium dose. In this study, both vaccines were given subcutaneously as usually recommended for live vaccines, but not for the inactivated HDC vaccine. This route of injection was selected as it best allowed a careful examination of the injection site, but this could explain the late appearance of antibodies in HDC recipients: indeed, none of the HDC recipients had an antibody increase at day 7, whereas, in most studies where HDC vaccine is give intramuscularly a significant proportion of subjects do (Klietmann et al., Geneva, 1981; Kuwert et al., 1981). However, this invention is not necessarily limited to the subcutaneous route of administration.
The GMT (geometric mean titers) of rabies neutralizing antibodies was lower with the investigational vaccine than with the HDC control vaccine, but still well above the minimum titer required for protection. The clear dose effect response obtained with the three dosages used in this study suggest that a higher dosage might induce a stronger response. Certainly from this disclosure the skilled artisan can select an appropriate dosage for a given patient.
The ability to boost the antibody response is another important result of this Example; indeed, an increase in rabies antibody titers was obtained in every subject after the 6 month dose whatever the immunization scheme, showing that preexisting immunity elicited by either the canarypox vector or the rabies glycoprotein had no blocking effect on the booster with the recombinant vaccine candidate or the conventional HDC rabies vaccine. This contrasts findings of others with vaccinia recombinants in humans that immune response may be blocked by pre-existing immunity (Cooney et al., 1991; Etinger et al., 1991).
Thus, this Example clearly demonstrates that a non-replicating poxvirus can serve as an immunizing vector in humans, with all of the advantages that replicating agents confer on the immune response, but without the safety problem created by a fully permissive virus. And, from this disclosure such as this Example and other Examples suitable dosages and modes or routes for administration or immunization of recombinants containing either rabies or other coding, or expression products thereof, are within the ambit of the skilled artisan as well modes for in vitro expression.
TABLE 11______________________________________Reactions in the 5 days following vaccinationvCP65 dosage H D C(TCID50) 10.sup.3.5 10.sup.4.5 10.sup.5.5 control______________________________________Injection 1st 2nd 1st 2nd 1st 2nd 1st 2ndNo. vaccinees 3 3 3 3 9 9 10 10temp >37.7.degree. C. 0 0 0 0 0 1 1 0soreness 0 0 1 1 6 8 8 6redness 0 0 0 0 0 4 5 4induration 0 0 0 0 0 4 5 4______________________________________
TABLE 12______________________________________Rabies neutralizing antibodies (REFIT; IU/ml)Individual titers and geometric mean titers (GMT)TCID50/ DaysNo. dose 0 7 28 35 56______________________________________1 10.sup.3.5 <0.1 <0.1 <0.1 <0.1 0.23 10.sup.3.5 <0.1 <0.1 <0.1 <0.1 <0.14 10.sup.3.5 <0.1 <0.1 <0.1 <0.1 <0.1 G.M.T. <0.1 <0.1 <0.1 <0.1 <0.16 10.sup.4.5 <0.1 <0.1 <0.1 <0.1 <0.17 10.sup.4.5 <0.1 <0.1 <0.1 2.4 1.910 10.sup.4.5 <0.1 <0.1 <0.1 1.6 1.1 G.M.T. <0.1 <0.1 0.1 0.58 0.4711 10.sup.5.5 <0.1 <0.1 1.0 3.2 4.313 10.sup.5.5 <0.1 <0.1 0.3 6.0 8.814 10.sup.5.5 <0.1 <0.1 0.2 2.1 9.417 10.sup.5.5 <0.1 <0.1 <0.1 1.2 2.518 10.sup.5.5 <0.1 <0.1 0.7 8.3 12.520 10.sup.5.5 <0.1 <0.1 <0.1 0.3 3.721 10.sup.5.5 <0.1 <0.1 0.2 2.6 3.923 10.sup.5.5 <0.1 <0.1 <0.1 1.7 4.225 10.sup.5.5 <0.1 <0.1 <0.1 0.6 0.9 G.M.T. <0.1 <0.1 0.16 1.9 4.4*2 HDC <0.1 <0.1 0.8 7.1 7.25 HDC <0.1 <0.1 9.9 12.8 18.78 HDC <0.1 <0.1 12.7 21.1 16.59 HDC <0.1 <0.1 6.0 9.9 14.312 HDC <0.1 <0.1 5.0 9.2 25.315 HDC <0.1 <0.1 2.2 5.2 8.616 HDC <0.1 <0.1 2.7 7.7 20.719 HDC <0.1 <0.1 2.6 9.9 9.122 HDC <0.1 <0.1 1.4 8.6 6.624 HDC <0.1 <0.1 0.8 5.8 4.7 G.M.T. <0.1 <0.1 2.96 9.0 11.5*______________________________________ p = 0.007 student t test
TABLE 13______________________________________Canarypox antibodies: ELISA Geometric Mean Titers*VCP65dosage DaysTCID50/dose 0 7 28 35 56______________________________________10.sup.3.5 0.69 ND 0.76 ND 0.6810.sup.4.5 0.49 0.45 0.56 0.63 0.8710.sup.5.5 0.38 0.38 0.77 1.42 1.63HDC control 0.45 0.39 0.40 0.35 0.39______________________________________ *optical density at 1/25 dilution
Example 10
Comparison of the LD.sub.50 of ALVAC and NYVAC with Various Vaccinia Virus Strains
Mice. Male outbred Swiss Webster mice were purchased from Taconic Farms (Germantown, N.Y.) and maintained on mouse chow and water ad libitum until use at 3 weeks of age ("normal" mice). Newborn outbred Swiss Webster mice were of both sexes and were obtained following timed pregnancies performed by Taconic Farms. All newborn mice used were delivered within a two day period.
Viruses. ALVAC was derived by plaque purification of a canarypox virus population and was prepared in primary chick embryo fibroblast cells (CEF). Following purification by centrifugation over sucrose density gradients, ALVAC was enumerated for plaque forming units in CEF cells. The WR(L) variant of vaccinia virus was derived by selection of large plaque phenotypes of WR (Panicali et al., 1981). The Wyeth New York State Board of Health vaccine strain of vaccinia virus was obtained from Pharmaceuticals Calf Lymph Type vaccine Dryvax, control number 302001B. Copenhagen strain vaccinia virus VC-2 was obtained from Institut Merieux, France. Vaccinia virus strain NYVAC was derived from Copenhagen VC-2. All vaccinia virus strains except the Wyeth strain were cultivated in Vero African green monkey kidney cells, purified by sucrose gradient density centrifugation and enumerated for plaque forming units on Vero cells. The Wyeth strain was grown in CEF cells and enumerated for plaque forming units in CEF cells.
Inoculations. Groups of 10 normal mice were inoculated intracranially (ic) with 0.05 ml of one of several dilutions of virus prepared by 10-fold serially diluting the stock preparations in sterile phosphate-buffered saline. In some instances, undiluted stock virus preparation was used for inoculation.
Groups of 10 newborn mice, 1 to 2 days old, were inoculated ic similarly to the normal mice except that an injection volume of 0.03 ml was used.
All mice were observed daily for mortality for a period of 14 days (newborn mice) or 21 days (normal mice) after inoculation. Mice found dead the morning following inoculation were excluded due to potential death by trauma.
The lethal dose required to produce mortality for 50% of the experimental population (LD.sub.50) was determined by the proportional method of Reed and Muench (Reed and Muench, 1938).
Comparison of the LD.sub.50 of ALVAC and NYVAC with Various Vaccinia Virus Strains for Normal, Young Outbred Mice by the ic Route. In young, normal mice, the virulence of NYVAC and ALVAC were several orders of magnitude lower than the other vaccinia virus strains tested (Table 14). NYVAC and ALVAC were found to be over 3,000 times less virulent in normal mice than the Wyeth strain; over 12,500 times less virulent than the parental VC-2 strain; and over 63,000,000 times less virulent than the WR(L) variant. These results would suggest that NYVAC is highly attenuated compared to other vaccinia strains, and that ALVAC is generally nonvirulent for young mice when administered intracranially, although both may cause mortality in mice at extremely high doses (3.85.times.10.sup.8 PFUs, ALVAC and 3.times.10.sup.8 PFUs, NYVAC) by an undetermined mechanism by this route of inoculation.
Comparison of the LD.sub.50 of ALVAC and NYVAC with Various Vaccinia Virus Strains for Newborn Outbred Mice by the ic Route. The relative virulence of 5 poxvirus strains for normal, newborn mice was tested by titration in an intracranial (ic) challenge model system (Table 15). With mortality as the endpoint, LD.sub.50 values indicated that ALVAC is over 100,000 times less virulent than the Wyeth vaccine strain of vaccinia virus; over 200,000 times less virulent than the Copenhagen VC-2 strain of vaccinia virus; and over 25,000,000 times less virulent than the WR-L variant of vaccinia virus. Nonetheless, at the highest dose tested, 6.3.times.10.sup.7 PFUs, 100% mortality resulted. Mortality rates of 33.3% were observed at 6.3.times.10.sup.6 PFUs. The cause of death, while not actually determined, was not likely of toxicological or traumatic nature since the mean survival time (MST) of mice of the highest dosage group (approximately 6.3 LD.sub.50) was 6.7.+-.1.5 days. When compared to WR(L) at a challenge dose of 5 LD.sub.50, wherein MST is 4.8.+-.0.6 days, the MST of ALVAC challenged mice was significantly longer (P=0.001).
Relative to NYVAC, Wyeth was found to be over 15,000 times more virulent; VC-2, greater than 35,000 times more virulent; and WR(L), over 3,000,000 times more virulent. Similar to ALVAC, the two highest doses of NYVAC, 6.times.10.sup.8 and 6.times.10.sup.7 PFUs, caused 100% mortality. However, the MST of mice challenged with the highest dose, corresponding to 380 LD.sub.50, was only 2 days (9 deaths on day 2 and 1 on day 4). In contrast, all mice challenged with the highest dose of WR-L, equivalent to 500 LD.sub.50, survived to day 4.
TABLE 14______________________________________Calculated 50% LethalDose for mice byvarious vacciniavirus strains and forcanarypox virus(ALVAC) by the icroute.POXVIRUS CALCULATEDSTRAIN LD.sub.50 (PFUs)______________________________________WR(L) 2.5VC-2 1.26 .times. 10.sup.4WYETH 5.00 .times. 10.sup.4NYVAC 1.58 .times. 10.sup.8ALVAC 1.58 .times. 10.sup.8______________________________________
TABLE 15______________________________________Calculated 50% LethalDose for newborn miceby various vacciniavirus strains and forcanarypox virus(ALVAC) by the icroute.POXVIRUS CALCULATEDSTRAIN LD.sub.50 (PFUs)______________________________________WR(L) 0.4VC-2 0.1WYETH 1.6NYVAC 1.58 .times. 10.sup.6ALVAC 1.00 .times. 10.sup.7______________________________________
Example 11
Evaluation of NYVAC (vP866) and NYVAC-RG (vP879)
Immunoprecipitations. Preformed monolayers of avian or non-avian cells were inoculated with 10 pfu per cell of parental NYVAC (vP866) or NYVAC-RG (vP879) virus. The inoculation was performed in EMEM free of methionine and supplemented with 2% dialyzed fetal bovine serum. After a one hour incubation, the inoculum was removed and the medium replaced with EMEM (methionine free) containing 20 .mu.Ci/ml of .sup.35 S-methionine. After an overnight incubation of approximately 16 hours, cells were lysed by the addition of Buffer A (1% Nonidet P-40, 10 mM Tris pH7.4, 150 mM NaCl, 1 mM EDTA, 0.01% sodium azide, 500 units per ml of aprotinin, and 0.02% phenyl methyl sulfonyl fluoride). Immunoprecipitation was performed using a rabies glycoprotein specific monoclonal antibody designated 24-3F10 supplied by Dr. C. Trinarchi, Griffith Laboratories, New York State Department of Health, Albany, N.Y., and a rat anti-mouse conjugate obtained from Boehringer Mannheim Corporation (Cat. #605-500). Protein A Sepharose CL-48 obtained from Pharmacia LKB Biotechnology Inc., Piscataway, N.J., was used as a support matrix. Immunoprecipitates were fractionated on 10% polyacrylamide gels according to the method of Dreyfuss et. al. (1984). Gels were fixed, treated for fluorography with 1M Na-salicylate for one hour, and exposed to Kodak XAR-2 film to visualize the immunoprecipitated protein species.
Sources of Animals. New Zealand White rabbits were obtained from Hare-Marland (Hewitt, N.J.). Three week old male Swiss Webster outbred mice, timed pregnant female Swiss Webster outbred mice, and four week old Swiss Webster nude (nu.sup.+ nu.sup.+) mice were obtained from Taconic Farms, Inc. (Germantown, N.Y.). All animals were maintained according to NIH guidelines. All animal protocols were approved by the institutional IACUC. When deemed necessary, mice which were obviously terminally ill were euthanized.
Evaluation of Lesions in Rabbits. Each of two rabbits was inoculated intradermally at multiple sites with 0.1 ml of PBS containing 10.sup.4, 10.sup.5, 10.sup.6, 10.sup.7, or 10.sup.8 pfu of each test virus or with PBS alone. The rabbits were observed daily from day 4 until lesion resolution. Indurations and ulcerations were measured and recorded.
Virus Recovery from Inoculation Sites. A single rabbit was inoculated intradermally at multiple sites with 0.1 ml of PBS containing 10.sup.6, 10.sup.7, or 10.sup.8 pfu of each test virus or with PBS alone. After 11 days, the rabbit was euthanized and skin biopsy specimens taken from each of the inoculation sites were aseptically prepared by mechanical disruption and indirect sonication for virus recovery. Infectious virus was assayed by plaque titration on CEF monolayers.
Virulence in Mice. Groups of ten mice, or five in the nude mice experiment, were inoculated ip with one of several dilutions of virus in 0.5 ml of sterile PBS. Reference is also made to Example 11.
Cyclophosphamide (CY) Treatment. Mice were injected by the ip route with 4 mg (0.02 ml) of CY (SIGMA) on day -2, followed by virus injection on day 0. On the following days post infection, mice were injected ip with CY: 4 mg on day 1; 2 mg on days 4, 7 and 11; 3 mg on days 14, 18, 21, 25 and 28. Immunosuppression was indirectly monitored by enumerating white blood cells with a Coulter Counter on day 11. The average white blood cell count was 13,500 cells per .mu.l for untreated mice (n=4) and 4,220cells per .mu.l for CY-treated control mice (n=5).
Calculation of LD.sub.50. The lethal dose required to produce 50% mortality (LD.sub.50) was determined by the proportional method of Reed and Muench (Reed and Muench 1938).
Potency Testing of NYVAC-RG in Mice. Four to six week old mice were inoculated in the footpad with 50 to 100 .mu.l of a range of dilutions (2.0-8.0 log.sub.10 tissue culture infective dose 50% (TCID.sub.50)) of either VV-RG (Kieny et al., 1984), ALVAC-RG (Taylor et al., 1991b), or the NYVAC-RG. Each group consisted of eight mice. At 14 days post-vaccination, the mice were challenged by intracranial inoculation with 15 LD.sub.50 of the rabies virus CVS strain (0.03 ml). On day 28, surviving mice were counted and protective does 50% (PD.sub.50) calculated.
Derivation of NYVAC (vP866). The NYVAC strain of vaccinia virus was generated from VC-2, a plaque cloned isolate of the COPENHAGEN vaccine strain. To generate NYVAC from VC-2, eighteen vaccinia ORFs, including a number of viral functions associated with virulence, were precisely deleted in a series of sequential manipulations as described earlier in this disclosure. These deletions were constructed in a manner designed to prevent the appearance of novel unwanted open reading frames. FIG. 10 schematically depicts the ORFs deleted to generate NYVAC. At the top of FIG. 10 is depicted the HindIII restriction map of the vaccinia virus genome (VC-2 plaque isolate, COPENHAGEN strain). Expanded are the six regions of VC-2 that were sequentially deleted in the generation of NYVAC. The deletions were described earlier in this disclosure (Examples 1 through 6). Below such deletion locus is listed the ORFs which were deleted from that locus, along with the functions or homologies and molecular weight of their gene products.
Replication Studies of NYVAC and ALVAC on Human Tissue Cell Lines. In order to determine the level of replication of NYVAC strain of vaccinia virus (vP866) in cells of human origin, six cell lines were inoculated at an input multiplicity of 0.1 pfu per cell under liquid culture and incubated for 72 hours. The COPENHAGEN parental clone (VC-2) was inoculated in parallel. Primary chick embryo fibroblast (CEF) cells (obtained from 10-11 day old embryonated eggs of SPF origin, Spafas, Inc., Storrs, Conn.) were included to represent a permissive cell substrate for all viruses. Cultures were analyzed on the basis of two criteria: the occurrence of productive viral replication and expression of an extrinsic antigen.
The replication potential of NYVAC in a number of human derived cells are shown in Table 16. Both VC-2 and NYVAC are capable of productive replication in CEF cells, although NYVAC with slightly reduced yields. VC-2 is also capable of productive replication in the six human derived cell lines tested with comparable yields except in the EBV transformed lymphoblastoid cell line JT-1 (human lymphoblastoid cell line transformed with Epstein-Barr virus, see Rickinson et al., 1984). In contrast, NYVAC is highly attenuated in its ability to productively replicate in any of the human derived cell lines tested. Small increases of infectious virus above residual virus levels were obtained from NYVAC-infected MRC-5 (ATCC #CCL171, human embryonic lung origin), DETROIT 532 (ATCC #CCL54, human foreskin, Downs Syndrome), HEL 299 (ATCC #CCL137, human embryonic lung cells) and HNK (human neonatal kidney cells, Whittiker Bioproducts, Inc. Walkersville, Md., Cat #70-151) cells. Replication on these cell lines was significantly reduced when compared to virus yields obtained from NYVAC-infected CEF cells or with parental VC-2 (Table 16). It should be noted that the yields at 24 hours in CEF cells for both NYVAC and VC-2 is equivalent to the 72-hour yield. Allowing the human cell line cultures to incubate an additional 48 hours (another two viral growth cycles) may, therefore, have amplified the relative virus yield obtained.
Consistent with the low levels of virus yields obtained in the human-derived cell lines, MRC-5 and DETROIT 532, detectable but reduced levels of NYVAC-specific DNA accumulation were noted. The level of DNA accumulation in the MRC-5 and DETROIT 532 NYVAC-infected cell lines relative to that observed in NYVAC-infected CEF cells paralleled the relative virus yields. NYVAC-specific viral DNA accumulation was not observed in any of the other human-derived cells.
An equivalent experiment was also performed using the avipox virus, ALVAC. The results of virus replication are also shown in Table 16. No progeny virus was detectable in any of the human cell lines consistent with the host range restriction of canarypox virus to avian species. Also consistent with a lack of productive replication of ALVAC in these human-derived cells is the observation that no ALVAC-specific DNA accumulation was detectable in any of the human-derived cell lines.
Expression of Rabies Glycoprotein by NYVAC-RG (vP879) in Human Cells. In order to determine whether efficient expression of a foreign gene could be obtained in the absence of significant levels of productive viral replication, the same cell lines were inoculated with the NYVAC recombinant expressing the rabies virus glycoprotein (vP879, Example 7) in the presence of .sup.35 S-methionine. Immunoprecipitation of the rabies glycoprotein was performed from the radiolabelled culture lysate using a monoclonal antibody specific for the rabies glycoprotein. Immunoprecipitation of a 67 kDa protein was detected consistent with a fully glycosylated form of the rabies glycoprotein. No serologically crossreactive product was detected in uninfected or parental NYVAC infected cell lysates. Equivalent results were obtained with all other human cells analyzed.
Inoculations on the Rabbit Skin. The induction and nature of skin lesions on rabbits following intradermal (id) inoculations has been previously used as a measure of pathogenicity of vaccinia virus strains (Buller et al., 1988; Child et al., 1990; Fenner, 1958, Flexner et al., 1987; Ghendon and Chernos 1964). Therefore, the nature of lesions associated with id inoculations with the vaccinia strains WR (ATCC #VR119 plaque purified on CV-1 cells, ATCC #CCL70, and a plaque isolate designated L variant, ATCC #VR2035 selected, as described in Panicali et al., 1981)), WYETH (ATCC #VR325 marketed as DRYVAC by Wyeth Laboratories, Marietta, Pa.), COPENHAGEN (VC-2), and NYVAC was evaluated by inoculation of two rabbits (A069 and A128). The two rabbits displayed different overall sensitivities to the viruses, with rabbit A128 displaying less severe reactions than rabbit A069. In rabbit A128, lesions were relatively small and resolved by 27 days post-inoculation. On rabbit A069, lesions were intense, especially for the WR inoculation sites, and resolved only after 49 days. Intensity of the lesions was also dependent on the location of the inoculation sites relative to the lymph drainage network. In particular, all sites located above the backspine displayed more intense lesions and required longer times to resolve the lesions located on the flanks. All lesions were measured daily from day 4 to the disappearance of the last lesion, and the means of maximum lesion size and days to resolution were calculated (Table 17). No local reactions were observed from sites injected with the control PBS. Ulcerative lesions were observed at sites injected with WR, VC-2 and WYETH vaccinia virus strains. Significantly, no induration or ulcerative lesions were observed at sites of inoculation with NYVAC.
Persistence of Infectious Virus at the Site of Inoculation. To assess the relative persistence of these viruses at the site of inoculation, a rabbit was inoculated intradermally at multiple sites with 0.1 ml PBS containing 10.sup.6, 10.sup.7 or 10.sup.8 pfu of VC-2, WR, WYETH or NYVAC. For each virus, the 10.sup.7 pfu dose was located above the backspine, flanked by the 10.sup.6 and 10.sup.8 doses. Sites of inoculation were observed daily for 11 days. WR elicited the most intense response, followed by VC-2 and WYETH (Table 18). Ulceration was first observed at day 9 for WR and WYETH and day 10 for VC-2. Sites inoculated with NYVAC or control PBS displayed no induration or ulceration. At day 11 after inoculation, skin samples from the sites of inoculation were excised, mechanically disrupted, and virus was titrated on CEF cells. The results are shown in Table 18. In no case was more virus recovered at this timepoint than was administered. Recovery of vaccinia strain, WR, was approximately 10.sup.6 pfu of virus at each site irrespective of amount of virus administered. Recovery of vaccinia strains WYETH and VC-2 was 10.sup.3 to 10.sup.4 pfu regardless of amount administered. No infectious virus was recovered from sites inoculated with NYVAC.
Inoculation of Genetically or Chemically Immune Deficient Mice. Intraperitoneal inoculation of high doses of NYVAC (5.times.10.sup.8 pfu) or ALVAC (10.sup.9 pfu) into nude mice caused no deaths, no lesions, and no apparent disease through the 100 day observation period. In contrast, mice inoculated with WR (10.sup.3 to 10.sup.4 pfu), WYETH (5.times.10.sup.7 or 5.times.10.sup.8 pfu) or VC-2 (10.sup.4 to 10.sup.9 pfu) displayed disseminated lesions typical of poxviruses first on the toes, then on the tail, followed by severe orchitis in some animals. In mice infected with WR or WYETH, the appearance of disseminated lesions generally led to eventual death, whereas most mice infected with VC-2 eventually recovered. Calculated LD.sub.50 values are given in Table 19.
In particular, mice inoculated with VC-2 began to display lesions on their toes (red papules) and 1 to 2 days later on the tail. These lesions occurred between 11 and 13 days post-inoculation (pi) in mice given the highest doses (10.sup.9, 10.sup.8, 10.sup.7 and 10.sup.6 pfu), on day 16 pi in mice given 10.sup.5 pfu and on day 21 pi in mice given 10.sup.4 pfu. No lesions were observed in mice inoculated with 10.sup.3 and 10.sup.2 pfu during the 100 day observation period. Orchitis was noticed on day 23 pi in mice given 10.sup.9 and 10.sup.8 pfu, and approximately 7 days later in the other groups (10.sup.7 to 10.sup.4 pfu). Orchitis was especially intense in the 10.sup.9 and 10.sup.8 pfu groups and, although receding, was observed until the end of the 100 day observation period. Some pox-like lesions were noticed on the skin of a few mice, occurring around 30-35 days pi. Most pox lesions healed normally between 60-90 days pi. only one mouse died in the group inoculated with 10.sup.9 pfu (Day 34 pi) and one mouse died in the group inoculated with 10.sup.8 pfu (Day 94 pi). No other deaths were observed in the VC-2 inoculated mice.
Mice inoculated with 10.sup.4 pfu of the WR strain of vaccinia started to display pox lesions on Day 17 pi. These lesions appeared identical to the lesions displayed by the VC-2 injected mice (swollen toes, tail). Mice inoculated with 10.sup.3 pfu of the WR strain did not develop lesions until 34 days pi. Orchitis was noticed only in the mice inoculated with the highest dose of WR (10.sup.4 pfu). During the latter stages of the observation period, lesions appeared around the mouth and the mice stopped eating. All mice inoculated with 10.sup.4 pfu of WR died or were euthanized when deemed necessary between 21 days and 31 days pi. Four out of the 5 mice injected with 10.sup.3 pfu of WR died or were euthanized when deemed necessary between 35 days and 57 days pi. No deaths were observed in mice inoculated with lower doses of WR (1 to 100 pfu).
Mice inoculated with the WYETH strain of vaccinia virus at higher doses 5.times.10.sup.7 and 5.times.10.sup.8 pfu) showed lesions on toes and tails, developed orchitis, and died. Mice injected with 5.times.10.sup.6 pfu or less of WYETH showed no signs of disease or lesions.
As shown in Table 19, CY-treated mice provided a more sensitive model for assaying poxvirus virulence than did nude mice. LD.sub.50 values for the WR, WYETH, and VC-2 vaccinia virus strains were significantly lower in this model system than in the nude mouse model. Additionally, lesions developed in mice injected with WYETH, WR and VC-2 vaccinia viruses, as noted below, with higher doses of each virus resulting in more rapid formation of lesions. As was seen with nude mice, CY-treated mice injected with NYVAC or ALVAC did not develop lesions. However, unlike nude mice, some deaths were observed in CY-treated mice challenged with NYVAC or ALVAC, regardless of the dose. These random incidences are suspect as to the cause of death.
Mice injected with all doses of WYETH (9.5.times.10.sup.4 to 9.5.times.10.sup.8 pfu) displayed pox lesions on their tail and/or on their toes between 7 and 15 days pi. In addition, the tails and toes were swollen. Evolution of lesions on the tail was typical of pox lesions with formation of a papule, ulceration and finally formation of a scab. Mice inoculated with all doses of VC-2 (1.65.times.10.sup.5 to 1.65.times.10.sup.9) also developed pox lesions on their tails and/or their toes analogous to those of WYETH injected mice. These lesions were observed between 7-12 days post inoculation. No lesions were observed on mice injected with lower doses of WR virus, although deaths occurred in these groups.
Potency Testing of NYVAC-RG. In order to determine that attenuation of the COPENHAGEN strain of vaccinia virus had been effected without significantly altering the ability of the resulting NYVAC strain to be a useful vector, comparative potency tests were performed. In order to monitor the immunogenic potential of the vector during the sequential genetic manipulations performed to attenuate the virus, a rabiesvirus glycoprotein was used as a reporter extrinsic antigen. The protective efficacy of the vectors expressing the rabies. glycoprotein gene was evaluated in the standard NIH mouse potency test for rabies (Seligmann, 1973). Table 20 demonstrates that the PD.sub.50 values obtained with the highly attenuated NYVAC vector are identical to those obtained using a COPENHAGEN-based recombinant containing the rabies glycoprotein gene in the tk locus (Kieny et al., 1984) and similar to PD.sub.50 values obtained with ALVAC-RG, a canarypox based vector restricted to replication to avian species.
Observations. NYVAC, deleted of known virulence genes and having restricted in vitro growth characteristics, was analyzed in animal model systems to assess its attenuation characteristics. These studies were performed in comparison with the neurovirulent vaccinia virus laboratory strain, WR, two vaccinia virus vaccine strains, WYETH (New York City Board of Health) and COPENHAGEN (VC-2), as well as with a canarypox virus strain, ALVAC (See also Example 11). Together, these viruses provided a spectrum of relative pathogenic potentials in the mouse challenge model and the rabbit skin model, with WR being the most virulent strain, WYETH and COPENHAGEN (VC-2) providing previously utilized attenuated vaccine strains with documented characteristics, and ALVAC providing an example of a poxvirus whose replication is restricted to avian species. Results from these in vivo analyses clearly demonstrate the highly attenuated properties of NYVAC relative to the vaccinia virus strains, WR, WYETH and COPENHAGEN (VC-2) (Tables 14-20). Significantly, the LD.sub.50 values for NYVAC were comparable to those observed with the avian host restricted avipoxvirus, ALVAC. Deaths due to NYVAC, as well as ALVAC, were observed only when extremely high doses of virus were administered via the intracranial route (Example 11, Tables 14, 15, 19). It has not yet been established whether these deaths were due to nonspecific consequences of inoculation of a high protein mass. Results from analyses in immunocompromised mouse models (nude and CY-treated) also demonstrate the relatively high attenuation characteristics of NYVAC, as compared to WR, WYETH and COPENHAGEN strains (Tables 17 and 18). Significantly, no evidence of disseminated vaccinia infection or vaccinial disease was observed in NYVAC-inoculated animals or ALVAC-inoculated animals over the observation period. The deletion of multiple virulence-associated genes in NYVAC shows a synergistic effect with respect to pathogenicity. Another measure of the inocuity of NYVAC was provided by the intradermal administration on rabbit skin (Tables 17 and 18). Considering the results with ALVAC, a virus unable to replicate in nonavian species, the ability to replicate at the site of inoculation is not the sole correlate with reactivity, since intradermal inoculation of ALVAC caused areas of induration in a dose dependent manner. Therefore, it is likely that factors other than the replicative capacity of the virus contribute to the formation of the lesions. Deletion of specific virulence-associated genes in NYVAC prevents lesion occurrence.
Together, the results in this Example and in foregoing Examples, including Example 10, demonstrate the highly attenuated nature of NYVAC relative to WR, and the previously utilized vaccinia virus vaccine strains, WYETH and COPENHAGEN. In fact, the pathogenic profile of NYVAC, in the animal model systems tested, was similar to that of ALVAC, a poxvirus known to productively replicate only in avian species. The apparently restricted capacity of NYVAC to productively replicate on cells derived from humans (Table 16) and other species, including the mouse, swine, dog and horse, provides a considerable barrier that limits or prevents potential transmission to unvaccinated contacts or to the general environment in addition to providing a vector with reduced probability of dissemination within the vaccinated individual.
Significantly, NYVAC-based vaccine candidates have been shown to be efficacious. NYVAC recombinants expressing foreign gene products from a number of pathogens have elicited immunological responses towards the foreign gene products in several animal species, including primates. In particular, a NYVAC-based recombinant expressing the rabies glycoprotein was able to protect mice against a lethal rabies challenge. The potency of the NYVAC-based rabies glycoprotein recombinant was comparable to the PD.sub.50 value for a COPENHAGEN-based recombinant containing the rabies glycoprotein in the tk locus (Table 20). NYVAC-based recombinants have also been shown to elicit measles virus neutralizing antibodies in rabbits and protection against pseudorabies virus and Japanese encephalitis virus challenge in swine. The highly attenuated NYVAC strain confers safety advantages with human, animal, medical and veterinary applications (Tartaglia et al., 1992). Furthermore, the use of NYVAC as a general laboratory expression vector system may greatly reduce the biological hazards associated with using vaccinia virus.
By the following criteria, the results of this Example and the Examples herein, including Example 10, show NYVAC to be highly attenuated: a) no detectable induration or ulceration at site of inoculation (rabbit skin); b) rapid clearance of infectious virus from intradermal site of inoculation (rabbit. skin); c) absence of testicular inflammation (nude mice); d) greatly reduced virulence (intracranial challenge, both three-week old and newborn mice); e) greatly reduced pathogenicity and failure to disseminate in immunodeficient subjects (nude and cyclophosphamide treated mice); and f) dramatically reduced ability to replicate on a variety of human tissue culture cells. Yet, in spite of being highly attenuated, NYVAC, as a vector, retains the ability to induce strong immune responses to extrinsic antigens.
TABLE 16______________________________________Replication of COPENHAGEN (VC-2), NYVAC andALVAC in avian or human derived cell lines Hours post- Yield.sup.a %Cells infection VC-2 NYVAC ALVAC Yield______________________________________CEF 0 3.8.sup.b 3.7 4.5 24 8.3 7.8 6.6 48 8.6 7.9 77 72 8.3 7.7 7.5 25 72A.sup.c <1.4 1.8 3.1MRC-5 0 3.8 3.8 4.7 72 7.2 4.6 3.8 0.25 72A 2.2 2.2 3.7WISH* 0 3.4 3.4 4.3 72 7.6 2.2 3.1 0.000 4 72A --.sup.d 1.9 2.9DETROIT 0 3.8 3.7 4.4 72 7.2 5.4 3.4 1.6 72A 1.7 1.7 2.9HEL 0 3.8 3.5 4.3 72 7.5 4.6 3.3 0.125 72A 2.5 2.1 3.6JT-1 0 3.1 3.1 4.1 72 6.5 3.1 4.2 0.039 72A 2.4 2.1 4.4HNK 0 3.8 3.7 4.7 72 7.6 4.5 3.6 0.079 72A 3.1 2.7 3.7______________________________________ .sup.a Yield of NYVAC at 72 hours postinfection expressed as a percentage of yield of VAC2 after 72 hours on the same cell line. .sup.b Titer expressed as LOG.sub.50 pfu per ml. .sup.c Sample was incubated in the presence of 40 .mu.g/ml of cytosine arabinoside. .sup.d Not determined. *ATCC #CCL25 Human amnionic cells.
TABLE 17______________________________________Induration and ulceration at the site ofintradermal inoculation of the rabbit skinVIRUS INDURATION ULCERATIONSTRAIN DOSE.sup.a Size.sup.b Days.sup.c Size Days______________________________________WR 10.sup.4 386 30 88 30 10.sup.5 622 35 149 32 10.sup.6 1057 34 271 34 10.sup.7 877 35 204 35 10.sup.8 581 25 88 26WYETH 10.sup.4 32 5 --.sup.d -- 10.sup.5 116 15 -- -- 10.sup.6 267 17 3 15 10.sup.7 202 17 3 24 10.sup.8 240 29 12 31VC-2 10.sup.4 64 7 -- -- 10.sup.5 86 8 -- -- 10.sup.6 136 17 -- -- 10.sup.7 167 21 6 10 10.sup.8 155 32 6 8NYVAC 10.sup.4 -- -- -- -- 10.sup.5 -- -- -- -- 10.sup.6 -- -- -- -- 10.sup.7 -- -- -- -- 10.sup.8 -- -- -- --______________________________________ .sup.a pfu of indicated vaccinia virus in 0.1 ml PBS inoculated intradermally into one site. .sup.b mean maximum size of lesions (mm.sup.2) .sup.c mean time after inoculation for complete healing of lesion. .sup.d no lesions discernable.
TABLE 18______________________________________Persistence of poxviruses at the site ofintradermal inoculation Total VirusVirus Inoculum Dose Recovered______________________________________WR 8.0.sup.a 6.14 7.0 6.26 6.0 6.21WYETH 8.0 3.66 7.0 4.10 6.0 3.59VC-2 8.0 4.47 7.0 4.74 6.0 3.97NYVAC 8.0 0 7.0 0 6.0 0______________________________________ .sup.a expressed as log.sub.10 pfu.
TABLE 19______________________________________Virulence studies in immunocompromised mice LD.sub.50.sup.aPoxvirus CyclophosphamideStrain Nude mice treated mice______________________________________WR 422 42VC-2 >10.sup.9 <1.65 .times. 10.sup.5WYETH 1.58 .times. 10.sup.7 1.83 .times. 10.sup.6NYVAC >5.50 .times. 10.sup.8 7.23 .times. 108ALVAC >10.sup.9 .gtoreq.5.00 .times. 10.sup.8b______________________________________ .sup.a Calculated 50% lethal dose (pfu) for nude or cyclophosphamide treated mice by the indicated vaccinia viruses and for ALVAC by intraperitoneal route. .sup.b 5 out of 10 mice died at the highest dose of 5 .times. 10.sup.8 pfu.
TABLE 20______________________________________Comparative efficacy of NYVAC-RG and ALVAC-RGin mice Recombinant PD.sub.50.sup.a______________________________________ VV-RG 3.74 ALVAC-RG 3.86 NYVAC-RG 3.70______________________________________ .sup.a Four to six week old mice were inoculated in the footpad with 5010 .mu.l of a range of dilutions (2.0-8.0 log.sub.10 tissue culture infectio dose 50% (TCID.sub.50) of either the VVRG (Kieny et al., 1984), ALVACRG (vCP65) or NYVACRG (vP879). At day 14, mice of each group were challenged by intracranial inoculation of 30 .mu.l of a live CVS strain rabies virus corresponding to 15 lethal dose 50% (LD.sub.50) per mouse. At day 28, surviving #mice were counted and a protective dose 50% (PD.sub.5) was calculated.
Example 12
Cloning of HCMV gB in Poxvirus Vectors
Cloning of the HCMV gB gene into vaccinia donor plasmid, pMP22BHP. The 4800 bp HindIII-BamHI fragment of the HindIII D fragment of the HCMV DNA (Towne strain) was cloned into the 2800 bp HindIII-BamHI fragment of the plasmid pIBI24 (International Biotechnologies, Inc., New Haven, Conn.). By in vitro mutagenesis (Kunkel, 1985) using the oligonucleotides CMVM5 (SEQ ID NO:74) (5'-GCCTCATCGCTGCTGGATATCCGTTAAGTTTGTATCGTAATGGAATCCAGGATCTG-3') and CMVM3 (SEQ ID NO:75) (5"-GACAGAGACTTGTGATTTTTATAAGCTTCGTAAGCTGTCA-3'), the gB gene was modified to be expressed under the control of the vaccinia H6 promoter (Taylor et al., 1988a,b; Perkus et al., 1989). The plasmid containing the modified gB was designated 24CMVgB (5+3). The DNA sequence of the CMVgB gene is shown in FIG. 12 (SEQ ID NO:37).
Plasmid pMP2VCL (containing a polylinker region with vaccinia sequences upstream of the KIL host range gene) was digested within the polylinker with HindIII and XhoI and ligated to annealed oligonucleotides SPHPRHA A through D generating SP131 containing a HindIII site, H6 promoter -124 through -1 (Perkus et al., 1989) and a polylinker region. SPHPRHA A (SEQ ID NO:76) (5'-AGCTTCTTTATTCTATACTTAAAAAGTGAAAATAAATACAAAGGTTCTTGAGGGT-3') SPHPRHA B (SEQ ID NO:77) (5'-TGTGTTAAATTGAAAGCGAGAAATAATCATAAATTATTTCATTATCGCGATATCCGTTAA GTTTGTATCGTAC-3') SPHPRHA C (SEQ ID NO:78) (3'-TTATTAGTATTTAATAAAGTAATAGCGCTATAGGCAATTCAAACATAGCATGAGCT-5') SPHPRHA D (SEQ ID NO:79) (3'-AGAAATAAGATATGAATTTTTCACTTTTATTTATGTTTCCAAGAACTCCCAACACAATTT AACTTTCGCTCT-5').
The 2900 bp EcoRV-BamHI fragment of 24CMVgB (5+3) was cloned into the 3100 bp EcoRV-BglII fragment of SP131. This cloning step put the gB gene under the control of the H6 promoter. The resulting plasmid was designated SP131CMVgB.
Plasmid pSD22-H contains a 2.9 kb BglII fragment derived from the HindIII F region of the WR strain of vaccinia virus ligated into the BamHI site of pUC8. The unique BamHI site in pSD22-H is a nonessential site used as an insertion locus for foreign genes (Panicali and Paoletti, 1982). Plasmid pMP22BHP is a derivative of pSD22-H in which the unique BamHI site was modified by the addition of an expanded polylinker region for the insertion of foreign DNA. Plasmid pMP22BHP was digested with HindIII and ligated to a 2.9 kb HindIII fragment from SP131CMVgB (containing the H6 promoted gB gene) generating plasmid SAg22CMVgB. To modify the polylinker region in sAg22CMVgB, the plasmid was digested with BamHI followed by partial digestion with HindIII and purified. Ligation to a 50 bp BamHI/HindIII polylinker derived from IBI24 resulted in plasmid 22CMVgB.
Cloning of the HCMVgB gene into NYVAC donor plasmid pSD542. Plasmid pSD542 (a NYVAC TK locus donor plasmid) was derived from plasmid pSD513 (Tartaglia et al., 1992). The polylinker region in pSD513 was modified by cutting with PstI/BamHI and ligating to annealed synthetic oligonucleotides MPSYN288 (SEQ ID NO:80) (5'-GGTCGACGGATCCT-3') and MPSYN289 (SEQ ID NO:81) (5'-GATCAGGATCCGTCGACCTGCA-3') resulting in plasmid pSD542.
22CMVgB was digested with BamHI and NsiI to generate a fragment containing the H6 promoter and part of the gB gene, and with NsiI and PstI to generate a fragment containing the remainder of the gB gene. These two fragments were ligated to pSD542 that had been digested with BamHI and PstI within its' polylinker creating the NYVAC donor plasmid 542CMVgB. The DNA sequence of the CMVgB gene and flanking sequences contained in 542CMVgB is shown in FIGS. 13A and B (SEQ ID NO:38).
Cloning of the HCMV gB gene into the ALVAC donor plasmid CP3LVQH6. An 8.5 kb canarypox BglII fragment was cloned in the BamHI site of PBS-SK plasmid vector (Stratagene, La Jolla, Calif.) to form pWW5. Nucleotide sequence analysis revealed a reading frame designated C3 initiated at position 1458 and terminated at position 2897 in the sequence in FIGS. 14A-C (SEQ ID NO:39). In order to construct a donor plasmid for insertion of foreign genes into the C3 locus with the complete excision of the C3 open reading frame, PCR primers were used to amplify the 5' and 3' sequences relative to C3. Primers for the 5' sequence were RG277 (SEQ ID NO:82) (5'-CAGTTGGTACCACTGGTATTTTATTTCAG-3') and RG278 (SEQ ID NO:83) (5'-TATCTGAATTCCTGCAGCCCGGGTTTTTATAGCTAATTAGTCAAATGTGAGTTAATATTA G -3').
Primers for the 3" sequences were RG279 (SEQ ID NO:84) (5'-TCGCTGAATTCGATATCAAGCTTATCGATTTTTATGACTAGTTAATCAAATAAAAAGCAT ACAAGC-3') and RG280 (SEQ ID NO:85) (5'-TTATCGAGCTCTGTAACATCAGTATCTAAC-3'). The primers were designed to include a multiple cloning site flanked by vaccinia transcriptional and translational termination signals. Also included at the 5'-end and 3'-end of the left arm and right arm were appropriate restriction sites (Asp718 and EcoRI for left arm and EcoRI and SacI for right arm) which enabled the two arms to ligate into Asp718/SacI digested pBS-SK plasmid vector. The resultant plasmid was designated as pC3I.
A 908 bp fragment of canarypox DNA, immediately upstream of the C3 locus was obtained by digestion of plasmid pWW5 with NsiI and SspI. A 604 bp fragment of canarypox DNA was derived by PCR (Engelke et al., 1988) using plasmid PWW5 as template and oligonucleotides CP16 (SEQ ID NO:86) (5'-TCCGGTACCGCGGCCGCAGATATTTGTTAGCTTCTGC-3') and CP17 (SEQ ID NO:87) (5'-TCGCTCGAGTAGGATACCTACCTACTACCTACG-3'). The 604 bp fragment was digested with Asp718 and XhoI (sites present at the 5' ends of oligonucleotides CP16 and CP17, respectively) and cloned into Asp718-XhoI digested and alkaline phosphatase treated IBI25 (International Biotechnologies, Inc., New Haven, Conn.) generating plasmid SPC3LA. SPC3LA was digested within IBI25 with EcoRV and within canarypox DNA with NsiI and ligated to the 908 bp NsiI-SspI fragment generating SPCPLAX which contains 1444 bp of canarypox DNA upstream of the C3 locus.
A 2178 bp BglII-StyI fragment of canarypox DNA was isolated from plasmids pXX4 (which contains a 6.5 kb NsiI fragment of canarypox DNA cloned into the PstI site of pBS-SK). A 279 bp fragment of canarypox DNA was isolated by PCR (Engelke et al., 1988) using plasmid pXX4 as template and oligonucleotides CP19 (SEQ ID NO:88) (5'-TCGCTCGAGCTTTCTTGACAATAACATAG-3') and CP20 (SEQ ID NO:89) (5'-TAGGAGCTCTTTATACT ACTGGGTTACAAC-3'). The 279 bp fragment was digested with XhoI and SacI (sites present at the 5' ends of oligonucleotides CP19 and CP20, respectively) and cloned into SacI-XhoI digested and alkaline phosphatase treated IBI25 generating plasmid SPC3RA.
To add additional unique sites to the polylinker, pC3I was digested within the polylinker region with EcoRI and ClaI, treated with alkaline phosphatase and ligated to kinased and annealed oligonucleotides CP12 (SEQ ID NO:90) (5'-AATTCCTCGAGGGATCC-3') and CP13 (SEQ ID NO:91) (5'-CGGGATCCCTCGAGG-3') (containing an EcoRI sticky end, XhoI site, BamHI site and a sticky end compatible with ClaI) generating plasmid SPCP3S. SPCP3S was digested within the canarypox sequences downstream of the C3 locus with StyI and SacI (pBS-SK) and ligated to a 261 bp BglII-SacI fragment from SPC3RA and the 2178 bp BglII-StyI fragment from pXX4 generating plasmid CPRAL containing 2572 bp of canarypox DNA downstream of the C3 locus. SPCP3S was digested within the canarypox sequences upstream of the C3 locus with Asp718 (in PBS-SK) and AccI and ligated to a 1436 bp Asp718-AccI fragment from SPCPLAX generating plasmid CPLAL containing 1457 bp of canarypox DNA upstream of the C3 locus. CPLAL was digested within the canarypox sequences downstream of the C3 locus with StyI and SacI (in pBS-SK) and ligated to a 2438 bp StvI-SacI fragment from CPRAL generating plasmid CP3L containing 1457 bp of canarypox DNA upstream of the C3 locus, stop codons in six reading frames, early transcription termination signal, a polylinker region, early transcription termination signal, stop codons in six reading frames, and 2572 bp of canarypox DNA downstream of the C3 locus.
The early/late H6 vaccinia virus promoter (Taylor et al., 1988a,b; Perkus et al., 1989) was derived by PCR (Engelke et al., 1988) using pRW838 (a plasmid containing the rabies glycoprotein gene (Kieny et al., 1984) linked to the H6 promoter) as template and oligonucleotides CP21 (SEQ ID NO:92) (5'-TCGGGATCCGGGTTAATTAATTAGTTATTAGACAAGGTG-3') and CP22 (SEQ ID NO:93) (5'-TAGGAATTCCTCGAGTACGATACAAACTTAAGCGGATATCG-3'). The PCR product was digested with BamHI and EcoRI (sites present at the 5' ends of oligonucleotides CP21 and CP22, respectively) and ligated to CP3L that was digested with BamHI and EcoRI in the polylinker generating plasmid VQH6CP3L.
ALVAC donor plasmid VQH6CP3L was digested within the polylinker with XhoI and within the H6 promoter with NruI and ligated to a NruI/HindIII fragment from 22CMVgB containing part of the H6 promoter and gB gene and a polylinker derived from pIBI24 by XhoI and HindIII digestion generating the ALVAC donor plasmid CP3LCMVgB. The DNA sequence of the CMVgB gene plus additional flanking DNA sequences in plasmid CP3LCMVgB is shown in FIGS. 15A-C (SEQ ID NO:40).
Cloning of the HCMV gB gene deleted of its transmembrane region into the NYVAC donor plasmid pSD553. Plasmid pSD553 is a vaccinia deletion/insertion plasmid of the COPAK series. It contains the vaccinia K1L host range gene (Gillard et al., 1986; Perkus et al., 1990) within flanking Copenhagen vaccinia arms, replacing the ATI region (ORFs A25L, A26L; Goebel et al., 1990a,b). pSD553 was constructed as follows.
Left and right vaccinia flanking arms were constructed by polymerase chain reaction (PCR) using pSD414, a pUC8-based clone of vaccinia SalI B (Goebel et al., 1990a,b) as template. The left arm was synthesized using synthetic deoxyoligonucleotides MPSYN267 (SEQ ID NO:94) (5'-GGGCTGAAGCTTGCTGGCCGCTCATTAGACAAGCGAATGAGGGAC-3') and MPSYN268 (SEQ ID NO:95) (5'-AGATCTCCCGGGCTCGAGTAATTAATTAATTTTTATTACACCAGAAAAGACGGCTTGAGA T C-3') as primers. The right arm was synthesized using synthetic deoxyoligonucleotides MPSYN269 (SEQ ID NO:96) (5'-TAATTACTCGAGCCCGGGAGATCTAATTTAATTTAATTTATATAACTCATTTTTTGAATA T ACT-3') and MPSYN270 (SEQ ID NO:97) 5'-TATCTCGAATTCCCGCGGCTTTAAATGGACGGAACTCTTTTCCCCC-3') as primers. The two PCR-derived DNA fragments containing the left and right arms were combined in a further PCR reaction. The resulting product was cut with EcoRI/HindIII and a 0.9 kb fragment isolated. The 0.9 kb fragment was ligated with pUC8 cut with EcoRI/HindIII, resulting in plasmid pSD541. The polylinker region located at the vaccinia ATI deletion locus was expanded as follows. pSD541 was cut with BglII/XhoI and ligated with annealed complementary synthetic oligonucleotides MPSYN333 (SEQ ID NO:98) (5'-GATCTTTTGTTAACAAAAACTAATCAGCTATCGCGAATCGATTCCCGGGGGATCCGGTAC CC-3') and MPSYN334 (SEQ ID NO:99) (5'-TCGAGGGTACCGGATCCCCCGGGAATCGATTCGCGATAGCTGATTAGTTTTTGTTAACAA A A-3') generating plasmid pSD552. The K1L host range gene was isolated as a 1 kb BglII (partial)/HpaI fragment from plasmid pSD452 (Perkus et al., 1990). pSD552 was cut with BglII/HpaI and ligated with the K1L containing fragment, generating pSD553.
A HindIII fragment from SP131CMVgB (containing the HCMVgB gene under the control of the H6 promoter) was filled in with the klenow fragment of DNA polymerase I and ligated into plasmid pSD553 which had been SmaI digested and alkaline phosphatase treated. The resulting NYVAC donor plasmid (in which the H6 promoted gB is in the same orientation as K1L) was designated 553H6CMVgB. The DNA sequence of the CMVgB gene plus additional flanking DNA sequences in plasmid 553H6CMVgB is shown in FIGS. 16A and B (SEQ ID NO:41).
The sequence of CMVgB deleted of its transmembrane region is presented in FIG. 17 (SEQ ID NO:42). The nucleotides encoding the transmembrane region were deleted in the following manner. Oligonucleotides SPgB3 (SEQ ID NO:100) (5'-GATCCATGGACTCGACAGCGGCGTCTCTGCATGCAGCCGCTGCAGA-3') and SPgB4 (SEQ ID NO:101) (5'-AGCTTCTGCAGCGGCTGCATGCAGAGACGCCGCTGTCGAGTCCATG-3') were kinased, annealed and cloned into BamHI/HindIII digested and alkaline phosphatase treated IBI24 generating plasmid SPCMVgB2. Oligonucleotides SPgB1 (SEQ ID NO:102) (5'-TACGAATTCTGCAGTTCACCTATGACACGTTGC-3') and SPgB2 (SEQ ID NO:103) (5'-ATAGGATCCATGGTCGTCCAGACCCTTGAGGTAGGGC-3') were used in PCR with plasmid SP131CMVgB as template to generate a 0.7 kb fragment. This fragment was digested with EcoRI/BamHI and cloned into EcoRI/BamHI digested and alkaline phosphase treated IBI24 generating plasmid SPCMVgB1. A 0.7 kb EcoRI/NcoI fragment from SPCMVgB1 was ligated to EcoRI/NcoI digested and phosphatase treated SPCMVgB2 generating plasmid SPCMVgB3. The unique NcoI site in SPCMVgB3 was deleted by mutagenesis (Mandecki, 1986) using oligonucleotide SPgB5 (SEQ ID NO:104) 5'-GCCCTACCTCAAGGGTCTGGACGACACTCGACAGCGGCGTCTCTGCAT-3') generating plasmid SPCMVgB4. A 0.7 kb PstI fragment from SPCMVgB4 was ligated to a 6.6 kb PstI fragment from 553H6CMVgB generating NYVAC donor plasmid 553H6CMVgBTM.sup.-. This plasmid contains the gB gene under the control of the H6 promoter with its transmembrane region deleted (amino acids 715-772; Spaete et al., 1988). The DNA sequence of the transmembrane deleted CMVgB gene plus additional flanking DNA sequences in plasmid 553H6CMVgBTM.sup.- is shown in FIGS. 18A and B (SEQ ID NO:43).
Clonina the HCMVgB gene deleted of its transmembrane region and containing an altered cleavage site into NYVAC donor plasmid pSD553. The sequence of CMVgB deleted of its transmembrane region and containing an altered cleavage site is presented in FIG. 19 (SEQ ID NO:44). The alteration of the cleavage site was accomplished in the following manner. Oligonucleotides SPgB8 (SEQ ID NO:105) (5'-AATTGGTGACCG-3') and SPgB9 (SEQ ID NO:106) (5'-GATCCGGTCACC-3') were kinased, annealed and cloned into EcoRI/BamHI digested and alkaline phosphatase treated IBI24 generating plasmid BstIBI. A 1.4 kb BstEII/SpHI fragment from 553H6CMVgBTM.sup.- was cloned into BstEII/SpHI digested and alkaline phosphatase treated BstIBI generating plasmid SPCMVgB5.
Oligonucleotides SPgB10 (SEQ ID NO:107) (5'-TGAAAGACCGAATTCTGCGT-3') plus SPgB11 (SEQ ID NO:108) (5'-TGCGATTCATCGGTTTGTTGTAGAT-3') and SPgB12 (SEQ ID NO:109) (5'-GACCCTTGAGGTAGGGCGGC-3') plus SPgB13 (SEQ ID NO:110) (5'-ACTCATAATAGAACCATAAGATCTACAGATGGCAACAAT-3') were used in PCR with plasmid 553H6CMVgBTM.sup.- to generate 0.7 and 0.8 kb fragments. These two fragments were combined in a PCR with oligonucleotides SPgB10 plus SPgB12 to generate a 1.2 kb fragment. The 1.2 kb fragment was digested with EcoRI and PstI and a 0.5 kb fragment isolated and cloned into EcoRI/PstI digested and alkaline phosphatase treated IBI24 generating plasmid SPCMVgB6. The 0.5 kb EcoRI/PstI fragment from SPCMVgB6 was used to replace the corresponding fragment in SPCMVgB5 generating plasmid SPCMVgB7. A 1.4 kb BstEII/SpHI fragment from SPCMVgB7 was used to replace the corresponding fragment in 553H6CMVgB generating NYVAC donor plasmid 553H6gBC.sup.- TM.sup.-. This plasmid contains the gB gene under the control of the H6 promoter with its transmembrane region deleted (amino acids 715-772) and an alteration at the cleavage site (RTKR*ST modified to RTIRST where the asterisk indicated where cleavage normally occurs (Spaete et al., 1988) the S codon was modified to create a BglII restriction site). The DNA sequence of the cleavage site altered and transmembrane deleted CMVgB gene plus additional flanking DNA sequences in plasmid 553H6gBC.sup.- TM.sup.- is shown in FIGS. 20A and B (SEQ ID NO:45).
Example 13
Construction of Recombinant Poxviruses Containing HCMVgB
Procedures for transfection of recombinant donor plasmids into tissue culture cells infected with a rescuing poxvirus and identification of recombinants by Ln situ hybridization on nitrocellulose filters have been described (Guo et al., 1989; Panicali and Paoletti, 1982; Piccini et al., 1987; Perkus et al., 1993). Plasmid 542CMVgB was transfected into NYVAC (vP866) infected Vero cells (ATCC CCL#81) to generate the recombinant vP1001 (NYVAC-gB). Plasmid CP3LCMVgB was transfected into ALVAC infected primary chicken embryo fibroblast (CEF) cells to generate the recombinant vCP139 (ALVAC-gB). Plasmids 553H6CMVgB, 553H6CMVgBTM.sup.- and 553H6gBC.sup.- TM.sup.- were transfected into NYVAC infected Vero cells to generate the recombinants vP1126, vP1128 and vP1145, respectively. Plasmid 22CMVgB was transfected into Vero cells infected with the WR L variant vaccinia virus (Panicali et al., 1981) to generate the recombinant vP992.
Example 14
Immunoprecipitation of HCMVgB Expressed by Poxvirus Recombinants
Immunoprecipitation assays were performed as described previously (Taylor et al., 1990) using gB specific guinea pig polyclonal serum (Gonczol et al., 1990). The apparent molecular weights of the gB specific bands corresponded to previously published results (Britt and Auger, 1986; Britt and Vugler, 1989; Reis et al., 1993). The intracellular fraction from vP992, vP1001, vCP139, vP1126, vP1128 and vP1145 contained a major band of apparent molecular weight 130-140 kDa, identifiable as the glycosylated uncleaved gB precursor. Fainter bands at approximately 110 kDa and 55 kDa, representing the N-terminal and C-terminal processed fragments were also seen in the cell fractions. The extracellular medium from vP1128 and vP1145 infected cells contained the uncleaved precursor and N-terminal and C-terminal processed fragments.
Example 15
Humoral Response of Laboratory Animals Inoculated with ALVAC-gB and NYVAC-gB
Following a single immunization of CBA mice with vP1001 (NYVAC-gB), neutralizing antibody titers of the sera of inoculated mice were assessed (Gonczol et al., 1986). Antibodies capable of neutralizing HCMV were detected (Table 21) in the sera of mice 14-21 days later (geometric mean titers of 1:16) and between 28-60 days post-immunization (gmt=1:26). A single immunization of CBA mice with vCP139 (ALVAC-gB) generated HCMV neutralizing antibody titers of 1:64 gmt (14-21 days pi) and 1:111 gmt (between 28 and 60 days pi). Thus, immunization of mice with NYVAC and ALVAC recombinants expressing HCMV gB elicited antibodies able to neutralize the infectivity of HCMV.
ALVAC-gB (vCP139) was evaluated for safety and immunogenicity in human volunteers. After two inoculations with 10.sup.6.3 TCID.sub.50 of this recombinant, no serious reactions were noted.
TABLE 21______________________________________HCMV Neutralizing Antibodies in CBA mice Days After ImmunizationImmunization 14-21 21-28 28-60______________________________________NYVAC-gB 16 16 32 24 32 24ALVAC-gB 32 64 128 64 64 128 128 96______________________________________ Immunization was i.p. with 2-4 .times. 10.sup.8 PFU of recombinant viruses.
Guinea pigs were immunized twice with ALVAC-gB (days 0 and 28) and sera were tested for the presence of HCMV neutralizing antibody. HCMV neutralizing antibody was detected (Table 22) in the sera on day 34 (gmt=60), day 42 (gmt=60) and day 56(gmt=60). Thus, immunization of guinea pigs with ALVAC-gB elicited antibodies able to neutralize the infectivity of HCMV.
TABLE 22______________________________________HCMV Neutralizing Antibodies in Guinea PigsInoculated with ALVAC-gB DaysGuinea Pig # 0 14 28 34 42 56______________________________________19 <4 <4 <4 64 64 6420 <4 <4 <4 32 64 6421 <4 <4 <4 12 32 6422 <4 <4 <4 48 48 3223 <4 <4 4 96 46 4624 <4 <4 <4 46 46 32______________________________________ Guinea pigs were inoculated by intramuscular route on days 0 and 28 with 10.sup.6.3 TCID.sub.50
Example 16
Cloning of HCMVgH in Poxvirus Vectors
Cloning of the HCMVgH gene into the NYVAC donor plasmid pSD550. The HCMVgH gene was isolated from genomic DNA (Towne strain) by PCR using oligonucleotides SPgH1 (SEQ ID NO:111) (5'-TATCTGCAGATGCGGCCAGGCCTCCCCTCCTAC-3') and SPgH2 (SEQ ID NO:112) (5'-CCGAAGCTTTCAGCATGTCTTGAGCATGC-3'). The resulting 2.3 kb fragment was digested with PstI (site at the 5' end of SPgH1) and HindIII (site at the 5' end of SPgH2) and cloned into PstI/HindIII digested and alkaline phosphatase treated IBI24 generating plasmid SPgH1. The sequence of CMVgH is presented in FIG. 21 (SEQ ID NO:46).
The 3' end of the gH gene in SPgH1 was modified to contain a vaccinia virus early transcription termination signal (Yuen and Moss, 1987) and a unique XhoI restriction site in the following manner. SPgH1 was digested within the 3' end of the gH gene with SpHI and within IBI24 with HindIII and the fragment containing gH was purified and ligated to kinased and annealed oligonucleotides SPgH16 (SEQ ID NO:113) (5'-CTCAAGACATGCTGATTTTTATCTCGAGA-3') and SPgH17 (SEQ ID NO:114) (5'-AGCTTCTCGAGATAAAAATCAGCATGTCTTGAGCATG-3') generating plasmid SPgH2.
Kinased and annealed oligonucleotides SPgH12 (SEQ ID NO:115) (5'-AATTCTCGAGTTTATTGGGAAGAATATGATAATATTTTGGGATTTC-3'), SPgH13 (SEQ ID NO:116) (5'-AAAATTGAAAATATATAATTACAATATAAAATGCGGCCCGGG-3'), SPgH14 (SEQ ID NO:117) (5'-GATCCCCGGGCCGCATTTTATATTGTAATTATAT-3') and SPgH15 (SEQ ID NO:118) (5'-ATTTTCAATTTTGAAATCCCAAAATATTATCATATTCTTCCCAATAAACTCGAG-3') were ligated to EcoRI/BamHI digested and alkaline phosphatase treated IBI24 generating plasmid SPgH3 which contains a unique XhoI site, the entomopox 42K promoter and nucleotide sequences encoding the first four amino acids of HCMVgH (underlined bases in codons three and four in oligonucleotides SPgH13 (SEQ ID NO:116) and SPgH14 (SEQ ID NO:117) were modified to create a SmaI site without altering the amino acid sequence). Oligonucleotides SPgH18 (SEQ ID NO:119) (5'-TTAGAATTCCCCGGGCTCCCCTCCTACCTCATCGT-3') and SPgH19 (SEQ ID NO:120) (5'-TTACTGCAGTAAGTGTTAAGTCTCTGTTGGTATC-3') were used in PCR with plasmid SPgH1 as template to derive a 0.4 kb fragment. This fragment was digested with SmaI and PstI and cloned into SmaI/PstI digested and alkaline phosphatase treated SPgH3 generating plasmid SPgH5 which contains a unique XhoI site, the 42K promoter and 5' 15% of the HCMVgH gene. A 0.4 kb EcoRI/BglII fragment from SPgH5 was ligated to a 4.7 kb EcoRI/BglII fragment from SPgH3 generating plasmid SPgH6 which contains the 42K promoted gH gene flanked by XhoI sites.
Plasmid pSD550 (an I4L locus donor plasmid) was derived from plasmid pSD548 (Tartaglia et al., 1992). The polylinker region in pSD548 was modified by cutting with BglII and SmaI and ligating to annealed synthetic oligonucleotides 539A (SEQ ID NO:121) (5'-AGAAAAATCAGTTAGCTAAGATCTCCCGGGCTCGAGGGTACCGGATCCTGATTAGTTAAT T TTTGT-3') and 539B (SEQ ID NO:122) (5'-GATCACAAAAATTAACTAATCAGGATCCGGTACCCTCGAGCCCGGGAGATCTTAGCTAAC T GATTTTTCT-3') resulting in plasmid pSD550. The 2.3 kb XhoI fragment from SPgH6 was cloned into XhoI digested and alkaline phosphatase treated pSD550 generating the NYVAC donor plasmid I4L42KgH in which the orientation of gH is in the same direction as the replaced I4L gene. The DNA sequence of CMVgH plus additional flanking DNA sequences in plasmid I4L42KgH are shown in FIGS. 22A and B (SEQ ID NO:47).
Cloning of the HCMVgH gene into the ALVAC donor plasmid NVQC5LSP. A C5 insertion vector containing 1535 bp upstream of C5, polylinker containing KpnI/SmaI/XbaI and NotI sites and 404 bp of canarypox DNA (31 base pairs of C5 coding sequence and 373 bp of downstream sequence) was derived in the following manner. A genomic library of canarypox DNA was constructed in the cosmid vector puK102 (Knauf and Nester, 1982) probed with pRW764.5 (a PuC9 based plasmid containing an 880 bp canarypox PvuII fragment which includes the C5 ORF Nucleotides 1372 to 2251 in FIG. 8 (SEQ ID NO:27)) and a clone containing a 29 kb insert identified (pHCOS1). A 3.3 kb ClaI fragment from pHCOS1 containing the C5 region was identified. The C5 open reading frame is initiated at position 1537 and terminated at position 1857 in the sequence shown in FIG. 8 (SEQ ID NO:27).
The C5 insertion vector was constructed in two steps. The 1535 bp upstream sequence was generated by PCR amplification using oligonucleotides C5A (SEQ ID NO:123) (5'-ATCATCGAATTCTGAATGTTAAATGTTATACTTTG-3') and C5B (SEQ ID NO:124) (5'-GGGGGTACCTTTGAGAGTACCACTTCAG-3') and purified genomic canarypox DNA as template. This fragment was digested with EcoRI (within oligoC5A) and cloned into EcoRI/SmaI digested pUC8 generating C5LAB. The 404 bp arm was generated by PCR amplification using oligonucleotides C5C (SEQ ID NO:125) (5'-GGGTCTAGAGCGGCCGCTTATAAAGATCTAAAATGCATAATTTC-3') and C5DA (SEQ ID NO:126) (5'-ATCATCCTGCAGGTATTCTAAACTAGGAATAGATG-3'). This fragment was digested with PstI (within oligoC5DA) and cloned into SmaI/PstI digested C5LAB generating pC5L.
pC5L was digested within the polylinker with Asp718 and NotI, treated with alkaline phosphatase and ligated to kinased and annealed oligonucleotides CP26 (SEQ ID NO:127) (5'-GTACGTGACTAATTAGCTATAAAAAGGATCCGGTACCCTCGAGTCTAGAATCGATCCCGG GTTTTTATGA CTAGTTAATCAC-3') and CP27 (SEQ ID NO:128) (5'-GGCCGTGATTAACTAGTCATAAAAACCCGGGATCGATTCTAGACTCGAGGGTACCGGATC C TTTTTATAGCTAATTAGTCAC-3') (containing a disabled Asp718 site, translation stop codons in six reading frames, vaccinia early transcription termination signal (Yuen and Moss, 1987), BamHI KpnI XhoI XbaI ClaI and SmaI restriction sites, vaccinia early transcription termination signal, translation stop codons in six reading frames, and a disabled NotI site) generating plasmid C5LSP. The polylinker region in C5LSP was further modified by digesting with BamHI and ligating to annealed oligonucleotides CP32 (SEQ ID NO:129) (5'-GATCTTAATTAATTAGTCATCAGGCAGGGCGAGAACGAGACTATCTGCTCGTTAATTAAT T AGGTCGACG-3') and CP33 (SEQ ID NO:130) (5'-GATCCGTCGACCTAATTAATTAACGAGCAGATAGTCTCGTTCTCGCCCTGCCTGATGACT A ATTAATTAA-3') generating plasmid VQC5LSP. VQC5LSP was digested with EcoRI, treated with alkaline phosphatase, ligated with kinased and annealed oligonucleotide CP29 (SEQ ID NO:131) (5'-AATTGCGGCCGC-3') and digested with NotI. The linearized plasmid was purified and self ligated to generate plasmid NVQC5LSP. The 2.3 kb XhoI fragment from SPgH6 was cloned into XhoI digested and alkaline phosphatase treated NVQC5LSP generating the ALVAC donor plasmid NVQC5L42KgH in which the orientation of gH is in the same direction as the deleted C5 gene. The DNA sequence of CMVgH plus additional flanking DNA sequences in plasmid NVQC5L42KgH are shown in FIGS. 23A and B (SEQ ID NO:27).
Cloning of the HCMVQH gene into the vaccinia donor plasmid pSD157K1LINS. Plasmid. pHK (which contains the WR vaccinia HindIII K fragment cloned in pBR322) was digested with HindIII/BglII and a 1.2 kb fragment isolated and cloned into BamHI/HindIII digested pBS-SK.sup.+ yielding plasmid pBS-HKARM. pBS-HKARM was digested with Asp718 in the polylinker region, blunt ended with the klenow fragment of E. Coli DNA polymerase, and digested with HindIII at the pBS/vaccinia junction. The resulting 4.1 kb vector fragment was ligated to a 2.0 kb NruI/HindIII fragment from pHM-1 (pHM-1 contains the WR vaccinia virus HindIII M fragment cloned in pBR322) resulting in plasmid PMPWRMK. pMPWRMK was cut with HpaI and ligated with annealed synthetic oligonucleotides MPSYN527 (SEQ ID NO:132) (5'-ATAAAAATTAGCTACTCAGGTACCCTGCAGTCGCGAGGATCCGAATTCCCCGGGCTCGAG T GATTAATTAGTTTTTAT-3') and MPSYN528 (SEQ ID NO:133) (5'-ATAAAAACTAATTAATCACTCGAGCCCGGGGAATTCGGATCCTCGCGACTGCAGGGTACC T GAGTAGCTAATTTTTAT-3'). The resulting plasmid is pSD157K1LINS. pSD157K1LINS was digested within its polylinker region with XhoI, treated with alkaline phosphatase and ligated to the 2.3 kb XhoI fragment from SPgH6 yielding plasmid MP804-42KgH (which contains the HCMVgH gene and vaccinia K1L gene both in the same orientation.) The DNA sequence of CMVgH plus additional flanking DNA sequences in plasmid MP804-42KgH are shown in FIG. 24 (SEQ ID NO:49).
Example 17
Construction of Recombinant Poxviruses Containing HCMVgH
Plasmid I4L42kgH was transfected into NYVAC infected CEF cells to generate the recombinant vP1173 (containing HCMVgH). The same plasmid was transfected into vP1001 infected Vero cells to generate the recombinant vP1183 (containing HCMVgB and gH).
Plasmid NVQC5L42KgH was transfected into ALVAC infected CEF cells to generate the recombinant vCP236 (containing HCMVgH). The same plasmid was transfected into vCP139 infected CEF cells to generate the recombinant vCP233 (containing HCMVgB and gH). Vaccinia virus vP1170 (which contains Ecogpt under the transcriptional control of the entomopoxvirus 42K promoter in place of the deleted K1L gene) was used to infect Vero cells transfected with plasmid MP804-42KgH to generate the recombinant vP1205B.
Example 18
Immunoprecipitation of HCMVgH Expressed by Poxvirus Recombinants
Immunoprecipitation performed with a monoclonal antibody specific for HCMVgH demonstrated the expression of an 86 kDa gH protein (Pachl et al., 1989) by recombinants vP1173, vP1183, vP1205B, vCP233 and vCP236. Immunoprecipitation with the gB specific guinea pig polyclonal serum demonstrated correct expression of gB by recombinants vP1183 and vCP233.
The HCMV 72-kDa immediate early 1 protein (IE1) is a target for CD8.sup.+ cytotoxic T cells in humans (Borysiewicz et al., 1988) and is recognized by CD4.sup.+ T cells (Alp et al., 1991). For one individual the peptide specificities of proliferative and MHC-class I-restricted cytotoxic determinants on IE1 were determined and found to be spatially distinct segments of the exon 4 coding region (Alp et al., 1991).
The IE1 protein has been shown to up-regulate expression from its own promoter (Cherrington and Mocarski, 1989) as well as expression from the HIV LTR (Biegalke and Geballe, 1991; Ghazal et al., 1991) and expression of the promoters for the cellular genes c-myc, c-fos and hsp70 (Hagemeier et al., 1992; Santomenna and Colberg-Poley, 1990; Colberg-Poley et al., 1992). Lafemina et al., (1989) reported that the IE1 protein expressed in stable cell lines preferentially associates with metaphase chromosomes and proposed that this protein may be involved in maintenance of a putative plasmid state for HCMV DNA during latency.
In the following Examples 19-30, the development of poxvirus recombinants expressing the entire IE1 gene, IE1 deleted of amino acids 2-32, IE1 deleted of amino acids 292-319 or the exon 4 segment of IE1 are provided. These studies were performed in order to develop a form of the IE1 gene product that would be incapable of translocation to the nucleus, thus decreasing its potential to act as a transactivator, while maintaining its ability to be recognized by CD8.sup.+ cytotoxic T cells. Example 45 demonstrates that an ALVAC recombinant expressing an altered form of the IE1 protein (deleted of amino acids 2-32) which unlike the full length gene product is found in both the nucleus and cytomplasm of infected cells, can re-stimulate cytotoxic effector cells from HCMV seropositive individuals.
Example 19
Cloning of the Entire HCMV IE1 Gene in Poxvirus Vectors
Cloning of the HCMV IE1 gene into the vaccinia donor plasmid pSD22-H. The entire HCMV IE1 gene (AD169 strain) was derived as a 1.5 kb fragment by PCR using plasmid pJD083 as template (Akrigg et al., 1985) along with oligonucleotides IE3 (SEQ ID NO:134) (5'-ACGGATCCATAAAAATTACTGGTCAGCCTTGCTTC-3') and IE5 (SEQ ID NO:135) (5'-ATCCGTTAAGTTTGTATCGTAATGGAGTCCTCTGCCAAGAGA-3'). The DNA sequence of CMV IE1 is presented in FIG. 25 (SEQ ID NO:50). Plasmid pSD486H6340 (which contains an irrelevant gene linked precisely to H6 promoter) was digested (within the H6 promoter) with NruI and (at the 3' end of the irrelevant gene) with BamHI and ligated to the BamHI digested 1.5 kb PCR fragment (BamHI site located at the 5' end of oligonucleotide IE3) generating plasmid pSD486H6HCMVIE1.
The H6 promoted IE1 gene was obtained from pSD486H6HCMVIE1 as a 1.6 kb fragment by digestion with BamHI followed by partial BglII digestion and ligated to BamHI digested pSD22-H yielding plasmid pSD22-HCMVIE1. The DNA sequence of CMV IE1 plus additional flanking DNA sequences in plasmid pSD22-HCMVIE1 are shown in FIG. 26 (SEQ ID NO:51).
Cloning of the HCMVIE1 gene into the vaccinia donor plasmid pSD554. Oligonucleotides SPIE1 (SEQ ID NO:136) (5'-CGCGAATTCTCGCGATATCCGTTAAGTTTGTATCGTAATGGAGT-3') and SPIE2 (SEQ ID NO:137) (5'-GCCTCTAGAGTTAACCTCCTTCCTCAACAT-3') were used in PCR with plasmid pSD486H6HCMVIE1 as template to generate a 181 bp fragment. This fragment was digested with EcoRI and XbaI and cloned into EcoRI/XbaI digested and alkaline phosphatase treated IBI24 generating plasmid SPIE1 containing part of the H6 promoter and the first 135 bp of the IE1 gene. Oligonucleotides SPIE3 (SEQ ID NO:138) (5'-CGGTCTAGAGGTTATCAGTGTAATGAAGC-3') and SPIE4 (SEQ ID NO:139) (5'-CCGAAGCTTCTCGAGATAAAAATTACTGGTCAGCCTTGCTTCTAGT-3') were used in PCR with plasmid pSD486H6HCMVIE1 as template to generate a 506 bp fragment. This fragment was digested with XbaI and HindIII and cloned into XbaI/HindIII digested and alkaline phosphatase treated IBI24 generating plasmid SPIE2 containing the 3' end of the IE1 gene, a vaccinia early transcription termination signal and an XhoI site. SPIE1 was digested at the 3' end of the inserted fragment of the IE1 gene with HindII and within the IBI24 polylinker with HindIII, alkaline phosphatase treated and ligated to a 903 bp HindII-BglII fragment from pSD486H6HCMVIE1 and a 464 bp BqlII-HindIII fragment from SPIE2 generating plasmid SPIE3 containing the entire IE1 gene linked to part of the H6 promoter.
Plasmid pSD553 was cut with NruI and ligated with a SmaI/NruI fragment containing the synthetic H6 promoter (Perkus et al., 1989) upstream from the NruI site located at -26 relative to the translation initiation codon. The resulting plasmid, pMP553H6, was digested with NruI and BamHI and ligated to annealed oligonucleotides MPSYN347 (SEQ ID NO:140) (5'-CGATATCCGTTAAGTTTGTATCGTAATCTGCAGCCCGGGGGGG-3') and MPSYN348 (SEQ ID NO:141) (5'-GATCCCCCGGGCTGCAGATTACGATACAAACTTAACGGATATCG-3'). The resulting plasmid, pSD554, contains the entire H6 promoter region through nucleotide -1 relative to the initiation codon, followed by a polylinker region. pSD554 was digested with NruI and XhoI and ligated to a 1.5 kb NruI/XhoI fragment from SPIE3 generating plasmid COPAKH6IE. The DNA sequence of CMV IE1 plus flanking DNA sequences in plasmid COPAKH6IE are shown in FIGS. 27A and B (SEQ ID NO:52).
Example 20
Construction of Recombinant Poxviruses Containing the Entire HCMVE1 Gene
Plasmid pSD22-HCMVIE1 was transfected into Vero cells infected with the WR L variant to generate the recombinant vP893. Plasmid COPAKH6IE was transfected into NYVAC infected Vero cells to generate the recombinant vP1161.
Example 21
Expression of the Entire IE1 Gene by Poxvirus Recombinants
Immunoprecipitation studies performed with a monoclonal antibody specific for HCMVIE1 demonstrated the expression of a 72 kDa IE1 protein (Blanton and Tevethia, 1981; Cameron and Preston, 1981) by recombinants vP893 and vP1161. Immunofluorescence studies (performed as described in Taylor et al., 1990) revealed nuclear localization of the IE1 gene product.
Example 22
Cloning of the HCMVEI1 Gene (Lacking Amino Acids 292-319) into the Vaccinia Donor Plasmid pSD554
The DNA sequence of CMVIE1 lacking amino acids 292-319 is shown in FIG. 28 (SEQ ID NO:53). This deletion was made in the following manner. Plasmid SPIE3 was digested with SpeI and a 4239 bp fragment isolated (which lacks nucleotides 868-958 encoding amino acids 292-319). This fragment was self ligated generating plasmid SPIE4. A 1.4 kb NruI/XhoI fragment from SPIE4 was ligated to NruI/XhoI digested pSD554 generating plasmid COPAKH6IEN.sup.-. The DNA sequence of CMVIE1 lacking amino acids 292-319 plus flanking DNA sequences in plasmid COPAKH6IEN.sup.- are shown in FIGS. 29A and B (SEQ ID NO:54).
Example 23
Construction of a Recombinant Poxvirus Containing the HCMV Ie1 Gene Lacking Amino Acids 292-319
Plasmid COPAKH6IEN.sup.- was transfected into NYVAC infected Vero cells to generate the recombinant vP1160.
Example 24
Expression of the HCMVIE1 Gene Lacking Amino Acids 292-319
Immunoprecipitation assays demonstrated the expression of a 69 kDa protein in cells infected with vP1160 consistent with the deletion of amino acids 292-319. Immunofluorescence studies revealed nuclear localization of this gene product.
Example 25
Cloning of the Exon 4 Segment of HCMVIE1 in Poxvirus Vectors
Cloning of the Exon 4 segment of HCMVIE1 in NYVAC donor plasmid SPI4LH6. The DNA sequence of the Exon 4 segment of HCMVIE1 is shown in FIG. 30 (SEQ ID NO:55). This segment of the gene was obtained in the following manner. Oligonucleotides SPIE5 (SEQ ID NO:142) (5'-CGCGAATTCTCGCGATATCCGTTAAGTTTGTATCGTAATGAAACAGATTAAGGTTCGAGT -3') and SPIE6 (SEQ ID NO:143) (5'-GCCTCTAGATGCCGCCATGGCCTGACT-3') were used in PCR with plasmid pSD486H6HCMVIE1 to generate a 0.5 kb fragment. This fragment was digested with EcoRI and XbaI and cloned into EcoRI/XbaI digested and alkaline phosphatase treated IBI24 generating plasmid SPIE5. Plasmid SPIE3 was digested with EcoRI and NcoI and a 3.6 kb fragment purified and ligated to a 0.47 kb EcoRI-NcoI fragment from SPIE5 generating plasmid SPIE6 which contains the Exon 4 segment of IE1 linked to part of the H6 promoter.
The early/late H6 vaccinia virus promoter (Guo et al., 1989; Perkus et al., 1989) was derived by PCR using PRW823 as template (a plasmid containing the H6 promoter linked to an irrelevant gene) and oligonucleotides CP30 (SEQ ID NO:144) (5'-TCGGGATCCGGGTTAATTAATTAGTCATCAGGCAGGGCG-3') and CP31 (SEQ ID NO:145) (5'-TAGCTCGAGGGTACCTACGATACAAACTTAACGGATATCG-3'). The PCR product was digested with BamHI and XhoI (sites present at the 5' end of CP30 and CP31, respectively) and ligated to BamHI/XhoI digested C5LSP generating plasmid VQH6C5LSP. This plasmid was used as template in PCR with oligonucleotides CP31 and RUB1 (SEQ ID NO:146) (5'-TCGGGATCCTTCTTTATTCTATACTTA-3'). The PCR product was digested with BamHI and XhoI (site present at the 5' ends of RUB1 and CP31, respectively) and ligated to BamHI/XhoI digested pSD550 generating plasmid SPI4LH6. A 1.3 kb NruI/XhoI fragment isolated from SPIE6 was cloned into NruI/XhoI digested and alkaline phosphatase treated SPI4LH6 generating plasmid I4LH6IE-Ex4 (in which the H6 promoted IE1 Exon 4 gene is in the same orientation as the replaced I4L gene). The DNA sequence of the Exon 4 segment of HCMVIE1 plus flanking DNA sequences in plasmid I4LH6IE-Ex4 are shown in FIG. 31 (SEQ ID NO:56).
Cloning of the Exon 4 fragment of HCMVIE1 in ALVAC donor plasmid NVQH6C5LSP. Plasmid VQH6C5LSP was digested with EcoRI, treated with alkaline phosphatase, ligated with kinased and annealed oligonucleotide CP29 and digested with NotI. The linearized plasmid was purified and self ligated generating plasmid NVQH6C5LSP. The 1.3 kb NruI/XhoI fragment from SPIE6 was cloned into NruI/XhoI digested and alkaline phosphatase treated NVQH6C5LSP generating plasmid NVQH6IE-Ex4 (in which the H6 promoted IE1 Exon 4 gene is in the same orientation as the replaced C5 gene). The DNA sequence of the Exon 4 segment of HCMVIE1 plus flanking DNA sequences in plasmid NVQH6IE-Ex4 are shown in FIG. 32A and B (SEQ ID NO:57).
Example 26
Construction of Recombinant Poxviruses Containing the Exon 4 Segment Of IE1
Plasmid I4LH6IE-Ex4 was transfected into NYVAC infected CEF cells to generate the recombinant vP1186. Plasmid NVQH6IE-Ex4 was transfected into ALVAC infected CEF cells to generate the recombinant vCP244.
Example 27
Expression of the Exon 4 Segment of HCMVIE1 by Poxvirus Recombinants
Immunofluorescence experiments revealed cytoplasmic localization of the IE-Exon 4 protein expressed by recombinants vP1186 and vCP244. Immunoprecipitation experiments with a monoclonal antibody specific for IE-Exon 4 demonstrated the expression of a 60 kDa protein in cells infected with vCP244 consistent with the predicted size of the exon 4 segment. Immunoprecipitation with a polyclonal rabbit serum raised against a bacterial Exon 4 fusion protein revealed the expression of a 60 kDa protein in cells infected with vP1186 and VCP244.
Example 28
Cloning of the HCMVIE1 Gene (Lacking Amino Acids 2-32) in Poxvirus Vectors
Cloning of the HCMVIE1 gene (lacking amino acids 2-32) in NYVAC donor plasmid SPI4LH6. The DNA sequence of HCMVIE1 lacking amino acids 2-32 is shown in FIG. 33 (SEQ ID NO:58). This segment was obtained in the following manner. Oligonucleotides SPIE9 (SEQ ID NO:147) 5'-AATTCTCGCGATATCCGTTAAGTTTGTATCGTAATGACGACGTTCCTGCAGACTATGTTG A GGAAGGAGGTT-3') and SPIE10 (SEQ ID NO:148) (5'-AACCTCCTTCCTCAACATAGTCTGCAGGAACGTCGTCATTACGATACAAACTTAACGGAT ATCGC GAG-3') were kinased, annealed and ligated to a 4.2 kb HindII/EcoRI digested and alkaline phosphatase treated fragment from SPIE3 generating plasmid SPIE8. A 1.4 kb NruI/XhoI fragment from SPIE8 (containing part of the H6 promoter and IE1 lacking amino acids 2-32) was ligated to NruI/XhoI digested and alkaline phosphatase treated SPI4LH6 generating plasmid I4LH6IEd32. The DNA sequence of HCMVIE1 lacking amino acids 2-32 plus flanking DNA sequences in plasmid I4LH6IEd32 are shown in FIG. 34 (SEQ ID NO:59).
Cloning of the HCMVIE1 gene (lacking amino acids 2-32) in ALVAC donor plasmid NVQH6C5LSP. The 1.4 kb NruI/XhoI fragment from SPIE8 was cloned into NruI/XhoI digested and alkaline phosphatase treated NVQH6C5LSP generating plasmid NVQH6IEd32. The DNA sequence of HCMVIE1 lacking amino acids 2-32 plus flanking DNA sequences in plasmid NVQH6IEd32 are shown in FIGS. 35A and B (SEQ ID NO:60).
Example 29
Construction of Poxvirus Recombinants Containing the IE1 Gene Lacking Amino Acids 2-32
Plasmid I4LH6IEd32 was transfected into NYVAC infected CEF cells to generate the recombinant vP1201. Plasmid NVQH6IEd32 was transfected into ALVAC infected CEF cells to generate the recombinant vCP256.
Example 30
Expression of IE1 Lacking Amino Acids 2-32 by Poxvirus Recombinants
Immunofluorescence experiments revealed both nuclear and cytoplasmic localization of the IE1 protein lacking amino acids 2-32 by recombinants vP1201 and vCP256. Immunoprecipitation with a polyclonal rabbit serum raised against a bacterial exon 4 fusion protein revealed the expression of a 68 kDa protein in cells infected with vP1201 consistent with the predicted size.
Example 31
Cloning of the HCMV pp65 Gene in Poxvirus Vectors
Cloning of the HCMV pp65 gene in NYVAC donor plasmid SPHA-H6. pSD456 is a subclone of Copenhagen vaccinia DNA containing the HA gene (A56R; Goebel et al., 1990a,b) and surrounding regions. pSD456 was used as a template in PCR for synthesis of left and right vaccinia arms flanking the A56R ORF. The left arm was synthesized using oligonucleotides MPSYN279 (SEQ ID NO:149) (5'-CCCCCCGAATTCGTCGACGATTGTTCATGATGGCAAGAT-3') and MPSYN280 (SEQ ID NO:150) (5'-CCCGGGGGATCCCTCGAGGGTACCAAGCTTAATTAATTAAATATTAGTATAAAAAGTGAT TTATTTTT-3'). The right arm was synthesized using oligonucleotides MPSYN281 (SEQ ID NO:151) (5'-AAGCTTGGTACCCTCGAGGGATCCCCCGGGTAGCTAGCTAATTTTTCTTTTACGTATTAT A TATGTAATAAACGTTC-3') and MSYN312 (SEQ ID NO:152) (5'-TTTTTTCTGCAGGTAAGTATTTTTAAAACTTCTAACACC-3'). The purified PCR fragments for the left and right arms were combined in a further PCR reaction. The resulting product was digested with EcoRI/HindIII. The resulting 0.9 kb fragment was cloned into EcoRI/HindIII digested pUC8 resulting in plasmid pSD544.
pSD544 was digested within its polylinker with XhoI, filled in with klenow and treated with alkaline phosphatase. Plasmid SP126 (equivalent to SP131) was digested with HindIII, treated with klenow and the H6 promoter isolated by digestion with SmaI. Ligation of the H6 promoter fragment to pSD544 generated SPHA-H6.
The HCMV pp65 gene was PCR amplified using HCMV genomic DNA as template (Towne strain) and oligonucleotides pp651 (SEQ ID NO:153) (5'-GATTATCGCGATATCCGTTAAGTTTGTATCGTAATGGCATCCGTACTGGGTCCCATTTCG GG-3') and pp651R (SEQ ID NO:154) (5'-GCATAGGTACCGGATCCATAAAAATCAACCTCGGTGCTTTTTGGGCG-3').The DNA sequence of CMVpp65 is shown in FIG. 36 (SEQ ID NO:61). The 1.6 kb product was digested with NruI and BamHI (site present at the 5' end of oligonucleotides pp651 and pp651R, respectively) and cloned into NruI/BamHI digested SPHA-H6 generating plasmid CMV65.1. This plasmid contained the pp65 gene linked to the H6 promoter, however, the first 30 bp of the pp65 gene were missing.
To derive a plasmid containing the first 30 bp of the pp65 gene oligonucleotides RNApp65I (SEQ ID NO:155) (5'-TAGTTCGGATCCCCGCTCAGTCGCCTACA-3') and pp65R4 (SEQ ID NO:156) (5'-ATCAAGGGATCCATCGAAAAAGAAGAGCG-3') were used in PCR with genomic DNA. The resulting 1 kb fragment was digested with BamHI (BamHI sites present at the 5' ends of both oligonucleotides) and cloned into BamHI digested IBI24 generating plasmid pp65.7. Plasmid pp65.7 was used in PCR with oligonucleotides pp651B (SEQ ID NO:157) (5'-GATTATCGCGATATCCGTTAAGTTTGTATCGTAATGGAGTCGCGCGGTCGCCGTTGTCCC G -3') and pp65BstXI (SEQ ID NO:158) (5'-ACCTGCATCTTGGTTGC-3') to generate a 0.5 kb fragment. This fragment was digested with NruI and BstXI (sites at the 5' ends of oligonucleotides pp651B and pp65BstXI, respectively) and ligated to a 4.8 kb NruI/BstXI fragment of CMV65.1 generating plasmid pCMV65.2. This plasmid contains the entire pp65 gene linked precisely to the H6 promoter oriented in the same direction as the replaced HA gene. The DNA sequence of CMVpp65 plus flanking DNA sequences in plasmid pCMV65.2 are shown in FIG. 37 (SEQ ID NO:62).
Cloning of the HCMV pp65 gene in ALVAC donor plasmid pMPC616E6VQ. FIGS. 38A and B (SEQ ID NO:63) is the sequence of a 3.7 kb segment of canarypox DNA. Analysis of the sequence revealed a reading frame designate C6L initiated at position 377 and terminated at position 2254. A C6 insertion vector containing 370 bp upstream of C6, polylinker containing SmaI, PstI, XhoI and EcoRI sites, and 1156 bp of downstream sequence was derived in the following manner. The 0.4 bp upstream sequence was generated by PCR amplification of a cosmid clone derived from purified genomic canarypox DNA using oligonucleotides C6A1SG (SEQ ID NO:159) (5'-ATCATCGAGCTCGCGGCCGCCTATCAAAAGTCTTAATGAGTT-3') and C6B1SG (SEQ ID NO:160) (5'-GAATTCCTCGAGCTGCAGCCCGGGTTTTTATAGCTAATTAGTCATTTTTTCGTAAGTAAG T ATTTTATTTAA-3'). The 1.2 kb downstream arm was generated by PCR amplification of the same template using oligonucleotides C6C1SG (SEQ ID NO:161) (5'-CCCGGGCTGCAGCTCGAGGAATTCTTTTTATTGATTAACTAGTCAAATGAGTATATATAA T TGAAAAAGTAA-3') and C6D1SG (SEQ ID NO:162) (5'-GATGATGGTACCTTCATAAATACAAGTTTGATTAAACTTAAGTTG-3'). These fragments were fused by a third PCR employing gel purified 0.4 and 1.2 kb fragments as template for primers C6A1SG (SEQ ID NO:159) and C6D1SG (SEQ ID NO:162). The resulting 1.6 kb fragment was isolated from an agarose gel, digested with SacI and KpnI and ligated to similarly digested pBS generating C6 insertion plasmid pC6L.
Plasmid pMPC616E6VQ was derived by cloning a HpaI-XhoI fragment containing the H6 promoter precisely linked to an irrelevant gene into Sma-XhoI digested pC6L. pMPC616E6VQ was digested with NruI and BamHI and the 4 kb vector fragment (NruI-BamHI) and 0.6 kb C6 flanking arm fragment (BamHI-BamHI) isolated. These two fragments were combined in a ligation with a 1.7 kb NruI-BamHI fragment from pCMV65.2 (containing part of the H6 promoter linked to the p65 gene) generating plasmid CMV65C6.1 which contained a C6 flanking arm, H6 promoter and the pp65 gene but lacked the 0.6 kb C6 flanking arm. CMV65C6.1 was digested with BamHI, treated with alkaline phosphatase and ligated to the 0.6 kb C6 flanking arm generating plasmid CMV65C6.2 in which C6 flanking arms are present on both sides of the H6-pp65 insert. The DNA sequence of CMVpp65 plus flanking DNA sequences in plasmid CMV65C6.2 are shown in FIGS. 39A and B (SEQ ID NO:64).
Cloning of the HCMVpp65 gene into the vaccinia donor plasmid pSD157 K1LINS. Plasmid pCMV65.2 was digested with KpnI, treated with Mung Bean Nuclease and digested with BamHI generating a 1.7 kb fragment containing H6-pp65. PSD157K1LINS was digested with BamHI and SmaI and ligated to the 1.7 kb fragment generating plasmid CMV65.WR. The DNA sequence of CMVpp65 plus flanking DNA sequences in plasmid CMV65.WR are shown in FIG. 40 (SEQ ID NO:65).
Example 32
Construction of Recombinant Poxviruses Containing HCMVpp65
Plasmid pCMV65.2 was transfected into NYVAC infected Vero cells to generate the recombinant vP1184 (containing HCMVpp65), into vP1001 infected Vero cells to generate the recombinant vP1196 (containing HCMVgB and pp65) and into vP1183 infected Vero cells to generate the recombinant vP1210 (containing HCMVgB, gH and pp65).
Plasmid CMV65C6.2 was transfected into ALVAC infected CEF cells to generate the recombinant vCP260 (containing HCMVpp65).
Plasmid CMV65.WR was transfected into vP1170 infected Vero cells to generate the recombinant vP1214 (WR-pp65).
Example 33
Expression of HCMVpp65 by Poxvirus Recombinants
Immunoprecipitation experiments with a monoclonal antibody specific for HCMV pp65 demonstrated the expression of a 65 kDa protein (Pande et al., 1991) by recombinants vP1184, vP1214, vCP260, vP1196 and vP1210. In addition, immunoprecipitation with gB specific guinea pig polyclonal sera demonstrated correct expression of gB by recombinants vP1196 and vP1210 and immunoprecipitation with a gH specific monoclonal antibody demonstrated correct expression of gH by recombinant vP1210.
Example 34
Cloning of the HCMV pp150 Gene in Poxvirus Vectors
Cloning of the pp150 gene into the NYVAC donor plasmid pSD541. The DNA sequence of CMVpp150 is shown in FIG. 41 (SEQ ID NO:66). Oligonucleotides pp150.1B (SEQ ID NO:163) (5'-TTCGGATCCGGTTCTGGAGAAAAGCC-3') and pp150R6 (SEQ ID NO:164) (5'-GCTTCCAAGCTTTCCTGAAGGGATTGTAAGCC-3') were used in PCR with Towne genomic DNA to generate a 2 kb fragment from the 5' end of pp150. This fragment was digested with BamHI and HindIII and cloned into BamHI/HindIII digested and alkaline phosphatase treated IBI24 generating plasmid pp150.5.
Oligonucleotides pp150.9 (SEQ ID NO:165) (5'-TTCGGATCCGGCTTTCAGTCTCGTCTCC-3') and pp150END2 (SEQ ID NO:166) (5'-TTCGGATCCATGCAATTGCCCGCGGACAAC-3') were used in PCR with Towne DNA to generated a 1.8 kb fragment which includes the 3' end of the gene. This fragment was digested with BamHI and cloned into BamHI digested and alkaline phosphatase treated PUC8 yielding pp150.3.
Oligonucleotides SP150-3 (SEQ ID NO:167) (5'-TTCGAATTCGCTAGCTTTATTGGGAAGAATATGATAATATTTTGGGATTTCAAAATTGAA A ATATATAATTACAATATAAAATGAGTTTGCAGTTTATC-3') and SP150-4 (SEQ ID NO:168) (5'-TTCTCTAGATGAGCTCGTTGAACAGCAC-3') were used in PCR with plasmid pp150.5 as template to generate a 259 bp fragment. This fragment was digested with EcoRI and XbaI and cloned into EcoRI/XbaI digested and alkaline phosphatase treated IBI24 generating plasmid 150.5MP. This plasmid contains a NheI site, 65 bp entomopoxvirus 42K promoter and bases 1-170 from the 5' end of the pp150 gene. The underlined base in the sequence of oligonucleotide SP150-3 (position -53 of the promoter) is missing in this clone.
Oligonucleotides SP150-1 (SEQ ID NO:169) (5'-CCGAAGCTTGCTAGCAATAAAAACTATTCCTCCGTGTTCTTAAT-3') and SP150-2 (SEQ ID NO:170) (5'-GCCTCTAGATACGTAAAGCTAAGTTATC-3') were used in PCR with plasmid pp150.3 as template to generate a 907 bp fragment. This fragment was digested with XbaI and HindIII and cloned into XbaI/HindIII digested and alkaline phosphatase treated IBI24 yielding plasmid 150.3MP. This plasmid contains nucleotides 2273-3141 from pp150 followed by a vaccinia early transcription termination signal (T.sub.5 ATT) (Yuen and Moss, 1987) and a NheI site. pp150 nucleotide 2748 (FIG. 41; SEQ ID NO:66) in this clone is an A not a C as in pp150.3, this change is silent.
Plasmid pp150.3 was digested with SnaBI and HindIII and a 3451 bp fragment isolated. Plasmid 150.3MP was digested with SnaBI and HindIII and 873 bp fragment isolated. Ligation of these two fragments yielded plasmid 150.3MC which contains pp150 nucleotides 1473-3141 followed by T.sub.5 ATT and a NheI site.
Plasmid 150.5MP was digested with SacI and HindIII and a 3056 bp fragment isolated. Plasmid pp150.5 was digested with SacI and HindIII and a 1816 bp fragment isolated. Ligation of these two fragments yielded plasmid 150.5MC which contains a NheI site, 65bp 42K promoter and pp150 nucleotides 1-1981.
Plasmid 150.5MC was digested with HpaI and HindIII and a 4634 bp fragment isolated. Plasmid 150.3MC was digested with HpaI and HindIII and a 1412 bp fragment isolated. Ligation of these two fragments yielded plasmid 150.1 which contains a NheI site, 65bp 42K promoter, nucleotides 1-3141 pp150, T.sub.5 ATT and a NheI site.
Plasmid pSD541 is a vaccinia insertion plasmid which is deleted for vaccinia sequences encompassing the A25L and A26L ORFs (Goebel et al., 1990a,b). The deletion junction consists of a polylinker region containing XhoI, SmaI and BglII restriction sites, flanked on both sides by stop codons and early vaccinia transcriptional terminators (Yuen and Moss, 1987). pSD541 was constructed by polymerase chain reaction (PCR) using cloned vaccinia SalI E plasmid pSD414 as template. Synthetic oligonucleotides MPSYN267 (SEQ ID NO:94) (5'-GGGCTCAAGCTTGCGGCCGCTCATTAGACAAGCGAATGAGGGAC-3') and MPSYN268 (SEQ ID NO:95) (5'-AGATCTCCCGGGCTCGAGTAATTAATTAATTTTTATTACACCAGAAAAGACGGCTTGAGA T C-3') were used as primers to generate the left vaccinia arm and synthetic oligonucleotides MPSYN269 (SEQ ID NO:96) (5'-TAATTACTCGAGCCCGGGAGATCTAATTTAATTTAATTTATATAACTCATTTTTTGAATA T ACT-3') and MPSYN270 (SEQ ID NO:97) (5'-TATCTCGAATTCCCGCGGCTTTAAATGGACGGAACTCTTTTCCCC-3') were used to generate the right vaccinia arm. PCR products consisting of the left and right vaccinia arms were combined, and subjected to PCR amplification. The PCR product was digested with EcoRI and HindIII and electrophoresed on a agarose gel. The 0.8 kb fragment was isolated and ligated into pUC8 cut with EcoRI/HindIII, resulting in plasmid pSD541.
Plasmid pSD541 was digested in its polylinker region with SmaI and alkaline phosphatase treated. Plasmid 150.1 was digested with NheI, treated with klenow and a 3224bp fragment (containing 42K-pp150) isolated. Ligation of these two fragments yielded plasmid 150.7. The DNA sequence of CMVpp150 plus flanking DNA sequences in plasmid 150.7 are shown in FIGS. 42A and B (SEQ ID NO:67).
Cloning of the pp150 gene into ALVAC donor plasmid PMM117. Plasmid PMM117 is a derivative of pC6L with a modified polylinker region. PMM117 was digested in its polylinker with EcoRI filled in with klenow and treated with alkaline phosphatase. Plasmid 150.1 was digested with NheI, treated with klenow and a 3224bp fragment (containing 42K-pp150) isolated. Ligation of these two fragments generated plasmid 150.6. The DNA sequence of CMVpp150 plus flanking DNA sequences in plasmid 150.6 are shown in FIGS. 43A and B (SEQ ID NO:68).
Cloning of the pp150 gene into vaccinia donor plasmid pSD157K1LINS. Plasmid pSD1571LINS was digested in its polylinker region with SmaI and alkaline phosphatase treated. Plasmid 150.1 was digested with NheI, treated with klenow and a 3224 bp fragment (containing 42K-pp150) isolated. Ligation of these two fragments generated plasmid 150.4. The DNA sequence of CMVpp150 plus flanking DNA sequences in plasmid 150.4 are shown in FIGS. 44A and B (SEQ ID NO:69).
Example 35
Construction of Recombinant Poxviruses Containing HCMVpp150
Plasmid 150.4 was transfected into vP1170 infected CEF cells to generate the recombinant vP1238 (WR-pp150).
Plasmid 150.7 was transfected into NYVAC infected CEF cells to generate the recombinant vP1247 (NYVAC-pp150).
Plasmid 150.6 was transfected into ALVAC infected CEF cells to generate the recombinant vCP284 (ALVAC-pp150).
Example 36
Expression of HCMVpp150 by Poxvirus Recombinants
Western blot (Harlow and Lane, 1988) with a monoclonal antibody specific for HCMVpp150 demonstrated the expression of a 150 kDa protein in cells infected with vP1238 which comigrated with a protein present in HCMV infected cells. Expression of a 150 kDa protein was observed in vP1247 and vCP284 infected cells by immunoprecipitation with the pp150 specific monoclonal antibody.
Example 37
Developing a NYVAC Donor Plasmid Containing the HCMVgH and IE1 Exon 4 Genes
Plasmid I4LH6IE-Ex4 was linearized with BamHI, filled in with klenow and treated with alkaline phosphatase yielding a 4.9 kb fragment. Plasmid gH6-3 was digested with XhoI, filled in with klenow and a 2.3 kb fragment (containing 42K-gH) isolated. These two fragments were ligated to generate plasmid I4L42KgHH6IE-Ex4. The DNA sequence of CMVgH and IE-Exon4 plus additional flanking sequences in plasmid I4L42KgHH6IE-Ex4 are shown in FIGS. 45A and B (SEQ ID NO:70).
Example 38
Construction of NYVAC Recombinants Containing HCMVgB..sup.+ gH..sup.+ pp65..sup.+ IE-EXON 4, HCMVgB..sup.+ gh..sup.+ pp65..sup.+ pp150 or HCMVgB..sup.+ gh..sup.+ pp65..sup.+ IE-EXON 4 and pp150
Plasmid I4L42KgHH6IE-Ex 4 was transfected into vP1196 infected Vero cells to generate the recombinant vP1216 (containing HCMVgB, gH, pp65, IE-Exon 4). Plasmid 150.7 was transfected into vP1216 infected CEF cells to generate the recombinant vP1251 (containing HCMVgB, gH, IE-Exon 4, pp65, pp150). Plasmid 150.7 was transfected into vP1210 infected Vero cells to generate the recombinant vP1262 (containing HCMV-gB, gH, pp65, pp150).
Example 39
Expression of the HCMV Genes in vP1216, vP1251, vP1262
Immunoprecipitation with monoclonal antibodies specific for gB, gH, pp65 and IE-Exon 4 demonstrated the correct expression of all four genes by recombinant vP1216. Immunoprecipitation with monoclonal antibodies specific for gB, gH, pp65 and IE-Exon 4 demonstrated the correct expression of these four genes by recombinant vP1251. Immunoprecipitation with monoclonal antibodies specific for gB, gH and pp65 demonstrated the correct expression of these three genes by recombinant vP1262. Western blot with a monoclonal antibody specific for pp150 demonstrated the correct expression of this gene by recombinants vP1251 and vP1262.
Example 40
Developing an ALVAC Donor Plasmid Containing the HCMV pp65 and pp150 genes
Plasmid CMV65C6.2 was linearized with EcoRI, filled in with klenow and treated with alkaline phosphatase generating a 6.3 kb fragment. Plasmid 150.1 was digested with NheI, filled in with klenow and a 3.2 kb fragment (42K-pp150) isolated. Ligation of these two fragments yielded plasmid 150.8. The DNA sequence of CMVpp65 and pp150 plus additional flanking sequences in plasmid 150.8 are shown in FIGS. 46A to C (SEQ ID NO:71).
Example 41
Construction of an ALVAC Recombinant Containing HCMVgB. gH, pp65 AND pp150
Plasmid 150.8 was transfected into vPC233 infected CEF cells to generate an ALVAC-gB, gH, pp65, pp150 recombinant (vCP280).
Example 42
Expression of the HCMV Genes in vCP280
Immunoprecipitation with monoclonal antibodies specific for gB, gH and pp65 demonstrated the correct expression of these three genes by recombinant vCP280.
Example 43
Cloning of HCMVgL in Poxvirus Vectors Deriving a NYVAC Donor Plasmid Containing gB and gL
Oligonucleotides UL115A (SEQ ID NO:171) (5'-GCCTCTAGAATGTGCCGCCGCCCGGATTGC-3') and UL115B (SEQ ID NO:172) (5'-CGCAAGCTTAGCGAGCATCCACTGCTTGAGGGC-3') were used in PCR with Towne DNA as template to generate a 853bp fragment. This fragment was digested with XbaI and HindIII and cloned into XbaI/HindIII digested and alkaline phosphatase treated IBI24 generating plasmid UL115.1. The sequence of CMVgL is presented in FIG. 47 (SEQ ID NO:72).
Oligonucleotides UL115M (SEQ ID NO:173) (5'-TCCAAGCTTAGATCTATAAAAATTAGCGAGCATCCACTGCTTGAGGGCCATAGC-3') and UL115N (SEQ ID NO:174) (5'-GCCTCTAGATGCTGACGCTGTTGAGCTCGGAC-3') were used in PCR with plasmid UL115.1 as template to generate a 498bp fragment. This fragment was digested with HindIII and XbaI and cloned into HindIII/XbaI digested and alkaline phosphatase treated IBI24 generating plasmid UL115.2.
Oligonucleotides UL115G2 (SEQ ID NO:175) (5'-CGCGAATTCTCGCGATATCCGTTAAGTTTGTATCGTAATGTGCCGCCGCCCGGATTGC -3') and UL115H2 (SEQ ID NO:176) (5'-GCCTCTAGATTCCAGCGCGGCGCTGTGTCCGAGC-3') were used in PCR with plasmid UL115.1 as template to generate a 450bp fragment. This fragment was digested with EcoRI and XbaI and cloned into EcoRI/XbaI digested and alkaline phosphatase treated IBI24 generating plasmid UL115.3.
Plasmid UL115.3 was digested with HindIII and SacI and a 3226bp fragment isolated. Plasmid UL115.2 was digested with HindIII and SacI and a 469bp fragment isolated. Ligation of these two fragments yielded plasmid UL115.4.
Plasmid UL115.4 was digested with NruI and BglII and a 865bp fragment isolated. Plasmid I4LH6 was digested with NruI and BglII and a 3683bp fragment isolated. Ligation of these two fragments yielded plasmid I4LH6gL.
To correct a one base deletion in the H6 promoter in I4LH6gL this plasmid was digested with EcoRV treated with alkaline phosphatase and a 3805bp fragment isolated. Plasmid I4LH6 was digested with EcoRV and a 736bp fragment isolated. Ligation of these two fragments yielded plasmid I4LH6CgL.
Plasmid 542CMVgB was linearized with BamHI and treated with alkaline phosphatase. Plasmid I4LH6CgL was digested with BamHI and BglII and a 968bp fragment (containing the H6 promoted gL gene) isolated. Ligation of these two fragments generated plasmid 542CMVgBgL. The DNA sequence of CMVgL and CMVgB plus additional flanking DNA sequences in plasmid 542CMVgBgL are shown in FIGS. 48A and B (SEQ ID NO:73).
Example 44
Developing a NYVAC Recombinant Containing gB, gH, gL, pp65, pp150, IE1-Exon 4 or gB, gH, gL, pp65, pp150
Plasmid 542CMVgBgL was transfected into vP1251 infected CEF cells to generate a NYVAC gB, gH, gL, pp65, pp150, IE1-Exon 4 recombinants (NYVAC-CMV6: vP1302 and vP1302B).
Plasmid 542CMVgBgL is transfected into vP1262 infected cells to generate NYVAC recombinant vP1312 (NYVAC-CMV5).
Example 45
Human Cytotoxic T Lymphocyte Responses to HCMV Proteins
Lymphocytes comprising the antigen-specific segment of the immune system may functionally react to antigen by producing antibodies (B-lymphocytes) or by becoming cytotoxic T lymphocytes (CD8+ T-lymphocytes). ALVAC recombinants expressing HCMV proteins that are known to be recognized by human cytotoxic T lymphocytes (CTLs) are capable of re-stimulating human cellular immune responses with characteristics of classical CTLs.
Thirteen individuals for which there was previously established EBV-transformed B-cell lines (LBCL) for use as CTL targets were screened for CTL responses to HCMV gB, IE1, and pp65. Although only one of these volunteer blood donors had an established clinical history of HCMV infection, seven were found to be HCMV seropositive by virtue of their sera containing antibodies which neutralized HCMV.
Stimulation of HCMV 1E1 CTLs by ALVAC-1E1 (vCP256): Whole blood was collected into heparinized Vacutainer tubes from each volunteer donor by venipuncture. The mononuclear cell fraction was separated from the remainder of the blood components by centrifugation over Leucoprep gradients, washed several times by centrifugation in Stim Medium (MEM containing 5% fetal bovine serum [FBS], 2 mM L-glutamine, 10.sup.-4 M 2-mercaptoethanol, 100 IU/ml penicillin, and 100 .mu.g/ml streptomycin), counted for viable cells with trypan blue, and resuspended at 5.times.10.sup.6 cells/ml in Stim Medium (responder cells). A portion of the mononuclear cells were resuspended at 10.sup.7 cells/ml in MEM containing 2% FBS and infected with recombinant ALVAC expressing HCMV 1E1 (vCP256) at a multiplicity of infection of 25 for approximately 1 hour at 37 C. Following incubation, sufficient Stim Medium was added to dilute the infected cells to 5.times.10.sup.5 cells/ml (stimulator cells). Equal volumes of responder cells and stimulator cells were added to upright 25 cm.sup.2 tissue culture flasks or to the wells of 24-well tissue culture plates and incubated in 5% CO.sub.2 /95% air at 37 C. for 6 days. Target cells were prepared by infecting LBCLs with recombinant WR vaccinia virus expressing HCMV IE1 (vP893) similarly to the infection of stimulator cells except the target cells were incubated overnight at 4.times.10.sup.5 cells/ml in RPMI 1640 medium containing 20% FBS. Following incubation, the mononuclear cells and the target cells were washed by centrifugation in Assay Medium (RPMI 1640 medium containing 10% FBS, 2 mM Lglutamine, 5.times.10.sup.-5 M 2-mercaptoethanol, 100 IU/ml penicillin, and 100 .mu.g/ml streptomycin). Target cells were incubated in Na.sub.2.sup.51 CrO.sub.4 for 1 hour, washed by centrifugation in Assay Medium, resuspended to 10.sup.5 cells/ml in Assay Medium, and held on ice until use. Following centrifugation, the mononuclear cells were diluted to 2.times.10.sup.6 cells/ml in Assay Medium. One tenth ml of mononuclear cells and 0.1 ml of .sup.51 Cr labelled, infected target cells were added to the wells of 96-well round bottom tissue culture plates. These volumes and cell densities resulted in an effector to target ratio (E:T) of 20:1. The tissue culture plates were centrifuged at 250 g for 2 minutes and incubated in 5% CO.sub.2 /95% air at 37 C. for 4 to 5 hours. Following incubation, 0.1 ml of supernatant fluid from each well was collected using Skatron filter wicks and counted for released radioactivity. Percent cytoxicity was calculated as: ##EQU1##
Maximum release was determined by the addition of 5% sodium dodecyl sulfate to target cells while spontaneous release was determined by incubating target cells in the absence of effector cells. In none of the experiments presented did spontaneous release of .sup.51 Cr from target cells exceed 20% of maximum .sup.51 Cr release.
Following in vitro stimulation with ALVAC recombinants expressing a single HCMV protein, mononuclear cells from four of the seven seropositive volunteer donors lysed autologous targets expressing HCMV IE1 (FIG. 49) and mononuclear cells from six of the seven seropositive donors lysed autologous targets expressing HCMV pp65 (FIG. 50). Re-stimulated mononuclear cells from none of the HCMV seropositive donors lysed autologous targets expressing HCMV gB.
The mononuclear cells from HCMV seronegative volunteer donors, when re-stimulated similarly to the mononuclear cells of the HCMV seropositive donors, failed to lyse autologous target cells expressing HCMV IE1 or HCMV pp65 (FIG. 49 and FIG. 50, respectively).
In all cases except one, the cytotoxic effector cells only lysed autologous, but not nonautologous, target cells expressing the appropriate HCMV protein. The single exception, mononuclear cells from Donor 7C, following re-stimulation with ALVAC pp65 (vCP260), was capable of lysing nonautologous target cells expressing HCMV pp65. However, it was later demonstrated that Donor 7C and the donor for the nonautologous target cell line share HLA-B7 of the human major histocompatibility complex (MHC).
Stimulation of HCMV IE1 CTLs by ALVAC-IE1 (vCP256): Human CTLs were stimulated in vitro and assayed for HCMV IE1 CTLs using similar methodology as in FIG. 49 except that following 6 days incubation for restimulation, the responder mononuclear cells were incubated with immunomagnetic beads coupled to monoclonal anti-human CD3, CD4, or CD8. Following incubation, the beads were removed by a magnet and therefore the CD3+, CD4+ or CD8+ cells. The cells adhering to the magnetic beads were uncoupled, washed and used in the cytotoxicity assay.
Representative of the phenotype of the cytotoxic responses of this HCMV seropositive cohort, the ALVAC-IE1 (vCP256) re-stimulated mononuclear cells from Donor 2A failed to lyse IE1-expressing targets following depletion of lymphocytes expressing CD3 and CD8, but not CD4 (FIG. 51). Furthermore, re-stimulated mononuclear cells that had been enriched for CD8, but not CD4, retained cytotoxic activity.
Thus, the cytotoxic effector cells derived from HCMV seropositive volunteer donors by re-stimulation in vitro with ALVAC recombinants expressing HCMV IE1 (vCP256) or HCMV pp65 (vCP260) were antigen specific, MHC-restricted, and expressed CD3 and CD8. These characteristics are consistent with those of classical cytotoxic T lymphocytes (CTLs).
These results show that ALVAC recombinants expressing HCMV proteins can serve as vaccines for the purpose of eliciting human cytotoxic T lymphocytes capable of mediating the destruction of HCMV-infected human cells. Furthermore, these data also show that these recombinant viruses can serve as reagents for the ex vivo stimulation and expansion of cytotoxic T lymphocyte clones for the purpose of immunotherapeutic applications (Riddell et al., 1992).
As discussed earlier, HCMV-gB can serve to elicit protective immunity in humans since 1) HCMV neutralizing antibody titer is reduced significantly when gB specific antibody is absorbed from human sera (Gonczol et al., 1991; Marshall et al., 1992) and 2) there is evidence for the activation of helper T cells by the gB protein in seropositive individuals (Liu et al., 1991). Gonczol et al., (1990) reported the immunoaffinity purified gB was immunogenic in human volunteers. In this study a single injection of the purified gB was able to induce high titers of HCMV neutralizing antibodies and lymphocyte proliferation in naturally seropositive individuals. In seronegative individuals three injections of the gB preparation induced transient HCMV neutralizing antibodies, a fourth injection induced a rapid reappearance and increase in titer of HCMV neutralizing antibodies.
These studies show the use of purified gB as a subunit vaccine. Additionally purified gB can also be used in prime/boost protocols in combination with NYVAC or ALVAC-gB recombinants. Recent studies have indicated that a prime/boost protocol, whereby immunization with a poxvirus recombinant expressing a foreign gene product is followed by a boost with a purified form of that gene product, elicits an enhanced immune response relative to the response elicited with either product alone. For example, humans immunized with a vaccinia recombinant expressing the HIV-1 envelope glycoprotein and boosted with purified HIV-1 envelope glycoprotein from a baculovirus recombinant exhibit higher HIV-1 neutralizing antibody titers than individuals immunized with just the vaccinia recombinant or purified envelope glycoprotein alone (Graham et al., 1993; Cooney et al., 1993). Humans immunized with two injections of ALVAC-HIV (vCP125) failed to develop HIV specific antibodies. Boosting with purified rgp160 from a vaccinia virus recombinant resulted in detectable HIV-1 neutralizing antibodies. Furthermore, specific lymphocyte T cell proliferation to rgp160 was clearly increased by the boost with rgp160. Envelope specific cytotoxic lymphocyte activity was also detected with this vaccination regimen (Pialoux et al., 1995). Macaques immunized with a vaccinia recombinant expressing the simian immunodeficiency virus (SIV) envelope glycoprotein and boosted with SIV envelope glycoprotein from a baculovirus recombinant are protected against a SIV challenge (Hu et al., 1991; 1992).
Example 46
Purification of HCMV Glycoprotein B
This Example involves purification of CMV glycoprotein B produced by a vaccinia recombinant, and the testing of its immunogenicity in laboratory animals in combination with ALVAC-CMV gB (vCP139).
COPAK recombinants vP1126, vP1128, and vP1145, each expressing a different form of gB, elicit CMV neutralizing antibodies in mice (Table 23) and therefore express gB in an immunogenic form. To select a virus and cell system, and an immunological reagent for CMV gB purification, gB expression by the three COPAK recombinants was compared by an immunoprecipitation assay, utilizing 5 different gB-specific monoclonal antibodies. Based on the assay results, a scheme was developed to purify gB from the medium of vP1145-infected VERO cells.
Immunoaffinity column bed material was prepared by crosslinking CMV gB-specific monoclonal antibody (mAb) CH380 to Protein A-agarose. This material was used to purify gB in a one-step procedure. Batches of gB were produced and evaluated for purity, as described in section III.
Immunoprecipitation Assay. Vero and HeLa cell monolayers in 60 mm dishes were infected with vP1126, vP1128, vP1145, or vP993 (described below) at an moi of 5 pfu/cell in serum-free medium. Medium and cells were harvested separately at 24 hours post infection. Immunoprecipitation (IP) assays were performed (Taylor et al., 1990) using the reagents described below, with rat anti-mouse IgG as a bridge to protein A for the monoclonals.
______________________________________Virus:vP1126: COPAK-CMV gB (entire). Full length wild type gBvP1128: COPAK-CMV gB (TM.sup.-). Lacks transmembrane regionvP1145: COPAK-CMV gB (TM.sup.-, Cl.sup.- lacks transmembrane region and has an altered cleavage site.vP993: COPAK controlReagents:Guinea pig anti-CMV gB: Obtained from Eva Gonczol (Wistar Institute)Monoclonal CH380: Obtained from PMs&v (Pereria and Hoffman, 1986)Monoclonal 13-127 Advanced Biotechnologies, Inc.Monoclonal 13-128 Advanced Biotechnologies, Inc., neutralizing, conformationally dependentMonoclonal HCMV-34 Cogent Diagnostics, neutralizingMonoclonal HCMV-37 Cogent Diagnostics, neutralizingRabbit anti-p25 (Vaccinia E3L) (obtained from Bert Jacobs, U. Arizona)______________________________________
Preparation of immunoaffinity chromatography bed material. One ml of immunoaffinity column bed material consisting of approximately 2.4 mg of mAb CH380 coupled to Protein A-agarose with the crosslinking agent dimethylpimelimidate was provided by Stephen Cockle, Connaught Laboratories, Limited (Willowdale, Ontario, Canada). mAb CH380 (Pereria and Hoffman, 1986) was used previously to purify CMV gB from a CMV viral envelope preparation (Gonczol et.al., 1990). The material from S. Cockle was used in preliminary experiments to further determine its utility in gB purification. To scale up gB production, additional bed material was prepared by the same method used by S. Cockle, as described below.
Preparation of monoclonal ch380. Four vials of lyophilized monoclonal CH380 (lot S1705, obtained from PMsv) were reconstituted in PBS (137 mM NaCl, 2.7 mM KCl, 1.5 mM KH.sub.2 PO.sub.4, 8.1 mM Na.sub.2 HPO.sub.4, pH 7.4) (1 ml each) and dialysed overnight versus PBS (final volume 3.5 ml). Protein concentration was determined to be 4.9 mg/ml by bicinchoninic acid assay (BCA assay, reagents obtained from Pierce, Rockford, Ill.). This preparation was then diluted in an equal volume of MAPS binding buffer (Bio-Rad cat# 153-6161; 31.4% w/v in milli-Q water, adjusted to pH 9, and filtered through a 22 mm membrane). To remove particulate material, the antibody preparation in MAPS buffer was centrifuged at 16,000.times.g for 30 min, and the protein concentration of the supernate was calculated from the absorbence at 280 nm, using 1.44 as the absorbence coefficient for IgG.
Preparation of protein a-agarose beads. Three ml of protein A-agarose beads (Bio-Rad cat # 153-6153) were washed 4 times with 2 volumes of MAPS binding buffer by gentle mixing in a closed tube and centrifugation for 5 min at 1000.times.g (1400 rpm in Beckman GPKR centrifuge, GH 3.7 rotor). The supernate was discarded after the last wash.
Bindina of monoclonal antibody to the beads. All of the mAb antibody from step 1 was added to the washed beads from step 2 and the mixture was rotated in a closed tube at 4.degree. C. The amount of mAb bound to the beads was determined at 6-12 hour intervals by pelleting the beads (1000 g/5 min) and determining concentration of IgG in the supernatant by reading OD at 280 nm, as described above. Approximately 48 hour of incubation at 4.degree. C. were required to reach 90% depletion of IgG from the supernate.
Covalent crosslinking of monoclonal antibody to the beads. After binding was 90% complete, the beads were washed 4 times with 6 ml (2 volumes) of 50 mM borate, 3M NaCl, pH9. The beads were then resuspended in 30 ml (10 volumes) of 200 mM borate, 3M NaCl, pH9, and the pH adjusted to 9.+-.0.1. A sample of beads (100 .mu.l) was removed for later evaluation of cross-linking. Cross linking reagent dimethylpimelimidate (DMP) was prepared immediately before use at a concentration of 500 mM in 200 mM borate, 3M NaCl, pH9. DMP was added to the beads to produce a final concentration of 20 mM, and the beads were mixed in a closed tube, end-over-end, for 30 min at room temperature. Another sample of beads (100 .mu.l) was removed for evaluation of crosslinking. To quench residual crosslinking reagent, the beads were washed 2 times with 6 ml (2 volumes) of 200 mM ethanolamine, pH8 and then incubated in 30 ml (10 volumes) of 200 mM ethanolamine, pH8 by mixing end-over-end for 2 hours at room temperature. Finally the beads were washed 4 times with 6 ml (2 volumes) of PBS and stored in 6 ml of PBS with 0.01% NaN.sub.3.
To determine the extent of crosslinking, the gel bead samples taken before and after DMP incubation were pelleted, supernates discarded, and the beads mixed with 2.times.SDS-PAGE sample buffer containing reducing agent. These samples were boiled and electrophoretically separated on a 10% polyacrylamide gel. After staining with Coomassie Blue, IgG heavy and light chains could be detected in the "before" samples, but not in the "after" samples, indicating good efficiency of crosslinking.
Based on protein concentration before and after incubation of the antibody with the beads, the resulting bed material was estimated to contain approximately 5 mg of monoclonal antibody per ml of protein A-agarose beads.
Purification of CMV gB by immunoaffinity column chromatography. Column buffers. PBS (137 mM NaCl, 2.7 mM KCl, 1.5 mM KH.sub.2 PO.sub.4, 8.1 mM Na.sub.2 HPO.sub.4), pH 7 (batch 1), pH 7.4 (batches 2-5), or pH 6.8 (batches 2-5); 0.1 M glycine, pH 2.5; 1 M tris, pH 8.5.
Columns. Column sizes varied from 0.3 to 4 ml volumes. When a new column was poured, it was stripped with 10 bed volumes (bv) of 0.1 M glycine, pH 2.5, followed by 10-20 bv of PBS, pH 7 or 7.4. At the end of each column run, the column was washed with at least 10 bv of PBS, pH 7. At the beginning of each run, it was washed again with at least 10 bv of PBS, pH 7. The columns were run at room temperature and, when not in use, stored at 4.degree. C. in PBS+0.01% NaN.sub.3.
Preparation of the crude gB sample. Roller bottles (850 cm.sup.2) were seeded with Vero cells in MEM+10% FBS. Medium was changed to serum-free MEM 2-12 hours before infection. Cells were infected with vP1145 at an MOI of 5 pfu/cell in a volume of 10 ml/RB of serum-free MEM. Virus was absorbed at 37.degree. C. for 60 min and then 30 ml of serum-free MEM was added to each RB and incubation continued at 37.degree. C. Medium was harvested at 16-24 hours post infection. The medium was clarified by centrifugation at 3000 rpm (Beckman GPKR centrifuge GH 3.7 rotor) for 15 min. The supernatant was recovered and further clarified by centrifugation at 20,000 rpm in a Beckman SW28 rotor for 60 min. The clarified medium was then concentrated (10 to 40-fold) by ultrafiltration with buffer exchange to PBS, pH 7.4, using one or more of the following ultrafiltration devices having 30,000 MWCO: Centricell-60 (Polysciences #19182-6), Centriprep-30 (Amicon #4306), or polysulfone immersible filter units (Polysciences #2250). This material was applied to the column as described below.
Column procedure. The crude gB sample was applied to the column at a flow rate of 0.03-0.09 ml/min, controlled by stopcock or peristaltic pump. After application of the sample, the column was washed at a flow rate of 0.2-0.6 ml/min with 10 bv PBS, pH7 (batch 1), or 20 bv of PBS, pH7.4 followed by 20 bv of PBS, pH6.8 (batches 2-5). Bound material was eluted with 10 bv of 0.1 M glycine, pH 2.5, collecting 500 .mu.l (Batch 1,3) or 1 ml (batch 2,4,5) fractions into tubes containing 50 .mu.l (Batch 1,3) or 100 .mu.l (batch 2,4,5) of 1.0 M Tris, pH 8.5. One column (#28) was eluted with 0.1N glycine+0.1M Tris, pH7. CMV gB fractions were identified by SDS-PAGE on a 10% gel, under reducing conditions, followed by silver stain (Bio-Rad kit #161-0443).
Treatment of eluted gB. After identification by SDS-PAGE and silver stain the CMV gB fractions were pooled and concentrated in one of 2 ways: 1) Dialysis against 0.1.times.PBS and 10-fold vacuum concentration (majority of batch 1), or 2) Precipitation with 70% ammonium sulfate and resuspension in PBS. Protein concentration of the gB samples was determined by bicinchoninic acid microplate assay (BCA reagents from Pierce, Rockford, Ill.). Five batches of gB were prepared and frozen in aliquots at -70.degree. C.
Evaluation of purified gB. Slot blot. Slot blot analysis was utilized to measure relative quantities of CMV gB in crude preparations, flow-through fractions, and elution fractions from affinity column purification. Serial two-fold dilutions in PBS were made of each test sample, and these were applied to nitrocellulose paper with the Schleicher and Scheull Manifold II slot blot apparatus. Each test included serially diluted samples of purified gB with a known protein concentration (determined by BCA microplate assay) as a standard. CMV gB was detected with monoclonal CH380 diluted 1:100 followed by 125I goat anti-mouse (NEN # NEX159, at 0.1 Ci/ml). Slot blot signals on the autoradiograph were scanned and analyzed by densitometry (PDI, Inc., Huntington Station, N.Y., Quantity One densitometer program). The amount of CMV gB in each test sample was determined by linear regression analysis as compared to a gB standard curve.
Western blot. Test samples were electrophoretically separated on a 10% gel under reducing conditions, and blotted onto nitrocellulose paper (Harlow and Lane, 1988). The blot was probed for the presence of CMVgB, mouse IgG, vaccinia, and Vero cell proteins with the following reagents:
______________________________________ANTIGEN PRIMARY ANTIBODY DETECTION______________________________________CMV gB Monoclonal CH380 .sup.125 I goat anti-mouse diluted 1:100 (NEN # NEX159), 0.1.mu. Ci/mlMouse .sup.125 I goat anti-mouse (See primary antibody)IgG (NEN # NEX159, at 0.1 .mu.Ci/mlVaccinia Rabbit anti-vP410, .sup.125 I Protein A (NENproteins rabbit #W29 week 39, #NEX-146), 0.1 .mu.Ci/ml 9/13/91, preabsorbed against Vero cells and diluted 1:100Vero Rabbit anti-Vero cells, .sup.25 I Protein A (NENcell obtained from B. #NEX-146), 0.1 .mu.Ci/mlproteins Meignier, PMsv, preabsorbed against ALVAC-infected CEF and diluted 1:100______________________________________
Immunoprecipitation/western blot assay. A combination IP/Western Blot was performed on Batch 1 gB utilizing the panel of monoclonal antibodies. Unlabeled crude and purified gB was subjected to immunoprecipitation followed by SDS-PAGE, the gel was blotted onto nitrocellulose, and gB-specific proteins detected with guinea pig anti-CMV gB (from Eva Gbnczbl), diluted 1:1000, and .sup.125 I Protein A (NEN #NEX146), 0.1.mu. Ci/ml.
Analysis of the purity of the gB product. Samples from each batch of gB were analyzed by electrophoretic separation on a 10% gel under reducing conditions, followed by staining with Coomassie Blue. The dried gel was scanned and analyzed by densitometry (PDI, Inc., Huntington Station, N.Y., Quantity One densitometer program).
Immunoprecipitation assay comparing expression of CMV gB by three vaccinia COPAK recombinants. To choose a suitable recombinant, cell substrate and antibody for production and immunoaffinity purification of CMV gB, COPAK recombinants expressing 3 different forms of gB were compared by immunoprecipitation assay using guinea pig antig-gB and a panel of monoclonal antibodies. Recombinants vP1126, vP1128, and vP1145 elicit CMV neutralizing antibodies in mice and therefore express gB in an immunogenic form (Table 23). All of the CMV gB antibodies tested produced similar IP results. A representative assay, with guinea pig serum using both medium and cell fractions from HeLa and Vero cell infections, is shown in FIGS. 52A to D. As expected, CMV gB specific material was precipitated from both the cell and medium fractions of vP1128 and vP1145 infected cells, but in only the cell fraction with vP1126 infected cells. The apparent molecular weights of the gB specific bands correspond to previously published results (Britt and Auger, 1986; Britt and Vugler, 1989; Reis et.al., 1993). The cell fractions of all three CMV gB recombinants contained a major band of apparent molecular weight 130-140 kDa, consistent with the apparent molecular weight of the glycosylated uncleaved gB precursor. Less intense protein species with apparent MW of 110 kDa and 55 kDa were observed in the cell fractions and are consistent with the proteolytically processed mature protein species. The N-terminal product was previously reported to be 90-110 kDa and the C-terminal product 55-58 kDa (Britt and Auger, 1986). In HeLa cells a protein species with an apparent higher molecular mass (approximately 150 kDa) was also present (e.g., FIG. 52D, lane 4). This species probably also represents an uncleaved precursor form that is more highly glcosylated. In the medium fractions three gB bands were precipitated from vP1128 and vP1145 infected cells, representing the uncleaved precursor, and N-terminal and C-terminal processed polypeptides. By densitometric analysis, there was more gB-specific material precipitated from the medium fractions of Vero cells compared to HeLa, with recombinant vP1145 producing more gB-specific material than vP1128. This difference may be explained by the observation that more vaccinia E3L was precipitated from the cell fraction of vP1145 than the vP1128 cell fraction, indicating an overall higher level of vaccinia expression in this sample (FIGS. 53A and B). With vP1145, there was more gB specific material precipitated from the medium fraction than from the cell fraction in both HeLa and Vero cells (compare FIG. 52 A,B vs. C,D).
The three different sizes of gB precipitated from the medium of HeLa infected cells appear to have higher molecular weights than the three species produced in Vero cells (compare FIG. 52A vs. 52B). These differences may be due to different levels of glycosylation in HeLa cells compared to Vero, but this hypothesis was not examined further. To determine if the higher molecular weight gB-specific proteins would also be produced by another human cell line, MRC-5, a western blot assay was performed comparing the gB proteins in the medium of vP1145 infected HeLa, MRC-5, and Vero cells using monoclonal CH380 (FIG. 54). The result shows that the two gB bands detectable in this assay, gB precursor (approx. 140 kDa) and C terminal processing fragment (55-58 kDa), had apparently higher molecular weights in HeLa and MRC-5 than in VERO cells. The N-terminal processing fragment is not detectable by western blot using either monoclonal CH380 or the guinea pig anti-CMV gB serum.
MAb CH380 was chosen for use in immunoaffinity purification of gB, since a large quantity was readily available and no apparent differences were seen in the gB-specific proteins detected by the five different monoclonals in the IP assay (FIG. 55). Based on the IP analysis and the considerations that purification of secreted gB from the medium of infected cells eliminates the need to solubilize gB from cell membranes and purify it from cellular proteins, purification of CMV gB was initiated using the medium fraction of vP1145-infected Vero cells. Infection was done in serum-free medium, further reducing contaminating proteins in the crude material.
Purification of CMV gB. Fifteen separate immunoaffinity chromatography column runs, yielding a total of 3.1 mg of gB, are summarized in Table 24. Some of the material was used for further assays and the remainder was pooled in 5 separate batches of purified product, totaling 2.6 mg (Table 25). Column runs 7, 8, 10, and 11 were sequential runs in the same column. The bed material from columns 19A, 19B, 19C, 21A, 21B, and 21C were pooled to make the column used for runs 28, 29, and 32, from which the largest amount of gB was obtained. Table 24 lists the Crude gB material applied to each column in terms of the number of vP1145-infected Vero roller bottles (1.times.10.sup.8 cells per RB) from which the crude material was derived, and amount of total protein and gB-specific protein in the crude. Based on analysis of 8 samples, the total protein content of the crude preparations ranged from 1.2 to 3.7 mg /RB with a mean value of 2.4 mg/RB (24 .mu.g per 10.sup.6 cells). Utilizing a slot blot assay with purified gB as standard, the amount of gB present in the crude material was measured for 7 of the preparations: values ranged from 50 to 350 .mu.g/RB with a mean of 153 .mu.g/RB (1.5 .mu.g/10.sup.6 cells). Together these calculations indicate that the protein in the crude preparations consisted of approximately 6% gB. CMV gB yields ranged from 8 to 29 .mu.g/RB with a mean of 20 .mu.g/RB (0.2 .mu.g/10.sup.6 cells) (Table 24). Approximately fifty roller bottles (1.times.10.sup.9 cells) were required to produce 1 mg of CMV gB.
The capacity of the immunoabsorbent gel for gB was not fully evaluated. The 4 ml bed material used for column runs 28, 29, and 32, was initially divided into 0.6 ml mini-columns (column runs 19A, 19B, 19C, 21A, 21B, and 21C) and varying amounts of crude gB were applied to each column to determine where saturation of binding would occur. Unfortunately, the quantity of gB in the crude material applied to the columns was overestimated, and saturation was not demonstrated. The highest binding result (from column 19C) was used as an estimate of column capacity (300 .mu.g/ml bed material). The amount of gB eluted from the minicolumns represented 8 to 25% of the gB protein applied to the columns (Table 24). Therefore, if the capacity of the 4 ml column is at least 1.2 mg and 25% of the gB applied is recovered, it was estimated that 4.9 mg of crude gB (from approximately 33 RB) must be applied to the column to obtain 1.2 mg of purified gB. The result from column 28 is close to this estimate: material from 36 roller bottles was applied to the column #28, and 1 mg of gB was eluted.
The gB applied to the columns but not eluted as purified material has not been quantitatively accounted for. Since only 8-25% of the gB applied to the column was recovered as purified gB, the remainder of the gB must be present in flow-through fractions, wash fractions, eluted fractions not pooled with the product, or bound to the column. CMV gB could be detected by western blot in the flow-through fractions (e.g., FIG. 56, lane 6). However, when the amount of gB in the flow-through fractions was estimated by slot blot analysis, it did not account for more than 20% of the applied gB. The wash fractions have not been evaluated. The pooled fractions chosen for the final gB product were peak fractions only and therefore trace amounts of gB in adjacent fractions could account for some of the missing gB. For example, FIG. 57 shows sequential fractions eluted from column 8. Fractions 8.17-8.21 were pooled for the gB product, but trace amounts remained in fractions 8.16 and 8.22. Evidence exists also for the retention of gB in the immunoabsorbent gel. Gel material, taken from columns 11 and 19C after elution and washes, contains gB specific material detectable by western blot (FIG. 56, lanes 2 and 3). The amount of gB remaining on the column has not been quantitatively evaluated.
Reapplication of flow-through material to the column was attempted when flow-through material from column run #7 was applied to column #10 (Table 24). The amount of gB eluted from column 10 (4.5 .mu.g) was only 4% of that obtained from column 7 (110 .mu.g). It was not possible to evaluate this result since the capacity of the bed material for gB, and the amounts of gB applied to the column and present in the flow-through fractions were not known. Because of the poor yield, this approach was not used again.
Evaluation of purified qB. After pooling gB-containing eluted fractions, evaluation of purified gB consisted of 1) determination of total protein concentration, 2) SDS-PAGE analysis to identify gB specific and non-specific bands, and 3) confirmation of these bands with immunological reagents. Additionally, the purified gB was analyzed for degree of purity by densitometer scan, and for native conformation by ability to bind to a panel of CMV monoclonal antibodies.
Fractions containing CMV gB eluted from each column were analyzed initially by SDS-PAGE and silver staining, and gB fractions were identified and pooled for each run. A typical elution profile is shown in FIG. 57. A portion of the eluted gB was used for analysis, and the remainder of the material was combined into 5 separate batches (Table 25). Each batch was analyzed by SDS-PAGE on a 10% gel under reducing conditions and stained with Coomassie Blue (FIG. 58). The stained gel was scanned on a densitometer and the molecular weight and relative quantity of each band was calculated: a typical scan is shown in FIGS. 59, 59A and analysis of the 5 batches is summarized in Table 26. By SDS-PAGE analysis batches 1-5 appear very similar (FIG. 58). The two major bands, having apparent molecular weights 120-130 and 51-59 kDa, represent the precursor gB protein and the C-terminal processing fragment. The wide diffuse appearance of these bands is probably due to variable glycosylation of this normally heavily glycosylated protein. The identity of these bands as gB-specific is supported by results from western blot analysis with monoclonal CH380 (FIG. 60B). The bands of apparent molecular weight 77-100 kDa, which appear as doublets in batches 2-5 (FIG. 58), are the correct size for the gB N-terminal processing fragment, identified in the medium of vP11145-infected cells by IP analysis (FIGS. 52A and B). These bands could not be verified as gB-specific by either western blot analysis (FIG. 60B), or a combination immunoprecipitation-western blot assay (FIGS. 61A and B), but the possibility should not be ruled out since neither the guinea pig anti-gB serum nor monoclonal CH380 are able to detect N-terminal processing fragments by western blot. A contaminating protein of approximately 39-45 kDa is present in each batch at a level of 6-15% of total protein (FIG. 58 and Table 26). Two more possible gB protein bands, one of greater than 200 kDa and the other 30-35 kDa are present in every batch (FIGS. 58, 59, and 59A; Table 26). Evidence that the large (.about.200 kDa) protein is gB is derived from western blot analysis with monoclonal CH380 which detects two proteins with molecular weights greater than 200 kDa (FIG. 60B, lanes 2 & 3). It is possible that the protein of approximately 30-35 kDa is also gB-specific (FIG. 58). In the IP analysis of medium of vP1145-infected cells, a protein of approximately 35 kDa was detected by 3 monoclonals (13-128, HCMV 34, and HCMV 37)(FIG. 55) and by the guinea pig serum (FIG. 52A and B). A protein of this size was described by Reis et al. (1993) as a degradation product of gB.
Assuming that contaminating proteins in the gB preparation would be derived from the cell substrate, the virus vector or the immunoabsorbent bed material, the preparation was probed for the presence of mouse IgG, Vero cell proteins, and vaccinia proteins; Proteins derived from Vero cells or mouse IgG could not be detected by western blot analysis (FIGS. 60A and 62A). However, contaminating vaccinia-specific proteins with molecular weights of approximately 35 and 20 kDa were detected in trace amounts (FIG. 62B, lane 5).
To determine if the eluted gB retained its native conformation, a combination immunoprecipitation/western blot assay was performed with a panel of monoclonals which included 3 neutralizing and one conformationally dependent antibody. Each monoclonal antibody precipitated the precursor and C-terminal fragment from purified gB (FIG. 61), suggesting that the gB eluted from the immunoaffinity column retained its native conformation .
In summary, the analysis of eluted gB in batches 1-5 demonstrates that the product contains at least two known gB-specific proteins, the precursor gB and C-terminal fragment, which together account for approximately 50% of the protein content (FIG. 58 and Table 26). Three other protein species, which account for 20-25% of total protein content (Table 26), could also be gB-specific although direct evidence has not been provided.
Immunogenicity of purified gB. The five CMV gB batches were pooled and the final concentration determined. Several amounts of purified gB were adjuvanted with either alum or QS21 and used to inoculate mice. Serum from the mice was evaluated for the presence of HCMV neutralizing antibody. Table 27 demonstrates that all of the amounts of purified gB tested with both adjuvants were able to elicit HCMV neutralizing antibody.
Purified gB was used in a prime/boost protocol in combination with ALVAC-gB (vCP139) in mice. Table 28 demonstrates that mice receiving ALVAC gB (vCP139) on day 0 and boosted on Day 29 with purified gB adjuvanted with QS21 or Alum developed higher levels of HCMV neutralizing antibody than mice receiving a second dose of ALVAC-gB (vCP1319).
TABLE 23______________________________________Induction of HCMV Neutralizing Antibody in Mice Days After ImmunizationImmunogen.sup.1 30 48 135______________________________________vP1126 .sup. 16.sup.2 8 256vP1128 16 8 106vP1145 16 8 106______________________________________ .sup.1 Mice were immunized with 1 .times. 10.sup.8 PFU of recombinant viruses (ip.) on day 0 and day 49. .sup.2 HCMV Neutralizing titer
TABLE 24__________________________________________________________________________SUMMARY OF IMMUNOAFFINITY PURIFICATION COLUMNS CRUDE MATERIAL APPLIED# VERO TO COLUMNCOLUMN ROLLER gB-specific gB YIELDRUN BOTTLES.sup.a COLUMN SIZE Total Protein.sup.b protein.sup.c (% of applied)__________________________________________________________________________7 4 1 ml 13.3 mg nd.sup.d 110 ug.sup.b8 6 1 ml 14.4 mg 2.2 mg 84 .mu.g.sup.b10 Col 7 1 ml nd nd 4.8 ug.sup.b flow thru11 4 1 ml nd nd 100 ug.sup.b13 1 0.3 ml nd nd 12 ug.sup.d19A 1 0.6 ml 2.9 mg 240 .mu.g 41 .mu.g.sup.c (17%)19B 2 0.6 ml 5.8 mg 480 .mu.g 93 .mu.g.sup.c (19%)19C 3 0.6 ml 8.7 mg 720 .mu.g 185 .mu.g.sup.c (25%)21A 3 0.6 ml 5.7 mg 300 .mu.g 29 .mu.g.sup.c (8%)21B 5 0.6 ml 9.5 mg 500 .mu.g 120 .mu.g.sup.c (13%)21C 7 0.6 ml 13.3 mg 700 .mu.g 150 .mu.g.sup.c (19%)23 3 6 ml 5.7 mg 300 .mu.g 25 .mu.g.sup.c (8%)28 36 4 ml 64.8 mg nd 1000 .mu.g.sup.b29 24 4 ml 30 mg nd 480 .mu.g.sup.b32 24 4 ml nd nd 700 .mu.g.sup.b__________________________________________________________________________ .sup.a Cells density: 1 .times. 10.sup.8 cells per roller bottle .sup.b Protein concentration determined by Pierce BCA assay .sup.c Estimated by slot blot analysis, using purified gB as standard .sup.d Not determined
TABLE 25______________________________________CMV gB BATCHES TOTAL COLUMNBATCH # gB VOLUME CONCENTRATION RUN______________________________________1 0.16 mg 0.55 ml 0.29 mg/ml 7 8 10 11 132 1.0 mg 1.0 ml 1.0 mg/ml 283 0.26 mg 0.5 ml 0.52 mg/ml 21A 21B 21C 234 0.48 mg 0.5 ml 0.96 mg/ml 295 0.7 mg 0.5 ml 1.4 mg/ml 32______________________________________
TABLE 26__________________________________________________________________________DENSITOMETRY ANALYSIS OF 5 BATCHES OF CMV gBPROTEIN APPARENT MOLECULAR WEIGHT (kDa).sup.a RELATIVE QUANTITY (%).sup.bBAND B1 B2 B3 B4 B5 B1 B2 B3 B4 B5__________________________________________________________________________>200 kDa 222 208 221 225 217 10.6 6.7 7.5 8.3 7.4(gB?) 192 8Precursor gB 128 120 124 128 134 39 30 36.1 30 27.4N fragment 83 94 99 101 100 9.6 3.6 3.2 4.5 3.5(?) 77 84 88 89 9.7 6.3 6.6 6.3C fragment 55 51 55.4 56.4 59 21 15.6 13.7 22.6 21Unknown 42 39 42 44 45 6.1 12 15.4 14.3 15.8contaminantgB 32 30 35 35 37 4.3 9.7 11.3 8.6 10degradationproduct (?)__________________________________________________________________________ .sup.a Calculated from densitometer scan using molecular weight markers a standards (refer to FIG. 59, 59A) .sup.b The density of each band is calculated from a 2 dimensional scan line through the band: the average pixel OD across the sample width is integrated under the curve to the baseline to obtain density (ODxem). Relative quantity is the percentage of the total density of all bands in the lane.
TABLE 27______________________________________HCMV Neutralizing Antibodies Elicited by purifiedgB protein in CBA Mice.sup.1 NT.sup.2 NT.sup.2 NT.sup.2 NT.sup.2Mouse dose.sup.3 Adjuvant.sup.3 4w 6w 8w 9w______________________________________201 2.5 Alum 32 256 256 256203 8 64 128 128204 8 12 16 16206 5.0 Alum 48 512 192 192207 12 192 512 512208 16 192 192 192209 16 128 256 256210 8 128 256 256211 10.0 Alum 32 256213 32 96 256 256214 32 256 256216 20.0 Alum 64 128 128 128217 64 256 256 256218 32 128 512 256219 16 128 256 256220 32 192 512 256222 2.5 QS21 8 192 512223 32 >4096 >4096 2048224 16 1536225 64 1024 1024 1024226 5.0 QS21 64 >4096 1624 1024227 96 >4096228 64 >4096 >4096 >4096229 64 >256 >4096230 32 >4096 1536 2048231 10.0 QS21 64 2048 2048 >4096232 96 1536 2048233 96 >4096234 64 2048 2048 1024236 20.0 QS21 128 3072239 96 >4096 >4096 >4096______________________________________ .sup.1 Mice were inoculated S.C. at weeks 0 and 4. .sup.2 Sera were obtained at 4, 6, 8 or 9 weeks after priming. .sup.3 .mu.g gB in either 15 .mu.g QS21 or 25 .mu.l Alum were used for each inoculation.
TABLE 28______________________________________Summary Of Prime-Boost Experiment NT antigen NT antigen NT NTMice Day 0 adj. Day 29 adj. Day 42 Day 56______________________________________381 4 ALV 32 gB + Alu 384 768382 <4 ALV 8 gB + Alu 192 192383 4 ALV 4 gB + Alu 192 256384 <4 ALV 48 gB + Alu 512 512385 4 ALV 16 gB + Alu 256 ND397 4 ALV 8 gB + Alu 128 192G.m. 4 13.5 248 326392 <4 ALV <4 gB + QS 128 128393 <4 ALV 4 gB + QS >1024 >1024394 <4 ALV 8 gB + QS >1024 >1024395 <4 ALV 16 gB + QS 512 384396 <4 ALV 4 gB + QS 256 384398 4 ALV 8 gB + QS >1624 >1024G.m. 4 6.3 >512 >522373 4 ALV 16 ALV 128 96376 4 ALV 4 ALV 8 12378 8 ALV 4 ALV 8 4379 4 ALV 8 ALV 128 128380 4 ALV 16 ALV 64 64399 4 ALV 4 ALV 96 192400 <4 ALV 4 ALV 64 128G.m. 4 6.5 45.6 51.2______________________________________ 5 .times. 10.sup.5 TCD.sub.50 of ALVACgB (vCP139), 5 .mu.g gB + Alu, 1 .mu.g gB + Q521 were given, s.c. G.m. = geometric mean
The results presented here demonstrate the ability of the NYVAC and ALVAC-HCMV recombinants and products therefrom to be employed in the compositions and utilities aforementioned, for instance, immunological, antigenic or vaccine compositions, or for use in preparing antigens or antibodies for assays, kits or tests, and, for example, as suitable for uses in vaccine or immunization strategies capable of preventing infection by HCMV; and, that the DNA of the recombinants is useful for probes or for preparing PCR primers.
Example 47
Expression of CMV genes in NYVAC-CMV6 and NYVAC-CMV5
Immunoprecipitation with monoclonal antibodies specific for gB, gH, pp65, pp150 and IE1-exon4 demonstrated the correct expression of these five genes by NYVAC-CMV6. FACScan analysis (Becton-Dickinson ) demonstrated surface expression of gH in vP1302B infected cells but not in cells infected with its parent (vP1251) indicating that a functional gL gene product is expressed in vP1302B.
Immunoprecipitation with monoclonal antibodies specific for gB, gH, pp65and pp150 demonstrated the correct expression of these four genes by NYVAC-CMV. FACScan analysis demonstrated surface expression of gH in vP1312 infected cells but not in cells infected with its parent (vP1262) indicating that a functional gL gene product is expressed in vP1312.
Example 48
Developing an ALVAC Donor Plasmid Containing the HCMV pp65 And pp150 Genes
Plasmid CMV65C6.2 was linearized with EcoRI, filled in with klenow and treated with alkaline phosphatase generating a 6.3 kb fragment. Plasmid 150.1 was digested with NheI, filled in with klenow and a 3.2 kb fragment (42K-pp150) isolated. Ligation of these two fragments yielded plasmid 150.8R1 in which transcription of pp65 and pp150 are in the same direction and pp150 is reversed from plasmid 150.8 in example 40. The DNA sequence of CMVpp65 and CMVpp150 plus additional flanking sequences in plasmid 150.8R1 are shown in FIGS. 63 A-C (SEQ ID NO:177).
Example 49
Construction of ALVAC-CMV4 (gB, gH, pp65, pp150)
Plasmid 150.8R1 was transfected into vCP233 infected CEF cells to generate ALVAC-CMV4 (vP1360).
Example 50
Expression of CMV Genes iN ALVAC-CMV4
Immunoprecipitation with monoclonal antibodies specific for gB, gH, pp65 and pp150 demonstrated the correct expression of all four genes by ALVAC-CMV4 (vP1360).
Example 51
Developing ALVAC Donor Plasmids Containing HCMV gL or gL Plus IE1-exon4
FIGS. 64A and B (SEQ ID NO:178) is the sequence of a 5.8 kd segment of canarypox DNA contained in plasmid pcPtk. The canarypox thymidine kinase gene (tk) is encoded within this segment initiating at nucleotide 4412 and terminating at nucleotide 4951. A tk (C7) insertion vector containing 2085bp upstream of C7, polylinker containing SmaI, NruI, EcoRI, XhoI and StuI sites, and 812bp downstream of C7 was derived in the following manner. A 3450bp PstI/NsiI fragment from pCPtk was cloned into the blunt ended Asp718/XbaI sites of pBS-SK+ generating plasmid pEU1. To delete the tk ORF and replace it with a polylinker, two PCR fragments were amplified from pCPtk using oligonucleotides RG578 (SEQ ID NO:179) (5'-GTACATAAGCTTTTTGCATG-3') plus RG581 (SEQ ID NO:180) (5'-TATGAATTCCTCGAGGGATCCAGGCCTTTTTTATTGACTAGTTAATCAGTCTAATATACG TACTAAATAC-3') and RG579 (SEQ ID NO:181) (5'-CTAATTTCGAATGTCCGACG-3') plus RG580 (SEQ ID NO:182) (5'-TTAGAATTCTCGCGACCCGGGTTTTTATAGCTAATTAGTACTTATTACAAATACTATAAT ATTTAG-3'). These fragments were purified, digested with HindIII/EcoRI or BstBI/EcoRI and ligated to pEU1 cut with HindIII/BstBI resulting in plasmid pC7.
The polylinker region in pC7 was modified in the following manner. pC7 was digested with EcoRI and StuI, purified and ligated to annealed oligonucleotides SDSYN154 (SEQ ID NO:183) (5'-AATTCGTCGACGGAT CCCTCGAGGGTACCGCATGC-3') and SDSYN155 (SEQ ID NO:184) (5'-GCATGCGGTACCCTCGAGGGATCCGTCGACG-3') generating plasmid pC7.sup.+.
Plasmid pC7.sup.+ was digested with BamHI and treated with alkaline phosphatase. Plasmid I4LH6CgL was digested with BamHI and BglII and a 968bp fragment (containing the H6 promoted gL gene ) isolated. Ligation of these two fragments generated plasmid C7gL in which transcription of gL is in the same direction as the deleted tk gene. The DNA sequence of HCMV gL plus additional flanking sequences in plasmid C7gL is shown in FIGS. 65A and B SEQ ID NO:189.
Plasmid C7gL was digested with BamHI and PspAI and treated with alkaline phosphatase. Plasmid I4LH6IEEX4 was digested with BamHI and PspAI and a 1363bp fragment (containing the H6 promoted IE1-exon4 gene) isolated. Ligation of these two fragments yielded plasmid C7gLIES2. The DNA sequence of HCMV gL and IE1-exon4 plus additional flanking sequences in plasmid C7gLIES2 is shown in FIGS. 66A and B SEQ ID NO190.
Example 52
Construction of ALVAC-CMV6 (gB, gH, gL, pp65, pp150, IE1-exon4 and ALVAC-CMV5 (gB, gH, gL, pp65, pp150)
Plasmid C7gLIES2 is transfected into vP1360 infected cells to generate ALVAC-CMV6 (gB, gH, gL, pp65, pp150, IE1-exon4).
Plasmid C7gL is transfected into vP1360 infected cells to generate ALVAC-CMV5 (gB, gH, gL, pp65, pp150).
Example 53
Cloning of HCMV gL and a gH Lacking its Transmembrane Region and Cytoplasmic Tail in NYVAC Donor Plasmid pSD553
The sequence of HCMV gH lacking its transmembrane region and cytoplasmic tail is presented in FIG. 67 (SEQ ID NO:188). Plasmid SPgH1 was used in PCR with oligonucleotides SPgHS1 (SEQ ID NO:185) (5'-CCGAAGCTTCTCGAGAT AAAAATCAACGACTGTCGGTAGCGTCCACGACGAC-3') and SPgH8 (SEQ ID NO:186) (5'-TCCACTCCATGCTAGT-3') to generate a 756bp fragment. This fragment was digested with NsiI and HindIII and a 275bp fragment isolated. Plasmid SPgH6 was digested with NsiI and HindIII and a 4779bp fragment isolated. Ligation of these two fragments yielded plasmid SPgH7 which contains the 42K promoted gH gene lacking its transmembrane region and cytoplasmic tail.
NYVAC insertion plasmid pSD553VC was digested with BamHI and treated with alkaline phosphatase. Plasmid I4LH6CgL was digested with BamHI and BglII and a 970 bp fragment (containing the H6 promoter and gL gene) isolated. Ligation of these two fragments generated plasmid COPAKgL-24.
Plasmid gH7 was digested with XhoI and ScaI and a 2239bp fragment isolated (containing the 42K promoter and truncated gH gene). Plasmid COPAKgL-24 was digested with XhoI, treated with alkaline phosphatase and ligated to the 2239bp fragment generating plasmid COPAKHL-15. The DNA sequence of gL and the truncated gH plus additional flanking DNA sequences in plasmid COPAKHL-15 is shown in FIGS. 68A and B (SEQ ID NO:187).
Example 54
Constructing a Poxvirus Recombinant Containing gL and gH Lacking its Transmembrane Region and Cytoplasmic Tail
Plasmid COPAKHL-15 was transfected into NYVAC infected CEF cells to generate the recombinant vP1399.
Example 55
Expression of gH by Recombinant vP1399
Immunoprecipitation with a monoclonal antibody specific for gH revealed the expression of a secreted gH protein of approximately 97 kDa by recombinant vP1399.
Having thus described in detail preferred embodiments of the present invention, it is to be understood that the invention defined by the appended claims is not to be limited by particular details set forth in the above description as many apparent variations thereof are possible without departing from the spirit or scope thereof.
REFERENCES
1. Akrigg, A., Wilkinson, G. W. G., and Oram, J. D., Virus Res. 2:107-121 (1985).
2. Albrecht, T. and Rapp, F., Virology 55:53-61 (1973).
3. Alp, N. J., Allport, T. D., Zanten, J. Van, Rodgers, B., Patrick Sissons, J. G. and Borysiewicz, L. K., J. Virol. 65:4812-4820 (1991).
4. Altenburger, W., C -P. Suter and J. Altenburger, Archives Virol. 105:15-27 (1989).
5. Aulitzky, W., Schulz, T., Tilg, H. et al., J. Infect. Dis. 163:1344-1347 (1991).
6. Baboonian, C., Blake, K., Booth, J. C., and Wiblin, C. N., J. Med. Virol. 29:139-145 (1989).
7. Behbehani, A. M., Microbiological Reviews 47:455-509 (1983).
8. Beninga, J., Kropff, B. and Mach, M., J. Gen. Virol. 76:153-160 (1995).
9. Bergoin, M., and Dales, S., In Comparative Virology, eds. K. Maramorosch and E. Kurstak, (Academic Press, NY) pp. 169-205 (1971).
10. Bertholet, C., Drillien, R., and Wittek, R., Proc. Natl. Acad. Sci. USA 82:2096-2100 (1985).
11. Biegalke, B. J. and Geballe, A. P., Virology 183:381-385 (1991).
12. Blanton, R., and Tevethia, M., Virology 112:262-273 (1981).
13. Borysiewicz, L. K., Hickling, J. K., Graham, S., Sinclair, J., Cranage, M. P., Smith, G. L., and Sissons, J. G. P., J. Exp. Med. 168:919-931 (1988).
14. Britt, W. J., Virology 135:369-378 (1984).
15. Britt, W. J. and Auger, D., J. Virol. 58:185-191 (1986).
16. Britt, W. J. and Vugler, L. G., J. Virol. 63:403-410 (1989).
17. Brockmeier, S., Lager, K., Tartaglia, J., Riviere, M., Paoletti, E. and Mengeling, W., Veterinary Microbiology 38:41-58 (1993).
18. Buller, R. M. L., G. L. Smith, Cremer, K., Notkins, A. L., and Moss, B., Nature 317:813-815 (1985).
19. Buller, R. M. L., Chakrabarti, S., Cooper, J. A., Twardzik, D. R., and Moss, B., J.Virol. 62:866-874 (1988).
20. Cadoz, M., A. Strady, B. Meignier, J. Taylor, J. Tartaglia, E. Paoletti and S. Plotkin, The Lancet, 339:1429-1432 (1992).
21. Cameron, J., and Preston, C., J. Gen. Virol. 54:421-424 (1981).
22. Charpentier, B., Michelson, S. and Martin, B., J. of Immunology 137:330-336 (1986).
23. Cherrington, J. M. and Mocarski, E. S., J. Virol. 63:1435-1440 (1989).
24. Child, S. J., Palumbo, G. J., Buller, R. M. L., and Hruby, D. E. Virology 174:625-629 (1990).
25. Clewell, D. B. and D. R. Helinski, Proc. Natl. Acad. Sci. USA 62:1159-1166 (1969).
26. Clewell, D. B., J. Bacteriol 110:667-676 (1972).
27. Colberg-Poley, A. M., Santomenna, L. D., Harlow, P. P., Benfield, P. A. and Tenney, D. J., J. Virol. 66:95-105 (1992).
28. Colinas, R. J., R. C. Condit and E. Paoletti, Virus Research 18:49-70 (1990).
29. Cooney, E. L., Corrier, A. C., Greenberg, P. D., et al., Lancet 337:567-572 (1991).
30. Cooney, E., McElrath, M., Corey, L., Hu, S., Collier, A., Arditti, D., Hoffman, M., Coombs, R., Smith, G., and Greenberg, P., Proc. Natl. Acad. Sci. USA 90:1882-1886 (1993).
31. Cranage, M. P., Smith, G. L., Bell, S. E., Hart, H., Brown, C., Bankier, A. T., Tomlinson, P., Barrell, B. G. and Minson, T. C., J. Virol. 62:1416-1422 (1988).
32. Cranage, M. P., Kouzarides, T., Bankier, A., Satchwell, S., Weston, K., Tomlinson, P. and Barrell, B., EMBO J. 5:3057-3063 (1986).
33. DeMarchi, J. M., Schmidt, C. A., and Kaplan, A. S., J. Virol. 35:277-286 (1980).
34. Dreyfus, G., Adam, S. A. and Choi, Y. D., Mol. Cell. Biol. 4:415-423 (1984).
35. Drilliem, R., Koehren, F. and Kirn, A., Virology 111:448-499 (1981).
36. Edbauer, C., R. Weinberg, J. Taylor, A. Rey-Senelonge, J. F. Bouquet, P. Desmettre, E. Paoletti, Virology 179:901-904 (1990).
37. Ehrlich, P. H., Moustafa, Z. A., Justice, J. C., Harfeldt, K. E., and Ostberg, L., Hybridoma 7:385-395 (1988).
38. Engelke, D. R., Hoener, P. A., and Collins, F. S., Proc. Natl. Acad. Sci. 85:544-548 (1988).
39. Etinger, H. M. and Altenburger, W., Vaccine 9:470-472 (1991).
40. Fenner, F., Virology 5:502-529 (1958).
41. Flexner, C., Hugen, A., and Moss, B., Nature 330:259-262 (1987).
42. Forman, S. J., Zaia, J. A., Clark, B. R., Wright, C. L., Mills, B. J., Pottathil, R., Racklin, B. C., Gallagher, M. T., Welte, K., and Blume, K. G., J. Immunol. 134:3391-3395 (1985).
43. Fries et al., 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, Calif. (October 1992).
44. Funahashi, S., T. Sato and H. Shida, J. Gen. Virol. 69:35-47 (1988).
45. Gallant, J. E., Moore, R. D., Richman, D. D. et al., J. Infect. Dis. 166:1223-1227 (1992).
46. Galloway, D. A., Buonaguro, F. M., Brandt, C. R., and McDougall, J. K., In Cancer Cells, DNA Tumor Viruses: Control of Gene Expression and Replication, eds. Botchan, M., Grodzicker, T., and Sharp, P. A. (Cold Spring Harbor Laboratory) 4:355-361 (1986).
47. Ghazal, P., Young, J., Giuletti, E., DeMattei, C., Garcia, J., Gaynor, J., Stenberg, R. M. and Nelson, J. A., J. Virol. 65:6735-6742 (1991).
48. Ghendon, Y. Z., and Chernos, V. I., Acta Virol. 8:359-368 (1964).
49. Gilbert, M. J., Riddell, S. R., Li, C. R. and Greenberg, P. D., J. Virol. 67:3461-3469 (1993).
50. Gillard, S., Spehner, D., Drillien, R., and Kirn, A., Proc. Natl. Acad. Sci. USA 83:5573-5577 (1986).
51. Glenn, J., Rev. Infect. Dis. 3:1151-1178 (1981).
52. Goebel, S. J., Johnson, G. P., Perkus, M. E., Davis, S. W., Winslow, J. P., Paoletti, E., Virology 179:247-266 (1990a).
53. Goebel, S. J., G. P. Johnson, M. E. Perkus, S. W. Davis, J. P. Winslow and E. Paoletti, Virology 179:517-563 (1990b).
54. Goldstein, D. J. and S. K. Weller, Virology 166:41-51 (1988).
55. Gonczol, E., Ianacone, W. H. O., Starr, S., Meignier, B., and Plotkin, S. A., Vaccine 8:130-136 (1990).
56. Gonczol, E., De Taisne, C., Hirka, G., Berencsi, K., Lin, W., Paoletti, E. and Plotkin, S., Vaccine 9:631-637 (1991).
57. Gonczol E., Furlini, G., Ianacone, J., and Plotkin, S., J. Virol. Meth. 14:37-41 (1986).
58. Graham, B., Mathes, T., Belshe, R., Clements, M., Dolin, R., Wright, P., Gorse, G., Schwartz, D., Keefer, M., Bolognesi, D., Corey, L., Stablein, D., Esterlitz, J., Hu, S. -L., Smith, G., Fast, P., Koff, W. and the HIAID AIDS Vaccine Clinical Trials Network, J. Infect. Dis. 167:533-537 (1993).
59. Gretch, D. R., Kari, B., Gehrz, R. C., and Stinski, M. F., J. Virol. 62:1956-1962 (1988a).
60. Gretch, D. R., Kari, B., Rasmussen, L., Gehrz, R. C., and Stinski, M. F., J. Virol. 62:875-881 (1988b).
61. Gross, J. G., Bozzette, S. A., Mathews, W. C. et al., Ophthalmology 97:681-686 (1990).
62. Guo et al., J. Virol. 64:2399-2406 (1990).
63. Guo, P., Goebel, S., Davis, S., Perkus, M. E., Languet, B., Desmettre, P., Allen, G., and Paoletti, E., J. Virol. 63:4189-4198 (1989).
64. Hagemeier, C., Walker, S. M., Sissons, P. J. G. and Sinclair, J. H., J. Gen. Virol. 73:2385-2393 (1992).
65. Harlow, E. and Lane D., In Antibodies: A Laboratory Manual (Cold Spring Harbor University, Cold Spring Harbor, N.Y.) (1988).
66. Hruby, D. E. and L. A. Ball, J. Virol. 43:403-409 (1982).
67. Hruby, D. E., R. A. Maki, D. B. Miller and L. A. Ball, Proc. Natl. Acad. Sci. USA 80:3411-3415 (1983).
68. Hu, S. -L., Klaniecki, J., Dykers, T., Sridhar, P. and Travis, B., AIDS RES. Hum. Retroviruses 3:615-620 (1991).
69. Hu, S. -L., Abrams, K., Barber, G., Moran, P., Zarling, J., Langlois, A., Kuller, L., Morton, W. and Benveniste, R., Science 255:456-459 (1992).
70. Ichihashi, Y. and Dales, S., Virology 46:533-543 (1971).
71. Itamura, S., H. Iinuma, H. Shida, Y. Morikawa, K. Nerome and A. Oya, J. Gen. Virol. 71:2859-2865 (1990).
72. Jacobson, J. G., D. A. Leib, D. J. Goldstein, C. L. Bogard, P. A. Schaffer, S. K. Weller and D. M. Coen, Virology 173:276-283 (1989).
73. Jahn, G., Scholl, B. -C., Traupe, B. and Fleckenstein, B., J. Gen. Virol. 68:1327-1337 (1987).
74. Jamieson, A. T., G. A. Gentry and J. H. Subak-Sharpe, J. Gen. Virol. 24:465-480 (1974).
75. Jonjic, S., del Val, M., Keil, G. M., Reddehasse, M. J. and Koszinowski, U. H., J. Virol. 62:1653-1658 (1988).
76. Kari, B. and Gehrz, R., Arch. Virol. 114:213-228 (1990).
77. Kari, B., Lussenhop, N., Goertz, R., Wabuke-Bunoti, M., Radeke, R. and Gehrz, R., J. Virol. 60:345-352 (1986).
78. Kari, B., Liu, Y. -N. C., Goertz, R., Lussenshop, N. and Stinski, M. F., J. Gen. Virol. 71:2673-2680 (1990).
79. Kato, S., M. Takahashi, S. Kameyama and J. Kamahora, Biken's 2:353-363 (1959).
80. Kaye, J. F., Gompels, U. A. and Minson, A. C., J. Gen. Virol. 72:2693-2698 (1992).
81. Kieny, M. P., Lathe, R., Drillien, R., Spehner, D., Skory, S., Schmitt, D., Wiktor, T., Koprowski, H., and Lecocq, J. P., Nature (London) 312:163-166 (1984).
82. Kleitman, W., Schottle, A., Kleitmann, B., et al., In Cell Culture Rabies Vaccines and Their Protective Effect in Man., eds. Kuwert/Wiktor/Koprowski (International Green Cross-Geneva) pp. 330-337 (1981).
83. Knauf, V. C., and Nester, E. W., Plasmid 8:45-54 (1982).
84. Konishi, E., Pincus, S., Paoletti, E., Laegreid, W. W., Shope, R. E. and Mason, P. W., Virology 190:454-458 (1992).
85. Kotwal, G. J. and Moss, B., Nature (London) 335:176-178 (1988a).
86. Kotwal, G. J. and Moss, B., Virology 167:524-537 (1988b).
87. Kotwal, G. J., S. N. Isaacs, R. McKenzie, M. M. Frank and B. Moss, Science 250:827-830 (1990).
88. Kotwal, G. J., A. W. Hugin and B. Moss, Virology 171:579-587 (1989a).
89. Kotwal, G. J. and B. Moss, J. Virol. 63:600-606 (1989b).
90. Kunkel, T. A., Proc. Natl. Acad. Sci. USA 82:488-492 (1985).
91. Kuwert, E. K., Barsenbach, C., Werner, J., et al., In Cell Culture Rabies Vaccines and Their Protective Effect in Man., eds. Kuwert/Witkor/Koprowski (International Green Cross-Geneva) pp. 160-167 (1981).
92. Lafemina, R., Pizzorno, M. C., Mosca, J. D. and Hayward, G. S., Virology 172:584-600 (1989).
93. Lai, C. -K., and B. G -T., Pogo Virus Res. 12:239-250 (1989).
94. Liu, Y. -N. C., Klaus, A., Kari, B., Stinski, M. F., Eckhardt, J. and Gehrz, R. C., J. Virology 65:1644-1648 (1991).
95. Mandecki, W., Proc. Natl. Acad. Sci. USA 83:7177-7182 (1986).
96. Maniatis, T., Fritsch, E. F., and Sambrook, J., In Molecular cloning: a laboratory manual, (Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.) (1982).
97. Marshall, G. S., Rabalais, G. P., Stout, G. G. and Waldeyer, S. L., J. Infect. Dis. 165:381-384 (1992).
98. Masuho, Y., Matsumoto, Y. -I., Sugano, T., Fujnaga, S. and Minamishima, Y., J. Gen. Virol. 68:1357-1461 (1987).
99. Matthews, R. E. F., Intervirology 17:42-44 (1982).
100. McDonough, S. and Spector, D., Virology 125:31-46 (1983).
101. Morgan, A. J., M. Mackett, S. Finerty, J. R. Arrand, F. T. Scullion and M. A. Epstein, J. Med. Virol. 25:189-195 (1988).
102. Moss, B., E. Winters and J. A. Cooper, J. Virol. 40:387-395 (1981).
103. Pachl, C., Probert, W. S., Hermsen, K. M., Masiarz, F. R., Rasmussen, L., Merigan, T. C. and Spaete, R. C., Virology 169:418-426 (1989).
104. Paez, E., Dallo, S. and Esteban, M., Proc. Natl. Acad. Sci. USA 82:3365-3369 (1985).
105. Palumbo, G. J., Pickup, D. J., Fredrickson, T. N., Mcintyre, L. J., and Buller, R. M. L., Virology 172:262-273 (1989).
106. Pande, H., Campo, K., Tanamachi, B. and Zaia, J. A., Virology 182:220-228 (1991).
107. Panicali, D. and E. Paoletti, Proc. Natl. Acad. Sci. USA 79:4927-4931 (1982).
108. Panicali, D., Davis, S. W., Mercer, S. R., and Paoletti, E., J. Virol. 37:1000-1010 (1981).
109. Patel, D. D., Ray, C. A., Drucker, R. P., and Pickup, D. J., Proc. Natl. Acad. Sci. USA 85:9431-9435 (1988).
110. Patel, D. D. and Pickup, D. J., EMBO 6:3787-3794 (1987).
111. Pereira, L., Hoffman, M., Tatsuno, M. and Dondero, D., Virology 139:73-86 (1984).
112. Pereira, L. and Hoffman, M., In Human Herpesvirus Infections: Pathogenesis, Diagnosis and Treatments, eds. Lopez, C. and Roizman, B. Second International Conference on Immunobiology and Prophyaxis of Human Herpesvirus Infections Oct. 13-16, 1985 (Raven Press, New York) pp. 69-92 (1986).
113. Perkus, M. E., D. Panicali, S. Mercer and E. Paoletti, Virology 152:285-297 (1986).
114. Perkus, M. E., Limbach, K., and Paoletti, E., J. Virol. 63:3829-3836 (1989).
115. Perkus, M. E., Taylor, J., Tartaglia, J., Pincus, S., Kauffman, E. B., Tine, J. A. and Paoletti, E., In Combined Vaccines and Simultaneous Administration: Current Issues and Perspective (Annals of the New York Academy of Sciences) in press (1994).
116. Perkus, M. E., Goebel, S. J., Davis, S. W., Johnson, G. P., Limbach, K., Norton, E. K., and Paoletti, E., Virology 179:276-286 (1990).
117. Perkus, M. E., Kauffman, E. B., Taylor, J., Mercer, S., Smith, D., VanderHoeven, J. and Paoletti, E., J. Tiss. Cult. Meth. 15:72-81 (1993).
118. Perkus, M. E., S. J. Goebel, S. W. Davis, G. P. Johnson, E. K. Norton and E. Paoletti, Virology 180:406-410 (1991).
119. Perkus, M. E., A. Piccini, B. R. Lipinskas and E. Paoletti, Science 229:981-984 (1985).
120. Pialoux, G., Excler, J. -L., Riviere, Y. et al., AIDS Research and Human Retroviruses 11:373-381 (1995).
121. Piccini, A., M. E. Perkus, and E. Paoletti, Methods in Enzymology 153:545-563 (1987).
122. Pickup, D. J., B. S. Ink, B. L. Parsons, W. Hu and W. K. Joklik, Proc. Natl. Acad. Sci. USA 81:6817-6821 (1984).
123. Pickup, D. J., B. S. Ink, W. Hu, C. A. Ray and W. K. Joklik, Proc. Natl. Acad. Sci. USA 83:7698-7702 (1986).
124. Plachter, B., Klages, S., Hagelmann, S., Britt, W., Landini, M. P. and Jahn, G., J. Clin. Microbiol. 28:1229-1235 (1990).
125. Plotkin, S. A., Smiley, M. L., Friedman, H. M., Starr, S. E., Fleisher, G. R. and Wrodaver, C., Lancet 1:528-530 (1984).
126. Plotkin, S. A., Starr, S. E., Friedman, H. M., Gonczol, E. and Weibel, R. E., J. Infect. Dis. 159:860-865 (1989).
127. Plotkin, S.A., Farquhar, J. and Hornberger, E., J. Infect. Dis. 134:470-475 (1976).
128. Rasmussen, L., Nelson, M., Neff, M. and Merigan, Jr., T. C., Virology 163:308-318 (1988).
129. Rasmussen, L., Matkin, C., Spaete, R., Pachl, C. and Merigan, T. C., J. Infect. Dis. 164:835-842 (1991).
130. Rasmussen, L., Nelson, R. M., Kelsall, D. C. and Merigan, T. C., Proc. Natl. Acad. Sci. USA 81:876-880 (1984).
131. Reed, J. and Muench, H., Am. J. Hyg. 27:493-497 (1938).
132. Reis, B., Bogner, E., Reschke, M., Richter, A., Mockenhaupt, T. and Radsak, K., J. Gen. Virol. 74:1371-1379 (1993).
133. Riddell, S. R., Rabin, M., Geballe, A. P., Britt, W. J. and Greenberg, P. D., J. Immunol. 146:2795-2804 (1991).
134. Riddell, S. R., Watanabe, K. S., Goodrich, J. M., Li, C. R., Agha, M. E. and Greenberg, P. D., Science 257:238-241 (1992).
135. Roarty, J. D., Fisher, E. J., and Nussbaum, J. J., Ophthalmology 100:1685-1688 (1993).
136. Sanger, F., Nickel, S. Coulson, A. R., Proc. Natl. Acad. Sci. 74:5463-5467 (1977).
137. Santomenna, L. D. and Colberg-Poley, A. M., J. Virol. 64:2033-2040 (1990).
138. Schmidtt, J. F. C. and H. G. Stunnenberg, J. Virol. 62:1889-1897 (1988).
139. Seligmann, E. B., In Laboratory Techniques in Rabies, eds. M. M. Kaplan and H. Koprowski, (World Health Organization, Geneva) pp. 279-285 (1973).
140. Shapira, S. K., Chou, J., Richaud, F. V. and Casadaban, M. J., Gene 25:71-82 (1983).
141. Shida, H., Virology 150:451-462 (1986).
142. Shida, H., Hinuma, Y., Hatanaka, M., Morita, M., Kidokoro, M., Suzuki, K., Maruyzam, T., Takahashi-Nishimaki, F., Sugimoto, M., Kitamura, R., Miyazawa, T., and Hayami, M., J. Virol. 62:4474-4480 (1988).
143. Shida, H., T. Tochikura, T. Sato, T. Konno, K. Hirayoshi, M. Seki, Y. Ito, M. Hatanaka, Y. Hinuma, M. Sugimoto, F. Takahashi-Nishimaki, T. Maruyama, K. Miki, K. Suzuki, M. Morita, H. Sashiyama and M. Hayami, EMBO 6:3379-3384 (1987).
144. Slabaugh, M., N. Roseman, R. Davis and C. Mathews, J. Virol. 62:519-527 (1988).
145. Smith, J. S., P. A. Yager and G. M. Baer, In Laboratory Techniques in Rabies, eds. M. M. Kaplan and H. Koprowski (WHO Geneva) pp. 354-357 (1973).
146. Spaete, R. R., Gehrz, R. C. and Landini, M. P., J. Gen. Virol. 75:3287-3308 (1994).
147. Spaete, R. R., Thayer, R. M., Probert, W. S., Masiarz, F. R., Chamberlain, S. H., Rasmussen, L., Merigan, T. C. and Pachl, C., Virology 167:207-225 (1988).
148. Spaete, R. R., Perot, K., Scott, P. I., Nelson, J. A., Stinski, M. F. and Pachl, C., Virology 193:853-861 (1993).
149. Spaete, R. R., Perot, K., Scott, P. I., Bauer, D., Lee, A. S., Scott, M. H., Rasmussen, L., Britt, W. J. and Pachl, C., In Progress in cytomegalovirus research, ed. M. P. Landini, pp. 133-136 (1991).
150. Speir, E., Modali, R., Huang, E. -S et al., Science 265:391-394 (1994).
151. Stagno, S., Pass, R. F., Dworsky, M. E. and Alford, C. A., Semin. Perinatol 7:31-42 (1983).
152. Stanberry, L. R., Kit, S., Myers, M. G., J. Virol. 55:322-328 (1985).
153. Tabor, S. and C. C. Richardson, Proc. Natl. Acad. Sci. USA 84:4767-4771 (1987).
154. Tartaglia, J., Perkus, M. E., Taylor, J., Norton, E. K., Audonnet, J -C., Cox, W. I., Davis, S. W., Van der Hoeven, J., Meignier, B., Riviere, M., Languet, B., Paoletti, E., Virology 188:217-232 (1992).
155. Tartaglia, J., R. Gettig & E. Paoletti, Virology (In press).
156. Tartaglia, J. and Paoletti, E., In Immunochemistry of Viruses, II, eds. M. H. V. van Regenmortel & A. R. Neurath, (Elsevier Science Publishers, Amsterdam) pp. 125-151 (1990b).
157. Tartaglia, J., Perkus, M. E., Taylor, J., Norton, E. K., Audonnet, J. -C., Cox, W. I., Davis, S. W., Van Der Hoeven, J., Meignier, B., Riviere, M., Languet, B., Paoletti, E., Virology 188:217-232 (1992).
158. Tartaglia, J., J. Taylor, W. I. Cox, J. -C. Audonnet, M. E. Perkus, A. Radaelli, C. de Giuli Morghen, B. Meignier, M. Riviere, K. Weinhold & E. Paoletti, In AIDS Research Reviews, eds. W. Koff, F. Wong-Staal & R. C. Kenedy, Vol. 3, (Marcel Dekker, NY) pp. 361-378 (1993a).
159. Tartaglia, J., Jarrett, O., Neil, J. C., Desmettre, P., Paoletti, E., J. Virol. 67:2370-2375 (1993b).
160. Tartaglia, J., Pincus, S., Paoletti, E., Critical Reviews in Immunology 10:13-30 (1990a).
161. Taylor, J., R. Weinberg, J. Tartaglia, C. Richardson, G. Alkhatib, D. Briedis, M. Appel, E. Norton & E. Paoletti, Virology 187:321-328 (1992).
162. Taylor, J., Tartaglia, J., Moran, T., Webster, R. G., Boquet, J. -F., Quimby, F., Holmes, D., Laplace, E., Mickle, T. and Paoletti, E., In Proceedings of the Third International Symposium on Avian Influenza, Univ of Wisconsin- Madison, Madison, Wis., pp. 311-335 (1993).
163. Taylor, J., Edbauer, C., Rey-Senelonge, A., Bouquet, J. -F., Norton, E., Goebel, S., Desmettre, P., Paoletti, E., J. Virol. 64:1441-1450 (1990).
164. Taylor, J., R. Weinberg, B. Lanquet, P. Desmettre, and E. Paoletti, Vaccine 6:497-503 (1988b).
165. Taylor, J., Weinberg, R., Kawaoka, Y., Webster, R. G., and Paoletti, E., Vaccine 6:504-508 (1988a).
166. Taylor, G., E. J. Stott, G. Wertz and A. Ball, J. Gen. Virol. 72:125-130 (1991a).
167. Taylor, J., C. Trimarchi, R. Weinberg, B. Languet, F. Guillemin, P. Desmettre and E. Paoletti, Vaccine 9:190-193 (1991b).
168. Wathen, M. W., Thomsen, D. R. and Stinski, M. F., J. Virol. 38:446-459 (1981).
169. Weir, J. P. and B. Moss, J. Virol. 46:530-537 (1983).
170. Weller, T. H., N. Engl. J. of Med. 285:203-214 (1971).
171. Yuen, L., and Moss, B., Proc. Natl. Acad. Sci. USA 84:6417-6421 (1987).
172. Zhou, J., L. Crawford, L. McLean, X. Sun, M. Stanley, N. Almond and G. L. Smith, J. Gen. Virol. 71:2185-2190 (1990).
__________________________________________________________________________# SEQUENCE LISTING- (1) GENERAL INFORMATION:- (iii) NUMBER OF SEQUENCES: 190- (2) INFORMATION FOR SEQ ID NO:1:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 20 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:# 20 CGGG- (2) INFORMATION FOR SEQ ID NO:2:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 28 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:# 28 GTTA ATTACATG- (2) INFORMATION FOR SEQ ID NO:3:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 73 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:- AGCTTCCCGG GTAAGTAATA CGTCAAGGAG AAAACGAAAC GATCTGTAGT TA - #GCGGCCGC 60# 73- (2) INFORMATION FOR SEQ ID NO:4:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 69 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:- ATTAGTTAAT TAGGCGGCCG CTAACTACAG ATCGTTTCGT TTTCTCCTTG AC - #GTATTACT 60# 69- (2) INFORMATION FOR SEQ ID NO:5:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 20 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:# 20 CCGC- (2) INFORMATION FOR SEQ ID NO:6:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 22 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:# 22CCG TT- (2) INFORMATION FOR SEQ ID NO:7:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 20 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:# 20 TAAT- (2) INFORMATION FOR SEQ ID NO:8:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 41 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:# 41 GCTC CCCGGGCTCG AGGGATCCGT T- (2) INFORMATION FOR SEQ ID NO:9:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 39 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:# 39 CCGG GGAGCTCAGA TCTAGTAAT- (2) INFORMATION FOR SEQ ID NO:10:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 16 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:# 16- (2) INFORMATION FOR SEQ ID NO:11:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 12 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:# 12- (2) INFORMATION FOR SEQ ID NO:12:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 75 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:- TATGAGTAAC TTAACTCTTT TGTTAATTAA AAGTATATTC AAAAAATAAG TT - #ATATAAAT 60# 75- (2) INFORMATION FOR SEQ ID NO:13:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 73 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:- AACGAATTCA GATCTATTTA TATAACTTAT TTTTTGAATA TACTTTTAAT TA - #ACAAAAGA 60# 73- (2) INFORMATION FOR SEQ ID NO:14:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 49 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:# 49TGTTA ACTTTATATA ACTTATTTTT TGAATATAC- (2) INFORMATION FOR SEQ ID NO:15:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 67 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:- ACACGAATGA TTTTCTAAAG TATTTGGAAA GTTTTATAGG TAGTTGATAG AA - #CAAAATAC 60# 67- (2) INFORMATION FOR SEQ ID NO:16:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 51 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:# 51TATAAAA CTTTCCAAAT ACTTTAGAAA ATCATTCGTG T- (2) INFORMATION FOR SEQ ID NO:17:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 46 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:# 46TTT TATACTAAGA TCTCCCGGGC TGCAGC- (2) INFORMATION FOR SEQ ID NO:18:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 66 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:- GGCCGCTGCA GCCCGGGAGA TCTTAGTATA AAAAGTGATT TATTTTTACA AA - #ATTATGTA 60# 66- (2) INFORMATION FOR SEQ ID NO:19:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 50 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:# 50CACCAA TTTAGATCTT ACTCAAAATA TGTAACAATA- (2) INFORMATION FOR SEQ ID NO:20:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 44 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:# 44 ACTC ATATTAATAA AAATAATATT TATT- (2) INFORMATION FOR SEQ ID NO:21:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 72 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:- GATCCTGAGT ACTTTGTAAT ATAATGATAT ATATTTTCAC TTTATCTCAT TT - #GAGAATAA 60# 72- (2) INFORMATION FOR SEQ ID NO:22:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 72 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:- AATTCCTAAG ATCTTTTTAT TCTCAAATGA GATAAAGTGA AAATATATAT CA - #TTATATTA 60# 72- (2) INFORMATION FOR SEQ ID NO:23:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 72 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:- GATCCAGATC TCCCGGGAAA AAAATTATTT AACTTTTCAT TAATAGGGAT TT - #GACGTATG 60# 72- (2) INFORMATION FOR SEQ ID NO:24:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 72 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:- AATTCCTAGT ACGCATCATA CGTCAAATCC CTATTAATGA AAAGTTAAAT AA - #TTTTTTTC 60# 72- (2) INFORMATION FOR SEQ ID NO:25:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 40 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:# 40 TGCA GGGCGCCGGA TCCTTTTTCT- (2) INFORMATION FOR SEQ ID NO:26:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 40 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:# 40 GCCC TGCAGCTCGA GAGATCTCCC- (2) INFORMATION FOR SEQ ID NO:27:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 3209 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:- TGAATGTTAA ATGTTATACT TTGGATGAAG CTATAAATAT GCATTGGAAA AA - #TAATCCAT 60- TTAAAGAAAG GATTCAAATA CTACAAAACC TAAGCGATAA TATGTTAACT AA - #GCTTATTC 120- TTAACGACGC TTTAAATATA CACAAATAAA CATAATTTTT GTATAACCTA AC - #AAATAACT 180- AAAACATAAA AATAATAAAA GGAAATGTAA TATCGTAATT ATTTTACTCA GG - #AATGGGGT 240- TAAATATTTA TATCACGTGT ATATCTATAC TGTTATCGTA TACTCTTTAC AA - #TTACTATT 300- ACGAATATGC AAGAGATAAT AAGATTACGT ATTTAAGAGA ATCTTGTCAT GA - #TAATTGGG 360- TACGACATAG TGATAAATGC TATTTCGCAT CGTTACATAA AGTCAGTTGG AA - #AGATGGAT 420- TTGACAGATG TAACTTAATA GGTGCAAAAA TGTTAAATAA CAGCATTCTA TC - #GGAAGATA 480- GGATACCAGT TATATTATAC AAAAATCACT GGTTGGATAA AACAGATTCT GC - #AATATTCG 540- TAAAAGATGA AGATTACTGC GAATTTGTAA ACTATGACAA TAAAAAGCCA TT - #TATCTCAA 600- CGACATCGTG TAATTCTTCC ATGTTTTATG TATGTGTTTC AGATATTATG AG - #ATTACTAT 660- AAACTTTTTG TATACTTATA TTCCGTAAAC TATATTAATC ATGAAGAAAA TG - #AAAAAGTA 720- TAGAAGCTGT TCACGAGCGG TTGTTGAAAA CAACAAAATT ATACATTCAA GA - #TGGCTTAC 780- ATGTACGTCT GTGAGGCTAT CATGGATAAT GACAATGCAT CTCTAAATAG GT - #TTTTGGAC 840- AATGGATTCG ACCCTAACAC GGAATATGGT ACTCTACAAT CTCCTCTTGA AA - #TGGCTGTA 900- ATGTTCAAGA ATACCGAGGC TATAAAAATC TTGATGAGGT ATGGAGCTAA AC - #CTGTAGTT 960- ACTGAATGCA CAACTTCTTG TCTGCATGAT GCGGTGTTGA GAGACGACTA CA - #AAATAGTA1020- AAAGATCTGT TGAAGAATAA CTATGTAAAC AATGTTCTTT ACAGCGGAGG CT - #TTACTCCT1080- TTGTGTTTGG CAGCTTACCT TAACAAAGTT AATTTGGTTA AACTTCTATT GG - #CTCATTCG1140- GCGGATGTAG ATATTTCAAA CACGGATCGG TTAACTCCTC TACATATAGC CG - #TATCAAAT1200- AAAAATTTAA CAATGGTTAA ACTTCTATTG AACAAAGGTG CTGATACTGA CT - #TGCTGGAT1260- AACATGGGAC GTACTCCTTT AATGATCGCT GTACAATCTG GAAATATTGA AA - #TATGTAGC1320- ACACTACTTA AAAAAAATAA AATGTCCAGA ACTGGGAAAA ATTGATCTTG CC - #AGCTGTAA1380- TTCATGGTAG AAAAGAAGTG CTCAGGCTAC TTTTCAACAA AGGAGCAGAT GT - #AAACTACA1440- TCTTTGAAAG AAATGGAAAA TCATATACTG TTTTGGAATT GATTAAAGAA AG - #TTACTCTG1500- AGACACAAAA GAGGTAGCTG AAGTGGTACT CTCAAAATGC AGAACGATGA CT - #GCGAAGCA1560- AGAAGTAGAG AAATAACACT TTATGACTTT CTTAGTTGTA GAAAAGATAG AG - #ATATAATG1620- ATGGTCATAG ATAACTCTGA TATTGCAAGT AAATGCAATA ATAAGTTAGA TT - #TATTTAAA1680- AGGATAGTTA AAAATAGAAA AAAAGAGTTA ATTTGTAGGG TTAAAATAAT AC - #ATAAGATC1740- TTAAAATTTA TAAATACGCA TAATAATAAA AATAGATTAT ACTTATTACC TT - #CAGAGATA1800- AAATTTAAGA TATTTACTTA TTTAACTTAT AAAGATCTAA AATGCATAAT TT - #CTAAATAA1860- TGAAAAAAAA GTACATCATG AGCAACGCGT TAGTATATTT TACAATGGAG AT - #TAACGCTC1920- TATACCGTTC TATGTTTATT GATTCAGATG ATGTTTTAGA AAAGAAAGTT AT - #TGAATATG1980- AAAACTTTAA TGAAGATGAA GATGACGACG ATGATTATTG TTGTAAATCT GT - #TTTAGATG2040- AAGAAGATGA CGCGCTAAAG TATACTATGG TTACAAAGTA TAACTCTATA CT - #ACTAATGG2100- CGACTTCTGC AAGAAGGTAT AGTATAGTGA AAATGTTGTT AGATTATGAT TA - #TGAAAAAC2160- CAAATAAATC AGATCCATAT CTAAAGGTAT CTCCTTTGCA CATAATTTCA TC - #TATTCCTA2220- GTTTAGAATA CTTTTCATTA TATTTGTTTA CAGCTGAAGA CGAAAAAAAT AT - #ATCGATAA2280- TAGAAGATTA TGTTAACTCT GCTAATAAGA TGAAATTGAA TGAGTCTGTG AT - #AATAGCTA2340- TAATCAGAGA AGTTCTAAAA GGAAATAAAA ATCTAACTGA TCAGGATATA AA - #AACATTGG2400- CTGATGAAAT CAACAAGGAG GAACTGAATA TAGCTAAACT ATTGTTAGAT AG - #AGGGGCCA2460- AAGTAAATTA CAAGGATGTT TACGGTTCTT CAGCTCTCCA TAGAGCTGCT AT - #TGGTAGGA2520- AACAGGATAT GATAAAGCTG TTAATCGATC ATGGAGCTGA TGTAAACTCT TT - #AACTATTG2580- CTAAAGATAA TCTTATTAAA AAAAAATAAT ATCACGTTTA GTAATATTAA AA - #TATATTAA2640- TAACTCTATT ACTAATAACT CCAGTGGATA TGAACATAAT ACGAAGTTTA TA - #CATTCTCA2700- TCAAAATCTT ATTGACATCA AGTTAGATTG TGAAAATGAG ATTATGAAAT TA - #AGGAATAC2760- AAAAATAGGA TGTAAGAACT TACTAGAATG TTTTATCAAT AATGATATGA AT - #ACAGTATC2820- TAGGGCTATA AACAATGAAA CGATTAAAAA TTATAAAAAT CATTTCCCTA TA - #TATAATAC2880- GCTCATAGAA AAATTCATTT CTGAAAGTAT ACTAAGACAC GAATTATTGG AT - #GGAGTTAT2940- AAATTCTTTT CAAGGATTCA ATAATAAATT GCCTTACGAG ATTCAGTACA TT - #ATACTGGA3000- GAATCTTAAT AACCATGAAC TAAAAAAAAT TTTAGATAAT ATACATTAAA AA - #GGTAAATA3060- GATCATCTGT TATTATAAGC AAAGATGCTT GTTGCCAATA ATATACAACA GG - #TATTTGTT3120- TTTATTTTTA ACTACATATT TGATGTTCAT TCTCTTTATA TAGTATACAC AG - #AAAATTCA3180# 3209 TCTA GTTATCTAG- (2) INFORMATION FOR SEQ ID NO:28:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 29 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:# 29 AGCT AGCTAGTTT- (2) INFORMATION FOR SEQ ID NO:29:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 46 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:# 46GGG AATTCTAGCT AGCTAGTTTT TATAAA- (2) INFORMATION FOR SEQ ID NO:30:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 50 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:# 50CTAGCT AGCTAGAATT CCCGGGAAGC TTTTGAGAGT- (2) INFORMATION FOR SEQ ID NO:31:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 71 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:- CTGAAATTAT TTCATTATCG CGATATCCGT TAAGTTTGTA TCGTAATGGT TC - #CTCAGGCT 60# 71- (2) INFORMATION FOR SEQ ID NO:32:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 48 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:# 48TAAC GGATATCGCG ATAATGAAAT AATTTCAG- (2) INFORMATION FOR SEQ ID NO:33:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 73 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:- ACCCCTTCTG GTTTTTCCGT TGTGTTTTGG GAAATTCCCT ATTTACACGA TC - #CCAGACAA 60# 73- (2) INFORMATION FOR SEQ ID NO:34:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 51 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:# 51TTGTCTG GGATCGTGTA AATAGGGAAT TTCCCAAAAC A- (2) INFORMATION FOR SEQ ID NO:35:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 45 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:#45 AGGG GTACAAACAG GAGAGCCTGA GGAAC- (2) INFORMATION FOR SEQ ID NO:36:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 11 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:# 11- (2) INFORMATION FOR SEQ ID NO:37:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 2724 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:- ATGGAATCCA GGATCTGGTG CCTGGTAGTC TGCGTTAACT TGTGTATCGT CT - #GTCTGGGT 60- GCTGCGGTTT CCTCATCTTC TACTCGTGGA ACTTCTGCTA CTCACAGTCA CC - #ATTCCTCT 120- CATACGACGT CTGCTGCTCA TTCTCGATCC GGTTCAGTCT CTCAACGCGT AA - #CTTCTTCC 180- CAAACGGTCA GCCATGGTGT TAACGAGACC ATCTACAACA CTACCCTCAA GT - #ACGGAGAT 240- GTGGTGGGGG TCAACACCAC CAAGTACCCC TATCGCGTGT GTTCTATGGC AC - #AGGGTACG 300- GATCTTATTC GCTTTGAACG TAATATCGTC TGCACCTCGA TGAAGCCCAT CA - #ATGAAGAC 360- CTGGACGAGG GCATCATGGT GGTCTACAAA CGCAACATCG TCGCGCACAC CT - #TTAAGGTA 420- CGAGTCTACC AGAAGGTTTT GACGTTTCGT CGTAGCTACG CTTACATCCA CA - #CCACTTAT 480- CTGCTGGGCA GCAACACGGA ATACGTGGCG CCTCCTATGT GGGAGATTCA TC - #ATATCAAC 540- AGTCACAGTC AGTGCTACAG TTCCTACAGC CGCGTTATAG CAGGCACGGT TT - #TCGTGGCT 600- TATCATAGGG ACAGCTATGA AAACAAAACC ATGCAATTAA TGCCCGACGA TT - #ATTCCAAC 660- ACCCACAGTA CCCGTTACGT GACGGTCAAG GATCAATGGC ACAGCCGCGG CA - #GCACCTGG 720- CTCTATCGTG AGACCTGTAA TCTGAATTGT ATGGTGACCA TCACTACTGC GC - #GCTCCAAG 780- TATCCCTATC ATTTTTTCGC AACTTCCACG GGTGATGTGG TTGACATTTC TC - #CTTTCTAC 840- AACGGAACTA ATCGCAATGC CAGCTATTTT GGAGAAAACG CCGACAAGTT TT - #TCATTTTT 900- CCGAACTACA CTATCGTCTC CGACTTTGAA AGACCGAATT CTGCGTTAGA GA - #CCCACAGG 960- TTGGTGGCTT TTCTTGAACG TGCGGACTCA GTGATCTCCT GGGATATACA GG - #ACGAGAAG1020- AATGTTACTT GTCAACTCAC TTTCTGGGAA GCCTCGGAAC GCACCATTCG TT - #CCGAAGCC1080- GAGGACTCGT ATCACTTTTC TTCTGCCAAA ATGACCGCCA CTTTCTTATC TA - #AGAAGCAA1140- GAGGTGAACA TGTCCGACTC TGCGCTGGAC TGTGTACGTG ATGAGGCCAT AA - #ATAAGTTA1200- CAGCAGATTT TCAATACTTC ATACAATCAA ACATATGAAA AATATGGAAA CG - #TGTCCGTC1260- TTTGAAACCA CTGGTGGTTT GGTGGTGTTC TGGCAAGGTA TCAAGCAAAA AT - #CTCTGGTG1320- GAACTCGAAC GTTTGGCCAA CCGCTCCAGT CTGAATCTTA CTCATAATAG AA - #CCAAAAGA1380- AGTACAGATG GCAACAATGC AACTCATTTA TCCAACATGG AGTCGGTGCA CA - #ATCTGGTC1440- TACGCCCAGC TGCAGTTCAC CTATGACACG TTGCGCGGTT ACATCAACCG GG - #CGCTGGCC1500- GAAATCGCAG AAGCCTGGTG TGTGGATCAA CGGCGCACCC TAGAGGTCTT CA - #AGGAACTT1560- AGCAAGATCA ACCCGTCAGC TATTCTCTCG GCCATCTACA ACAAACCGAT TG - #CCGCGCGT1620- TTCATGGGTG ATGTCCTGGG TCTGGCCAGC TGCGTGACCA TTAACCAAAC CA - #GCGTCAAG1680- GTGCTGCGTG ATATGAATGT GAAGGAATCG CCAGGACGCT GCTACTCACG AC - #CAGTGGTC1740- ATCTTTAATT TCGCCAACAG CTCGTACGTG CAGTACGGTC AACTGGGCGA GG - #ATAACGAA1800- ATCCTGTTGG GCAACCACCG CACTGAGGAA TGTCAGCTTC CCAGCCTCAA GA - #TCTTCATC1860- GCCGGCAACT CGGCCTACGA GTACGTGGAC TACCTCTTCA AACGCATGAT TG - #ACCTCAGC1920- AGCATCTCCA CCGTCGACAG CATGATCGCC CTAGACATCG ACCCGCTGGA AA - #ACACCGAC1980- TTCAGGGTAC TGGAACTTTA CTCGCAGAAA GAATTGCGTT CCAGCAACGT TT - #TTGATCTC2040- GAGGAGATCA TGCGCGAGTT CAATTCGTAT AAGCAGCGGG TAAAGTACGT GG - #AGGACAAG2100- GTAGTCGACC CGCTGCCGCC CTACCTCAAG GGTCTGGACG ACCTCATGAG CG - #GCCTGGGC2160- GCCGCGGGAA AGGCCGTTGG CGTAGCCATT GGGGCCGTGG GTGGCGCGGT GG - #CCTCCGTG2220- GTCGAAGGCG TTGCCACCTT CCTCAAAAAC CCCTTCGGAG CCTTCACCAT CA - #TCCTCGTG2280- GCCATAGCCG TCGTCATTAT CATTTATTTG ATCTATATCC GACAGCGGCG TC - #TCTGCATG2340- CAGCCGCTGC AGAACCTCTT TCCCTATCTG GTGTCCGCCG ACGGGACCAC CG - #TGACGTCG2400- GGCAACACCA AAGACACGTC GTTACAGGCT CCGCCTTCCT ACGAGGAAAG TG - #TTTATAAT2460- TCTGGTCGCA AAGGACCGGG ACCACCGTCG TCTGATGCAT CCACGGCGGC TC - #CGCCTTAC2520- ACCAACGAGC AGGCTTACCA GATGCTTCTG GCCCTGGTCC GTCTGGACGC AG - #AGCAGCGA2580- GCGCACGAGA ACGGTACAGA TTCTTTGGAC GGACAGACTG GCACGCAGGA CA - #AGGGACAG2640- AAGCCCAACC TGCTAGACCG ACTGCGACAC CGCAAAAACG GCTACCGACA CT - #TGAAAGAC2700# 2724ACGT CTGA- (2) INFORMATION FOR SEQ ID NO:38:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 4260 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:- AAGCTTTTGC GATCAATAAA TGGATCACAA CCAGTATCTC TTAACGATGT TC - #TTCGCAGA 60- TGATGATTCA TTTTTTAAGT ATTTGGCTAG TCAAGATGAT GAATCTTCAT TA - #TCTGATAT 120- ATTGCAAATC ACTCAATATC TAGACTTTCT GTTATTATTA TTGATCCAAT CA - #AAAAATAA 180- ATTAGAAGCC GTGGGTCATT GTTATGAATC TCTTTCAGAG GAATACAGAC AA - #TTGACAAA 240- ATTCACAGAC TCTCAAGATT TTAAAAAACT GTTTAACAAG GTCCCTATTG TT - #ACAGATGG 300- AAGGGTCAAA CTTAATAAAG GATATTTGTT CGACTTTGTG ATTAGTTTGA TG - #CGATTCAA 360- AAAAGAATCC TCTCTAGCTA CCACCGCAAT AGATCCTATT AGATACATAG AT - #CCTCGTCG 420- CGATATCGCA TTTTCTAACG TGATGGATAT ATTAAAGTCG AATAAAGTGA AC - #AATAATTA 480- ATTCTTTATT GTCATCATGT AATTAACTAG CTACCCGGGA GATCTCTCGA GC - #TGCAGAAG 540- CTTATAAAAA TCACAAGTCT CTGTCACTTT TTTTGTCTAG TTTTTTTTTC TC - #CTCTTGGT 600- TCAGACGTTC TCTTCTTCGT CGGAGTCTTT CAAGTGTCGG TAGCCGTTTT TG - #CGGTGTCG 660- CAGTCGGTCT AGCAGGTTGG GCTTCTGTCC CTTGTCCTGC GTGCCAGTCT GT - #CCGTCCAA 720- AGAATCTGTA CCGTTCTCGT GCGCTCGCTG CTCTGCGTCC AGACGGACCA GG - #GCCAGAAG 780- CATCTGGTAA GCCTGCTCGT TGGTGTAAGG CGGAGCCGCC GTGGATGCAT CA - #GACGACGG 840- TGGTCCCGGT CCTTTGCGAC CAGAATTATA AACACTTTCC TCGTAGGAAG GC - #GGAGCCTG 900- TAACGACGTG TCTTTGGTGT TGCCCGACGT CACGGTGGTC CCGTCGGCGG AC - #ACCAGATA 960- GGGAAAGAGG TTCTGCAGCG GCTGCATGCA GAGACGCCGC TGTCGAGTAT AG - #ATCAAATA1020- AATGATAATG ACGACGGCTA TGGCCACGAG GATGATGGTG AAGGCTCCGA AG - #GGGTTTTT1080- GAGGAAGGTG GCAACGCCTT CGACCACGGA GGCCACCGCG CCACCCACGG CC - #CCAATGGC1140- TACGCCAACG GCCTTTCCCG CGGCGCCCAG GCCGCTCATG AGGTCGTCCA GA - #CCCTTGAG1200- GTAGGGCGGC AGCGGGTCGA CTACCTTGTC CTCCACGTAC TTTACCCGCT GC - #TTATACGA1260- ATTGAACTCG CGCATGATCT CCTCGAGATC AAAAACGTTG CTGGAACGCA AT - #TCTTTCTG1320- CGAGTAAAGT TCCAGTACCC TGAAGTCGGT GTTTTCCAGC GGGTCGATGT CT - #AGGGCGAT1380- CATGCTGTCG ACGGTGGAGA TGCTGCTGAG GTCAATCATG CGTTTGAAGA GG - #TAGTCCAC1440- GTACTCGTAG GCCGAGTTGC CGGCGATGAA GATCTTGAGG CTGGGAAGCT GA - #CATTCCTC1500- AGTGCGGTGG TTGCCCAACA GGATTTCGTT ATCCTCGCCC AGTTGACCGT AC - #TGCACGTA1560- CGAGCTGTTG GCGAAATTAA AGATGACCAC TGGTCGTGAG TAGCAGCGTC CT - #GGCGATTC1620- CTTCACATTC ATATCACGCA GCACCTTGAC GCTGGTTTGG TTAATGGTCA CG - #CAGCTGGC1680- CAGACCCAGG ACATCACCCA TGAAACGCGC GGCAATCGGT TTGTTGTAGA TG - #GCCGAGAG1740- AATAGCTGAC GGGTTGATCT TGCTAAGTTC CTTGAAGACC TCTAGGGTGC GC - #CGTTGATC1800- CACACACCAG GCTTCTGCGA TTTCGGCCAG CGCCCGGTTG ATGTAACCGC GC - #AACGTGTC1860- ATAGGTGAAC TGCAGCTGGG CGTAGACCAG ATTGTGCACC GACTCCATGT TG - #GATAAATG1920- AGTTGCATTG TTGCCATCTG TACTTCTTTT GGTTCTATTA TGAGTAAGAT TC - #AGACTGGA1980- GCGGTTGGCC AAACGTTCGA GTTCCACCAG AGATTTTTGC TTGATACCTT GC - #CAGAACAC2040- CACCAAACCA CCAGTGGTTT CAAAGACGGA CACGTTTCCA TATTTTTCAT AT - #GTTTGATT2100- GTATGAAGTA TTGAAAATCT GCTGTAACTT ATTTATGGCC TCATCACGTA CA - #CAGTCCAG2160- CGCAGAGTCG GACATGTTCA CCTCTTGCTT CTTAGATAAG AAAGTGGCGG TC - #ATTTTGGC2220- AGAAGAAAAG TGATACGAGT CCTCGGCTTC GGAACGAATG GTGCGTTCCG AG - #GCTTCCCA2280- GAAAGTGAGT TGACAAGTAA CATTCTTCTC GTCCTGTATA TCCCAGGAGA TC - #ACTGAGTC2340- CGCACGTTCA AGAAAAGCCA CCAACCTGTG GGTCTCTAAC GCAGAATTCG GT - #CTTTCAAA2400- GTCGGAGACG ATAGTGTAGT TCGGAAAAAT GAAAAACTTG TCGGCGTTTT CT - #CCAAAATA2460- GCTGGCATTG CGATTAGTTC CGTTGTAGAA AGGAGAAATG TCAACCACAT CA - #CCCGTGGA2520- AGTTGCGAAA AAATGATAGG GATACTTGGA GCGCGCAGTA GTGATGGTCA CC - #ATACAATT2580- CAGATTACAG GTCTCACGAT AGAGCCAGGT GCTGCCGCGG CTGTGCCATT GA - #TCCTTGAC2640- CGTCACGTAA CGGGTACTGT GGGTGTTGGA ATAATCGTCG GGCATTAATT GC - #ATGGTTTT2700- GTTTTCATAG CTGTCCCTAT GATAAGCCAC GAAAACCGTG CCTGCTATAA CG - #CGGCTGTA2760- GGAACTGTAG CACTGACTGT GACTGTTGAT ATGATGAATC TCCCACATAG GA - #GGCGCCAC2820- GTATTCCGTG TTGCTGCCCA GCAGATAAGT GGTGTGGATG TAAGCGTAGC TA - #CGACGAAA2880- CGTCAAAACC TTCTGGTAGA CTCGTACCTT AAAGGTGTGC GCGACGATGT TG - #CGTTTGTA2940- GACCACCATG ATGCCCTCGT CCAGGTCTTC ATTGATGGGC TTCATCGAGG TG - #CAGACGAT3000- ATTACGTTCA AAGCGAATAA GATCCGTACC CTGAGCCATA GAACACACGC GA - #TAGGGGTA3060- CTTGGTGGTG TTGACCCCCA CCACATCTCC GTACTTGAGG GTAGTGTTGT AG - #ATGGTCTC3120- GTTAACACCA TGGCTGACCG TTTGGGAAGA AGTTACGCGT TGAGAGACTG AA - #CCGGATCG3180- AGAATGAGCA GCAGACGTCG TATGAGAGGA ATGGTGACTG TGAGTAGCAG AA - #GTTCCACG3240- AGTAGAAGAT GAGGAAACCG CAGCACCCAG ACAGACGATA CACAAGTTAA CG - #CAGACTAC3300- CAGGCACCAG ATCCTGGATT CCATTACGAT ACAAACTTAA CGGATATCGC GA - #TAATGAAA3360- TAATTTATGA TTATTTCTCG CTTTCAATTT AACACAACCC TCAAGAACCT TT - #GTATTTAT3420- TTTCACTTTT AAGTATAGAA TAAAGAAGCT TGCATGCCAC GCGTCTCGAG GG - #CCCCTGCA3480- GGTCGACTCT AGAGGATCCT GATCCTTTTT CTGGGTAAGT AATACGTCAA GG - #AGAAAACG3540- AAACGATCTG TAGTTAGCGG CCGCCTAATT AACTAATATT ATATTTTTTA TC - #TAAAAAAC3600- TAAAAATAAA CATTGATTAA ATTTTAATAT AATACTTAAA AATGGATGTT GT - #GTCGTTAG3660- ATAAACCGTT TATGTATTTT GAGGAAATTG ATAATGAGTT AGATTACGAA CC - #AGAAAGTG3720- CAAATGAGGT CGCAAAAAAA CTGCCGTATC AAGGACAGTT AAAACTATTA CT - #AGGAGAAT3780- TATTTTTTCT TAGTAAGTTA CAGCGACACG GTATATTAGA TGGTGCCACC GT - #AGTGTATA3840- TAGGATCGGC TCCTGGTACA CATATACGTT ATTTGAGAGA TCATTTCTAT AA - #TTTAGGAA3900- TGATTATCAA ATGGATGCTA ATTGACGGAC GCCATCATGA TCCTATTTTA AA - #TGGATTGC3960- GTGATGTGAC TCTAGTGACT CGGTTCGTTG ATGAGGAATA TCTACGATCC AT - #CAAAAAAC4020- AACTGCATCC TTCTAAGATT ATTTTAATTT CTGATGTGAG ATCCAAACGA GG - #AGGAAATG4080- AACCTAGTAC GGCGGATTTA CTAAGTAATT ACGCTCTACA AAATGTCATG AT - #TAGTATTT4140- TAAACCCCGT GGCGTCTAGT CTTAAATGGA GATGCCCGTT TCCAGATCAA TG - #GATCAAGG4200- ACTTTTATAT CCCACACGGT AATAAAATGT TACAACCTTT TGCTCCTTCA TA - #TTCAGCTG4260- (2) INFORMATION FOR SEQ ID NO:39:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 7351 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:- AGATATTTGT TAGCTTCTGC CGGAGATACC GTGAAAATCT ATTTTCTGGA AG - #GAAAGGGA 60- GGTCTTATCT ATTCTGTCAG CAGAGTAGGT TCCTCTAATG ACGAAGACAA TA - #GTGAATAC 120- TTGCATGAAG GTCACTGTGT AGAGTTCAAA ACTGATCATC AGTGTTTGAT AA - #CTCTAGCG 180- TGTACGAGTC CTTCTAACAC TGTGGTTTAT TGGCTGGAAT AAAAGGATAA AG - #ACACCTAT 240- ACTGATTCAT TTTCATCTGT CAACGTTTCT CTAAGAGATT CATAGGTATT AT - #TATTACAT 300- CGATCTAGAA GTCTAATAAC TGCTAAGTAT ATTATTGGAT TTAACGCGCT AT - #AAACGCAT 360- CCAAAACCTA CAAATATAGG AGAAGCTTCT CTTATGAAAC TTCTTAAAGC TT - #TACTCTTA 420- CTATTACTAC TCAAAAGAGA TATTACATTA ATTATGTGAT GAGGCATCCA AC - #ATATAAAG 480- AAGACTAAAG CTGTAGAAGC TGTTATGAAG AATATCTTAT CAGATATATT AG - #ATGCATTG 540- TTAGTTCTGT AGATCAGTAA CGTATAGCAT ACGAGTATAA TTATCGTAGG TA - #GTAGGTAT 600- CCTAAAATAA ATCTGATACA GATAATAACT TTGTAAATCA ATTCAGCAAT TT - #CTCTATTA 660- TCATGATAAT GATTAATACA CAGCGTGTCG TTATTTTTTG TTACGATAGT AT - #TTCTAAAG 720- TAAAGAGCAG GAATCCCTAG TATAATAGAA ATAATCCATA TGAAAAATAT AG - #TAATGTAC 780- ATATTTCTAA TGTTAACATA TTTATAGGTA AATCCAGGAA GGGTAATTTT TA - #CATATCTA 840- TATACGCTTA TTACAGTTAT TAAAAATATA CTTGCAAACA TGTTAGAAGT AA - #AAAAGAAA 900- GAACTAATTT TACAAAGTGC TTTACCAAAA TGCCAATGGA AATTACTTAG TA - #TGTATATA 960- ATGTATAAAG GTATGAATAT CACAAACAGC AAATCGGCTA TTCCCAAGTT GA - #GAAACGGT1020- ATAATAGATA TATTTCTAGA TACCATTAAT AACCTTATAA GCTTGACGTT TC - #CTATAATG1080- CCTACTAAGA AAACTAGAAG ATACATACAT ACTAACGCCA TACGAGAGTA AC - #TACTCATC1140- GTATAACTAC TGTTGCTAAC AGTGACACTG ATGTTATAAC TCATCTTTGA TG - #TGGTATAA1200- ATGTATAATA ACTATATTAC ACTGGTATTT TATTTCAGTT ATATACTATA TA - #GTATTAAA1260- AATTATATTT GTATAATTAT ATTATTATAT TCAGTGTAGA AAGTAAAATA CT - #ATAAATAT1320- GTATCTCTTA TTTATAACTT ATTAGTAAAG TATGTACTAT TCAGTTATAT TG - #TTTTATAA1380- AAGCTAAATG CTACTAGATT GATATAAATG AATATGTAAT AAATTAGTAA TG - #TAGTATAC1440- TAATATTAAC TCACATTATG AATACTACTA ATCACGAAGA ATGCAGTAAA AC - #ATATGATA1500- CAAACATGTT AACAGTTTTA AAAGCCATTA GTAATAAACA GTACAATATA AT - #TAAGTCTT1560- TACTTAAAAA AGATATTAAT GTTAATAGAT TATTAACTAG TTATTCTAAC GA - #AATATATA1620- AACATTTAGA CATTACATTA TGTAATATAC TTATAGAACG TGCAGCAGAC AT - #AAACATTA1680- TAGATAAGAA CAATCGTACA CCGTTGTTTT ATGCGGTAAA GAATAATGAT TA - #TGATATGG1740- TTAAACTCCT ATTAAAAAAT GGCGCGAATG TAAATTTACA AGATAGTATA GG - #ATATTCAT1800- GTCTTCACAT CGCAGGTATA CATAATAGTA ACATAGAAAT AGTAGATGCA TT - #GATATCAT1860- ACAAACCAGA TTTAAACTCC CGCGATTGGG TAGGTAGAAC ACCGCTACAT AT - #CTTCGTGA1920- TAGAATCTAA CTTTGAAGCT GTGAAATTAT TATTAAAGTC AGGTGCATAT GT - #AGGTTTGA1980- AAGACAAATG TAAGCATTTT CCTATACACC ATTCTGTAAT GAAATTAGAT CA - #CTTAATAT2040- CAGGATTGTT ATTAAAATAT GGAGCAAATC CAAATACAAT TAACGGCAAT GG - #AAAAACAT2100- TATTAAGCAT TGCTGTAACA TCTAATAATA CACTACTGGT AGAACAGCTG CT - #GTTATATG2160- GAGCAGAAGT TAATAATGGT GGTTATGATG TTCCAGCTCC TATTATATCC GC - #TGTCAGTG2220- TTAACAATTA TGATATTGTT AAGATACTGA TACATAATGG TGCGAATATA AA - #TGTATCCA2280- CGGAAGATGG TAGAACGTCT TTACATACAG CTATGTTTTG GAATAACGCT AA - #AATAATAG2340- ATGAGTTGCT TAACTATGGA AGTGACATAA ACAGCGTAGA TACTTATGGT AG - #AACTCCGT2400- TATCTTGTTA TCGTAGCTTA AGTTATGATA TCGCTACTAA ACTAATATCA CG - #TATCATTA2460- TAACAGATGT CTATCGTGAA GCACCAGTAA ATATCAGCGG ATTTATAATT AA - #TTTAAAAA2520- CTATAGAAAA TAATGATATA TTCAAATTAA TTAAAGATGA TTGTATTAAA GA - #GATAAACA2580- TACTTAAAAG TATAACCCTT AATAAATTTC ATTCATCTGA CATATTTATA CG - #ATATAATA2640- CTGATATATG TTTATTAACG AGATTTATTC AACATCCAAA GATAATAGAA CT - #AACAAAAA2700- ACTCTACGCT TATAAATCTA TAGTCAACGA GAGAAAAATC AAAGCTACTT AC - #AGGTATTA2760- TCAAATAAAA AAAGTATTAA CTGTACTACC TTTTTCAGGA TATTTCTCTA TA - #TTGCCGTT2820- TGATGTGTTA GTATATATAC TTGAATTCAT CTATGATAAT AATATGTTGG TA - #CTTATGAG2880- AGCGTTATCA TTAAAATGAA ATAAAAAGCA TACAAGCTAT TGCTTCGCTA TC - #GTTACAAA2940- ATGGCAGGAA TTTTGTGTAA ACTAAGCCAC ATACTTGCCA ATGAAAAAAA TA - #GTAGAAAG3000- GATACTATTT TAATGGGATT AGATGTTAAG GTTCCTTGGG ATTATAGTAA CT - #GGGCATCT3060- GTTAACTTTT ACGACGTTAG GTTAGATACT GATGTTACAG ATTATAATAA TG - #TTACAATA3120- AAATACATGA CAGGATGTGA TATTTTTCCT CATATAACTC TTGGAATAGC AA - #ATATGGAT3180- CAATGTGATA GATTTGAAAA TTTCAAAAAG CAAATAACTG ATCAAGATTT AC - #AGACTATT3240- TCTATAGTCT GTAAAGAAGA GATGTGTTTT CCTCAGAGTA ACGCCTCTAA AC - #AGTTGGGA3300- GCGAAAGGAT GCGCTGTAGT TATGAAACTG GAGGTATCTG ATGAACTTAG AG - #CCCTAAGA3360- AATGTTCTGC TGAATGCGGT ACCCTGTTCG AAGGACGTGT TTGGTGATAT CA - #CAGTAGAT3420- AATCCGTGGA ATCCTCACAT AACAGTAGGA TATGTTAAGG AGGACGATGT CG - #AAAACAAG3480- AAACGCCTAA TGGAGTGCAT GTCCAAGTTT AGGGGGCAAG AAATACAAGT TC - #TAGGATGG3540- TATTAATAAG TATCTAAGTA TTTGGTATAA TTTATTAAAT AGTATAATTA TA - #ACAAATAG3600- ATAAATAACA TGATAACGGT TTTTATTAGA ATAAAATAGA GATAATATCA TA - #ATGATATA3660- TAATACTTCA TTACCAGAAA TGAGTAATGG AAGACTTATA AATGAACTGC AT - #AAAGCTAT3720- AAGGTATAGA GATATAAATT TAGTAAGGTA TATACTTAAA AAATGCAAAT AC - #AATAACGT3780- AAATATACTA TCAACGTCTT TGTATTTAGC CGTAAGTATT TCTGATATAG AA - #ATGGTAAA3840- ATTATTACTA GAACACGGTG CCGATATTTT AAAATGTAAA AATCCTCCTC TT - #CATAAAGC3900- TGCTAGTTTA GATAATACAG AAATTGCTAA ACTACTAATA GATTCTGGCG CT - #GACATAGA3960- ACAGATACAT TCTGGAAATA GTCCGTTATA TATTTCTGTA TATAGAAACA AT - #AAGTCATT4020- AACTAGATAT TTATTAAAAA AAGGTGTTAA TTGTAATAGA TTCTTTCTAA AT - #TATTACGA4080- TGTACTGTAT GATAAGATAT CTGATGATAT GTATAAAATA TTTATAGATT TT - #AATATTGA4140- TCTTAATATA CAAACTAGAA ATTTTGAAAC TCCGTTACAT TACGCTATAA AG - #TATAAGAA4200- TATAGATTTA ATTAGGATAT TGTTAGATAA TAGTATTAAA ATAGATAAAA GT - #TTATTTTT4260- GCATAAACAG TATCTCATAA AGGCACTTAA AAATAATTGT AGTTACGATA TA - #ATAGCGTT4320- ACTTATAAAT CACGGAGTGC CTATAAACGA ACAAGATGAT TTAGGTAAAA CC - #CCATTACA4380- TCATTCGGTA ATTAATAGAA GAAAAGATGT AACAGCACTT CTGTTAAATC TA - #GGAGCTGA4440- TATAAACGTA ATAGATGACT GTATGGGCAG TCCCTTACAT TACGCTGTTT CA - #CGTAACGA4500- TATCGAAACA ACAAAGACAC TTTTAGAAAG AGGATCTAAT GTTAATGTGG TT - #AATAATCA4560- TATAGATACC GTTCTAAATA TAGCTGTTGC ATCTAAAAAC AAAACTATAG TA - #AACTTATT4620- ACTGAAGTAC GGTACTGATA CAAAGTTGGT AGGATTAGAT AAACATGTTA TT - #CACATAGC4680- TATAGAAATG AAAGATATTA ATATACTGAA TGCGATCTTA TTATATGGTT GC - #TATGTAAA4740- CGTCTATAAT CATAAAGGTT TCACTCCTCT ATACATGGCA GTTAGTTCTA TG - #AAAACAGA4800- ATTTGTTAAA CTCTTACTTG ACCACGGTGC TTACGTAAAT GCTAAAGCTA AG - #TTATCTGG4860- AAATACTCCT TTACATAAAG CTATGTTATC TAATAGTTTT AATAATATAA AA - #TTACTTTT4920- ATCTTATAAC GCCGACTATA ATTCTCTAAA TAATCACGGT AATACGCCTC TA - #ACTTGTGT4980- TAGCTTTTTA GATGACAAGA TAGCTATTAT GATAATATCT AAAATGATGT TA - #GAAATATC5040- TAAAAATCCT GAAATAGCTA ATTCAGAAGG TTTTATAGTA AACATGGAAC AT - #ATAAACAG5100- TAATAAAAGA CTACTATCTA TAAAAGAATC ATGCGAAAAA GAACTAGATG TT - #ATAACACA5160- TATAAAGTTA AATTCTATAT ATTCTTTTAA TATCTTTCTT GACAATAACA TA - #GATCTTAT5220- GGTAAAGTTC GTAACTAATC CTAGAGTTAA TAAGATACCT GCATGTATAC GT - #ATATATAG5280- GGAATTAATA CGGAAAAATA AATCATTAGC TTTTCATAGA CATCAGCTAA TA - #GTTAAAGC5340- TGTAAAAGAG AGTAAGAATC TAGGAATAAT AGGTAGGTTA CCTATAGATA TC - #AAACATAT5400- AATAATGGAA CTATTAAGTA ATAATGATTT ACATTCTGTT ATCACCAGCT GT - #TGTAACCC5460- AGTAGTATAA AGTGATTTTA TTCAATTACG AAGATAAACA TTAAATTTGT TA - #ACAGATAT5520- GAGTTATGAG TATTTAACTA AAGTTACTTT AGGTACAAAT AAAATATTAT GT - #AATATAAT5580- AGAAAATTAT CTTGAGTCTT CATTTCCATC ACCGTCTAAA TTTATTATTA AA - #ACCTTATT5640- ATATAAGGCT GTTGAGTTTA GAAATGTAAA TGCTGTAAAA AAAATATTAC AG - #AATGATAT5700- TGAATATGTT AAAGTAGATA GTCATGGTGT CTCGCCTTTA CATATTATAG CT - #ATGCCTTC5760- AAATTTTTCT CTCATAGACG CTGACATGTA TTCAGAATTT AATGAAATTA GT - #AATAGACT5820- TCAAAAATCT AAAGATAGTA ACGAATTTCA ACGAGTTAGT CTACTAAGGA CA - #ATTATAGA5880- ATATGGTAAT GATAGTGATA TTAATAAGTG TCTAACATTA GTAAAAACGG AT - #ATACAGAG5940- TAACGAAGAG ATAGATATTA TAGATCTTTT GATAAATAAA GGAATAGATA TA - #AATATTAA6000- AGACGATTTA GGAAACACAG CTTTGCATTA CTCGTGTGAT TATGCTAAGG GA - #TCAAAGAT6060- AGCTAAAAAG TTACTAGATT GTGGAGCAGA TCCTAACATA GTTAATGATT TA - #GGTGTTAC6120- ACCACTAGCG TGTGCCGTTA ATACTTGCAA CGAGATACTA GTAGATATTC TG - #TTAAATAA6180- TGATGCGAAT CCTGATTCAT CTTCCTCATA TTTTTTAGGT ACTAATGTGT TA - #CATACAGC6240- CGTAGGTACC GGTAATATAG ATATTGTAAG ATCTTTACTT ACGGCTGGTG CC - #AATCCTAA6300- TGTAGGAGAT AAATCTGGAG TTACTCCTTT GCACGTTGCT GCAGCTGATA AA - #GACAGTTA6360- TCTGTTAATG GAGATGCTAC TAGATAGCGG GGCAGATCCA AATATAAAAT GC - #GCAAACGG6420- TTTTACTCCT TTGTTTAATG CAGTATATGA TCATAACCGT ATAAAGTTAT TA - #TTTCTTTA6480- CGGGGCTGAT ATCAATATTA CTGACTCTTA CGGAAATACT CCTCTTACTT AT - #ATGACTAA6540- TTTTGATAAT AAATATGTAA ATTCAATAAT TATCTTACAA ATATATCTAC TT - #AAAAAAGA6600- ATATAACGAT GAAAGATTGT TTCCACCTGG TATGATAAAA AATTTAAACT TT - #ATAGAATC6660- AAACGATAGT CTTAAAGTTA TAGCTAAAAA GTGTAATTCG TTAATACGCT AT - #AAGAAAAA6720- TAAAGACATA GATGCAGATA ACGTATTATT GGAGCTTTTA GAGGAAGAGG AA - #GAAGATGA6780- AATAGACAGA TGGCATACTA CATGTAAAAT ATCTTAAATA GTAATTAAAT CA - #TTGAAATA6840- TTAACTTACA AGATGATCGA GGTCACTTAT TATACTCTTT AATAATGGGT AC - #AAAGAGTA6900- TTCATACGTT AGTTAAATCT AACGATGTAA TACGTGTTCG TGAATTAATA AA - #GGATGATA6960- GATGTTTGAT AAATAAAAGA AATAGAAGAA ATCAGTCACC TGTATATATA GC - #TATATACA7020- AAGGACTTTA TGAAATGACT GAAATGTTAT TGCTAAATAA TGCAAGTCTA GA - #TACTAAAA7080- TACCTTCTTT AATTATAGCA GCTAAAAATA ATGACTTACC TATGATAAAA TT - #ATTGATAC7140- AATACGGGGC AAAATTAAAT GATATTTATT TAAGGGACAC AGCATTAATG AT - #AGCTCTCA7200- GAAATGGTTA CCTAGATATA GCTGAATATT TACTTTCATT AGGAGCAGAA TT - #TGTTAAAT7260- ACAGACATAA GGTAATATAT AAATATCTAT CAAAAGATGC GTATGAATTA CT - #TTTTAGAT7320# 7351 TATA ATAGATTGAG A- (2) INFORMATION FOR SEQ ID NO:40:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 7091 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:- AGATATTTGT TAGCTTCTGC CGGAGATACC GTGAAAATCT ATTTTCTGGA AG - #GAAAGGGA 60- GGTCTTATCT ATTCTGTCAG CAGAGTAGGT TCCTCTAATG ACGAAGACAA TA - #GTGAATAC 120- TTGCATGAAG GTCACTGTGT AGAGTTCAAA ACTGATCATC AGTGTTTGAT AA - #CTCTAGCG 180- TGTACGAGTC CTTCTAACAC TGTGGTTTAT TGGCTGGAAT AAAAGGATAA AG - #ACACCTAT 240- ACTGATTCAT TTTCATCTGT CAACGTTTCT CTAAGAGATT CATAGGTATT AT - #TATTACAT 300- CGATCTAGAA GTCTAATAAC TGCTAAGTAT ATTATTGGAT TTAACGCGCT AT - #AAACGCAT 360- CCAAAACCTA CAAATATAGG AGAAGCTTCT CTTATGAAAC TTCTTAAAGC TT - #TACTCTTA 420- CTATTACTAC TCAAAAGAGA TATTACATTA ATTATGTGAT GAGGCATCCA AC - #ATATAAAG 480- AAGACTAAAG CTGTAGAAGC TGTTATGAAG AATATCTTAT CAGATATATT AG - #ATGCATTG 540- TTAGTTCTGT AGATCAGTAA CGTATAGCAT ACGAGTATAA TTATCGTAGG TA - #GTAGGTAT 600- CCTAAAATAA ATCTGATACA GATAATAACT TTGTAAATCA ATTCAGCAAT TT - #CTCTATTA 660- TCATGATAAT GATTAATACA CAGCGTGTCG TTATTTTTTG TTACGATAGT AT - #TTCTAAAG 720- TAAAGAGCAG GAATCCCTAG TATAATAGAA ATAATCCATA TGAAAAATAT AG - #TAATGTAC 780- ATATTTCTAA TGTTAACATA TTTATAGGTA AATCCAGGAA GGGTAATTTT TA - #CATATCTA 840- TATACGCTTA TTACAGTTAT TAAAAATATA CTTGCAAACA TGTTAGAAGT AA - #AAAAGAAA 900- GAACTAATTT TACAAAGTGC TTTACCAAAA TGCCAATGGA AATTACTTAG TA - #TGTATATA 960- ATGTATAAAG GTATGAATAT CACAAACAGC AAATCGGCTA TTCCCAAGTT GA - #GAAACGGT1020- ATAATAGATA TATTTCTAGA TACCATTAAT AACCTTATAA GCTTGACGTT TC - #CTATAATG1080- CCTACTAAGA AAACTAGAAG ATACATACAT ACTAACGCCA TACGAGAGTA AC - #TACTCATC1140- GTATAACTAC TGTTGCTAAC AGTGACACTG ATGTTATAAC TCATCTTTGA TG - #TGGTATAA1200- ATGTATAATA ACTATATTAC ACTGGTATTT TATTTCAGTT ATATACTATA TA - #GTATTAAA1260- AATTATATTT GTATAATTAT ATTATTATAT TCAGTGTAGA AAGTAAAATA CT - #ATAAATAT1320- GTATCTCTTA TTTATAACTT ATTAGTAAAG TATGTACTAT TCAGTTATAT TG - #TTTTATAA1380- AAGCTAAATG CTACTAGATT GATATAAATG AATATGTAAT AAATTAGTAA TG - #TAGTATAC1440- TAATATTAAC TCACATTTGA CTAATTAGCT ATAAAAACCC GGGCTGCAGG AA - #TTCCTCGA1500- GACGCGTGGC ATGCAAGCTT ATAAAAATCA CAAGTCTCTG TCACTTTTTT TG - #TCTAGTTT1560- TTTTTTCTCC TCTTGGTTCA GACGTTCTCT TCTTCGTCGG AGTCTTTCAA GT - #GTCGGTAG1620- CCGTTTTTGC GGTGTCGCAG TCGGTCTAGC AGGTTGGGCT TCTGTCCCTT GT - #CCTGCGTG1680- CCAGTCTGTC CGTCCAAAGA ATCTGTACCG TTCTCGTGCG CTCGCTGCTC TG - #CGTCCAGA1740- CGGACCAGGG CCAGAAGCAT CTGGTAAGCC TGCTCGTTGG TGTAAGGCGG AG - #CCGCCGTG1800- GATGCATCAG ACGACGGTGG TCCCGGTCCT TTGCGACCAG AATTATAAAC AC - #TTTCCTCG1860- TAGGAAGGCG GAGCCTGTAA CGACGTGTCT TTGGTGTTGC CCGACGTCAC GG - #TGGTCCCG1920- TCGGCGGACA CCAGATAGGG AAAGAGGTTC TGCAGCGGCT GCATGCAGAG AC - #GCCGCTGT1980- CGAGTATAGA TCAAATAAAT GATAATGACG ACGGCTATGG CCACGAGGAT GA - #TGGTGAAG2040- GCTCCGAAGG GGTTTTTGAG GAAGGTGGCA ACGCCTTCGA CCACGGAGGC CA - #CCGCGCCA2100- CCCACGGCCC CAATGGCTAC GCCAACGGCC TTTCCCGCGG CGCCCAGGCC GC - #TCATGAGG2160- TCGTCCAGAC CCTTGAGGTA GGGCGGCAGC GGGTCGACTA CCTTGTCCTC CA - #CGTACTTT2220- ACCCGCTGCT TATACGAATT GAACTCGCGC ATGATCTCCT CGAGATCAAA AA - #CGTTGCTG2280- GAACGCAATT CTTTCTGCGA GTAAAGTTCC AGTACCCTGA AGTCGGTGTT TT - #CCAGCGGG2340- TCGATGTCTA GGGCGATCAT GCTGTCGACG GTGGAGATGC TGCTGAGGTC AA - #TCATGCGT2400- TTGAAGAGGT AGTCCACGTA CTCGTAGGCC GAGTTGCCGG CGATGAAGAT CT - #TGAGGCTG2460- GGAAGCTGAC ATTCCTCAGT GCGGTGGTTG CCCAACAGGA TTTCGTTATC CT - #CGCCCAGT2520- TGACCGTACT GCACGTACGA GCTGTTGGCG AAATTAAAGA TGACCACTGG TC - #GTGAGTAG2580- CAGCGTCCTG GCGATTCCTT CACATTCATA TCACGCAGCA CCTTGACGCT GG - #TTTGGTTA2640- ATGGTCACGC AGCTGGCCAG ACCCAGGACA TCACCCATGA AACGCGCGGC AA - #TCGGTTTG2700- TTGTAGATGG CCGAGAGAAT AGCTGACGGG TTGATCTTGC TAAGTTCCTT GA - #AGACCTCT2760- AGGGTGCGCC GTTGATCCAC ACACCAGGCT TCTGCGATTT CGGCCAGCGC CC - #GGTTGATG2820- TAACCGCGCA ACGTGTCATA GGTGAACTGC AGCTGGGCGT AGACCAGATT GT - #GCACCGAC2880- TCCATGTTGG ATAAATGAGT TGCATTGTTG CCATCTGTAC TTCTTTTGGT TC - #TATTATGA2940- GTAAGATTCA GACTGGAGCG GTTGGCCAAA CGTTCGAGTT CCACCAGAGA TT - #TTTGCTTG3000- ATACCTTGCC AGAACACCAC CAAACCACCA GTGGTTTCAA AGACGGACAC GT - #TTCCATAT3060- TTTTCATATG TTTGATTGTA TGAAGTATTG AAAATCTGCT GTAACTTATT TA - #TGGCCTCA3120- TCACGTACAC AGTCCAGCGC AGAGTCGGAC ATGTTCACCT CTTGCTTCTT AG - #ATAAGAAA3180- GTGGCGGTCA TTTTGGCAGA AGAAAAGTGA TACGAGTCCT CGGCTTCGGA AC - #GAATGGTG3240- CGTTCCGAGG CTTCCCAGAA AGTGAGTTGA CAAGTAACAT TCTTCTCGTC CT - #GTATATCC3300- CAGGAGATCA CTGAGTCCGC ACGTTCAAGA AAAGCCACCA ACCTGTGGGT CT - #CTAACGCA3360- GAATTCGGTC TTTCAAAGTC GGAGACGATA GTGTAGTTCG GAAAAATGAA AA - #ACTTGTCG3420- GCGTTTTCTC CAAAATAGCT GGCATTGCGA TTAGTTCCGT TGTAGAAAGG AG - #AAATGTCA3480- ACCACATCAC CCGTGGAAGT TGCGAAAAAA TGATAGGGAT ACTTGGAGCG CG - #CAGTAGTG3540- ATGGTCACCA TACAATTCAG ATTACAGGTC TCACGATAGA GCCAGGTGCT GC - #CGCGGCTG3600- TGCCATTGAT CCTTGACCGT CACGTAACGG GTACTGTGGG TGTTGGAATA AT - #CGTCGGGC3660- ATTAATTGCA TGGTTTTGTT TTCATAGCTG TCCCTATGAT AAGCCACGAA AA - #CCGTGCCT3720- GCTATAACGC GGCTGTAGGA ACTGTAGCAC TGACTGTGAC TGTTGATATG AT - #GAATCTCC3780- CACATAGGAG GCGCCACGTA TTCCGTGTTG CTGCCCAGCA GATAAGTGGT GT - #GGATGTAA3840- GCGTAGCTAC GACGAAACGT CAAAACCTTC TGGTAGACTC GTACCTTAAA GG - #TGTGCGCG3900- ACGATGTTGC GTTTGTAGAC CACCATGATG CCCTCGTCCA GGTCTTCATT GA - #TGGGCTTC3960- ATCGAGGTGC AGACGATATT ACGTTCAAAG CGAATAAGAT CCGTACCCTG AG - #CCATAGAA4020- CACACGCGAT AGGGGTACTT GGTGGTGTTG ACCCCCACCA CATCTCCGTA CT - #TGAGGGTA4080- GTGTTGTAGA TGGTCTCGTT AACACCATGG CTGACCGTTT GGGAAGAAGT TA - #CGCGTTGA4140- GAGACTGAAC CGGATCGAGA ATGAGCAGCA GACGTCGTAT GAGAGGAATG GT - #GACTGTGA4200- GTAGCAGAAG TTCCACGAGT AGAAGATGAG GAAACCGCAG CACCCAGACA GA - #CGATACAC4260- AAGTTAACGC AGACTACCAG GCACCAGATC CTGGATTCCA TTACGATACA AA - #CTTAACGG4320- ATATCGCGAT AATGAAATAA TTTATGATTA TTTCTCGCTT TCAATTTAAC AC - #AACCCTCA4380- AGAACCTTTG TATTTATTTT CACTTTTTAA GTATAGAATA AAGAAGCTCT AA - #TTAATTAA4440- GCTACAAATA GTTTCGTTTT CACCTTGTCT AATAACTAAT TAATTAACCC GG - #ATCCCGAT4500- TTTTATGACT AGTTAATCAA ATAAAAAGCA TACAAGCTAT TGCTTCGCTA TC - #GTTACAAA4560- ATGGCAGGAA TTTTGTGTAA ACTAAGCCAC ATACTTGCCA ATGAAAAAAA TA - #GTAGAAAG4620- GATACTATTT TAATGGGATT AGATGTTAAG GTTCCTTGGG ATTATAGTAA CT - #GGGCATCT4680- GTTAACTTTT ACGACGTTAG GTTAGATACT GATGTTACAG ATTATAATAA TG - #TTACAATA4740- AAATACATGA CAGGATGTGA TATTTTTCCT CATATAACTC TTGGAATAGC AA - #ATATGGAT4800- CAATGTGATA GATTTGAAAA TTTCAAAAAG CAAATAACTG ATCAAGATTT AC - #AGACTATT4860- TCTATAGTCT GTAAAGAAGA GATGTGTTTT CCTCAGAGTA ACGCCTCTAA AC - #AGTTGGGA4920- GCGAAAGGAT GCGCTGTAGT TATGAAACTG GAGGTATCTG ATGAACTTAG AG - #CCCTAAGA4980- AATGTTCTGC TGAATGCGGT ACCCTGTTCG AAGGACGTGT TTGGTGATAT CA - #CAGTAGAT5040- AATCCGTGGA ATCCTCACAT AACAGTAGGA TATGTTAAGG AGGACGATGT CG - #AAAACAAG5100- AAACGCCTAA TGGAGTGCAT GTCCAAGTTT AGGGGGCAAG AAATACAAGT TC - #TAGGATGG5160- TATTAATAAG TATCTAAGTA TTTGGTATAA TTTATTAAAT AGTATAATTA TA - #ACAAATAA5220- TAAATAACAT GATAACGGTT TTTATTAGAA TAAAATAGAG ATAATATCAT AA - #TGATATAT5280- AATACTTCAT TACCAGAAAT GAGTAATGGA AGACTTATAA ATGAACTGCA TA - #AAGCTATA5340- AGGTATAGAG ATATAAATTT AGTAAGGTAT ATACTTAAAA AATGCAAATA CA - #ATAACGTA5400- AATATACTAT CAACGTCTTT GTATTTAGCC GTAAGTATTT CTGATATAGA AA - #TGGTAAAA5460- TTATTACTAG AACACGGTGC CGATATTTTA AAATGTAAAA ATCCTCCTCT TC - #ATAAAGCT5520- GCTAGTTTAG ATAATACAGA AATTGCTAAA CTACTAATAG ATTCTGGCGC TG - #ACATAGAA5580- CAGATACATT CTGGAAATAG TCCGTTATAT ATTTCTGTAT ATAGAAACAA TA - #AGTCATTA5640- ACTAGATATT TATTAAAAAA AGGTGTTAAT TGTAATAGAT TCTTTCTAAA TT - #ATTACGAT5700- GTACTGTATG ATAAGATATC TGATGATATG TATAAAATAT TTATAGATTT TA - #ATATTGAT5760- CTTAATATAC AAACTAGAAA TTTTGAAACT CCGTTACATT ACGCTATAAA GT - #ATAAGAAT5820- ATAGATTTAA TTAGGATATT GTTAGATAAT AGTATTAAAA TAGATAAAAG TT - #TATTTTTG5880- CATAAACAGT ATCTCATAAA GGCACTTAAA AATAATTGTA GTTACGATAT AA - #TAGCGTTA5940- CTTATAAATC ACGGAGTGCC TATAAACGAA CAAGATGATT TAGGTAAAAC CC - #CATTACAT6000- CATTCGGTAA TTAATAGAAG AAAAGATGTA ACAGCACTTC TGTTAAATCT AG - #GAGCTGAT6060- ATAAACGTAA TAGATGACTG TATGGGCAGT CCCTTACATT ACGCTGTTTC AC - #GTAACGAT6120- ATCGAAACAA CAAAGACACT TTTAGAAAGA GGATCTAATG TTAATGTGGT TA - #ATAATCAT6180- ATAGATACCG TTCTAAATAT AGCTGTTGCA TCTAAAAACA AAACTATAGT AA - #ACTTATTA6240- CTGAAGTACG GTACTGATAC AAAGTTGGTA GGATTAGATA AACATGTTAT TC - #ACATAGCT6300- ATAGAAATGA AAGATATTAA TATACTGAAT GCGATCTTAT TATATGGTTG CT - #ATGTAAAC6360- GTCTATAATC ATAAAGGTTT CACTCCTCTA TACATGGCAG TTAGTTCTAT GA - #AAACAGAA6420- TTTGTTAAAC TCTTACTTGA CCACGGTGCT TACGTAAATG CTAAAGCTAA GT - #TATCTGGA6480- AATACTCCTT TACATAAAGC TATGTTATCT AATAGTTTTA ATAATATAAA AT - #TACTTTTA6540- TCTTATAACG CCGACTATAA TTCTCTAAAT AATCACGGTA ATACGCCTCT AA - #CTTGTGTT6600- AGCTTTTTAG ATGACAAGAT AGCTATTATG ATAATATCTA AAATGATGTT AG - #AAATATCT6660- AAAAATCCTG AAATAGCTAA TTCAGAAGGT TTTATAGTAA ACATGGAACA TA - #TAAACAGT6720- AATAAAAGAC TACTATCTAT AAAAGAATCA TGCGAAAAAG AACTAGATGT TA - #TAACACAT6780- ATAAAGTTAA ATTCTATATA TTCTTTTAAT ATCTTTCTTG ACAATAACAT AG - #ATCTTATG6840- GTAAAGTTCG TAACTAATCC TAGAGTTAAT AAGATACCTG CATGTATACG TA - #TATATAGG6900- GAATTAATAC GGAAAAATAA ATCATTAGCT TTTCATAGAC ATCAGCTAAT AG - #TTAAAGCT6960- GTAAAAGAGA GTAAGAATCT AGGAATAATA GGTAGGTTAC CTATAGATAT CA - #AACATATA7020- ATAATGGAAC TATTAAGTAA TAATGATTTA CATTCTGTTA TCACCAGCTG TT - #GTAACCCA7080# 7091- (2) INFORMATION FOR SEQ ID NO:41:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 4768 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:- AAGCTTGCGG CCGCTCATTA GACAAGCGAA TGAGGGACGA AAACGTGGAG GA - #GGTATTAA 60- GTTTGGAGAA ATGGAGAGAG ACTGTTTAAT AGCGCATGGC GCAGCCAATA CT - #ATTACAGA 120- AGTTTTGAAA GATTCGGAAG AAGATTATCA AGATGTGTAT GTTTGTGAAA AT - #TGTGGAGA 180- CATAGCAGCA CAAATCAAGG GTATTAATAC ATGTCTTAGA TGTTCAAAAC TT - #AATCTCTC 240- TCCTCTCTTA ACAAAAATTG ATACCACGCA CGTATCTAAA GTATTTCTTA CT - #CAAATGAA 300- CGCCAGAGGC GTAAAAGTCA AATTAGATTT CGAACGAAGG CCTCCTTCGT TT - #TATAAACC 360- ATTAGATAAA GTTGATCTCA AGCCGTCTTT TCTGGTGTAA TAAAAATTAA TT - #AATTACTC 420- GAGGGTACCG GATCCCCCAG CTTATAAAAA TCACAAGTCT CTGACACTTT TT - #TTGTCTAG 480- TTTTTTTTTC TCCTCTTGGT TCAGACGTTC TCTTCTTCGT CGGAGTCTTT CA - #AGTGTCGG 540- TAGCCGTTTT TGCGGTGTCG CAGTCGGTCT AGCAGGTTGG GCTTCTGTCC CT - #TGTCCTGC 600- GTGCCAGTCT GTCCGTCCAA AGAATCTGTA CCGTTCTCGT GCGCTCGCTG CT - #CTGCGTCC 660- AGACGGACCA GGGCCAGAAG CATCTGGTAA GCCTGCTCGT TGGTGTAAGG CG - #GAGCCGCC 720- GTGGATGCAT CAGACGACGG TGGTCCCGGT CCTTTGCGAC CAGAATTATA AA - #CACTTTCC 780- TCGTAGGAAG GCGGAGCCTG TAACGACGTG TCTTTGGTGT TGCCCGACGT CA - #CGGTGGTC 840- CCGTCGGCGG ACACCAGATA GGGAAAGAGG TTCTGCAGCG GCTGCATGCA GA - #GACGCCGC 900- TGTCGAGTAT AGATCAAATA AATGATAATG ACGACGGCTA TGGCCACGAG GA - #TGATGGTG 960- AAGGCTCCGA AGGGGTTTTT GAGGAAGGTG GCAACGCCTT CGACCACGGA GG - #CCACCGCG1020- CCACCCACGG CCCCAATGGC TACGCCAACG GCCTTTCCCG CGGCGCCCAG GC - #CGCTCATG1080- AGGTCGTCCA GACCCTTGAG GTAGGGCGGC AGCGGGTCGA CTACCTTGTC CT - #CCACGTAC1140- TTTACCCGCT GCTTATACGA ATTGAACTCG CGCATGATCT CCTCGAGATC AA - #AAACGTTG1200- CTGGAACGCA ATTCTTTCTG CGAGTAAAGT TCCAGTACCC TGAAGTCGGT GT - #TTTCCAGC1260- GGGTCGATGT CTAGGGCGAT CATGCTGTCG ACGGTGGAGA TGCTGCTGAG GT - #CAATCATG1320- CGTTTGAAGA GGTAGTCCAC GTACTCGTAG GCCGAGTTGC CGGCGATGAA GA - #TCTTGAGG1380- CTGGGAAGCT GACATTCCTC AGTGCGGTGG TTGCCCAACA GGATTTCGTT AT - #CCTCGCCC1440- AGTTGACCGT ACTGCACGTA CGAGCTGTTG GCGAAATTAA AGATGACCAC TG - #GTCGTGAG1500- TAGCAGCGTC CTGGCGATTC CTTCACATTC ATATCACGCA GCACCTTGAC GC - #TGGTTTGG1560- TTAATGGTCA CGCAGCTGGC CAGACCCAGG ACATCACCCA TGAAACGCGC GG - #CAATCGGT1620- TTGTTGTAGA TGGCCGAGAG AATAGCTGAC GGGTTGATCT TGCTAAGTTC CT - #TGAAGACC1680- TCTAGGGTGC GCCGTTGATC CACACACCAG GCTTCTGCGA TTTCGGCCAG CG - #CCCGGTTG1740- ATGTAACCGC GCAACGTGTC ATAGGTGAAC TGCAGCTGGG CGTAGACCAG AT - #TGTGCACC1800- GACTCCATGT TGGATAAATG AGTTGCATTG TTGCCATCTG TACTTCTTTT GG - #TTCTATTA1860- TGAGTAAGAT TCAGACTGGA GCGGTTGGCC AAACGTTCGA GTTCCACCAG AG - #ATTTTTGC1920- TTGATACCTT GCCAGAACAC CACCAAACCA CCAGTGGTTT CAAAGACGGA CA - #CGTTTCCA1980- TATTTTTCAT ATGTTTGATT GTATGAAGTA TTGAAAATCT GCTGTAACTT AT - #TTATGGCC2040- TCATCACGTA CACAGTCCAG CGCAGAGTCG GACATGTTCA CCTCTTGCTT CT - #TAGATAAG2100- AAAGTGGCGG TCATTTTGGC AGAAGAAAAG TGATACGAGT CCTCGGCTTC GG - #AACGAATG2160- GTGCGTTCCG AGGCTTCCCA GAAAGTGAGT TGACAAGTAA CATTCTTCTC GT - #CCTGTATA2220- TCCCAGGAGA TCACTGAGTC CGCACGTTCA AGAAAAGCCA CCAACCTGTG GG - #TCTCTAAC2280- GCAGAATTCG GTCTTTCAAA GTCGGAGACG ATAGTGTAGT TCGGAAAAAT GA - #AAAACTTG2340- TCGGCGTTTT CTCCAAAATA GCTGGCATTG CGATTAGTTC CGTTGTAGAA AG - #GAGAAATG2400- TCAACCACAT CACCCGTGGA AGTTGCGAAA AAATGATAGG GATACTTGGA GC - #GCGCAGTA2460- GTGATGGTCA CCATACAATT CAGATTACAG GTCTCACGAT AGAGCCAGGT GC - #TGCCGCGG2520- CTGTGCCATT GATCCTTGAC CGTCACGTAA CGGGTACTGT GGGTGTTGGA AT - #AATCGTCG2580- GGCATTAATT GCATGGTTTT GTTTTCATAG CTGTCCCTAT GATAAGCCAC GA - #AAACCGTG2640- CCTGCTATAA CGCGGCTGTA GGAACTGTAG CACTGACTGT GACTGTTGAT AT - #GATGAATC2700- TCCCACATAG GAGGCGCCAC GTATTCCGTG TTGCTGCCCA GCAGATAAGT GG - #TGTGGATG2760- TAAGCGTAGC TACGACGAAA CGTCAAAACC TTCTGGTAGA CTCGTACCTT AA - #AGGTGTGC2820- GCGACGATGT TGCGTTTGTA GACCACCATG ATGCCCTCGT CCAGGTCTTC AT - #TGATGGGC2880- TTCATCGAGG TGCAGACGAT ATTACGTTCA AAGCGAATAA GATCCGTACC CT - #GAGCCATA2940- GAACACACGC GATAGGGGTA CTTGGTGGTG TTGACCCCCA CCACATCTCC GT - #ACTTGAGG3000- GTAGTGTTGT AGATGGTCTC GTTAACACCA TGGCTGACCG TTTGGGAAGA AG - #TTACGCGT3060- TGAGAGACTG AACCGGATCG AGAATGAGCA GCAGACGTCG TATGAGAGGA AT - #GGTGACTG3120- TGAGTAGCAG AAGTTCCACG AGTAGAAGAT GAGGAAACCG CAGCACCCAG AC - #AGACGATA3180- CACAAGTTAA CGCAGACTAC CAGGCACCAG ATCCTGGATT CCATTACGAT AC - #AAACTTAA3240- CGGATATCGC GATAATGAAA TAATTTATGA TTATTTCTCG CTTTCAATTT AA - #CACAACCC3300- TCAAGAACCT TTGTATTTAT TTTCACTTTT TAAGTATAGA ATAAAGAAGC TG - #GGAATCGA3360- TTCGCGATAG CTGATTAGTT TTTGTTAACA AAAATGTGGG AGAATCTAAT TA - #GTTTTTCT3420- TTACACAATT GACGTACATG AGTCTGAGTT CCTTGTTTTT GCTAATTATT TC - #ATCCAATT3480- TATTATTCTT GACGATATCG AGATCTTTTG TATAGGAGTC AGACTTGTAT TC - #AACATGCT3540- TTTCTATAAT CATCTTAGTT ATTTCGGCAT CATCCAATAG TACATTTTCC AG - #ATTAACAG3600- AGTAGATATT AATGTCGTAT TTGAACAGAG CCTGTAACAT CTCAATGTCT TT - #ATTATCTA3660- TAGCCAATTT AATGTCCGGA ATGAAGAGAA GGGAATTATT GGTGTTTGTC GA - #CGTCATAT3720- AGTCGAGCAA GAGAATCATC ATATCCACGT GTCCATTTTT TATAGTGGTG TG - #AATACAAC3780- TAAGGAGAAT AGCCAGATCA AAAGTAGATG GTATTTCTGA AAGAAAGTAT GA - #TACAATAC3840- TTACATCATT AAGCATGACG GCATGATAAA ATGAAGTTTT CCATCCAGTT TT - #CCCATAGA3900- ACATCAGTCT CCAATTTTTC TTAAACAGTT TCACCGTTTG CATGTTACCA CT - #ATCAACCG3960- CATAATACAA TGCGGTGTTT CCTTTGTCAT CAAATTGTGA ATCATCCATT CC - #ACTGAATA4020- GCAAAATCTT TACTATTTTG GTATCTTCTA ATGTGGCTGC CTGATGTAAT GG - #AAATTCAT4080- TCTCTAGAAG ATTTTTCAAT GCTCCAGCGT TCAACAACGT ACATACTAGA CG - #CACGTTAT4140- TATCAGCTAT TGCATAATAC AAGGCACTAT GTCCATGGAC ATCCGCCTTA AA - #TGTATCTT4200- TACTAGAGAG AAAGCTTTTC AGCTGCTTAG ACTTCCAAGT ATTAATTCGT GA - #CAGATCCA4260- TGTCTGAAAC GAGACGCTAA TTAGTGTATA TTTTTTCATT TTTTATAATT TT - #GTCATATT4320- GCACCAGAAT TAATAATATC TCTAATAGAT CTAATTTAAT TTAATTTATA TA - #ACTTATTT4380- TTTGAATATA CTTTTAATTA ACAAAAGAGT TAAGTTACTC ATATGGACGC CG - #TCCAGTCT4440- GAACATCAAT CTTTTTAGCC AGAGATATCA TAGCCGCTCT TAGAGTTTCA GC - #GTGATTTT4500- CCAACCTAAA TAGAACTTCA TCGTTGCGTT TACAACACTT TTCTATTTGT TC - #AAACTTTG4560- TTGTTACATT AGTAATCTTT TTTTCCAAAT TAGTTAGCCG TTGTTTGAGA GT - #TTCCTCAT4620- TGTCGTCTTC ATCGGCTTTA ACAATTGCTT CGCGTTTAGC CTCCTGGCTG TT - #CTTATCAG4680- CCTTTGTAGA AAAAAATTCA GTTGCTGGAA TTGCAAGATC GTCATCTCCG GG - #GAAAAGAG4740# 4768 CCGC GGGAATTC- (2) INFORMATION FOR SEQ ID NO:42:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 2550 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:- ATGGAATCCA GGATCTGGTG CCTGGTAGTC TGCGTTAACT TGTGTATCGT CT - #GTCTGGGT 60- GCTGCGGTTT CCTCATCTTC TACTCGTGGA ACTTCTGCTA CTCACAGTCA CC - #ATTCCTCT 120- CATACGACGT CTGCTGCTCA TTCTCGATCC GGTTCAGTCT CTCAACGCGT AA - #CTTCTTCC 180- CAAACGGTCA GCCATGGTGT TAACGAGACC ATCTACAACA CTACCCTCAA GT - #ACGGAGAT 240- GTGGTGGGGG TCAACACCAC CAAGTACCCC TATCGCGTGT GTTCTATGGC TC - #AGGGTACG 300- GATCTTATTC GCTTTGAACG TAATATCGTC TGCACCTCGA TGAAGCCCAT CA - #ATGAAGAC 360- CTGGACGAGG GCATCATGGT GGTCTACAAA CGCAACATCG TCGCGCACAC CT - #TTAAGGTA 420- CGAGTCTACC AGAAGGTTTT GACGTTTCGT CGTAGCTACG CTTACATCCA CA - #CCACTTAT 480- CTGCTGGGCA GCAACACGGA ATACGTGGCG CCTCCTATGT GGGAGATTCA TC - #ATATCAAC 540- AGTCACAGTC AGTGCTACAG TTCCTACAGC CGCGTTATAG CAGGCACGGT TT - #TCGTGGCT 600- TATCATAGGG ACAGCTATGA AAACAAAACC ATGCAATTAA TGCCCGACGA TT - #ATTCCAAC 660- ACCCACAGTA CCCGTTACGT GACGGTCAAG GATCAATGGC ACAGCCGCGG CA - #GCACCTGG 720- CTCTATCGTG AGACCTGTAA TCTGAATTGT ATGGTGACCA TCACTACTGC GC - #GCTCCAAG 780- TATCCCTATC ATTTTTTCGC AACTTCCACG GGTGATGTGG TTGACATTTC TC - #CTTTCTAC 840- AACGGAACTA ATCGCAATGC CAGCTATTTT GGAGAAAACG CCGACAAGTT TT - #TCATTTTT 900- CCGAACTACA CTATCGTCTC CGACTTTGAA AGACCGAATT CTGCGTTAGA GA - #CCCACAGG 960- TTGGTGGCTT TTCTTGAACG TGCGGACTCA GTGATCTCCT GGGATATACA GG - #ACGAGAAG1020- AATGTTACTT GTCAACTCAC TTTCTGGGAA GCCTCGGAAC GCACCATTCG TT - #CCGAAGCC1080- GAGGACTCGT ATCACTTTTC TTCTGCCAAA ATGACCGCCA CTTTCTTATC TA - #AGAAGCAA1140- GAGGTGAACA TGTCCGACTC TGCGCTGGAC TGTGTACGTG ATGAGGCCAT AA - #ATAAGTTA1200- CAGCAGATTT TCAATACTTC ATACAATCAA ACATATGAAA AATATGGAAA CG - #TGTCCGTC1260- TTTGAAACCA CTGGTGGTTT GGTGGTGTTC TGGCAAGGTA TCAAGCAAAA AT - #CTCTGGTG1320- GAACTCGAAC GTTTGGCCAA CCGCTCCAGT CTGAATCTTA CTCATAATAG AA - #CCAAAAGA1380- AGTACAGATG GCAACAATGC AACTCATTTA TCCAACATGG AGTCGGTGCA CA - #ATCTGGTC1440- TACGCCCAGC TGCAGTTCAC CTATGACACG TTGCGCGGTT ACATCAACCG GG - #CGCTGGCC1500- GAAATCGCAG AAGCCTGGTG TGTGGATCAA CGGCGCACCC TAGAGGTCTT CA - #AGGAACTT1560- AGCAAGATCA ACCCGTCAGC TATTCTCTCG GCCATCTACA ACAAACCGAT TG - #CCGCGCGT1620- TTCATGGGTG ATGTCCTGGG TCTGGCCAGC TGCGTGACCA TTAACCAAAC CA - #GCGTCAAG1680- GTGCTGCGTG ATATGAATGT GAAGGAATCG CCAGGACGCT GCTACTCACG AC - #CAGTGGTC1740- ATCTTTAATT TCGCCAACAG CTCGTACGTG CAGTACGGTC AACTGGGCGA GG - #ATAACGAA1800- ATCCTGTTGG GCAACCACCG CACTGAGGAA TGTCAGCTTC CCAGCCTCAA GA - #TCTTCATC1860- GCCGGCAACT CGGCCTACGA GTACGTGGAC TACCTCTTCA AACGCATGAT TG - #ACCTCAGC1920- AGCATCTCCA CCGTCGACAG CATGATCGCC CTAGACATCG ACCCGCTGGA AA - #ACACCGAC1980- TTCAGGGTAC TGGAACTTTA CTCGCAGAAA GAATTGCGTT CCAGCAACGT TT - #TTGATCTC2040- GAGGAGATCA TGCGCGAGTT CAATTCGTAT AAGCAGCGGG TAAAGTACGT GG - #AGGACAAG2100- GTAGTCGACC CGCTGCCGCC CTACCTCAAG GGTCTGGACG ACACTCGACA GC - #GGCGTCTC2160- TGCATGCAGC CGCTGCAGAA CCTCTTTCCC TATCTGGTGT CCGCCGACGG GA - #CCACCGTG2220- ACGTCGGGCA ACACCAAAGA CACGTCGTTA CAGGCTCCGC CTTCCTACGA GG - #AAAGTGTT2280- TATAATTCTG GTCGCAAAGG ACCGGGACCA CCGTCGTCTG ATGCATCCAC GG - #CGGCTCCG2340- CCTTACACCA ACGAGCAGGC TTACCAGATG CTTCTGGCCC TGGTCCGTCT GG - #ACGCAGAG2400- CAGCGAGCGC ACGAGAACGG TACAGATTCT TTGGACGGAC AGACTGGCAC GC - #AGGACAAG2460- GGACAGAAGC CCAACCTGCT AGACCGACTG CGACACCGCA AAAACGGCTA CC - #GACACTTG2520# 2550 AAGA GAACGTCTGA- (2) INFORMATION FOR SEQ ID NO:43:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 4594 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:- AAGCTTGCGG CCGCTCATTA GACAAGCGAA TGAGGGACGA AAACGTGGAG GA - #GGTATTAA 60- GTTTGGAGAA ATGGAGAGAG ACTGTTTAAT AGCGCATGGC GCAGCCAATA CT - #ATTACAGA 120- AGTTTTGAAA GATTCGGAAG AAGATTATCA AGATGTGTAT GTTTGTGAAA AT - #TGTGGAGA 180- CATAGCAGCA CAAATCAAGG GTATTAATAC ATGTCTTAGA TGTTCAAAAC TT - #AATCTCTC 240- TCCTCTCTTA ACAAAAATTG ATACCACGCA CGTATCTAAA GTATTTCTTA CT - #CAAATGAA 300- CGCCAGAGGC GTAAAAGTCA AATTAGATTT CGAACGAAGG CCTCCTTCGT TT - #TATAAACC 360- ATTAGATAAA GTTGATCTCA AGCCGTCTTT TCTGGTGTAA TAAAAATTAA TT - #AATTACTC 420- GAGGGTACCG GATCCCCCAG CTTATAAAAA TCACAAGACT CTGTCACTTT TT - #TTGACTAG 480- TTTTTTTTTC TCCTCTTGGT TCAGACGTTC TCTTCTTCGT CGGAGTCTTT CA - #AGTGTCGG 540- TAGCCGTTTT TGCGGTGTCG CAGTCGGTCT AGCAGGTTGG GCTTCTGTCC CT - #TGTCCTGC 600- GTGCCAGTCT GTCCGTCCAA AGAATCTGTA CCGTTCTCGT GCGCTCGCTG CT - #CTGCGTCC 660- AGACGGACCA GGGCCAGAAG CATCTGGTAA GCCTGCTCGT TGGTGTAAGG CG - #GAGCCGCC 720- GTGGATGCAT CAGACGACGG TGGTCCCGGT CCTTTGCGAC CAGAATTATA AA - #CACTTTCC 780- TCGTAGGAAG GCGGAGCCTG TAACGACGTG TCTTTGGTGT TGCCCGACGT CA - #CGGTGGTC 840- CCGTCGGCGG ACACCAGATA GGGAAAGAGG TTCTGCAGCG GCTGCATGCA GA - #GACGCCGC 900- TGTCGAGTGT CGTCCAGACC CTTGAGGTAG GGCGGCAGCG GGTCGACTAC CT - #TGTCCTCC 960- ACGTACTTTA CCCGCTGCTT ATACGAATTG AACTCGCGCA TGATCTCCTC GA - #GATCAAAA1020- ACGTTGCTGG AACGCAATTC TTTCTGCGAG TAAAGTTCCA GTACCCTGAA GT - #CGGTGTTT1080- TCCAGCGGGT CGATGTCTAG GGCGATCATG CTGTCGACGG TGGAGATGCT GC - #TGAGGTCA1140- ATCATGCGTT TGAAGAGGTA GTCCACGTAC TCGTAGGCCG AGTTGCCGGC GA - #TGAAGATC1200- TTGAGGCTGG GAAGCTGACA TTCCTCAGTG CGGTGGTTGC CCAACAGGAT TT - #CGTTATCC1260- TCGCCCAGTT GACCGTACTG CACGTACGAG CTGTTGGCGA AATTAAAGAT GA - #CCACTGGT1320- CGTGAGTAGC AGCGTCCTGG CGATTCCTTC ACATTCATAT CACGCAGCAC CT - #TGACGCTG1380- GTTTGGTTAA TGGTCACGCA GCTGGCCAGA CCCAGGACAT CACCCATGAA AC - #GCGCGGCA1440- ATCGGTTTGT TGTAGATGGC CGAGAGAATA GCTGACGGGT TGATCTTGCT AA - #GTTCCTTG1500- AAGACCTCTA GGGTGCGCCG TTGATCCACA CACCAGGCTT CTGCGATTTC GG - #CCAGCGCC1560- CGGTTGATGT AACCGCGCAA CGTGTCATAG GTGAACTGCA GCTGGGCGTA GA - #CCAGATTG1620- TGCACCGACT CCATGTTGGA TAAATGAGTT GCATTGTTGC CATCTGTACT TC - #TTTTGGTT1680- CTATTATGAG TAAGATTCAG ACTGGAGCGG TTGGCCAAAC GTTCGAGTTC CA - #CCAGAGAT1740- TTTTGCTTGA TACCTTGCCA GAACACCACC AAACCACCAG TGGTTTCAAA GA - #CGGACACG1800- TTTCCATATT TTTCATATGT TTGATTGTAT GAAGTATTGA AAATCTGCTG TA - #ACTTATTT1860- ATGGCCTCAT CACGTACACA GTCCAGCGCA GAGTCGGACA TGTTCACCTC TT - #GCTTCTTA1920- GATAAGAAAG TGGCGGTCAT TTTGGCAGAA GAAAAGTGAT ACGAGTCCTC GG - #CTTCGGAA1980- CGAATGGTGC GTTCCGAGGC TTCCCAGAAA GTGAGTTGAC AAGTAACATT CT - #TCTCGTCC2040- TGTATATCCC AGGAGATCAC TGAGTCCGCA CGTTCAAGAA AAGCCACCAA CC - #TGTGGGTC2100- TCTAACGCAG AATTCGGTCT TTCAAAGTCG GAGACGATAG TGTAGTTCGG AA - #AAATGAAA2160- AACTTGTCGG CGTTTTCTCC AAAATAGCTG GCATTGCGAT TAGTTCCGTT GT - #AGAAAGGA2220- GAAATGTCAA CCACATCACC CGTGGAAGTT GCGAAAAAAT GATAGGGATA CT - #TGGAGCGC2280- GCAGTAGTGA TGGTCACCAT ACAATTCAGA TTACAGGTCT CACGATAGAG CC - #AGGTGCTG2340- CCGCGGCTGT GCCATTGATC CTTGACCGTC ACGTAACGGG TACTGTGGGT GT - #TGGAATAA2400- TCGTCGGGCA TTAATTGCAT GGTTTTGTTT TCATAGCTGT CCCTATGATA AG - #CCACGAAA2460- ACCGTGCCTG CTATAACGCG GCTGTAGGAA CTGTAGCACT GACTGTGACT GT - #TGATATGA2520- TGAATCTCCC ACATAGGAGG CGCCACGTAT TCCGTGTTGC TGCCCAGCAG AT - #AAGTGGTG2580- TGGATGTAAG CGTAGCTACG ACGAAACGTC AAAACCTTCT GGTAGACTCG TA - #CCTTAAAG2640- GTGTGCGCGA CGATGTTGCG TTTGTAGACC ACCATGATGC CCTCGTCCAG GT - #CTTCATTG2700- ATGGGCTTCA TCGAGGTGCA GACGATATTA CGTTCAAAGC GAATAAGATC CG - #TACCCTGA2760- GCCATAGAAC ACACGCGATA GGGGTACTTG GTGGTGTTGA CCCCCACCAC AT - #CTCCGTAC2820- TTGAGGGTAG TGTTGTAGAT GGTCTCGTTA ACACCATGGC TGACCGTTTG GG - #AAGAAGTT2880- ACGCGTTGAG AGACTGAACC GGATCGAGAA TGAGCAGCAG ACGTCGTATG AG - #AGGAATGG2940- TGACTGTGAG TAGCAGAAGT TCCACGAGTA GAAGATGAGG AAACCGCAGC AC - #CCAGACAG3000- ACGATACACA AGTTAACGCA GACTACCAGG CACCAGATCC TGGATTCCAT TA - #CGATACAA3060- ACTTAACGGA TATCGCGATA ATGAAATAAT TTATGATTAT TTCTCGCTTT CA - #ATTTAACA3120- CAACCCTCAA GAACCTTTGT ATTTATTTTC ACTTTTTAAG TATAGAATAA AG - #AAGCTGGG3180- AATCGATTCG CGATAGCTGA TTAGTTTTTG TTAACAAAAA TGTGGGAGAA TC - #TAATTAGT3240- TTTTCTTTAC ACAATTGACG TACATGAGTC TGAGTTCCTT GTTTTTGCTA AT - #TATTTCAT3300- CCAATTTATT ATTCTTGACG ATATCGAGAT CTTTTGTATA GGAGTCAGAC TT - #GTATTCAA3360- CATGCTTTTC TATAATCATC TTAGTTATTT CGGCATCATC CAATAGTACA TT - #TTCCAGAT3420- TAACAGAGTA GATATTAATG TCGTATTTGA ACAGAGCCTG TAACATCTCA AT - #GTCTTTAT3480- TATCTATAGC CAATTTAATG TCCGGAATGA AGAGAAGGGA ATTATTGGTG TT - #TGTCGACG3540- TCATATAGTC GAGCAAGAGA ATCATCATAT CCACGTGTCC ATTTTTTATA GT - #GGTGTGAA3600- TACAACTAAG GAGAATAGCC AGATCAAAAG TAGATGGTAT TTCTGAAAGA AA - #GTATGATA3660- CAATACTTAC ATCATTAAGC ATGACGGCAT GATAAAATGA AGTTTTCCAT CC - #AGTTTTCC3720- CATAGAACAT CAGTCTCCAA TTTTTCTTAA ACAGTTTCAC CGTTTGCATG TT - #ACCACTAT3780- CAACCGCATA ATACAATGCG GTGTTTCCTT TGTCATCAAA TTGTGAATCA TC - #CATTCCAC3840- TGAATAGCAA AATCTTTACT ATTTTGGTAT CTTCTAATGT GGCTGCCTGA TG - #TAATGGAA3900- ATTCATTCTC TAGAAGATTT TTCAATGCTC CAGCGTTCAA CAACGTACAT AC - #TAGACGCA3960- CGTTATTATC AGCTATTGCA TAATACAAGG CACTATGTCC ATGGACATCC GC - #CTTAAATG4020- TATCTTTACT AGAGAGAAAG CTTTTCAGCT GCTTAGACTT CCAAGTATTA AT - #TCGTGACA4080- GATCCATGTC TGAAACGAGA CGCTAATTAG TGTATATTTT TTCATTTTTT AT - #AATTTTGT4140- CATATTGCAC CAGAATTAAT AATATCTCTA ATAGATCTAA TTTAATTTAA TT - #TATATAAC4200- TTATTTTTTG AATATACTTT TAATTAACAA AAGAGTTAAG TTACTCATAT GG - #ACGCCGTC4260- CAGTCTGAAC ATCAATCTTT TTAGCCAGAG ATATCATAGC CGCTCTTAGA GT - #TTCAGCGT4320- GATTTTCCAA CCTAAATAGA ACTTCATCGT TGCGTTTACA ACACTTTTCT AT - #TTGTTCAA4380- ACTTTGTTGT TACATTAGTA ATCTTTTTTT CCAAATTAGT TAGCCGTTGT TT - #GAGAGTTT4440- CCTCATTGTC GTCTTCATCG GCTTTAACAA TTGCTTCGCG TTTAGCCTCC TG - #GCTGTTCT4500- TATCAGCCTT TGTAGAAAAA AATTCAGTTG CTGGAATTGC AAGATCGTCA TC - #TCCGGGGA4560# 4594 TTAA AGCCGCGGGA ATTC- (2) INFORMATION FOR SEQ ID NO:44:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 2550 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:- ATGGAATCCA GGATCTGGTG CCTGGTAGTC TGCGTTAACT TGTGTATCGT CT - #GTCTGGGT 60- GCTGCGGTTT CCTCATCTTC TACTCGTGGA ACTTCTGCTA CTCACAGTCA CC - #ATTCCTCT 120- CATACGACGT CTGCTGCTCA TTCTCGATCC GGTTCAGTCT CTCAACGCGT AA - #CTTCTTCC 180- CAAACGGTCA GCCATGGTGT TAACGAGACC ATCTACAACA CTACCCTCAA GT - #ACGGAGAT 240- GTGGTGGGGG TCAACACCAC CAAGTACCCC TATCGCGTGT GTTCTATGGC TC - #AGGGTACG 300- GATCTTATTC GCTTTGAACG TAATATCGTC TGCACCTCGA TGAAGCCCAT CA - #ATGAAGAC 360- CTGGACGAGG GCATCATGGT GGTCTACAAA CGCAACATCG TCGCGCACAC CT - #TTAAGGTA 420- CGAGTCTACC AGAAGGTTTT GACGTTTCGT CGTAGCTACG CTTACATCCA CA - #CCACTTAT 480- CTGCTGGGCA GCAACACGGA ATACGTGGCG CCTCCTATGT GGGAGATTCA TC - #ATATCAAC 540- AGTCACAGTC AGTGCTACAG TTCCTACAGC CGCGTTATAG CAGGCACGGT TT - #TCGTGGCT 600- TATCATAGGG ACAGCTATGA AAACAAAACC ATGCAATTAA TGCCCGACGA TT - #ATTCCAAC 660- ACCCACAGTA CCCGTTACGT GACGGTCAAG GATCAATGGC ACAGCCGCGG CA - #GCACCTGG 720- CTCTATCGTG AGACCTGTAA TCTGAATTGT ATGGTGACCA TCACTACTGC GC - #GCTCCAAG 780- TATCCCTATC ATTTTTTCGC AACTTCCACG GGTGATGTGG TTGACATTTC TC - #CTTTCTAC 840- AACGGAACTA ATCGCAATGC CAGCTATTTT GGAGAAAACG CCGACAAGTT TT - #TCATTTTT 900- CCGAACTACA CTATCGTCTC CGACTTTGAA AGACCGAATT CTGCGTTAGA GA - #CCCACAGG 960- TTGGTGGCTT TTCTTGAACG TGCGGACTCA GTGATCTCCT GGGATATACA GG - #ACGAGAAG1020- AATGTTACTT GTCAACTCAC TTTCTGGGAA GCCTCGGAAC GCACCATTCG TT - #CCGAAGCC1080- GAGGACTCGT ATCACTTTTC TTCTGCCAAA ATGACCGCCA CTTTCTTATC TA - #AGAAGCAA1140- GAGGTGAACA TGTCCGACTC TGCGCTGGAC TGTGTACGTG ATGAGGCCAT AA - #ATAAGTTA1200- CAGCAGATTT TCAATACTTC ATACAATCAA ACATATGAAA AATATGGAAA CG - #TGTCCGTC1260- TTTGAAACCA CTGGTGGTTT GGTGGTGTTC TGGCAAGGTA TCAAGCAAAA AT - #CTCTGGTG1320- GAACTCGAAC GTTTGGCCAA CCGCTCCAGT CTGAATCTTA CTCATAATAG AA - #CCATAAGA1380- TCTACAGATG GCAACAATGC AACTCATTTA TCCAACATGG AGTCGGTGCA CA - #ATCTGGTC1440- TACGCCCAGC TGCAGTTCAC CTATGACACG TTGCGCGGTT ACATCAACCG GG - #CGCTGGCC1500- GAAATCGCAG AAGCCTGGTG TGTGGATCAA CGGCGCACCC TAGAGGTCTT CA - #AGGAACTT1560- AGCAAGATCA ACCCGTCAGC TATTCTCTCG GCCATCTACA ACAAACCGAT TG - #CCGCGCGT1620- TTCATGGGTG ATGTCCTGGG TCTGGCCAGC TGCGTGACCA TTAACCAAAC CA - #GCGTCAAG1680- GTGCTGCGTG ATATGAATGT GAAGGAATCG CCAGGACGCT GCTACTCACG AC - #CAGTGGTC1740- ATCTTTAATT TCGCCAACAG CTCGTACGTG CAGTACGGTC AACTGGGCGA GG - #ATAACGAA1800- ATCCTGTTGG GCAACCACCG CACTGAGGAA TGTCAGCTTC CCAGCCTCAA GA - #TCTTCATC1860- GCCGGCAACT CGGCCTACGA GTACGTGGAC TACCTCTTCA AACGCATGAT TG - #ACCTCAGC1920- AGCATCTCCA CCGTCGACAG CATGATCGCC CTAGACATCG ACCCGCTGGA AA - #ACACCGAC1980- TTCAGGGTAC TGGAACTTTA CTCGCAGAAA GAATTGCGTT CCAGCAACGT TT - #TTGATCTC2040- GAGGAGATCA TGCGCGAGTT CAATTCGTAT AAGCAGCGGG TAAAGTACGT GG - #AGGACAAG2100- GTAGTCGACC CGCTGCCGCC CTACCTCAAG GGTCTGGACG ACACTCGACA GC - #GGCGTCTC2160- TGCATGCAGC CGCTGCAGAA CCTCTTTCCC TATCTGGTGT CCGCCGACGG GA - #CCACCGTG2220- ACGTCGGGCA ACACCAAAGA CACGTCGTTA CAGGCTCCGC CTTCCTACGA GG - #AAAGTGTT2280- TATAATTCTG GTCGCAAAGG ACCGGGACCA CCGTCGTCTG ATGCATCCAC GG - #CGGCTCCG2340- CCTTACACCA ACGAGCAGGC TTACCAGATG CTTCTGGCCC TGGTCCGTCT GG - #ACGCAGAG2400- CAGCGAGCGC ACGAGAACGG TACAGATTCT TTGGACGGAC AGACTGGCAC GC - #AGGACAAG2460- GGACAGAAGC CCAACCTGCT AGACCGACTG CGACACCGCA AAAACGGCTA CC - #GACACTTG2520# 2550 AAGA GAACGTCTGA- (2) INFORMATION FOR SEQ ID NO:45:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 4594 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:- AAGCTTGCGG CCGCTCATTA GACAAGCGAA TGAGGGACGA AAACGTGGAG GA - #GGTATTAA 60- GTTTGGAGAA ATGGAGAGAG ACTGTTTAAT AGCGCATGGC GCAGCCAATA CT - #ATTACAGA 120- AGTTTTGAAA GATTCGGAAG AAGATTATCA AGATGTGTAT GTTTGTGAAA AT - #TGTGGAGA 180- CATAGCAGCA CAAATCAAGG GTATTAATAC ATGTCTTAGA TGTTCAAAAC TT - #AATCTCTC 240- TCCTCTCTTA ACAAAAATTG ATACCACGCA CGTATCTAAA GTATTTCTTA CT - #CAAATGAA 300- CGCCAGAGGC GTAAAAGTCA AATTAGATTT CGAACGAAGG CCTCCTTCGT TT - #TATAAACC 360- ATTAGATAAA GTTGATCTCA AGCCGTCTTT TCTGGTGTAA TAAAAATTAA TT - #AATTACTC 420- GAGGGTACCG GATCCCCCAG CTTATAAAAA TCACAAGTCT CTGACACTTT TT - #TTGTCTAG 480- TTTTTTTTTC TCCTCTTGGT TCAGACGTTC TCTTCTTCGT CGGAGTCTTT CA - #AGTGTCGG 540- TAGCCGTTTT TGCGGTGTCG CAGTCGGTCT AGCAGGTTGG GCTTCTGTCC CT - #TGTCCTGC 600- GTGCCAGTCT GTCCGTCCAA AGAATCTGTA CCGTTCTCGT GCGCTCGCTG CT - #CTGCGTCC 660- AGACGGACCA GGGCCAGAAG CATCTGGTAA GCCTGCTCGT TGGTGTAAGG CG - #GAGCCGCC 720- GTGGATGCAT CAGACGACGG TGGTCCCGGT CCTTTGCGAC CAGAATTATA AA - #CACTTTCC 780- TCGTAGGAAG GCGGAGCCTG TAACGACGTG TCTTTGGTGT TGCCCGACGT CA - #CGGTGGTC 840- CCGTCGGCGG ACACCAGATA GGGAAAGAGG TTCTGCAGCG GCTGCATGCA GA - #GACGCCGC 900- TGTCGAGTGT CGTCCAGACC CTTGAGGTAG GGCGGCAGCG GGTCGACTAC CT - #TGTCCTCC 960- ACGTACTTTA CCCGCTGCTT ATACGAATTG AACTCGCGCA TGATCTCCTC GA - #GATCAAAA1020- ACGTTGCTGG AACGCAATTC TTTCTGCGAG TAAAGTTCCA GTACCCTGAA GT - #CGGTGTTT1080- TCCAGCGGGT CGATGTCTAG GGCGATCATG CTGTCGACGG TGGAGATGCT GC - #TGAGGTCA1140- ATCATGCGTT TGAAGAGGTA GTCCACGTAC TCGTAGGCCG AGTTGCCGGC GA - #TGAAGATC1200- TTGAGGCTGG GAAGCTGACA TTCCTCAGTG CGGTGGTTGC CCAACAGGAT TT - #CGTTATCC1260- TCGCCCAGTT GACCGTACTG CACGTACGAG CTGTTGGCGA AATTAAAGAT GA - #CCACTGGT1320- CGTGAGTAGC AGCGTCCTGG CGATTCCTTC ACATTCATAT CACGCAGCAC CT - #TGACGCTG1380- GTTTGGTTAA TGGTCACGCA GCTGGCCAGA CCCAGGACAT CACCCATGAA AC - #GCGCGGCA1440- ATCGGTTTGT TGTAGATGGC CGAGAGAATA GCTGACGGGT TGATCTTGCT AA - #GTTCCTTG1500- AAGACCTCTA GGGTGCGCCG TTGATCCACA CACCAGGCTT CTGCGATTTC GG - #CCAGCGCC1560- CGGTTGATGT AACCGCGCAA CGTGTCATAG GTGAACTGCA GCTGGGCGTA GA - #CCAGATTG1620- TGCACCGACT CCATGTTGGA TAAATGAGTT GCATTGTTGC CATCTGTAGA TC - #TTATGGTT1680- CTATTATGAG TAAGATTCAG ACTGGAGCGG TTGGCCAAAC GTTCGAGTTC CA - #CCAGAGAT1740- TTTTGCTTGA TACCTTGCCA GAACACCACC AAACCACCAG TGGTTTCAAA GA - #CGGACACG1800- TTTCCATATT TTTCATATGT TTGATTGTAT GAAGTATTGA AAATCTGCTG TA - #ACTTATTT1860- ATGGCCTCAT CACGTACACA GTCCAGCGCA GAGTCGGACA TGTTCACCTC TT - #GCTTCTTA1920- GATAAGAAAG TGGCGGTCAT TTTGGCAGAA GAAAAGTGAT ACGAGTCCTC GG - #CTTCGGAA1980- CGAATGGTGC GTTCCGAGGC TTCCCAGAAA GTGAGTTGAC AAGTAACATT CT - #TCTCGTCC2040- TGTATATCCC AGGAGATCAC TGAGTCCGCA CGTTCAAGAA AAGCCACCAA CC - #TGTGGGTC2100- TCTAACGCAG AATTCGGTCT TTCAAAGTCG GAGACGATAG TGTAGTTCGG AA - #AAATGAAA2160- AACTTGTCGG CGTTTTCTCC AAAATAGCTG GCATTGCGAT TAGTTCCGTT GT - #AGAAAGGA2220- GAAATGTCAA CCACATCACC CGTGGAAGTT GCGAAAAAAT GATAGGGATA CT - #TGGAGCGC2280- GCAGTAGTGA TGGTCACCAT ACAATTCAGA TTACAGGTCT CACGATAGAG CC - #AGGTGCTG2340- CCGCGGCTGT GCCATTGATC CTTGACCGTC ACGTAACGGG TACTGTGGGT GT - #TGGAATAA2400- TCGTCGGGCA TTAATTGCAT GGTTTTGTTT TCATAGCTGT CCCTATGATA AG - #CCACGAAA2460- ACCGTGCCTG CTATAACGCG GCTGTAGGAA CTGTAGCACT GACTGTGACT GT - #TGATATGA2520- TGAATCTCCC ACATAGGAGG CGCCACGTAT TCCGTGTTGC TGCCCAGCAG AT - #AAGTGGTG2580- TGGATGTAAG CGTAGCTACG ACGAAACGTC AAAACCTTCT GGTAGACTCG TA - #CCTTAAAG2640- GTGTGCGCGA CGATGTTGCG TTTGTAGACC ACCATGATGC CCTCGTCCAG GT - #CTTCATTG2700- ATGGGCTTCA TCGAGGTGCA GACGATATTA CGTTCAAAGC GAATAAGATC CG - #TACCCTGA2760- GCCATAGAAC ACACGCGATA GGGGTACTTG GTGGTGTTGA CCCCCACCAC AT - #CTCCGTAC2820- TTGAGGGTAG TGTTGTAGAT GGTCTCGTTA ACACCATGGC TGACCGTTTG GG - #AAGAAGTT2880- ACGCGTTGAG AGACTGAACC GGATCGAGAA TGAGCAGCAG ACGTCGTATG AG - #AGGAATGG2940- TGACTGTGAG TAGCAGAAGT TCCACGAGTA GAAGATGAGG AAACCGCAGC AC - #CCAGACAG3000- ACGATACACA AGTTAACGCA GACTACCAGG CACCAGATCC TGGATTCCAT TA - #CGATACAA3060- ACTTAACGGA TATCGCGATA ATGAAATAAT TTATGATTAT TTCTCGCTTT CA - #ATTTAACA3120- CAACCCTCAA GAACCTTTGT ATTTATTTTC ACTTTTTAAG TATAGAATAA AG - #AAGCTGGG3180- AATCGATTCG CGATAGCTGA TTAGTTTTTG TTAACAAAAA TGTGGGAGAA TC - #TAATTAGT3240- TTTTCTTTAC ACAATTGACG TACATGAGTC TGAGTTCCTT GTTTTTGCTA AT - #TATTTCAT3300- CCAATTTATT ATTCTTGACG ATATCGAGAT CTTTTGTATA GGAGTCAGAC TT - #GTATTCAA3360- CATGCTTTTC TATAATCATC TTAGTTATTT CGGCATCATC CAATAGTACA TT - #TTCCAGAT3420- TAACAGAGTA GATATTAATG TCGTATTTGA ACAGAGCCTG TAACATCTCA AT - #GTCTTTAT3480- TATCTATAGC CAATTTAATG TCCGGAATGA AGAGAAGGGA ATTATTGGTG TT - #TGTCGACG3540- TCATATAGTC GAGCAAGAGA ATCATCATAT CCACGTGTCC ATTTTTTATA GT - #GGTGTGAA3600- TACAACTAAG GAGAATAGCC AGATCAAAAG TAGATGGTAT TTCTGAAAGA AA - #GTATGATA3660- CAATACTTAC ATCATTAAGC ATGACGGCAT GATAAAATGA AGTTTTCCAT CC - #AGTTTTCC3720- CATAGAACAT CAGTCTCCAA TTTTTCTTAA ACAGTTTCAC CGTTTGCATG TT - #ACCACTAT3780- CAACCGCATA ATACAATGCG GTGTTTCCTT TGTCATCAAA TTGTGAATCA TC - #CATTCCAC3840- TGAATAGCAA AATCTTTACT ATTTTGGTAT CTTCTAATGT GGCTGCCTGA TG - #TAATGGAA3900- ATTCATTCTC TAGAAGATTT TTCAATGCTC CAGCGTTCAA CAACGTACAT AC - #TAGACGCA3960- CGTTATTATC AGCTATTGCA TAATACAAGG CACTATGTCC ATGGACATCC GC - #CTTAAATG4020- TATCTTTACT AGAGAGAAAG CTTTTCAGCT GCTTAGACTT CCAAGTATTA AT - #TCGTGACA4080- GATCCATGTC TGAAACGAGA CGCTAATTAG TGTATATTTT TTCATTTTTT AT - #AATTTTGT4140- CATATTGCAC CAGAATTAAT AATATCTCTA ATAGATCTAA TTTAATTTAA TT - #TATATAAC4200- TTATTTTTTG AATATACTTT TAATTAACAA AAGAGTTAAG TTACTCATAT GG - #ACGCCGTC4260- CAGTCTGAAC ATCAATCTTT TTAGCCAGAG ATATCATAGC CGCTCTTAGA GT - #TTCAGCGT4320- GATTTTCCAA CCTAAATAGA ACTTCATCGT TGCGTTTACA ACACTTTTCT AT - #TTGTTCAA4380- ACTTTGTTGT TACATTAGTA ATCTTTTTTT CCAAATTAGT TAGCCGTTGT TT - #GAGAGTTT4440- CCTCATTGTC GTCTTCATCG GCTTTAACAA TTGCTTCGCG TTTAGCCTCC TG - #GCTGTTCT4500- TATCAGCCTT TGTAGAAAAA AATTCAGTTG CTGGAATTGC AAGATCGTCA TC - #TCCGGGGA4560# 4594 TTAA AGCCGCGGGA ATTC- (2) INFORMATION FOR SEQ ID NO:46:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 2229 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:- ATGCGGCCAG GCCTCCCCTC CTACCTCATC GTCCTCGCCG TCTGTCTCCT CA - #GCCACCTA 60- CTTTCGTCAC GATATGGCGC AGAAGCCATA TCCGAACCGC TGGACAAAGC GT - #TTCACCTA 120- CTGCTCAACA CCTACGGGAG ACCCATCCGC TTCCTGCGTG AAAACACCAC CC - #AGTGTACC 180- TACAATAGCA GCCTCCGTAA CAGCACGGTC GTCAGGGAAA ACGCCATCAG TT - #TCAACTTT 240- TTCCAAAGCT ATAATCAATA CTATGTATTC CATATGCCTC GATGTCTTTT TG - #CGGGTCCT 300- CTGGCGGAGC AGTTTCTGAA CCAGGTAGAT CTGACCGAAA CCCTGGAAAG AT - #ACCAACAG 360- AGACTTAACA CTTACGCGCT GGTATCCAAA GACCTGGCCA GCTACCGATC TT - #TTTCGCAG 420- CAGCTAAAGG CACAGGACAG CCTAGGTGAA CAGCCCACCA CTGTGCCACC AC - #CCATTGAC 480- CTGTCAATAC CTCACGTTTG GATGCCACCG CAAACCACTC CACACGGCTG GA - #CAGAATCA 540- CATACCACCT CAGGACTACA CCGACCACAC TTTAACCAGA CCTGTATCCT CT - #TTGATGGA 600- CACGATCTAC TATTCAGCAC CGTCACACCT TGTTTGCACC AAGGCTTTTA CC - #TCATCGAC 660- GAACTACGTT ACGTTAAAAT AACACTGACC GAGGACTTCT TCGTAGTTAC GG - #TGTCCATA 720- GACGACGACA CACCCATGCT GCTTATCTTC GGCCATCTTC CACGCGTACT CT - #TTAAAGCG 780- CCCTATCAAC GCGACAACTT TATACTACGA CAAACTGAAA AACACGAGCT CC - #TGGTGCTA 840- GTTAAGAAAG ATCAACTGAA CCGTCACTCT TATCTCAAAG ACCCGGACTT TC - #TTGACGCC 900- GCACTTGACT TCAACTACCT GGACCTCAGC GCACTACTAC GTAACAGCTT TC - #ACCGTTAC 960- GCCGTGGATG TACTCAAAAG CGGTCGATGT CAGATGCTGG ACCGCCGCAC GG - #TAGAAATG1020- GCCTTCGCCT ACGCATTAGC ACTGTTCGCA GCAGCCCGAC AAGAAGAGGC CG - #GCGCCCAA1080- GTCTCCGTCC CACGGGCCCT AGACCGCCAG GCCGCACTCT TACAAATACA AG - #AATTTATG1140- ATCACCTGCC TCTCACAAAC ACCACCACGC ACCACGTTGC TGCTGTATCC CA - #CGGCCGTG1200- GACCTGGCCA AACGAGCCCT TTGGACACCG AATCAGATCA CCGACATCAC CA - #GCCTCGTA1260- CGCCTGGTCT ACATACTCTC TAAACAGAAT CAGCAACATC TCATCCCCCA GT - #GGGCACTA1320- CGACAGATCG CCGACTTTGC CCTAAAACTA CACAAAACGC ACCTGGCCTC TT - #TTCTTTCA1380- GCCTTCGCGC GTCAAGAACT CTACCTCATG GGCAGCCTCG TCCACTCCAT GC - #TAGTACAT1440- ACGACGGAGA GACGCGAAAT CTTCATCGTA GAAACGGGCC TCTGTTCATT AG - #CCGAGCTA1500- TCACACTTTA CGCAGTTGCT AGCTCATCCG CACCACGAAT ACCTCAGCGA CC - #TGTACACA1560- CCCTGTTCCA GTAGCGGGCG ACGCGATCAC TCGCTCGAAC GCCTCACACG TC - #TCTTCCCC1620- GATGCCACCG TCCCCACTAC CGTTCCCGCC GCCCTCTCCA TCCTATCTAC CA - #TGCAACCA1680- AGCACGCTAG AAACCTTCCC CGACCTGTTT TGTCTGCCGC TCGGCGAATC CT - #TCTCCGCG1740- CTGACCGTCT CCGAACACGT CAGTTATGTC GTAACAAACC AGTACCTGAT CA - #AAGGTATC1800- TCCTACCCTG TCTCCACCAC CGTCGTAGGC CAGAGCCTCA TCATCACCCA GA - #CGGACAGT1860- CAAACTAAAT GCGAACTGAC GCGCAACATG CATACCACAC ACAGCATCAC AG - #CGGCGCTC1920- AACATTTCCC TAGAAAACTG CGCCTTTTGC CAAAGCGCCC TACTAGAATA CG - #ACGACACG1980- CAAGGCGTCA TCAACATCAT GTACATGCAC GACTCGGACG ACGTCCTTTT CG - #CCCTGGAT2040- CCCTACAACG AAGTGGTGGT CTCATCTCCG CGAACTCACT ACCTCATGCT TT - #TGAAAAAC2100- GGTACGGTCC TAGAAGTAAC TGACGTCGTC GTGGACGCTA CCGACAGTCG TC - #TCCTCATG2160- ATGTCCGTCT ACGCGCTATC GGCCATCATC GGCATCTATC TGCTCTACCG CA - #TGCTCAAG2220# 2229- (2) INFORMATION FOR SEQ ID NO:47:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 3539 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:- CTGCAGGTCG ACGGATCTGA GAATGGATGA TTCTCCAGCC GAAACATATT CT - #ACCATGGC 60- TCCGTTTAAT TTGTTGATGA AGATGGATTC ATCCTTAAAT GTTTTCTCTG TA - #ATAGTTTC 120- CACCGAAAGA CTATGCAAAG AATTTGGAAT GCGTTCCTTG TGCTTAATGT TT - #CCATAGAC 180- GGCTTCTAGA AGTTGATACA ACATAGGACT AGCCGCGGTA ACTTTTATTT TT - #AGAAAGTA 240- TCCATCGCTT CTATCTTGTT TAGATTTATT TTTATAAAGT TTAGTCTCTC CT - #TCCAACAT 300- AATAAAAGTG GAAGTCATTT GACTAGATAA ACTATCAGTA AGTTTTATAG AG - #ATAGACGA 360- ACAATTAGCG TATTGAGAAG CATTTAGTGT AACGTATTCG ATACATTTTG CA - #TTAGATTT 420- ACTAATCGAT TTTGCATACT CTATAACACC CGCACAAGTC TGTAGAGAAT CG - #CTAGATGC 480- AGTAGGTCTT GGTGAAGTTT CAACTCTCTT CTTGATTACC TTACTCATGA TT - #AAACCTAA 540- ATAATTGTAC TTTGTAATAT AATGATATAT ATTTTCACTT TATCTCATTT GA - #GAATAAAA 600- AGATCACAAA AATTAACTAA TCAGGATCCG GTACCCTCGA GTTTATTGGG AA - #GAATATGA 660- TAATATTTTG GGATTTCAAA ATTGAAAATA TATAATTACA ATATAAAATG CG - #GCCCGGGC 720- TCCCCTCCTA CCTCATCGTC CTCGCCGTCT GTCTCCTCAG CCACCTACTT TC - #GTCACGAT 780- ATGGCGCAGA AGCCATATCC GAACCGCTGG ACAAAGCGTT TCACCTACTG CT - #CAACACCT 840- ACGGGAGACC CATCCGCTTC CTGCGTGAAA ACACCACCCA GTGTACCTAC AA - #TAGCAGCC 900- TCCGTAACAG CACGGTCGTC AGGGAAAACG CCATCAGTTT CAACTTTTTC CA - #AAGCTATA 960- ATCAATACTA TGTATTCCAT ATGCCTCGAT GTCTTTTTGC GGGTCCTCTG GC - #GGAGCAGT1020- TTCTGAACCA GGTAGATCTG ACCGAAACCC TGGAAAGATA CCAACAGAGA CT - #TAACACTT1080- ACGCGCTGGT ATCCAAAGAC CTGGCCAGCT ACCGATCTTT TTCGCAGCAG CT - #AAAGGCAC1140- AGGACAGCCT AGGTGAACAG CCCACCACTG TGCCACCACC CATTGACCTG TC - #AATACCTC1200- ACGTTTGGAT GCCACCGCAA ACCACTCCAC ACGGCTGGAC AGAATCACAT AC - #CACCTCAG1260- GACTACACCG ACCACACTTT AACCAGACCT GTATCCTCTT TGATGGACAC GA - #TCTACTAT1320- TCAGCACCGT CACACCTTGT TTGCACCAAG GCTTTTACCT CATCGACGAA CT - #ACGTTACG1380- TTAAAATAAC ACTGACCGAG GACTTCTTCG TAGTTACGGT GTCCATAGAC GA - #CGACACAC1440- CCATGCTGCT TATCTTCGGC CATCTTCCAC GCGTACTCTT TAAAGCGCCC TA - #TCAACGCG1500- ACAACTTTAT ACTACGACAA ACTGAAAAAC ACGAGCTCCT GGTGCTAGTT AA - #GAAAGATC1560- AACTGAACCG TCACTCTTAT CTCAAAGACC CGGACTTTCT TGACGCCGCA CT - #TGACTTCA1620- ACTACCTGGA CCTCAGCGCA CTACTACGTA ACAGCTTTCA CCGTTACGCC GT - #GGATGTAC1680- TCAAAAGCGG TCGATGTCAG ATGCTGGACC GCCGCACGGT AGAAATGGCC TT - #CGCCTACG1740- CATTAGCACT GTTCGCAGCA GCCCGACAAG AAGAGGCCGG CGCCCAAGTC TC - #CGTCCCAC1800- GGGCCCTAGA CCGCCAGGCC GCACTCTTAC AAATACAAGA ATTTATGATC AC - #CTGCCTCT1860- CACAAACACC ACCACGCACC ACGTTGCTGC TGTATCCCAC GGCCGTGGAC CT - #GGCCAAAC1920- GAGCCCTTTG GACACCGAAT CAGATCACCG ACATCACCAG CCTCGTACGC CT - #GGTCTACA1980- TACTCTCTAA ACAGAATCAG CAACATCTCA TCCCCCAGTG GGCACTACGA CA - #GATCGCCG2040- ACTTTGCCCT AAAACTACAC AAAACGCACC TGGCCTCTTT TCTTTCAGCC TT - #CGCGCGTC2100- AAGAACTCTA CCTCATGGGC AGCCTCGTCC ACTCCATGCT AGTACATACG AC - #GGAGAGAC2160- GCGAAATCTT CATCGTAGAA ACGGGCCTCT GTTCATTAGC CGAGCTATCA CA - #CTTTACGC2220- AGTTGCTAGC TCATCCGCAC CACGAATACC TCAGCGACCT GTACACACCC TG - #TTCCAGTA2280- GCGGGCGACG CGATCACTCG CTCGAACGCC TCACACGTCT CTTCCCCGAT GC - #CACCGTCC2340- CCACTACCGT TCCCGCCGCC CTCTCCATCC TATCTACCAT GCAACCAAGC AC - #GCTAGAAA2400- CCTTCCCCGA CCTGTTTTGT CTGCCGCTCG GCGAATCCTT CTCCGCGCTG AC - #CGTCTCCG2460- AACACGTCAG TTATGTCGTA ACAAACCAGT ACCTGATCAA AGGTATCTCC TA - #CCCTGTCT2520- CCACCACCGT CGTAGGCCAG AGCCTCATCA TCACCCAGAC GGACAGTCAA AC - #TAAATGCG2580- AACTGACGCG CAACATGCAT ACCACACACA GCATCACAGC GGCGCTCAAC AT - #TTCCCTAG2640- AAAACTGCGC CTTTTGCCAA AGCGCCCTAC TAGAATACGA CGACACGCAA GG - #CGTCATCA2700- ACATCATGTA CATGCACGAC TCGGACGACG TCCTTTTCGC CCTGGATCCC TA - #CAACGAAG2760- TGGTGGTCTC ATCTCCGCGA ACTCACTACC TCATGCTTTT GAAAAACGGT AC - #GGTCCTAG2820- AAGTAACTGA CGTCGTCGTG GACGCTACCG ACAGTCGTCT CCTCATGATG TC - #CGTCTACG2880- CGCTATCGGC CATCATCGGC ATCTATCTGC TCTACCGCAT GCTCAAGACA TG - #CTGATTTT2940- TATCTCGAGC CCGGGAGATC TTAGCTAACT GATTTTTCTG GGAAAAAAAT TA - #TTTAACTT3000- TTCATTAATA GGGATTTGAC GTATGTAGCG TACAAAATTA TCGTTCCTGG TA - #TATAGATA3060- AAGAGTCCTA TATATTTGAA AATCGTTACG GCTCGATTAA ACTTTAATGA TT - #GCATAGTG3120- AATATATCAT TAGGATTTAA CTCCTTGACT ATCATGGCGG CGCCAGAAAT TA - #CCATCAAA3180- AGCATTAATA CAGTTATGCC GATCGCAGTT AGAACGGTTA TAGCATCCAC CA - #TTTATATC3240- TAAAAATTAG ATCAAAGAAT ATGTGACAAA GTCCTAGTTG TATACTGAGA AT - #TGACGAAA3300- CAATGTTTCT TACATATTTT TTTCTTATTA GTAACTGACT TAATAGTAGG AA - #CTGGAAAG3360- CTAGACTTGA TTATTCTATA AGTATAGATA CCCTTCCAGA TAATGTTCTC TT - #TGATAAAA3420- GTTCCAGAAA ATGTAGAATT TTTTAAAAAG TTATCTTTTG CTATTACCAA GA - #TTGTGTTT3480- AGACGCTTAT TATTAATATG AGTAATGAAA TCCACACCGC CTCTAGATAT GG - #GGAATTC3539- (2) INFORMATION FOR SEQ ID NO:48:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 4427 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:- GAATTGCGGC CGCTGAATGT TAAATGTTAT ACTTTGGATG AAGCTATAAA TA - #TGCATTGG 60- AAAAATAATC CATTTAAAGA AAGGATTCAA ATACTACAAA ACCTAAGCGA TA - #ATATGTTA 120- ACTAAGCTTA TTCTTAACGA CGCTTTAAAT ATACACAAAT AAACATAATT TT - #TGTATAAC 180- CTAACAAATA ACTAAAACAT AAAAATAATA AAAGGAAATG TAATATCGTA AT - #TATTTTAC 240- TCAGGAATGG GGTTAAATAT TTATATCACG TGTATATCTA TACTGTTATC GT - #ATACTCTT 300- TACAATTACT ATTACGAATA TGCAAGAGAT AATAAGATTA CGTATTTAAG AG - #AATCTTGT 360- CATGATAATT GGGTACGACA TAGTGATAAA TGCTATTTCG CATCGTTACA TA - #AAGTCAGT 420- TGGAAAGATG GATTTGACAG ATGTAACTTA ATAGGTGCAA AAATGTTAAA TA - #ACAGCATT 480- CTATCGGAAG ATAGGATACC AGTTATATTA TACAAAAATC ACTGGTTGGA TA - #AAACAGAT 540- TCTGCAATAT TCGTAAAAGA TGAAGATTAC TGCGAATTTG TAAACTATGA CA - #ATAAAAAG 600- CCATTTATCT CAACGACATC GTGTAATTCT TCCATGTTTT ATGTATGTGT TT - #CAGATATT 660- ATGAGATTAC TATAAACTTT TTGTATACTT ATATTCCGTA AACTATATTA AT - #CATGAAGA 720- AAATGAAAAA GTATAGAAGC TGTTCACGAG CGGTTGTTGA AAACAACAAA AT - #TATACATT 780- CAAGATGGCT TACATATACG TCTGTGAGGC TATCATGGAT AATGACAATG CA - #TCTCTAAA 840- TAGGTTTTTG GACAATGGAT TCGACCCTAA CACGGAATAT GGTACTCTAC AA - #TCTCCTCT 900- TGAAATGGCT GTAATGTTCA AGAATACCGA GGCTATAAAA ATCTTGATGA GG - #TATGGAGC 960- TAAACCTGTA GTTACTGAAT GCACAACTTC TTGTCTGCAT GATGCGGTGT TG - #AGAGACGA1020- CTACAAAATA GTGAAAGATC TGTTGAAGAA TAACTATGTA AACAATGTTC TT - #TACAGCGG1080- AGGCTTTACT CCTTTGTGTT TGGCAGCTTA CCTTAACAAA GTTAATTTGG TT - #AAACTTCT1140- ATTGGCTCAT TCGGCGGATG TAGATATTTC AAACACGGAT CGGTTAACTC CT - #CTACATAT1200- AGCCGTATCA AATAAAAATT TAACAATGGT TAAACTTCTA TTGAACAAAG GT - #GCTGATAC1260- TGACTTGCTG GATAACATGG GACGTACTCC TTTAATGATC GCTGTACAAT CT - #GGAAATAT1320- TGAAATATGT AGCACACTAC TTAAAAAAAA TAAAATGTCC AGAACTGGGA AA - #AATTGATC1380- TTGCCAGCTG TAATTCATGG TAGAAAAGAA GTGCTCAGGC TACTTTTCAA CA - #AAGGAGCA1440- GATGTAAACT ACATCTTTGA AAGAAATGGA AAATCATATA CTGTTTTGGA AT - #TGATTAAA1500- GAAAGTTACT CTGAGACACA AAAGAGGTAG CTGAAGTGGT ACTCTCAAAG GT - #ACGTGACT1560- AATTAGCTAT AAAAAGGATC TTAATTAATT AGTCATCAGG CAGGGCGAGA AC - #GAGACTAT1620- CTGCTCGTTA ATTAATTAGG TCGACGGATC CGGTACCCTC GAGTTTATTG GG - #AAGAATAT1680- GATAATATTT TGGGATTTCA AAATTGAAAA TATATAATTA CAATATAAAA TG - #CGGCCCGG1740- GCTCCCCTCC TACCTCATCG TCCTCGCCGT CTGTCTCCTC AGCCACCTAC TT - #TCGTCACG1800- ATATGGCGCA GAAGCCATAT CCGAACCGCT GGACAAAGCG TTTCACCTAC TG - #CTCAACAC1860- CTACGGGAGA CCCATCCGCT TCCTGCGTGA AAACACCACC CAGTGTACCT AC - #AATAGCAG1920- CCTCCGTAAC AGCACGGTCG TCAGGGAAAA CGCCATCAGT TTCAACTTTT TC - #CAAAGCTA1980- TAATCAATAC TATGTATTCC ATATGCCTCG ATGTCTTTTT GCGGGTCCTC TG - #GCGGAGCA2040- GTTTCTGAAC CAGGTAGATC TGACCGAAAC CCTGGAAAGA TACCAACAGA GA - #CTTAACAC2100- TTACGCGCTG GTATCCAAAG ACCTGGCCAG CTACCGATCT TTTTCGCAGC AG - #CTAAAGGC2160- ACAGGACAGC CTAGGTGAAC AGCCCACCAC TGTGCCACCA CCCATTGACC TG - #TCAATACC2220- TCACGTTTGG ATGCCACCGC AAACCACTCC ACACGGCTGG ACAGAATCAC AT - #ACCACCTC2280- AGGACTACAC CGACCACACT TTAACCAGAC CTGTATCCTC TTTGATGGAC AC - #GATCTACT2340- ATTCAGCACC GTCACACCTT GTTTGCACCA AGGCTTTTAC CTCATCGACG AA - #CTACGTTA2400- CGTTAAAATA ACACTGACCG AGGACTTCTT CGTAGTTACG GTGTCCATAG AC - #GACGACAC2460- ACCCATGCTG CTTATCTTCG GCCATCTTCC ACGCGTACTC TTTAAAGCGC CC - #TATCAACG2520- CGACAACTTT ATACTACGAC AAACTGAAAA ACACGAGCTC CTGGTGCTAG TT - #AAGAAAGA2580- TCAACTGAAC CGTCACTCTT ATCTCAAAGA CCCGGACTTT CTTGACGCCG CA - #CTTGACTT2640- CAACTACCTG GACCTCAGCG CACTACTACG TAACAGCTTT CACCGTTACG CC - #GTGGATGT2700- ACTCAAAAGC GGTCGATGTC AGATGCTGGA CCGCCGCACG GTAGAAATGG CC - #TTCGCCTA2760- CGCATTAGCA CTGTTCGCAG CAGCCCGACA AGAAGAGGCC GGCGCCCAAG TC - #TCCGTCCC2820- ACGGGCCCTA GACCGCCAGG CCGCACTCTT ACAAATACAA GAATTTATGA TC - #ACCTGCCT2880- CTCACAAACA CCACCACGCA CCACGTTGCT GCTGTATCCC ACGGCCGTGG AC - #CTGGCCAA2940- ACGAGCCCTT TGGACACCGA ATCAGATCAC CGACATCACC AGCCTCGTAC GC - #CTGGTCTA3000- CATACTCTCT AAACAGAATC AGCAACATCT CATCCCCCAG TGGGCACTAC GA - #CAGATCGC3060- CGACTTTGCC CTAAAACTAC ACAAAACGCA CCTGGCCTCT TTTCTTTCAG CC - #TTCGCGCG3120- TCAAGAACTC TACCTCATGG GCAGCCTCGT CCACTCCATG CTAGTACATA CG - #ACGGAGAG3180- ACGCGAAATC TTCATCGTAG AAACGGGCCT CTGTTCATTA GCCGAGCTAT CA - #CACTTTAC3240- GCAGTTGCTA GCTCATCCGC ACCACGAATA CCTCAGCGAC CTGTACACAC CC - #TGTTCCAG3300- TAGCGGGCGA CGCGATCACT CGCTCGAACG CCTCACACGT CTCTTCCCCG AT - #GCCACCGT3360- CCCCACTACC GTTCCCGCCG CCCTCTCCAT CCTATCTACC ATGCAACCAA GC - #ACGCTAGA3420- AACCTTCCCC GACCTGTTTT GTCTGCCGCT CGGCGAATCC TTCTCCGCGC TG - #ACCGTCTC3480- CGAACACGTC AGTTATGTCG TAACAAACCA GTACCTGATC AAAGGTATCT CC - #TACCCTGT3540- CTCCACCACC GTCGTAGGCC AGAGCCTCAT CATCACCCAG ACGGACAGTC AA - #ACTAAATG3600- CGAACTGACG CGCAACATGC ATACCACACA CAGCATCACA GCGGCGCTCA AC - #ATTTCCCT3660- AGAAAACTGC GCCTTTTGCC AAAGCGCCCT ACTAGAATAC GACGACACGC AA - #GGCGTCAT3720- CAACATCATG TACATGCACG ACTCGGACGA CGTCCTTTTC GCCCTGGATC CC - #TACAACGA3780- AGTGGTGGTC TCATCTCCGC GAACTCACTA CCTCATGCTT TTGAAAAACG GT - #ACGGTCCT3840- AGAAGTAACT GACGTCGTCG TGGACGCTAC CGACAGTCGT CTCCTCATGA TG - #TCCGTCTA3900- CGCGCTATCG GCCATCATCG GCATCTATCT GCTCTACCGC ATGCTCAAGA CA - #TGCTGATT3960- TTTATCTCGA GTCTAGAATC GATCCCGGGT TTTTATGACT AGTTAATCAC GG - #CCGCTTAT4020- AAAGATCTAA AATGCATAAT TTCTAAATAA TGAAAAAAAA GTACATCATG AG - #CAACGCGT4080- TAGTATATTT TACAATGGAG ATTAACGCTC TATACCGTTC TATGTTTATT GA - #TTCAGATG4140- ATGTTTTAGA AAAGAAAGTT ATTGAATATG AAAACTTTAA TGAAGATGAA GA - #TGACGACG4200- ATGATTATTG TTGTAAATCT GTTTTAGATG AAGAAGATGA CGCGCTAAAG TA - #TACTATGG4260- TTACAAAGTA TAAGTCTATA CTACTAATGG CGACTTGTGC AAGAAGGTAT AG - #TATAGTGA4320- AAATGTTGTT AGATTATGAT TATGAAAAAC CAAATAAATC AGATCCATAT CT - #AAAGGTAT4380# 4427TTCA TCTATTCCTA GTTTAGAATA CCTGCAG- (2) INFORMATION FOR SEQ ID NO:49:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 2651 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:- AAGACTAATT TGTAAACCAT CTTACTCAAA ATATGTAACA ATAGTACGAT GC - #AATGAGTA 60- AGACAATAGG AAATCTATCT TATATACACA TAATTATTCT ATCAATTTTA CC - #AATTAGTT 120- AGTGTAATGT TATAAAAACT AATTAATCAC TCGAGATAAA AATCAGCATG TC - #TTGAGCAT 180- GCGGTAGAGC AGATAGATGC CGATGATGGC CGATAGCGCG TAGACGGACA TC - #ATGAGGAG 240- ACGACTGTCG GTAGCGTCCA CGACGACGTC AGTTACTTCT AGGACCGTAC CG - #TTTTTCAA 300- AAGCATGAGG TAGTGAGTTC GCGGAGATGA GACCACCACT TCGTTGTAGG GA - #TCCAGGGC 360- GAAAAGGACG TCGTCCGAGT CGTGCATGTA CATGATGTTG ATGACGCCTT GC - #GTGTCGTC 420- GTATTCTAGT AGGGCGCTTT GGCAAAAGGC GCAGTTTTCT AGGGAAATGT TG - #AGCGCCGC 480- TGTGATGCTG TGTGTGGTAT GCATGTTGCG CGTCAGTTCG CATTTAGTTT GA - #CTGTCCGT 540- CTGGGTGATG ATGAGGCTCT GGCCTACGAC GGTGGTGGAG ACAGGGTAGG AG - #ATACCTTT 600- GATCAGGTAC TGGTTTGTTA CGACATAACT GACGTGTTCG GAGACGGTCA GC - #GCGGAGAA 660- GGATTCGCCG AGCGGCAGAC AAAACAGGTC GGGGAAGGTT TCTAGCGTGC TT - #GGTTGCAT 720- GGTAGATAGG ATGGAGAGGG CGGCGGGAAC GGTAGTGGGG ACGGTGGCAT CG - #GGGAAGAG 780- ACGTGTGAGG CGTTCGAGCG AGTGATCGCG TCGCCCGCTA CTGGAACAGG GT - #GTGTACAG 840- GTCGCTGAGG TATTCGTGGT GCGGATGAGC TAGCAACTGC GTAAAGTGTG AT - #AGCTCGGC 900- TAATGAACAG AGGCCCGTTT CTACGATGAA GATTTCGCGT CTCTCCGTCG TA - #TGTACTAG 960- CATGGAGTGG ACGAGGCTGC CCATGAGGTA GAGTTCTTGA CGCGCGAAGG CT - #GAAAGAAA1020- AGAGGCCAGG TGCGTTTTGT GTAGTTTTAG GGCAAAGTCG GCGATCTGTC GT - #AGTGCCCA1080- CTGGGGGATG AGATGTTGCT GATTCTGTTT AGAGAGTATG TAGACCAGGC GT - #ACGAGGCT1140- GGTGATGTCG GTGATCTGAT TCGGTGTCCA AAGGGCTCGT TTGGCCAGGT CC - #ACGGCCGT1200- GGGATACAGC AGCAACGTGG TGCGTGGTGG TGTTTGTGAG AGGCAGGTGA TC - #ATAAATTC1260- TTGTATTTGT AAGAGTGCGG CCTGGCGGTC TAGGGCCCGT GGGACGGAGA CT - #TGGGCGCC1320- GGCCTCTTCT TGTCGGGCTG CTGCGAACAG TGCTAATGCG TAGGCGAAGG CC - #ATTTCTAC1380- CGTGCGGCGG TCCAGCATCT GACATCGACC GCTTTTGAGT ACATCCACGG CG - #TAACGGTG1440- AAAGCTGTTA CGTAGTAGTG CGCTGAGGTC CAGGTAGTTG AAGTCAAGTG CG - #GCGTCAAG1500- AAAGTCCGGG TCTTTGAGAT AAGAGTGACG GTTCAGTTGA TCTTTCTTAA CT - #AGCACCAG1560- GAGCTCGTGT TTTTCAGTTT GTCGTAGTAT AAAGTTGTCG CGTTGATAGG GC - #GCTTTAAA1620- GAGTACGCGT GGAAGATGGC CGAAGATAAG CAGCATGGGT GTGTCGTCGT CT - #ATGGACAC1680- CGTAACTACG AAGAAGTCCT CGGTCAGTGT TATTTTAACG TAACGTAGTT CG - #TCGATGAG1740- GTAAAAGCCT TGGTGCAAAC AAGGTGTGAC GGTGCTGAAT AGTAGATCGT GT - #CCATCAAA1800- GAGGATACAG GTCTGGTTAA AGTGTGGTCG GTGTAGTCCT GAGGTGGTAT GT - #GATTCTGT1860- CCAGCCGTGT GGAGTGGTTT GCGGTGGCAT CCAAACGTGA GGTATTGACA GG - #TCAATGGG1920- TGGTGGCACA GTGGTGGGCT GTTCACCTAG GCTGTCCTGT GCCTTTAGCT GC - #TGCGAAAA1980- AGATCGGTAG CTGGCCAGGT CTTTGGATAC CAGCGCGTAA GTGTTAAGTC TC - #TGTTGGTA2040- TCTTTCCAGG GTTTCGGTCA GATCTACCTG GTTCAGAAAC TGCTCCGCCA GA - #GGACCCGC2100- AAAAAGACAT CGAGGCATAT GGAATACATA GTATTGATTA TAGCTTTGGA AA - #AAGTTGAA2160- ACTGATGGCG TTTTCCCTGA CGACCGTGCT GTTACGGAGG CTGCTATTGT AG - #GTACACTG2220- GGTGGTGTTT TCACGCAGGA AGCGGATGGG TCTCCCGTAG GTGTTGAGCA GT - #AGGTGAAA2280- CGCTTTGTCC AGCGGTTCGG ATATGGCTTC TGCGCCATAT CGTGACGAAA GT - #AGGTGGCT2340- GAGGAGACAG ACGGCGAGGA CGATGAGGTA GGAGGGGAGC CCGGGCCGCA TT - #TTATATTG2400- TAATTATATA TTTTCAATTT TGAAATCCCA AAATATTATC ATATTCTTCC CA - #ATAAACTC2460- GAGCCCGGGG AATTCGGATC CTCGCGACTG CAGGGTACCT GAGTAGCTAA TT - #TTTAAACA2520- AAAATGTGGG AGAATCTAAT TAGTTTTTCT TTACACAATT GACGTACATG AG - #TCTGAGTT2580- CCTTGTTTTT GCTAATTATT TCATCCAATT TATTATTCTT GACGATATCG AG - #ATCTTTTG2640# 2651- (2) INFORMATION FOR SEQ ID NO:50:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 1476 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:- ATGGAGTCCT CTGCCAAGAG AAAGATGGAC CCTGATAATC CTGACGAGGG CC - #CTTCCTCC 60- AAGGTGCCAC GGCCCGAGAC ACCCGTGACC AAGGCCACGA CGTTCCTGCA GA - #CTATGTTG 120- AGGAAGGAGG TTAACAGTCA GCTGAGTCTG GGAGACCCGC TGTTTCCAGA GT - #TGGCCGAA 180- GAATCCCTCA AAACTTTTGA ACAAGTGACC GAGGATTGCA ACGAGAACCC CG - #AGAAAGAT 240- GTCCTGGCAG AACTCGTCAA ACAGATTAAG GTTCGAGTGG ACATGGTGCG GC - #ATAGAATC 300- AAGGAGCACA TGCTGAAAAA ATATACCCAG ACGGAAGAGA AATTCACTGG CG - #CCTTTAAT 360- ATGATGGGAG GATGTTTGCA GAATGCCTTA GATATCTTAG ATAAGGTTCA TG - #AGCCTTTC 420- GAGGAGATGA AGTGTATTGG GCTAACTATG CAGAGCATGT ATGAGAACTA CA - #TTGTACCT 480- GAGGATAAGC GGGAGATGTG GATGGCTTGT ATTAAGGAGC TGCATGATGT GA - #GCAAGGGC 540- GCCGCTAACA AGTTGGGGGG TGCACTGCAG GCTAAGGCCC GTGCTAAAAA GG - #ATGAACTT 600- AGGAGAAAGA TGATGTATAT GTGCTACAGG AATATAGAGT TCTTTACCAA GA - #ACTCAGCC 660- TTCCCTAAGA CCACCAATGG CTGCAGTCAG GCCATGGCGG CACTGCAGAA CT - #TGCCTCAG 720- TGCTCCCCTG ATGAGATTAT GGCTTATGCC CAGAAAATAT TTAAGATTTT GG - #ATGAGGAG 780- AGAGACAAGG TGCTCACGCA CATTGATCAC ATATTTATGG ATATCCTCAC TA - #CATGTGTG 840- GAAACAATGT GTAATGAGTA CAAGGTCACT AGTGACGCTT GTATGATGAC CA - #TGTACGGG 900- GGCATCTCTC TCTTAAGTGA GTTCTGTCGG GTGCTGTGCT GCTATGTCTT AG - #AGGAGACT 960- AGTGTGATGC TGGCCAAGCG GCCTCTGATA ACCAAGCCTG AGGTTATCAG TG - #TAATGAAG1020- CGCCGCATTG AGGAGATCTG CATGAAGGTC TTTGCCCAGT ACATTCTGGG GG - #CCGATCCT1080- CTGAGAGTCT GCTCTCCTAG TGTGGATGAC CTACGGGCCA TCGCCGAGGA GT - #CAGATGAG1140- GAAGAGGCTA TTGTAGCCTA CACTTTGGCC ACCGCTGGTG TCAGCTCCTC TG - #ATTCTCTG1200- GTGTCACCCC CAGAGTCCCC TGTACCCGCG ACTATCCCTC TGTCCTCAGT AA - #TTGTGGCT1260- GAGAACAGTG ATCAGGAAGA AAGTGAGCAG AGTGATGAGG AAGAGGAGGA GG - #GTGCTCAG1320- GAGGAGCGGG AGGACACTGT GTCTGTCAAG TCTGAGCCAG TGTCTGAGAT AG - #AGGAAGTT1380- GCCCCAGAGG AAGAGGAGGA TGGTGCTGAG GAACCCACCG CCTCTGGAGG TA - #AGAGTACC1440# 1476 GAAG CAAGGCTGAC CAGTAA- (2) INFORMATION FOR SEQ ID NO:51:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 1975 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:- ATATAATCCT CCACCAAAAT AGAGAATATA TATATCATCA TTTCATGATG TA - #TACTACTG 60- ACATAGTTTC AATGTGAACT TTTCACTTTC TTGCCGGTTA TGAAGAATAT TT - #TTTATTTT 120- AATGGTCATT ACTAATCGTA TATTATAATT GAAAATGAAT TAGTTTAATA TG - #ACGCTCGT 180- CATGGGATCC ATAAAAATTA CTGGTCAGCC TTGCTTCTAG TCACCATAGG GT - #GGGTACTC 240- TTACCTCCAG AGGCGGTGGG TTCCTCAGCA CCATCCTCCT CTTCCTCTGG GG - #CAACTTCC 300- TCTATCTCAG ACACTGGCTC AGACTTGACA GACACAGTGT CCTCCCGCTC CT - #CCTGAGCA 360- CCCTCCTCCT CTTCCTCATC ACTCTGCTCA CTTTCTTCCT GATCACTGTT CT - #CAGCCACA 420- ATTACTGAGG ACAGAGGGAT AGTCGCGGGT ACAGGGGACT CTGGGGGTGA CA - #CCAGAGAA 480- TCAGAGGAGC TGACACCAGC GGTGGCCAAA GTGTAGGCTA CAATAGCCTC TT - #CCTCATCT 540- GACTCCTCGG CGATGGCCCG TAGGTCATCC ACACTAGGAG AGCAGACTCT CA - #GAGGATCG 600- GCCCCCAGAA TGTACTGGGC AAAGACCTTC ATGCAGATCT CCTCAATGCG GC - #GCTTCATT 660- ACACTGATAA CCTCAGGCTT GGTTATCAGA GGCCGCTTGG CCAGCATCAC AC - #TAGTCTCC 720- TCTAAGACAT AGCAGCACAG CACCCGACAG AACTCACTTA AGAGAGAGAT GC - #CCCCGTAC 780- ATGGTCATCA TACAAGCGTC ACTAGTGACC TTGTACTCAT TACACATTGT TT - #CCACACAT 840- GTAGTGAGGA TATCCATAAA TATGTGATCA ATGTGCGTGA GCACCTTGTC TC - #TCTCCTCA 900- TCCAAAATCT TAAATATTTT CTGGGCATAA GCCATAATCT CATCAGGGGA GC - #ACTGAGGC 960- AAGTTCTGCA GTGCCGCCAT GGCCTGACTG CAGCCATTGG TGGTCTTAGG GA - #AGGCTGAG1020- TTCTTGGTAA AGAACTCTAT ATTCCTGTAG CACATATACA TCATCTTTCT CC - #TAAGTTCA1080- TCCTTTTTAG CACGGGCCTT AGCCTGCAGT GCACCCCCCA ACTTGTTAGC GG - #CGCCCTTG1140- CTCACATCAT GCAGCTCCTT AATACAAGCC ATCCACATCT CCCGCTTATC CT - #CAGGTACA1200- ATGTAGTTCT CATACATGCT CTGCATAGTT AGCCCAATAC ACTTCATCTC CT - #CGAAAGGC1260- TCATGAACCT TATCTAAGAT ATCTAAGGCA TTCTGCAAAC ATCCTCCCAT CA - #TATTAAAG1320- GCGCCAGTGA ATTTCTCTTC CGTCTGGGTA TATTTTTTCA GCATGTGCTC CT - #TGATTCTA1380- TGCCGCACCA TGTCCACTCG AACCTTAATC TGTTTGACGA GTTCTGCCAG GA - #CATCTTTC1440- TCGGGGTTCT CGTTGCAATC CTCGGTCACT TGTTCAAAAG TTTTGAGGGA TT - #CTTCGGCC1500- AACTCTGGAA ACAGCGGGTC TCCCAGACTC AGCTGACTGT TAACCTCCTT CC - #TCAACATA1560- GTCTGCAGGA ACGTCGTGGC CTTGGTCACG GGTGTCTCGG GCCGTGGCAC CT - #TGGAGGAA1620- GGGCCCTCGT CAGGATTATC AGGGTCCATC TTTCTCTTGG CAGAGGACTC CA - #TTACGATA1680- CAAACTTAAC GGATATCGCG ATAATGAAAT AATTTATGAT TATTTCTCGC TT - #TCAATTTA1740- ACACAACCCT CAAGAACCTT TGTATTTATT TTCACTTTTT AAGTATAGAA TA - #AAGAGATC1800- CTGCTGTGGT AGATTCTGTG ACGCTAAGAA TAAGAATAAG AAGGAAGATG TA - #GAAGAGGG1860- AAGAGAAGGA TGTTACAATT ATAAGAACCT TAATGATCTG GATGAATCCG AA - #GCACGTGT1920- AGAATTTGGA CCATTATATA TGATAAATGA AGAAAAATCA GACATAAATA CA - #TTG1975- (2) INFORMATION FOR SEQ ID NO:52:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 3499 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:- AAGCTTGCGG CCGCTCATTA GACAAGCGAA TGAGGGACGA AAACGTGGAG GA - #GGTATTAA 60- GTTTGGAGAA ATGGAGAGAG ACTGTTTAAT AGCGCATGGC GCAGCCAATA CT - #ATTACAGA 120- AGTTTTGAAA GATTCGGAAG AAGATTATCA AGATGTGTAT GTTTGTGAAA AT - #TGTGGAGA 180- CATAGCAGCA CAAATCAAGG GTATTAATAC ATGTCTTAGA TGTTCAAAAC TT - #AATCTCTC 240- TCCTCTCTTA ACAAAAATTG ATACCACGCA CGTATCTAAA GTATTTCTTA CT - #CAAATGAA 300- CGCCAGAGGC GTAAAAGTCA AATTAGATTT CGAACGAAGG CCTCCTTCGT TT - #TATAAACC 360- ATTAGATAAA GTTGATCTCA AGCCGTCTTT TCTGGTGTAA TAAAAATTAA TT - #AATTACTC 420- GAGATAAAAA TTACTGGTCA GCCTTGCTTC TAGTCACCAT AGGGTGGGTA CT - #CTTACCTC 480- CAGAGGCGGT GGGTTCCTCA GCACCATCCT CCTCTTCCTC TGGGGCAACT TC - #CTCTATCT 540- CAGACACTGG CTCAGACTTG ACAGACACAG TGTCCTCCCG CTCCTCCTGA GC - #ACCCTCCT 600- CCTCTTCCTC ATCACTCTGC TCACTTTCTT CCTGATCACT GTTCTCAGCC AC - #AATTACTG 660- AGGACAGAGG GATAGTCGCG GGTACAGGGG ACTCTGGGGG TGACACCAGA GA - #ATCAGAGG 720- AGCTGACACC AGCGGTGGCC AAAGTGTAGG CTACAATAGC CTCTTCCTCA TC - #TGACTCCT 780- CGGCGATGGC CCGTAGGTCA TCCACACTAG GAGAGCAGAC TCTCAGAGGA TC - #GGCCCCCA 840- GAATGTACTG GGCAAAGACC TTCATGCAGA TCTCCTCAAT GCGGCGCTTC AT - #TACACTGA 900- TAACCTCAGG CTTGGTTATC AGAGGCCGCT TGGCCAGCAT CACACTAGTC TC - #CTCTAAGA 960- CATAGCAGCA CAGCACCCGA CAGAACTCAC TTAAGAGAGA GATGCCCCCG TA - #CATGGTCA1020- TCATACAAGC GTCACTAGTG ACCTTGTACT CATTACACAT TGTTTCCACA CA - #TGTAGTGA1080- GGATATCCAT AAATATGTGA TCAATGTGCG TGAGCACCTT GTCTCTCTCC TC - #ATCCAAAA1140- TCTTAAATAT TTTCTGGGCA TAAGCCATAA TCTCATCAGG GGAGCACTGA GG - #CAAGTTCT1200- GCAGTGCCGC CATGGCCTGA CTGCAGCCAT TGGTGGTCTT AGGGAAGGCT GA - #GTTCTTGG1260- TAAAGAACTC TATATTCCTG TAGCACATAT ACATCATCTT TCTCCTAAGT TC - #ATCCTTTT1320- TAGCACGGGC CTTAGCCTGC AGTGCACCCC CCAACTTGTT AGCGGCGCCC TT - #GCTCACAT1380- CATGCAGCTC CTTAATACAA GCCATCCACA TCTCCCGCTT ATCCTCAGGT AC - #AATGTAGT1440- TCTCATACAT GCTCTGCATA GTTAGCCCAA TACACTTCAT CTCCTCGAAA GG - #CTCATGAA1500- CCTTATCTAA GATATCTAAG GCATTCTGCA AACATCCTCC CATCATATTA AA - #GGCGCCAG1560- TGAATTTCTC TTCCGTCTGG GTATATTTTT TCAGCATGTG CTCCTTGATT CT - #ATGCCGCA1620- CCATGTCCAC TCGAACCTTA ATCTGTTTGA CGAGTTCTGC CAGGACATCT TT - #CTCGGGGT1680- TCTCGTTGCA ATCCTCGGTC ACTTGTTCAA AAGTTTTGAG GGATTCTTCG GC - #CAACTCTG1740- GAAACAGCGG GTCTCCCAGA CTCAGCTGAC TGTTAACCTC CTTCCTCAAC AT - #AGTCTGCA1800- GGAACGTCGT GGCCTTGGTC ACGGGTGTCT CGGGCCGTGG CACCTTGGAG GA - #AGGGCCCT1860- CGTCAGGATT ATCAGGGTCC ATCTTTCTCT TGGCAGAGGA CTCCATTACG AT - #ACAAACTT1920- AACGGATATC GCGATAATGA AATAATTTAT GATTATTTCT CGCTTTCAAT TT - #AACACAAC1980- CCTCAAGAAC CTTTGTATTT ATTTTCACTT TTTAAGTATA GAATAAAGAA GC - #TCTAATTA2040- ATTAAGCTAC AAATAGTTTC GTTTTCACCT TGTCTAATAA CTAATTAATT AA - #CCCCGATA2100- GCTGATTAGT TTTTGTTAAC AAAAATGTGG GAGAATCTAA TTAGTTTTTC TT - #TACACAAT2160- TGACGTACAT GAGTCTGAGT TCCTTGTTTT TGCTAATTAT TTCATCCAAT TT - #ATTATTCT2220- TGACGATATC GAGATCTTTT GTATAGGAGT CAGACTTGTA TTCAACATGC TT - #TTCTATAA2280- TCATCTTAGT TATTTCGGCA TCATCCAATA GTACATTTTC CAGATTAACA GA - #GTAGATAT2340- TAATGTCGTA TTTGAACAGA GCCTGTAACA TCTCAATGTC TTTATTATCT AT - #AGCCAATT2400- TAATGTCCGG AATGAAGAGA AGGGAATTAT TGGTGTTTGT CGACGTCATA TA - #GTCGAGCA2460- AGAGAATCAT CATATCCACG TGTCCATTTT TTATAGTGGT GTGAATACAA CT - #AAGGAGAA2520- TAGCCAGATC AAAAGTAGAT GGTATTTCTG AAAGAAAGTA TGATACAATA CT - #TACATCAT2580- TAAGCATGAC GGCATGATAA AATGAAGTTT TCCATCCAGT TTTCCCATAG AA - #CATCAGTC2640- TCCAATTTTT CTTAAACAGT TTCACCGTTT GCATGTTACC ACTATCAACC GC - #ATAATACA2700- ATGCGGTGTT TCCTTTGTCA TCAAATTGTG AATCATCCAT TCCACTGAAT AG - #CAAAATCT2760- TTACTATTTT GGTATCTTCT AATGTGGCTG CCTGATGTAA TGGAAATTCA TT - #CTCTAGAA2820- GATTTTTCAA TGCTCCAGCG TTCAACAACG TACATACTAG ACGCACGTTA TT - #ATCAGCTA2880- TTGCATAATA CAAGGCACTA TGTCCATGGA CATCCGCCTT AAATGTATCT TT - #ACTAGAGA2940- GAAAGCTTTT CAGCTGCTTA GACTTCCAAG TATTAATTCG TGACAGATCC AT - #GTCTGAAA3000- CGAGACGCTA ATTAGTGTAT ATTTTTTCAT TTTTTATAAT TTTGTCATAT TG - #CACCAGAA3060- TTATAATATC TCTAATAGAT CTAATTTAAT TTAATTTATA TAACTTATTT TT - #TGAATATA3120- CTTTTAATTA ACAAAAGAGT TAAGTTACTC ATATGGACGC CGTCCAGTCT GA - #ACATCAAT3180- CTTTTTAGCC AGAGATATCA TAGCCGCTCT TAGAGTTTCA GCGTGATTTT CC - #AACCTAAA3240- TAGAACTTCA TCGTTGCGTT TACAACACTT TTCTATTTGT TCAAACTTTG TT - #GTTACATT3300- AGTAATCTTT TTTTCCAAAT TAGTTAGCCG TTGTTTGAGA GTTTCCTCAT TG - #TCGTCTTG3360- CATCGGCTTT AACAATTGCT TCGCGTTTAG CCTCCTGGCT GTTCTTATCA GC - #CTTTGTAG3420- AAAAAAATTC AGTTGCTGGA ATTGCAAGAT CGTCATCTCC GGGGAAAAGA GT - #TCCGTCCA3480# 349 - #9- (2) INFORMATION FOR SEQ ID NO:53:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 1386 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:- ATGGAGTCCT CTGCCAAGAG AAAGATGGAC CCTGATAATC CTGACGAGGG CC - #CTTCCTCC 60- AAGGTGCCAC GGCCCGAGAC ACCCGTGACC AAGGCCACGA CGTTCCTGCA GA - #CTATGTTG 120- AGGAAGGAGG TTAACAGTCA GCTGAGTCTG GGAGACCCGC TGTTTCCAGA GT - #TGGCCGAA 180- GAATCCCTCA AAACTTTTGA ACAAGTGACC GAGGATTGCA ACGAGAACCC CG - #AGAAAGAT 240- GTCCTGGCAG AACTCGTCAA ACAGATTAAG GTTCGAGTGG ACATGGTGCG GC - #ATAGAATC 300- AAGGAGCACA TGCTGAAAAA ATATACCCAG ACGGAAGAGA AATTCACTGG CG - #CCTTTAAT 360- ATGATGGGAG GATGTTTGCA GAATGCCTTA GATATCTTAG ATAAGGTTCA TG - #AGCCTTTC 420- GAGGAGATGA AGTGTATTGG GCTAACTATG CAGAGCATGT ATGAGAACTA CA - #TTGTACCT 480- GAGGATAAGC GGGAGATGTG GATGGCTTGT ATTAAGGAGC TGCATGATGT GA - #GCAAGGGC 540- GCCGCTAACA AGTTGGGGGG TGCACTGCAG GCTAAGGCCC GTGCTAAAAA GG - #ATGAACTT 600- AGGAGAAAGA TGATGTATAT GTGCTACAGG AATATAGAGT TCTTTACCAA GA - #ACTCAGCC 660- TTCCCTAAGA CCACCAATGG CTGCAGTCAG GCCATGGCGG CACTGCAGAA CT - #TGCCTCAG 720- TGCTCCCCTG ATGAGATTAT GGCTTATGCC CAGAAAATAT TTAAGATTTT GG - #ATGAGGAG 780- AGAGACAAGG TGCTCACGCA CATTGATCAC ATATTTATGG ATATCCTCAC TA - #CATGTGTG 840- GAAACAATGT GTAATGAGTA CAAGGTCACT AGTGTGATGC TGGCCAAGCG GC - #CTCTGATA 900- ACCAAGCCTG AGGTTATCAG TGTAATGAAG CGCCGCATTG AGGAGATCTG CA - #TGAAGGTC 960- TTTGCCCAGT ACATTCTGGG GGCCGATCCT CTGAGAGTCT GCTCTCCTAG TG - #TGGATGAC1020- CTACGGGCCA TCGCCGAGGA GTCAGATGAG GAAGAGGCTA TTGTAGCCTA CA - #CTTTGGCC1080- ACCGCTGGTG TCAGCTCCTC TGATTCTCTG GTGTCACCCC CAGAGTCCCC TG - #TACCCGCG1140- ACTATCCCTC TGTCCTCAGT AATTGTGGCT GAGAACAGTG ATCAGGAAGA AA - #GTGAGCAG1200- AGTGATGAGG AAGAGGAGGA GGGTGCTCAG GAGGAGCGGG AGGACACTGT GT - #CTGTCAAG1260- TCTGAGCCAG TGTCTGAGAT AGAGGAAGTT GCCCCAGAGG AAGAGGAGGA TG - #GTGCTGAG1320- GAACCCACCG CCTCTGGAGG TAAGAGTACC CACCCTATGG TGACTAGAAG CA - #AGGCTGAC1380# 1386- (2) INFORMATION FOR SEQ ID NO:54:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 3409 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:- AAGCTTGCGG CCGCTCATTA GACAAGCGAA TGAGGGACGA AAACGTGGAG GA - #GGTATTAA 60- GTTTGGAGAA ATGGAGAGAG ACTGTTTAAT AGCGCATGGC GCAGCCAATA CT - #ATTACAGA 120- AGTTTTGAAA GATTCGGAAG AAGATTATCA AGATGTGTAT GTTTGTGAAA AT - #TGTGGAGA 180- CATAGCAGCA CAAATCAAGG GTATTAATAC ATGTCTTAGA TGTTCAAAAC TT - #AATCTCTC 240- TCCTCTCTTA ACAAAAATTG ATACCACGCA CGTATCTAAA GTATTTCTTA CT - #CAAATGAA 300- CGCCAGAGGC GTAAAAGTCA AATTAGATTT CGAACGAAGG CCTCCTTCGT TT - #TATAAACC 360- ATTAGATAAA GTTGATCTCA AGCCGTCTTT TCTGGTGTAA TAAAAATTAA TT - #AATTACTC 420- GAGATAAAAA TTACTGGTCA GCCTTGCTTC TAGTCACCAT AGGGTGGGTA CT - #CTTACCTC 480- CAGAGGCGGT GGGTTCCTCA GCACCATCCT CCTCTTCCTC TGGGGCAACT TC - #CTCTATCT 540- CAGACACTGG CTCAGACTTG ACAGACACAG TGTCCTCCCG CTCCTCCTGA GC - #ACCCTCCT 600- CCTCTTCCTC ATCACTCTGC TCACTTTCTT CCTGATCACT GTTCTCAGCC AC - #AATTACTG 660- AGGACAGAGG GATAGTCGCG GGTACAGGGG ACTCTGGGGG TGACACCAGA GA - #ATCAGAGG 720- AGCTGACACC AGCGGTGGCC AAAGTGTAGG CTACAATAGC CTCTTCCTCA TC - #TGACTCCT 780- CGGCGATGGC CCGTAGGTCA TCCACACTAG GAGAGCAGAC TCTCAGAGGA TC - #GGCCCCCA 840- GAATGTACTG GGCAAAGACC TTCATGCAGA TCTCCTCAAT GCGGCGCTTC AT - #TACACTGA 900- TAACCTCAGG CTTGGTTATC AGAGGCCGCT TGGCCAGCAT CACACTAGTG AC - #CTTGTACT 960- CATTACACAT TGTTTCCACA CATGTAGTGA GGATATCCAT AAATATGTGA TC - #AATGTGCG1020- TGAGCACCTT GTCTCTCTCC TCATCCAAAA TCTTAAATAT TTTCTGGGCA TA - #AGCCATAA1080- TCTCATCAGG GGAGCACTGA GGCAAGTTCT GCAGTGCCGC CATGGCCTGA CT - #GCAGCCAT1140- TGGTGGTCTT AGGGAAGGCT GAGTTCTTGG TAAAGAACTC TATATTCCTG TA - #GCACATAT1200- ACATCATCTT TCTCCTAAGT TCATCCTTTT TAGCACGGGC CTTAGCCTGC AG - #TGCACCCC1260- CCAACTTGTT AGCGGCGCCC TTGCTCACAT CATGCAGCTC CTTAATACAA GC - #CATCCACA1320- TCTCCCGCTT ATCCTCAGGT ACAATGTAGT TCTCATACAT GCTCTGCATA GT - #TAGCCCAA1380- TACACTTCAT CTCCTCGAAA GGCTCATGAA CCTTATCTAA GATATCTAAG GC - #ATTCTGCA1440- AACATCCTCC CATCATATTA AAGGCGCCAG TGAATTTCTC TTCCGTCTGG GT - #ATATTTTT1500- TCAGCATGTG CTCCTTGATT CTATGCCGCA CCATGTCCAC TCGAACCTTA AT - #CTGTTTGA1560- CGAGTTCTGC CAGGACATCT TTCTCGGGGT TCTCGTTGCA ATCCTCGGTC AC - #TTGTTCAA1620- AAGTTTTGAG GGATTCTTCG GCCAACTCTG GAAACAGCGG GTCTCCCAGA CT - #CAGCTGAC1680- TGTTAACCTC CTTCCTCAAC ATAGTCTGCA GGAACGTCGT GGCCTTGGTC AC - #GGGTGTCT1740- CGGGCCGTGG CACCTTGGAG GAAGGGCCCT CGTCAGGATT ATCAGGGTCC AT - #CTTTCTCT1800- TGGCAGAGGA CTCCATTACG ATACAAACTT AACGGATATC GCGATAATGA AA - #TAATTTAT1860- GATTATTTCT CGCTTTCAAT TTAACACAAC CCTCAAGAAC CTTTGTATTT AT - #TTTCACTT1920- TTTAAGTATA GAATAAAGAA GCTCTAATTA ATTAAGCTAC AAATAGTTTC GT - #TTTCACCT1980- TGTCTAATAA CTAATTAATT AACCCCGATA GCTGATTAGT TTTTGTTAAC AA - #AAATGTGG2040- GAGAATCTAA TTAGTTTTTC TTTACACAAT TGACGTACAT GAGTCTGAGT TC - #CTTGTTTT2100- TGCTAATTAT TTCATCCAAT TTATTATTCT TGACGATATC GAGATCTTTT GT - #ATAGGAGT2160- CAGACTTGTA TTCAACATGC TTTTCTATAA TCATCTTAGT TATTTCGGCA TC - #ATCCAATA2220- GTACATTTTC CAGATTAACA GAGTAGATAT TAATGTCGTA TTTGAACAGA GC - #CTGTAACA2280- TCTCAATGTC TTTATTATCT ATAGCCAATT TAATGTCCGG AATGAAGAGA AG - #GGAATTAT2340- TGGTGTTTGT CGACGTCATA TAGTCGAGCA AGAGAATCAT CATATCCACG TG - #TCCATTTT2400- TTATAGTGGT GTGAATACAA CTAAGGAGAA TAGCCAGATC AAAAGTAGAT GG - #TATTTCTG2460- AAAGAAAGTA TGATACAATA CTTACATCAT TAAGCATGAC GGCATGATAA AA - #TGAAGTTT2520- TCCATCCAGT TTTCCCATAG AACATCAGTC TCCAATTTTT CTTAAACAGT TT - #CACCGTTT2580- GCATGTTACC ACTATCAACC GCATAATACA ATGCGGTGTT TCCTTTGTCA TC - #AAATTGTG2640- AATCATCCAT TCCACTGAAT AGCAAAATCT TTACTATTTT GGTATCTTCT AA - #TGTGGCTG2700- CCTGATGTAA TGGAAATTCA TTCTCTAGAA GATTTTTCAA TGCTCCAGCG TT - #CAACAACG2760- TACATACTAG ACGCACGTTA TTATCAGCTA TTGCATAATA CAAGGCACTA TG - #TCCATGGA2820- CATCCGCCTT AAATGTATCT TTACTAGAGA GAAAGCTTTT CAGCTGCTTA GA - #CTTCCAAG2880- TATTAATTCG TGACAGATCC ATGTCTGAAA CGAGACGCTA ATTAGTGTAT AT - #TTTTTCAT2940- TTTTTATAAT TTTGTCATAT TGCACCAGAA TTAATAATAT CTCTAATAGA TC - #TAATTTAA3000- TTTAATTTAT ATAACTTATT TTTTGAATAT ACTTTTAATT AACAAAAGAG TT - #AAGTTACT3060- CATATGGACG CCGTCCAGTC TGAACATCAA TCTTTTTAGC CAGAGATATC AT - #AGCCGCTC3120- TTAGAGTTTC AGCGTGATTT TCCAACCTAA ATAGAACTTC ATCGTTGCGT TT - #ACAACACT3180- TTTCTATTTG TTCAAACTTT GTTGTTACAT TAGTAATCTT TTTTTCCAAA TT - #AGTTAGCC3240- GTTGTTTGAG AGTTTCCTCA TTGTCGTCTT CATCGGCTTT AACAATTGCT TC - #GCGTTTAG3300- CCTCCTGGCT GTTCTTATCA GCCTTTGTAG AAAAAAATTC AGTTGCTGGA AT - #TGCAAGAT3360# 3409AAAGA GTTCCGTCCA TTTAAAGCCG CGGGAATTC- (2) INFORMATION FOR SEQ ID NO:55:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 1221 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:- ATGAAACAGA TTAAGGTTCG AGTGGACATG GTGCGGCATA GAATCAAGGA GC - #ACATGCTG 60- AAAAAATATA CCCAGACGGA AGAGAAATTC ACTGGCGCCT TTAATATGAT GG - #GAGGATGT 120- TTGCAGAATG CCTTAGATAT CTTAGATAAG GTTCATGAGC CTTTCGAGGA GA - #TGAAGTGT 180- ATTGGGCTAA CTATGCAGAG CATGTATGAG AACTACATTG TACCTGAGGA TA - #AGCGGGAG 240- ATGTGGATGG CTTGTATTAA GGAGCTGCAT GATGTGAGCA AGGGCGCCGC TA - #ACAAGTTG 300- GGGGGTGCAC TGCAGGCTAA GGCCCGTGCT AAAAAGGATG AACTTAGGAG AA - #AGATGATG 360- TATATGTGCT ACAGGAATAT AGAGTTCTTT ACCAAGAACT CAGCCTTCCC TA - #AGACCACC 420- AATGGCTGCA GTCAGGCCAT GGCGGCACTG CAGAACTTGC CTCAGTGCTC CC - #CTGATGAG 480- ATTATGGCTT ATGCCCAGAA AATATTTAAG ATTTTGGATG AGGAGAGAGA CA - #AGGTGCTC 540- ACGCACATTG ATCACATATT TATGGATATC CTCACTACAT GTGTGGAAAC AA - #TGTGTAAT 600- GAGTACAAGG TCACTAGTGA CGCTTGTATG ATGACCATGT ACGGGGGCAT CT - #CTCTCTTA 660- AGTGAGTTCT GTCGGGTGCT GTGCTGCTAT GTCTTAGAGG AGACTAGTGT GA - #TGCTGGCC 720- AAGCGGCCTC TGATAACCAA GCCTGAGGTT ATCAGTGTAA TGAAGCGCCG CA - #TTGAGGAG 780- ATCTGCATGA AGGTCTTTGC CCAGTACATT CTGGGGGCCG ATCCTCTGAG AG - #TCTGCTCT 840- CCTAGTGTGG ATGACCTACG GGCCATCGCC GAGGAGTCAG ATGAGGAAGA GG - #CTATTGTA 900- GCCTACACTT TGGCCACCGC TGGTGTCAGC TCCTCTGATT CTCTGGTGTC AC - #CCCCAGAG 960- TCCCCTGTAC CCGCGACTAT CCCTCTGTCC TCAGTAATTG TGGCTGAGAA CA - #GTGATCAG1020- GAAGAAAGTG AGCAGAGTGA TGAGGAAGAG GAGGAGGGTG CTCAGGAGGA GC - #GGGAGGAC1080- ACTGTGTCTG TCAAGTCTGA GCCAGTGTCT GAGATAGAGG AAGTTGCCCC AG - #AGGAAGAG1140- GAGGATGGTG CTGAGGAACC CACCGCCTCT GGAGGTAAGA GTACCCACCC TA - #TGGTGACT1200# 1221TA A- (2) INFORMATION FOR SEQ ID NO:56:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 2577 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:- CTGCAGGTCG ACGGATCTGA GAATGGATGA TTCTCCAGCC GAAACATATT CT - #ACCATGGC 60- TCCGTTTAAT TTGTTGATGA AGATGGATTC ATCCTTAAAT GTTTTCTCTG TA - #ATAGTTTC 120- CACCGAAAGA CTATGCAAAG AATTTGGAAT GCGTTCCTTG TGCTTAATGT TT - #CCATAGAC 180- GGCTTCTAGA AGTTGATACA ACATAGGACT AGCCGCGGTA ACTTTTATTT TT - #AGAAAGTA 240- TCCATCGCTT CTATCTTGTT TAGATTTATT TTTATAAAGT TTAGTCTCTC CT - #TCCAACAT 300- AATAAAAGTG GAAGTCATTT GACTAGATAA ACTATCAGTA AGTTTTATAG AG - #ATAGACGA 360- ACAATTAGCG TATTGAGAAG CATTTAGTGT AACGTATTCG ATACATTTTG CA - #TTAGATTT 420- ACTAATCGAT TTTGCATACT CTATAACACC CGCACAAGTC TGTAGAGAAT CG - #CTAGATGC 480- AGTAGGTCTT GGTGAAGTTT CAACTCTCTT CTTGATTACC TTACTCATGA TT - #AAACCTAA 540- ATAATTGTAC TTTGTAATAT AATGATATAT ATTTTCACTT TATCTCATTT GA - #GAATAAAA 600- AGATCACAAA AATTAACTAA TCAGGATCCT TCTTTATTCT ATACTTAAAA AG - #TGAAAATA 660- AATACAAAGG TTCTTGAGGG TTGTGTTAAA TTGAAAGCGA GAAATAATCA TA - #AATTATTT 720- CATTATCGCG ATATCCGTTA AGTTTGTATC GTAATGAAAC AGATTAAGGT TC - #GAGTGGAC 780- ATGGTGCGGC ATAGAATCAA GGAGCACATG CTGAAAAAAT ATACCCAGAC GG - #AAGAGAAA 840- TTCACTGGCG CCTTTAATAT GATGGGAGGA TGTTTGCAGA ATGCCTTAGA TA - #TCTTAGAT 900- AAGGTTCATG AGCCTTTCGA GGAGATGAAG TGTATTGGGC TAACTATGCA GA - #GCATGTAT 960- GAGAACTACA TTGTACCTGA GGATAAGCGG GAGATGTGGA TGGCTTGTAT TA - #AGGAGCTG1020- CATGATGTGA GCAAGGGCGC CGCTAACAAG TTGGGGGGTG CACTGCAGGC TA - #AGGCCCGT1080- GCTAAAAAGG ATGAACTTAG GAGAAAGATG ATGTATATGT GCTACAGGAA TA - #TAGAGTTC1140- TTTACCAAGA ACTCAGCCTT CCCTAAGACC ACCAATGGCT GCAGTCAGGC CA - #TGGCGGCA1200- CTGCAGAACT TGCCTCAGTG CTCCCCTGAT GAGATTATGG CTTATGCCCA GA - #AAATATTT1260- AAGATTTTGG ATGAGGAGAG AGACAAGGTG CTCACGCACA TTGATCACAT AT - #TTATGGAT1320- ATCCTCACTA CATGTGTGGA AACAATGTGT AATGAGTACA AGGTCACTAG TG - #ACGCTTGT1380- ATGATGACCA TGTACGGGGG CATCTCTCTC TTAAGTGAGT TCTGTCGGGT GC - #TGTGCTGC1440- TATGTCTTAG AGGAGACTAG TGTGATGCTG GCCAAGCGGC CTCTGATAAC CA - #AGCCTGAG1500- GTTATCAGTG TAATGAAGCG CCGCATTGAG GAGATCTGCA TGAAGGTCTT TG - #CCCAGTAC1560- ATTCTGGGGG CCGATCCTCT GAGAGTCTGC TCTCCTAGTG TGGATGACCT AC - #GGGCCATC1620- GCCGAGGAGT CAGATGAGGA AGAGGCTATT GTAGCCTACA CTTTGGCCAC CG - #CTGGTGTC1680- AGCTCCTCTG ATTCTCTGGT GTCACCCCCA GAGTCCCCTG TACCCGCGAC TA - #TCCCTCTG1740- TCCTCAGTAA TTGTGGCTGA GAACAGTGAT CAGGAAGAAA GTGAGCAGAG TG - #ATGAGGAA1800- GAGGAGGAGG GTGCTCAGGA GGAGCGGGAG GACACTGTGT CTGTCAAGTC TG - #AGCCAGTG1860- TCTGAGATAG AGGAAGTTGC CCCAGAGGAA GAGGAGGATG GTGCTGAGGA AC - #CCACCGCC1920- TCTGGAGGTA AGAGTACCCA CCCTATGGTG ACTAGAAGCA AGGCTGACCA GT - #AATTTTTA1980- TCTCGAGCCC GGGAGATCTT AGCTAACTGA TTTTTCTGGG AAAAAAATTA TT - #TAACTTTT2040- CATTAATAGG GATTTGACGT ATGTAGCGTA CAAAATTATC GTTCCTGGTA TA - #TAGATAAA2100- GAGTCCTATA TATTTGAAAA TCGTTACGGC TCGATTAAAC TTTAATGATT GC - #ATAGTGAA2160- TATATCATTA GGATTTAACT CCTTGACTAT CATGGCGGCG CCAGAAATTA CC - #ATCAAAAG2220- CATTAATACA GTTATGCCGA TCGCAGTTAG AACGGTTATA GCATCCACCA TT - #TATATCTA2280- AAAATTAGAT CAAAGAATAT GTGACAAAGT CCTAGTTGTA TACTGAGAAT TG - #ACGAAACA2340- ATGTTTCTTA CATATTTTTT TCTTATTAGT AACTGACTTA ATAGTAGGAA CT - #GGAAAGCT2400- AGACTTGATT ATTCTATAAG TATAGATACC CTTCCAGATA ATGTTCTCTT TG - #ATAAAAGT2460- TCCAGAAAAT GTAGAATTTT TTAAAAAGTT ATCTTTTGCT ATTACCAAGA TT - #GTGTTTAG2520- ACGCTTATTA TTAATATGAG TAATGAAATC CACACCGCCT CTAGATATGG GG - #AATTC2577- (2) INFORMATION FOR SEQ ID NO:57:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 3460 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:- GAATTGCGGC CGCTGAATGT TAAATGTTAT ACTTTGGATG AAGCTATAAA TA - #TGCATTGG 60- AAAAATAATC CATTTAAAGA AAGGATTCAA ATACTACAAA ACCTAAGCGA TA - #ATATGTTA 120- ACTAAGCTTA TTCTTAACGA CGCTTTAAAT ATACACAAAT AAACATAATT TT - #TGTATAAC 180- CTAACAAATA ACTAAAACAT AAAAATAATA AAAGGAAATG TAATATCGTA AT - #TATTTTAC 240- TCAGGAATGG GGTTAAATAT TTATATCACG TGTATATCTA TACTGTTATC GT - #ATACTCTT 300- TACAATTACT ATTACGAATA TGCAAGAGAT AATAAGATTA CGTATTTAAG AG - #AATCTTGT 360- CATGATAATT GGGTACGACA TAGTGATAAA TGCTATTTCG CATCGTTACA TA - #AAGTCAGT 420- TGGAAAGATG GATTTGACAG ATGTAACTTA ATAGGTGCAA AAATGTTAAA TA - #ACAGCATT 480- CTATCGGAAG ATAGGATACC AGTTATATTA TACAAAAATC ACTGGTTGGA TA - #AAACAGAT 540- TCTGCAATAT TCGTAAAAGA TGAAGATTAC TGCGAATTTG TAAACTATGA CA - #ATAAAAAG 600- CCATTTATCT CAACGACATC GTGTAATTCT TCCATGTTTT ATGTATGTGT TT - #CAGATATT 660- ATGAGATTAC TATAAACTTT TTGTATACTT ATATTCCGTA AACTATATTA AT - #CATGAAGA 720- AAATGAAAAA GTATAGAAGC TGTTCACGAG CGGTTGTTGA AAACAACAAA AT - #TATACATT 780- CAAGATGGCT TACATATACG TCTGTGAGGC TATCATGGAT AATGACAATG CA - #TCTCTAAA 840- TAGGTTTTTG GACAATGGAT TCGACCCTAA CACGGAATAT GGTACTCTAC AA - #TCTCCTCT 900- TGAAATGGCT GTAATGTTCA AGAATACCGA GGCTATAAAA ATCTTGATGA GG - #TATGGAGC 960- TAAACCTGTA GTTACTGAAT GCACAACTTC TTGTCTGCAT GATGCGGTGT TG - #AGAGACGA1020- CTACAAAATA GTGAAAGATC TGTTGAAGAA TAACTATGTA AACAATGTTC TT - #TACAGCGG1080- AGGCTTTACT CCTTTGTGTT TGGCAGCTTA CCTTAACAAA GTTAATTTGG TT - #AAACTTCT1140- ATTGGCTCAT TCGGCGGATG TAGATATTTC AAACACGGAT CGGTTAACTC CT - #CTACATAT1200- AGCCGTATCA AATAAAAATT TAACAATGGT TAAACTTCTA TTGAACAAAG GT - #GCTGATAC1260- TGACTTGCTG GATAACATGG GACGTACTCC TTTAATGATC GCTGTACAAT CT - #GGAAATAT1320- TGAAATATGT AGCACACTAC TTAAAAAAAA TAAAATGTCC AGAACTGGGA AA - #AATTGATC1380- TTGCCAGCTG TAATTCATGG TAGAAAAGAA GTGCTCAGGC TACTTTTCAA CA - #AAGGAGCA1440- GATGTAAACT ACATCTTTGA AAGAAATGGA AAATCATATA CTGTTTTGGA AT - #TGATTAAA1500- GAAAGTTACT CTGAGACACA AAAGAGGTAG CTGAAGTGGT ACTCTCAAAG GT - #ACGTGACT1560- AATTAGCTAT AAAAAGGATC CGGGTTAATT AATTAGTCAT CAGGCAGGGC GA - #GAACGAGA1620- CTATCTGCTC GTTAATTAAT TAGAGCTTCT TTATTCTATA CTTAAAAAGT GA - #AAATAAAT1680- ACAAAGGTTC TTGAGGGTTG TGTTAAATTG AAAGCGAGAA ATAATCATAA AT - #TATTTCAT1740- TATCGCGATA TCCGTTAAGT TTGTATCGTA ATGAAACAGA TTAAGGTTCG AG - #TGGACATG1800- GTGCGGCATA GAATCAAGGA GCACATGCTG AAAAAATATA CCCAGACGGA AG - #AGAAATTC1860- ACTGGCGCCT TTAATATGAT GGGAGGATGT TTGCAGAATG CCTTAGATAT CT - #TAGATAAG1920- GTTCATGAGC CTTTCGAGGA GATGAAGTGT ATTGGGCTAA CTATGCAGAG CA - #TGTATGAG1980- AACTACATTG TACCTGAGGA TAAGCGGGAG ATGTGGATGG CTTGTATTAA GG - #AGCTGCAT2040- GATGTGAGCA AGGGCGCCGC TAACAAGTTG GGGGGTGCAC TGCAGGCTAA GG - #CCCGTGCT2100- AAAAAGGATG AACTTAGGAG AAAGATGATG TATATGTGCT ACAGGAATAT AG - #AGTTCTTT2160- ACCAAGAACT CAGCCTTCCC TAAGACCACC AATGGCTGCA GTCAGGCCAT GG - #CGGCACTG2220- CAGAACTTGC CTCAGTGCTC CCCTGATGAG ATTATGGCTT ATGCCCAGAA AA - #TATTTAAG2280- ATTTTGGATG AGGAGAGAGA CAAGGTGCTC ACGCACATTG ATCACATATT TA - #TGGATATC2340- CTCACTACAT GTGTGGAAAC AATGTGTAAT GAGTACAAGG TCACTAGTGA CG - #CTTGTATG2400- ATGACCATGT ACGGGGGCAT CTCTCTCTTA AGTGAGTTCT GTCGGGTGCT GT - #GCTGCTAT2460- GTCTTAGAGG AGACTAGTGT GATGCTGGCC AAGCGGCCTC TGATAACCAA GC - #CTGAGGTT2520- ATCAGTGTAA TGAAGCGCCG CATTGAGGAG ATCTGCATGA AGGTCTTTGC CC - #AGTACATT2580- CTGGGGGCCG ATCCTCTGAG AGTCTGCTCT CCTAGTGTGG ATGACCTACG GG - #CCATCGCC2640- GAGGAGTCAG ATGAGGAAGA GGCTATTGTA GCCTACACTT TGGCCACCGC TG - #GTGTCAGC2700- TCCTCTGATT CTCTGGTGTC ACCCCCAGAG TCCCCTGTAC CCGCGACTAT CC - #CTCTGTCC2760- TCAGTAATTG TGGCTGAGAA CAGTGATCAG GAAGAAAGTG AGCAGAGTGA TG - #AGGAAGAG2820- GAGGAGGGTG CTCAGGAGGA GCGGGAGGAC ACTGTGTCTG TCAAGTCTGA GC - #CAGTGTCT2880- GAGATAGAGG AAGTTGCCCC AGAGGAAGAG GAGGATGGTG CTGAGGAACC CA - #CCGCCTCT2940- GGAGGTAAGA GTACCCACCC TATGGTGACT AGAAGCAAGG CTGACCAGTA AT - #TTTTATCT3000- CGAGTCTAGA ATCGATCCCG GGTTTTTATG ACTAGTTAAT CACGGCCGCT TA - #TAAAGATC3060- TAAAATGCAT AATTTCTAAA TAATGAAAAA AAAGTACATC ATGAGCAACG CG - #TTAGTATA3120- TTTTACAATG GAGATTAACG CTCTATACCG TTCTATGTTT ATTGATTCAG AT - #GATGTTTT3180- AGAAAAGAAA GTTATTGAAT ATGAAAACTT TAATGAAGAT GAAGATGACG AC - #GATGATTA3240- TTGTTGTAAA TCTGTTTTAG ATGAAGAAGA TGACGCGCTA AAGTATACTA TG - #GTTACAAA3300- GTATAAGTCT ATACTACTAA TGGCGACTTG TGCAAGAAGG TATAGTATAG TG - #AAAATGTT3360- GTTAGATTAT GATTATGAAA AACCAAATAA ATCAGATCCA TATCTAAAGG TA - #TCTCCTTT3420# 3460 ATTC CTAGTTTAGA ATACCTGCAG- (2) INFORMATION FOR SEQ ID NO:58:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 1383 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:- ATGACGACGT TCCTGCAGAC TATGTTGAGG AAGGAGGTTA ACAGTCAGCT GA - #GTCTGGGA 60- GACCCGCTGT TTCCAGAGTT GGCCGAAGAA TCCCTCAAAA CTTTTGAACA AG - #TGACCGAG 120- GATTGCAACG AGAACCCCGA GAAAGATGTC CTGGCAGAAC TCGTCAAACA GA - #TTAAGGTT 180- CGAGTGGACA TGGTGCGGCA TAGAATCAAG GAGCACATGC TGAAAAAATA TA - #CCCAGACG 240- GAAGAGAAAT TCACTGGCGC CTTTAATATG ATGGGAGGAT GTTTGCAGAA TG - #CCTTAGAT 300- ATCTTAGATA AGGTTCATGA GCCTTTCGAG GAGATGAAGT GTATTGGGCT AA - #CTATGCAG 360- AGCATGTATG AGAACTACAT TGTACCTGAG GATAAGCGGG AGATGTGGAT GG - #CTTGTATT 420- AAGGAGCTGC ATGATGTGAG CAAGGGCGCC GCTAACAAGT TGGGGGGTGC AC - #TGCAGGCT 480- AAGGCCCGTG CTAAAAAGGA TGAACTTAGG AGAAAGATGA TGTATATGTG CT - #ACAGGAAT 540- ATAGAGTTCT TTACCAAGAA CTCAGCCTTC CCTAAGACCA CCAATGGCTG CA - #GTCAGGCC 600- ATGGCGGCAC TGCAGAACTT GCCTCAGTGC TCCCCTGATG AGATTATGGC TT - #ATGCCCAG 660- AAAATATTTA AGATTTTGGA TGAGGAGAGA GACAAGGTGC TCACGCACAT TG - #ATCACATA 720- TTTATGGATA TCCTCACTAC ATGTGTGGAA ACAATGTGTA ATGAGTACAA GG - #TCACTAGT 780- GACGCTTGTA TGATGACCAT GTACGGGGGC ATCTCTCTCT TAAGTGAGTT CT - #GTCGGGTG 840- CTGTGCTGCT ATGTCTTAGA GGAGACTAGT GTGATGCTGG CCAAGCGGCC TC - #TGATAACC 900- AAGCCTGAGG TTATCAGTGT AATGAAGCGC CGCATTGAGG AGATCTGCAT GA - #AGGTCTTT 960- GCCCAGTACA TTCTGGGGGC CGATCCTCTG AGAGTCTGCT CTCCTAGTGT GG - #ATGACCTA1020- CGGGCCATCG CCGAGGAGTC AGATGAGGAA GAGGCTATTG TAGCCTACAC TT - #TGGCCACC1080- GCTGGTGTCA GCTCCTCTGA TTCTCTGGTG TCACCCCCAG AGTCCCCTGT AC - #CCGCGACT1140- ATCCCTCTGT CCTCAGTAAT TGTGGCTGAG AACAGTGATC AGGAAGAAAG TG - #AGCAGAGT1200- GATGAGGAAG AGGAGGAGGG TGCTCAGGAG GAGCGGGAGG ACACTGTGTC TG - #TCAAGTCT1260- GAGCCAGTGT CTGAGATAGA GGAAGTTGCC CCAGAGGAAG AGGAGGATGG TG - #CTGAGGAA1320- CCCACCGCCT CTGGAGGTAA GAGTACCCAC CCTATGGTGA CTAGAAGCAA GG - #CTGACCAG1380# 1383- (2) INFORMATION FOR SEQ ID NO:59:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 2739 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:- CTGCAGGTCG ACGGATCTGA GAATGGATGA TTCTCCAGCC GAAACATATT CT - #ACCATGGC 60- TCCGTTTAAT TTGTTGATGA AGATGGATTC ATCCTTAAAT GTTTTCTCTG TA - #ATAGTTTC 120- CACCGAAAGA CTATGCAAAG AATTTGGAAT GCGTTCCTTG TGCTTAATGT TT - #CCATAGAC 180- GGCTTCTAGA AGTTGATACA ACATAGGACT AGCCGCGGTA ACTTTTATTT TT - #AGAAAGTA 240- TCCATCGCTT CTATCTTGTT TAGATTTATT TTTATAAAGT TTAGTCTCTC CT - #TCCAACAT 300- AATAAAAGTG GAAGTCATTT GACTAGATAA ACTATCAGTA AGTTTTATAG AG - #ATAGACGA 360- ACAATTAGCG TATTGAGAAG CATTTAGTGT AACGTATTCG ATACATTTTG CA - #TTAGATTT 420- ACTAATCGAT TTTGCATACT CTATAACACC CGCACAAGTC TGTAGAGAAT CG - #CTAGATGC 480- AGTAGGTCTT GGTGAAGTTT CAACTCTCTT CTTGATTACC TTACTCATGA TT - #AAACCTAA 540- ATAATTGTAC TTTGTAATAT AATGATATAT ATTTTCACTT TATCTCATTT GA - #GAATAAAA 600- AGATCACAAA AATTAACTAA TCAGGATCCT TCTTTATTCT ATACTTAAAA AG - #TGAAAATA 660- AATACAAAGG TTCTTGAGGG TTGTGTTAAA TTGAAAGCGA GAAATAATCA TA - #AATTATTT 720- CATTATCGCG ATATCCGTTA AGTTTGTATC GTAATGACGA CGTTCCTGCA GA - #CTATGTTG 780- AGGAAGGAGG TTAACAGTCA GCTGAGTCTG GGAGACCCGC TGTTTCCAGA GT - #TGGCCGAA 840- GAATCCCTCA AAACTTTTGA ACAAGTGACC GAGGATTGCA ACGAGAACCC CG - #AGAAAGAT 900- GTCCTGGCAG AACTCGTCAA ACAGATTAAG GTTCGAGTGG ACATGGTGCG GC - #ATAGAATC 960- AAGGAGCACA TGCTGAAAAA ATATACCCAG ACGGAAGAGA AATTCACTGG CG - #CCTTTAAT1020- ATGATGGGAG GATGTTTGCA GAATGCCTTA GATATCTTAG ATAAGGTTCA TG - #AGCCTTTC1080- GAGGAGATGA AGTGTATTGG GCTAACTATG CAGAGCATGT ATGAGAACTA CA - #TTGTACCT1140- GAGGATAAGC GGGAGATGTG GATGGCTTGT ATTAAGGAGC TGCATGATGT GA - #GCAAGGGC1200- GCCGCTAACA AGTTGGGGGG TGCACTGCAG GCTAAGGCCC GTGCTAAAAA GG - #ATGAACTT1260- AGGAGAAAGA TGATGTATAT GTGCTACAGG AATATAGAGT TCTTTACCAA GA - #ACTCAGCC1320- TTCCCTAAGA CCACCAATGG CTGCAGTCAG GCCATGGCGG CACTGCAGAA CT - #TGCCTCAG1380- TGCTCCCCTG ATGAGATTAT GGCTTATGCC CAGAAAATAT TTAAGATTTT GG - #ATGAGGAG1440- AGAGACAAGG TGCTCACGCA CATTGATCAC ATATTTATGG ATATCCTCAC TA - #CATGTGTG1500- GAAACAATGT GTAATGAGTA CAAGGTCACT AGTGACGCTT GTATGATGAC CA - #TGTACGGG1560- GGCATCTCTC TCTTAAGTGA GTTCTGTCGG GTGCTGTGCT GCTATGTCTT AG - #AGGAGACT1620- AGTGTGATGC TGGCCAAGCG GCCTCTGATA ACCAAGCCTG AGGTTATCAG TG - #TAATGAAG1680- CGCCGCATTG AGGAGATCTG CATGAAGGTC TTTGCCCAGT ACATTCTGGG GG - #CCGATCCT1740- CTGAGAGTCT GCTCTCCTAG TGTGGATGAC CTACGGGCCA TCGCCGAGGA GT - #CAGATGAG1800- GAAGAGGCTA TTGTAGCCTA CACTTTGGCC ACCGCTGGTG TCAGCTCCTC TG - #ATTCTCTG1860- GTGTCACCCC CAGAGTCCCC TGTACCCGCG ACTATCCCTC TGTCCTCAGT AA - #TTGTGGCT1920- GAGAACAGTG ATCAGGAAGA AAGTGAGCAG AGTGATGAGG AAGAGGAGGA GG - #GTGCTCAG1980- GAGGAGCGGG AGGACACTGT GTCTGTCAAG TCTGAGCCAG TGTCTGAGAT AG - #AGGAAGTT2040- GCCCCAGAGG AAGAGGAGGA TGGTGCTGAG GAACCCACCG CCTCTGGAGG TA - #AGAGTACC2100- CACCCTATGG TGACTAGAAG CAAGGCTGAC CAGTAATTTT TATCTCGAGC CC - #GGGAGATC2160- TTAGCTAACT GATTTTTCTG GGAAAAAAAT TATTTAACTT TTCATTAATA GG - #GATTTGAC2220- GTATGTAGCG TACAAAATTA TCGTTCCTGG TATATAGATA AAGAGTCCTA TA - #TATTTGAA2280- AATCGTTACG GCTCGATTAA ACTTTAATGA TTGCATAGTG AATATATCAT TA - #GGATTTAA2340- CTCCTTGACT ATCATGGCGG CGCCAGAAAT TACCATCAAA AGCATTAATA CA - #GTTATGCC2400- GATCGCAGTT AGAACGGTTA TAGCATCCAC CATTTATATC TAAAAATTAG AT - #CAAAGAAT2460- ATGTGACAAA GTCCTAGTTG TATACTGAGA ATTGACGAAA CAATGTTTCT TA - #CATATTTT2520- TTTCTTATTA GTAACTGACT TAATAGTAGG AACTGGAAAG CTAGACTTGA TT - #ATTCTATA2580- AGTATAGATA CCCTTCCAGA TAATGTTCTC TTTGATAAAA GTTCCAGAAA AT - #GTAGAATT2640- TTTTAAAAAG TTATCTTTTG CTATTACCAA GATTGTGTTT AGACGCTTAT TA - #TTAATATG2700# 2739 CCGC CTCTAGATAT GGGGAATTC- (2) INFORMATION FOR SEQ ID NO:60:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 3622 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:- GAATTGCGGC CGCTGAATGT TAAATGTTAT ACTTTGGATG AAGCTATAAA TA - #TGCATTGG 60- AAAAATAATC CATTTAAAGA AAGGATTCAA ATACTACAAA ACCTAAGCGA TA - #ATATGTTA 120- ACTAAGCTTA TTCTTAACGA CGCTTTAAAT ATACACAAAT AAACATAATT TT - #TGTATAAC 180- CTAACAAATA ACTAAAACAT AAAAATAATA AAAGGAAATG TAATATCGTA AT - #TATTTTAC 240- TCAGGAATGG GGTTAAATAT TTATATCACG TGTATATCTA TACTGTTATC GT - #ATACTCTT 300- TACAATTACT ATTACGAATA TGCAAGAGAT AATAAGATTA CGTATTTAAG AG - #AATCTTGT 360- CATGATAATT GGGTACGACA TAGTGATAAA TGCTATTTCG CATCGTTACA TA - #AAGTCAGT 420- TGGAAAGATG GATTTGACAG ATGTAACTTA ATAGGTGCAA AAATGTTAAA TA - #ACAGCATT 480- CTATCGGAAG ATAGGATACC AGTTATATTA TACAAAAATC ACTGGTTGGA TA - #AAACAGAT 540- TCTGCAATAT TCGTAAAAGA TGAAGATTAC TGCGAATTTG TAAACTATGA CA - #ATAAAAAG 600- CCATTTATCT CAACGACATC GTGTAATTCT TCCATGTTTT ATGTATGTGT TT - #CAGATATT 660- ATGAGATTAC TATAAACTTT TTGTATACTT ATATTCCGTA AACTATATTA AT - #CATGAAGA 720- AAATGAAAAA GTATAGAAGC TGTTCACGAG CGGTTGTTGA AAACAACAAA AT - #TATACATT 780- CAAGATGGCT TACATATACG TCTGTGAGGC TATCATGGAT AATGACAATG CA - #TCTCTAAA 840- TAGGTTTTTG GACAATGGAT TCGACCCTAA CACGGAATAT GGTACTCTAC AA - #TCTCCTCT 900- TGAAATGGCT GTAATGTTCA AGAATACCGA GGCTATAAAA ATCTTGATGA GG - #TATGGAGC 960- TAAACCTGTA GTTACTGAAT GCACAACTTC TTGTCTGCAT GATGCGGTGT TG - #AGAGACGA1020- CTACAAAATA GTGAAAGATC TGTTGAAGAA TAACTATGTA AACAATGTTC TT - #TACAGCGG1080- AGGCTTTACT CCTTTGTGTT TGGCAGCTTA CCTTAACAAA GTTAATTTGG TT - #AAACTTCT1140- ATTGGCTCAT TCGGCGGATG TAGATATTTC AAACACGGAT CGGTTAACTC CT - #CTACATAT1200- AGCCGTATCA AATAAAAATT TAACAATGGT TAAACTTCTA TTGAACAAAG GT - #GCTGATAC1260- TGACTTGCTG GATAACATGG GACGTACTCC TTTAATGATC GCTGTACAAT CT - #GGAAATAT1320- TGAAATATGT AGCACACTAC TTAAAAAAAA TAAAATGTCC AGAACTGGGA AA - #AATTGATC1380- TTGCCAGCTG TAATTCATGG TAGAAAAGAA GTGCTCAGGC TACTTTTCAA CA - #AAGGAGCA1440- GATGTAAACT ACATCTTTGA AAGAAATGGA AAATCATATA CTGTTTTGGA AT - #TGATTAAA1500- GAAAGTTACT CTGAGACACA AAAGAGGTAG CTGAAGTGGT ACTCTCAAAG GT - #ACGTGACT1560- AATTAGCTAT AAAAAGGATC CGGGTTAATT AATTAGTCAT CAGGCAGGGC GA - #GAACGAGA1620- CTATCTGCTC GTTAATTAAT TAGAGCTTCT TTATTCTATA CTTAAAAAGT GA - #AAATAAAT1680- ACAAAGGTTC TTGAGGGTTG TGTTAAATTG AAAGCGAGAA ATAATCATAA AT - #TATTTCAT1740- TATCGCGATA TCCGTTAAGT TTGTATCGTA ATGACGACGT TCCTGCAGAC TA - #TGTTGAGG1800- AAGGAGGTTA ACAGTCAGCT GAGTCTGGGA GACCCGCTGT TTCCAGAGTT GG - #CCGAAGAA1860- TCCCTCAAAA CTTTTGAACA AGTGACCGAG GATTGCAACG AGAACCCCGA GA - #AAGATGTC1920- CTGGCAGAAC TCGTCAAACA GATTAAGGTT CGAGTGGACA TGGTGCGGCA TA - #GAATCAAG1980- GAGCACATGC TGAAAAAATA TACCCAGACG GAAGAGAAAT TCACTGGCGC CT - #TTAATATG2040- ATGGGAGGAT GTTTGCAGAA TGCCTTAGAT ATCTTAGATA AGGTTCATGA GC - #CTTTCGAG2100- GAGATGAAGT GTATTGGGCT AACTATGCAG AGCATGTATG AGAACTACAT TG - #TACCTGAG2160- GATAAGCGGG AGATGTGGAT GGCTTGTATT AAGGAGCTGC ATGATGTGAG CA - #AGGGCGCC2220- GCTAACAAGT TGGGGGGTGC ACTGCAGGCT AAGGCCCGTG CTAAAAAGGA TG - #AACTTAGG2280- AGAAAGATGA TGTATATGTG CTACAGGAAT ATAGAGTTCT TTACCAAGAA CT - #CAGCCTTC2340- CCTAAGACCA CCAATGGCTG CAGTCAGGCC ATGGCGGCAC TGCAGAACTT GC - #CTCAGTGC2400- TCCCCTGATG AGATTATGGC TTATGCCCAG AAAATATTTA AGATTTTGGA TG - #AGGAGAGA2460- GACAAGGTGC TCACGCACAT TGATCACATA TTTATGGATA TCCTCACTAC AT - #GTGTGGAA2520- ACAATGTGTA ATGAGTACAA GGTCACTAGT GACGCTTGTA TGATGACCAT GT - #ACGGGGGC2580- ATCTCTCTCT TAAGTGAGTT CTGTCGGGTG CTGTGCTGCT ATGTCTTAGA GG - #AGACTAGT2640- GTGATGCTGG CCAAGCGGCC TCTGATAACC AAGCCTGAGG TTATCAGTGT AA - #TGAAGCGC2700- CGCATTGAGG AGATCTGCAT GAAGGTCTTT GCCCAGTACA TTCTGGGGGC CG - #ATCCTCTG2760- AGAGTCTGCT CTCCTAGTGT GGATGACCTA CGGGCCATCG CCGAGGAGTC AG - #ATGAGGAA2820- GAGGCTATTG TAGCCTACAC TTTGGCCACC GCTGGTGTCA GCTCCTCTGA TT - #CTCTGGTG2880- TCACCCCCAG AGTCCCCTGT ACCCGCGACT ATCCCTCTGT CCTCAGTAAT TG - #TGGCTGAG2940- AACAGTGATC AGGAAGAAAG TGAGCAGAGT GATGAGGAAG AGGAGGAGGG TG - #CTCAGGAG3000- GAGCGGGAGG ACACTGTGTC TGTCAAGTCT GAGCCAGTGT CTGAGATAGA GG - #AAGTTGCC3060- CCAGAGGAAG AGGAGGATGG TGCTGAGGAA CCCACCGCCT CTGGAGGTAA GA - #GTACCCAC3120- CCTATGGTGA CTAGAAGCAA GGCTGACCAG TAATTTTTAT CTCGAGTCTA GA - #ATCGATCC3180- CGGGTTTTTA TGACTAGTTA ATCACGGCCG CTTATAAAGA TCTAAAATGC AT - #AATTTCTA3240- AATAATGAAA AAAAAGTACA TCATGAGCAA CGCGTTAGTA TATTTTACAA TG - #GAGATTAA3300- CGCTCTATAC CGTTCTATGT TTATTGATTC AGATGATGTT TTAGAAAAGA AA - #GTTATTGA3360- ATATGAAAAC TTTAATGAAG ATGAAGATGA CGACGATGAT TATTGTTGTA AA - #TCTGTTTT3420- AGATGAAGAA GATGACGCGC TAAAGTATAC TATGGTTACA AAGTATAAGT CT - #ATACTACT3480- AATGGCGACT TGTGCAAGAA GGTATAGTAT AGTGAAAATG TTGTTAGATT AT - #GATTATGA3540- AAAACCAAAT AAATCAGATC CATATCTAAA GGTATCTCCT TTGCACATAA TT - #TCATCTAT3600# 3622TGC AG- (2) INFORMATION FOR SEQ ID NO:61:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 1686 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:- ATGGAGTCGC GCGGTCGCCG TTGTCCCGAA ATGATATCCG TACTGGGTCC CA - #TTTCGGGG 60- CACGTGCTGA AAGCCGTGTT TAGTCGCGGC GACACGCCGG TGCTGCCGCA CG - #AGACGCGA 120- CTCCTGCAGA CGGGTATCCA CGTGCGCGTG AGCCAGCCCT CGCTGATCCT GG - #TGTCGCAG 180- TACACGCCCG ACTCGACGCC ATGCCACCGC GGCGACAATC AGCTGCAGGT GC - #AGCACACG 240- TACTTTACGG GCAGCGAGGT GGAGAACGTG TCGGTCAACG TGCACAACCC CA - #CGGGCCGG 300- AGCATCTGCC CCAGCCAAGA GCCCATGTCG ATCTATGTGT ACGCGCTGCC GC - #TCAAGATG 360- CTGAACATCC CCAGCATCAA CGTGCACCAC TACCCGTCGG CGGCCGAGCG CA - #AACACCGA 420- CACCTGCCCG TAGCTGACGC TGTGATTCAC GCGTCGGGCA AGCAGATGTG GC - #AGGCGCGT 480- CTCACGGTCT CGGGACTGGC CTGGACGCGT CAGCAGAACC AGTGGAAAGA GC - #CCGACGTC 540- TACTACACGT CAGCGTTCGT GTTTCCCACC AAGGACGTGG CACTGCGGCA CG - #TGGTGTGC 600- GCGCACGAGC TGGTTTGCTC CATGGAGAAC ACGCGCGCAA CCAAGATGCA GG - #TGATAGGT 660- GACCAGTACG TCAAGGTGTA CCTGGAGTCC TTCTGCGAGG ACGTGCCCTC CG - #GCAAGCTC 720- TTTATGCACG TCACGCTGGG CTCTGACGTG GAAGAGGACC TGACGATGAC CC - #GCAACCCG 780- CAACCCTTCA TGCGCCCCCA CGAGCGCAAC GGCTTTACGG TGTTGTGTCC CA - #AAAATATG 840- ATAATCAAAC CGGGCAAGAT CTCGCACATC ATGCTGGATG TGGCTTTTAC CT - #CACACGAG 900- CATTTTGGGC TGCTGTGTCC CAAGAGCATC CCGGGCCTGA GCATCTCAGG TA - #ACCTATTG 960- ATGAACGGGC AGCAGATCTT CCTGGAGGTG CAAGCGATAC GCGAGACCGT GG - #AACTGCGT1020- CAGTACGATC CCGTGGCTGC GCTCTTCTTT TTCGATATCG ACTTGCTGCT GC - #AGCGCGGG1080- CCTCAGTACA GCGAACACCC CACCTTCACC AGCCAGTATC GCATCCAGGG CA - #AGCTTGAG1140- TACCGACACA CCTGGGACCG GCACGACGAG GGTGCCGCCC AGGGCGACGA CG - #ACGTCTGG1200- ACCAGCGGAT CGGACTCCGA CGAGGAACTC GTAACCACCG AGCGCAAGAC GC - #CCCGCGTT1260- ACCGGCGGCG GCGCCATGGC GGGCGCCTCC ACTTCCGCGG GCCGCAAACG CA - #AATCAGCA1320- TCCTCGGCGA CGGCGTGCAC GGCGGGCGTT ATGACACGCG GCCGCCTTAA GG - #CCGAGTCC1380- ACCGTCGCGC CCGAAGAGGA CACCGACGAG GATTCCGACA ACGAAATCCA CA - #ATCCGGCC1440- GTGTTCACCT GGCCGCCCTG GCAGGCCGGC ATCCTGGCCC GCAACCTGGT GC - #CCATGGTG1500- GCTACGGTTC AGGGTCAGAA TCTGAAGTAC CAGGAGTTCT TCTGGGACGC CA - #ACGACATC1560- TACCGCATCT TCGCCGAATT GGAAGGCGTA TGGCAGCCCG CTGCGCAACC CA - #AACGTCGC1620- CGCCACCGGC AAGACGCCTT GCCCGGGCCA TGCATCGCCT CGACGCCCAA AA - #AGCACCGA1680# 1686- (2) INFORMATION FOR SEQ ID NO:62:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 2745 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:- GTCGACGATT GTTCATGATG GCAAGATTTA TATATCTGGA GGTTACAACA AT - #AGTAGTGT 60- AGTTAATGTA ATATCGAATC TAGTCCTTAG CTATAATCCG ATATATGATG AA - #TGGACCAA 120- ATTATCATCA TTAAACATTC CTAGAATTAA TCCCGCTCTA TGGTCAGCGC AT - #AATAAATT 180- ATATGTAGGA GGAGGAATAT CTGATGATGT TCGAACTAAT ACATCTGAAA CA - #TACGATAA 240- AGAAAAAGAT TGTTGGACAT TGGATAATGG TCACGTGTTA CCACGCAATT AT - #ATAATGTA 300- TAAATGCGAA CCGATTAAAC ATAAATATCC ATTGGAAAAA ACACAGTACA CG - #AATGATTT 360- TCTAAAGTAT TTGGAAAGTT TTATAGGTAG TTGATAGAAC AAAATACATA AT - #TTTGTAAA 420- AATAAATCAC TTTTTATACT AATATTTAAT TAATTAAGCT TGGTACCCTC GA - #AGCTTCTT 480- TATTCTATAC TTAAAAAGTG AAAATAAATA CAAAGGTTCT TGAGGGTTGT GT - #TAAATTGA 540- AAGCGAGAAA TAATCATAAA TTATTTCATT ATCGCGATAT CCGTTAAGTT TG - #TATCGTAA 600- TGGAGTCGCG CGGTCGCCGT TGTCCCGAAA TGATATCCGT ACTGGGTCCC AT - #TTCGGGGC 660- ACGTGCTGAA AGCCGTGTTT AGTCGCGGCG ACACGCCGGT GCTGCCGCAC GA - #GACGCGAC 720- TCCTGCAGAC GGGTATCCAC GTGCGCGTGA GCCAGCCCTC GCTGATCCTG GT - #GTCGCAGT 780- ACACGCCCGA CTCGACGCCA TGCCACCGCG GCGACAATCA GCTGCAGGTG CA - #GCACACGT 840- ACTTTACGGG CAGCGAGGTG GAGAACGTGT CGGTCAACGT GCACAACCCC AC - #GGGCCGGA 900- GCATCTGCCC CAGCCAAGAG CCCATGTCGA TCTATGTGTA CGCGCTGCCG CT - #CAAGATGC 960- TGAACATCCC CAGCATCAAC GTGCACCACT ACCCGTCGGC GGCCGAGCGC AA - #ACACCGAC1020- ACCTGCCCGT AGCTGACGCT GTGATTCACG CGTCGGGCAA GCAGATGTGG CA - #GGCGCGTC1080- TCACGGTCTC GGGACTGGCC TGGACGCGTC AGCAGAACCA GTGGAAAGAG CC - #CGACGTCT1140- ACTACACGTC AGCGTTCGTG TTTCCCACCA AGGACGTGGC ACTGCGGCAC GT - #GGTGTGCG1200- CGCACGAGCT GGTTTGCTCC ATGGAGAACA CGCGCGCAAC CAAGATGCAG GT - #GATAGGTG1260- ACCAGTACGT CAAGGTGTAC CTGGAGTCCT TCTGCGAGGA CGTGCCCTCC GG - #CAAGCTCT1320- TTATGCACGT CACGCTGGGC TCTGACGTGG AAGAGGACCT GACGATGACC CG - #CAACCCGC1380- AACCCTTCAT GCGCCCCCAC GAGCGCAACG GCTTTACGGT GTTGTGTCCC AA - #AAATATGA1440- TAATCAAACC GGGCAAGATC TCGCACATCA TGCTGGATGT GGCTTTTACC TC - #ACACGAGC1500- ATTTTGGGCT GCTGTGTCCC AAGAGCATCC CGGGCCTGAG CATCTCAGGT AA - #CCTATTGA1560- TGAACGGGCA GCAGATCTTC CTGGAGGTGC AAGCGATACG CGAGACCGTG GA - #ACTGCGTC1620- AGTACGATCC CGTGGCTGCG CTCTTCTTTT TCGATATCGA CTTGCTGCTG CA - #GCGCGGGC1680- CTCAGTACAG CGAACACCCC ACCTTCACCA GCCAGTATCG CATCCAGGGC AA - #GCTTGAGT1740- ACCGACACAC CTGGGACCGG CACGACGAGG GTGCCGCCCA GGGCGACGAC GA - #CGTCTGGA1800- CCAGCGGATC GGACTCCGAC GAGGAACTCG TAACCACCGA GCGCAAGACG CC - #CCGCGTTA1860- CCGGCGGCGG CGCCATGGCG GGCGCCTCCA CTTCCGCGGG CCGCAAACGC AA - #ATCAGCAT1920- CCTCGGCGAC GGCGTGCACG GCGGGCGTTA TGACACGCGG CCGCCTTAAG GC - #CGAGTCCA1980- CCGTCGCGCC CGAAGAGGAC ACCGACGAGG ATTCCGACAA CGAAATCCAC AA - #TCCGGCCG2040- TGTTCACCTG GCCGCCCTGG CAGGCCGGCA TCCTGGCCCG CAACCTGGTG CC - #CATGGTGG2100- CTACGGTTCA GGGTCAGAAT CTGAAGTACC AGGAGTTCTT CTGGGACGCC AA - #CGACATCT2160- ACCGCATCTT CGCCGAATTG GAAGGCGTAT GGCAGCCCGC TGCGCAACCC AA - #ACGTCGCC2220- GCCACCGGCA AGACGCCTTG CCCGGGCCAT GCATCGCCTC GACGCCCAAA AA - #GCACCGAG2280- GTTGATTTTT ATGGATCCCC CGGGTAGCTA GCTAATTTTT CTTTTACGTA TT - #ATATATGT2340- AATAAACGTT CACGTAAATA CAAAACAGAG AACAAAGTCT AGATTTTTGA CT - #TACATAAA2400- TGTCTGGGAT AGTAAAATCT ATCATATTGA GCGGACCATC TGGTTCAGGA AA - #GACAGCCA2460- TAGCCAAAAG ACTATGGGAA TATATTTGGA TTTGTGGTGT CCCATACCAC TA - #GATTTCCT2520- CGTCCTATGG AACGAGAAGG TGTCGATTAC CATTACGTTA ACAGAGAGGC CA - #TCTGGAAG2580- GGAATAGCCG CCGGAAACTT TCTAGAACAT ACTGAGTTTT TAGGAAATAT TT - #ACGGAACT2640- TCTAAAACTG CTGTGAATAC AGCGGCTATT AATAATCGTA TTTGTGTGAT GG - #ATTTAAAC2700# 2745TT TAAAAATACT TACCTGCAGA AGCTT- (2) INFORMATION FOR SEQ ID NO:63:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 3706 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:- AAGCTTCTAT CAAAAGTCTT AATGAGTTAG GTGTAGATAG TATAGATATT AC - #TACAAAGG 60- TATTCATATT TCCTATCAAT TCTAAAGTAG ATGATATTAA TAACTCAAAG AT - #GATGATAG 120- TAGATAATAG ATACGCTCAT ATAATGACTG CAAATTTGGA CGGTTCACAT TT - #TAATCATC 180- ACGCGTTCAT AAGTTTCAAC TGCATAGATC AAAATCTCAC TAAAAAGATA GC - #CGATGTAT 240- TTGAGAGAGA TTGGACATCT AACTACGCTA AAGAAATTAC AGTTATAAAT AA - #TACATAAT 300- GGATTTTGTT ATCATCAGTT ATATTTAACA TAAGTACAAT AAAAAGTATT AA - #ATAAAAAT 360- ACTTACTTAC GAAAAAATGT CATTATTACA AAAACTATAT TTTACAGAAC AA - #TCTATAGT 420- AGAGTCCTTT AAGAGTTATA ATTTAAAAGA TAACCATAAT GTAATATTTA CC - #ACATCAGA 480- TGTTGATACT GTTGTAGTAA TAAATGAAGA TAATGTACTG TTATCTACAA GA - #TTATTATC 540- ATTTGATAAA ATTCTGTTTT TTAACTCCTT TAATAACGGT TTATCAAAAT AC - #GAAACTAT 600- TAGTGATACA ATATTAGATA TAGATACTCA TAATTATTAT ATACCTAGTT CT - #TCTTCTTT 660- GTTAGATATT CTAAAAAAAA GAGCGTGTGA TTTAGAATTA GAAGATCTAA AT - #TATGCGTT 720- AATAGGAGAC AATAGTAACT TATATTATAA AGATATGACT TACATGAATA AT - #TGGTTATT 780- TACTAAAGGA TTATTAGATT ACAAGTTTGT ATTATTGCGC GATGTAGATA AA - #TGTTACAA 840- ACAGTATAAT AAAAAGAATA CTATAATAGA TATAATACAT CGCGATAACA GA - #CAGTATAA 900- CATATGGGTT AAAAATGTTA TAGAATACTG TTCTCCTGGC TATATATTAT GG - #TTACATGA 960- TCTAAAAGCC GCTGCTGAAG ATGATTGGTT AAGATACGAT AACCGTATAA AC - #GAATTATC1020- TGCGGATAAA TTATACACTT TCGAGTTCAT AGTTATATTA GAAAATAATA TA - #AAACATTT1080- ACGAGTAGGT ACAATAATTG TACATCCAAA CAAGATAATA GCTAATGGTA CA - #TCTAATAA1140- TATACTTACT GATTTTCTAT CTTACGTAGA AGAACTAATA TATCATCATA AT - #TCATCTAT1200- AATATTGGCC GGATATTTTT TAGAATTCTT TGAGACCACT ATTTTATCAG AA - #TTTATTTC1260- TTCATCTTCT GAATGGGTAA TGAATAGTAA CTGTTTAGTA CACCTGAAAA CA - #GGGTATGA1320- AGCTATACTC TTTGATGCTA GTTTATTTTT CCAACTCTCT ACTAAAAGCA AT - #TATGTAAA1380- ATATTGGACA AAGAAAACTT TGCAGTATAA GAACTTTTTT AAAGACGGTA AA - #CAGTTAGC1440- AAAATATATA ATTAAGAAAG ATAGTCAGGT GATAGATAGA GTATGTTATT TA - #CACGCAGC1500- TGTATATAAT CACGTAACTT ACTTAATGGA TACGTTTAAA ATTCCTGGTT TT - #GATTTTAA1560- ATTCTCCGGA ATGATAGATA TACTACTGTT TGGAATATTG CATAAGGATA AT - #GAGAATAT1620- ATTTTATCCG AAACGTGTTT CTGTAACTAA TATAATATCA GAATCTATCT AT - #GCAGATTT1680- TTACTTTATA TCAGATGTTA ATAAATTCAG TAAAAAGATA GAATATAAAA CT - #ATGTTTCC1740- TATACTCGCA GAAAACTACT ATCCAAAAGG AAGGCCCTAT TTTACACATA CA - #TCTAACGA1800- AGATCTTCTG TCTATCTGTT TATGCGAAGT AACAGTTTGT AAAGATATAA AA - #AATCCATT1860- ATTATATTCT AAAAAGGATA TATCAGCAAA ACGATTCATA GGTTTATTTA CA - #TCTGTCGA1920- TATAAATACG GCTGTTGAGT TAAGAGGATA TAAAATAAGA GTAATAGGAT GT - #TTAGAATG1980- GCCTGAAAAG ATAAAAATAT TTAATTCTAA TCCTACATAC ATTAGATTAT TA - #CTAACAGA2040- AAGACGTTTA GATATTCTAC ATTCCTATCT GCTTAAATTT AATATAACAG AG - #GATATAGC2100- TACCAGAGAT GGAGTCAGAA ATAATTTACC TATAATTTCT TTTATCGTCA GT - #TATTGTAG2160- ATCGTATACT TATAAATTAC TAAATTGCCA TATGTACAAT TCGTGTAAGA TA - #ACAAAGTG2220- TAAATATAAT CAGGTAATAT ATAATCCTAT ATAGGAGTAT ATATAATTGA AA - #AAGTAAAA2280- ATAAATCATA TAATAATGAA ACGAAATATC AGTAATAGAC AGGAACTGGC AG - #ATTCTTCT2340- TCTAATGAAG TAAGTACTGC TAAATCTCCA AAATTAGATA AAAATGATAC AG - #CAAATACA2400- GCTTCATTCA ACGAATTACC TTTTAATTTT TTCAGACACA CCTTATTACA AA - #CTAACTAA2460- GTCAGATGAT GAGAAAGTAA ATATAAATTT AACTTATGGG TATAATATAA TA - #AAGATTCA2520- TGATATTAAT AATTTACTTA ACGATGTTAA TAGACTTATT CCATCAACCC CT - #TCAAACCT2580- TTCTGGATAT TATAAAATAC CAGTTAATGA TATTAAAATA GATTGTTTAA GA - #GATGTAAA2640- TAATTATTTG GAGGTAAAGG ATATAAAATT AGTCTATCTT TCACATGGAA AT - #GAATTACC2700- TAATATTAAT AATTATGATA GGAATTTTTT AGGATTTACA GCTGTTATAT GT - #ATCAACAA2760- TACAGGCAGA TCTATGGTTA TGGTAAAACA CTGTAACGGG AAGCAGCATT CT - #ATGGTAAC2820- TGGCCTATGT TTAATAGCCA GATCATTTTA CTCTATAAAC ATTTTACCAC AA - #ATAATAGG2880- ATCCTCTAGA TATTTAATAT TATATCTAAC AACAACAAAA AAATTTAACG AT - #GTATGGCC2940- AGAAGTATTT TCTACTAATA AAGATAAAGA TAGTCTATCT TATCTACAAG AT - #ATGAAAGA3000- AGATAATCAT TTAGTAGTAG CTACTAATAT GGAAAGAAAT GTATACAAAA AC - #GTGGAAGC3060- TTTTATATTA AATAGCATAT TACTAGAAGA TTTAAAATCT AGACTTAGTA TA - #ACAAAACA3120- GTTAAATGCC AATATCGATT CTATATTTCA TCATAACAGT AGTACATTAA TC - #AGTGATAT3180- ACTGAAACGA TCTACAGACT CAACTATGCA AGGAATAAGC AATATGCCAA TT - #ATGTCTAA3240- TATTTTAACT TTAGAACTAA AACGATTCTA CCAATACTAA AAATAGGATA CG - #TGATAGGC3300- TGTTAAAAGC TGCAATAAAT AGTAAGGATG TAGAAGAAAT ACTTTGTTCT AT - #ACCTTCGG3360- AGGAAAGAAC TTTAGAACAA CTTAAGTTTA ATCAAACTTG TATTTATGAA CA - #CTATAAAA3420- AAATTATGGA AGATACAAGT AAAAGAATGG ATGTTGAATG TCGTAGTTTA GA - #ACATAACT3480- ATACGGCTAA CTTATATAAA GTGTACGGAC AAAACGAATA TATGATTACT TA - #TATACTAG3540- CTCTCATAAG TAGGATTAAT AATATTATAG AAACTTTAAA ATATAATCTG GT - #GGGGCTAG3600- ACGAATCTAC AATACGTAAT ATAAATTATA TAATTTCACA AAGAACAAAA AA - #AAATCAGT3660# 3706TAA ACTATATTTT TTACCACTGA CAACAC- (2) INFORMATION FOR SEQ ID NO:64:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 3521 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:- GAGCTCGCGG CCGCCTATCA AAAGTCTTAA TGAGTTAGGT GTAGATAGTA TA - #GATATTAC 60- TACAAAGGTA TTCATATTTC CTATCAATTC TAAAGTAGAT GATATTAATA AC - #TCAAAGAT 120- GATGATAGTA GATAATAGAT ACGCTCATAT AATGACTGCA AATTTGGACG GT - #TCACATTT 180- TAATCATCAC GCGTTCATAA GTTTCAACTG CATAGATCAA AATCTCACTA AA - #AAGATAGC 240- CGATGTATTT GAGAGAGATT GGACATCTAA CTACGCTAAA GAAATTACAG TT - #ATAAATAA 300- TACATAATGG ATTTTGTTAT CATCAGTTAT ATTTAACATA AGTACAATAA AA - #AGTATTAA 360- ATAAAAATAC TTACTTACGA AAAAATGACT AATTAGCTAT AAAAACCCAA CA - #AAAACTAA 420- TCAGCTATCG GGGTTAATTA ATTAGTTATT AGACAAGGTG AAAACGAAAC TA - #TTTGTAGC 480- TTAATTAATT AGAGCTTCTT TATTCTATAC TTAAAAAGTG AAAATAAATA CA - #AAGGTTCT 540- TGAGGGTTGT GTTAAATTGA AAGCGAGAAA TAATCATAAA TTATTTCATT AT - #CGCGATAT 600- CCGTTAAGTT TGTATCGTAA TGGAGTCGCG CGGTCGCCGT TGTCCCGAAA TG - #ATATCCGT 660- ACTGGGTCCC ATTTCGGGGC ACGTGCTGAA AGCCGTGTTT AGTCGCGGCG AC - #ACGCCGGT 720- GCTGCCGCAC GAGACGCGAC TCCTGCAGAC GGGTATCCAC GTGCGCGTGA GC - #CAGCCCTC 780- GCTGATCCTG GTGTCGCAGT ACACGCCCGA CTCGACGCCA TGCCACCGCG GC - #GACAATCA 840- GCTGCAGGTG CAGCACACGT ACTTTACGGG CAGCGAGGTG GAGAACGTGT CG - #GTCAACGT 900- GCACAACCCC ACGGGCCGGA GCATCTGCCC CAGCCAAGAG CCCATGTCGA TC - #TATGTGTA 960- CGCGCTGCCG CTCAAGATGC TGAACATCCC CAGCATCAAC GTGCACCACT AC - #CCGTCGGC1020- GGCCGAGCGC AAACACCGAC ACCTGCCCGT AGCTGACGCT GTGATTCACG CG - #TCGGGCAA1080- GCAGATGTGG CAGGCGCGTC TCACGGTCTC GGGACTGGCC TGGACGCGTC AG - #CAGAACCA1140- GTGGAAAGAG CCCGACGTCT ACTACACGTC AGCGTTCGTG TTTCCCACCA AG - #GACGTGGC1200- ACTGCGGCAC GTGGTGTGCG CGCACGAGCT GGTTTGCTCC ATGGAGAACA CG - #CGCGCAAC1260- CAAGATGCAG GTGATAGGTG ACCAGTACGT CAAGGTGTAC CTGGAGTCCT TC - #TGCGAGGA1320- CGTGCCCTCC GGCAAGCTCT TTATGCACGT CACGCTGGGC TCTGACGTGG AA - #GAGGACCT1380- GACGATGACC CGCAACCCGC AACCCTTCAT GCGCCCCCAC GAGCGCAACG GC - #TTTACGGT1440- GTTGTGTCCC AAAAATATGA TAATCAAACC GGGCAAGATC TCGCACATCA TG - #CTGGATGT1500- GGCTTTTACC TCACACGAGC ATTTTGGGCT GCTGTGTCCC AAGAGCATCC CG - #GGCCTGAG1560- CATCTCAGGT AACCTATTGA TGAACGGGCA GCAGATCTTC CTGGAGGTGC AA - #GCGATACG1620- CGAGACCGTG GAACTGCGTC AGTACGATCC CGTGGCTGCG CTCTTCTTTT TC - #GATATCGA1680- CTTGCTGCTG CAGCGCGGGC CTCAGTACAG CGAACACCCC ACCTTCACCA GC - #CAGTATCG1740- CATCCAGGGC AAGCTTGAGT ACCGACACAC CTGGGACCGG CACGACGAGG GT - #GCCGCCCA1800- GGGCGACGAC GACGTCTGGA CCAGCGGATC GGACTCCGAC GAGGAACTCG TA - #ACCACCGA1860- GCGCAAGACG CCCCGCGTTA CCGGCGGCGG CGCCATGGCG GGCGCCTCCA CT - #TCCGCGGG1920- CCGCAAACGC AAATCAGCAT CCTCGGCGAC GGCGTGCACG GCGGGCGTTA TG - #ACACGCGG1980- CCGCCTTAAG GCCGAGTCCA CCGTCGCGCC CGAAGAGGAC ACCGACGAGG AT - #TCCGACAA2040- CGAAATCCAC AATCCGGCCG TGTTCACCTG GCCGCCCTGG CAGGCCGGCA TC - #CTGGCCCG2100- CAACCTGGTG CCCATGGTGG CTACGGTTCA GGGTCAGAAT CTGAAGTACC AG - #GAGTTCTT2160- CTGGGACGCC AACGACATCT ACCGCATCTT CGCCGAATTG GAAGGCGTAT GG - #CAGCCCGC2220- TGCGCAACCC AAACGTCGCC GCCACCGGCA AGACGCCTTG CCCGGGCCAT GC - #ATCGCCTC2280- GACGCCCAAA AAGCACCGAG GTTGATTTTT ATGGATCCGG TACCCTCGAG GA - #ATTCTTTT2340- TATTGATTAA CTAGTCAAAT GAGTATATAT AATTGAAAAA GTAAAATATA AA - #TCATATAA2400- TAATGAAACG AAATATCAGT AATAGACAGG AACTGGCAGA TTCTTCTTCT AA - #TGAAGTAA2460- GTACTGCTAA ATCTCCAAAA TTAGATAAAA ATGATACAGC AAATACAGCT TC - #ATTCAACG2520- AATTACCTTT TAATTTTTTC AGACACACCT TATTACAAAC TAACTAAGTC AG - #ATGATGAG2580- AAAGTAAATA TAAATTTAAC TTATGGGTAT AATATAATAA AGATTCATGA TA - #TTAATAAT2640- TTACTTAACG ATGTTAATAG ACTTATTCCA TCAACCCCTT CAAACCTTTC TG - #GATATTAT2700- AAAATACCAG TTAATGATAT TAAAATAGAT TGTTTAAGAG ATGTAAATAA TT - #ATTTGGAG2760- GTAAAGGATA TAAAATTAGT CTATCTTTCA CATGGAAATG AATTACCTAA TA - #TTAATAAT2820- TATGATAGGA ATTTTTTAGG ATTTACAGCT GTTATATGTA TCAACAATAC AG - #GCAGATCT2880- ATGGTTATGG TAAAACACTG TAACGGGAAG CAGCATTCTA TGGTAACTGG CC - #TATGTTTA2940- ATAGCCAGAT CATTTTACTC TATAAACATT TTACCACAAA TAATAGGATC CT - #CTAGATAT3000- TTAATATTAT ATCTAACAAC AACAAAAAAA TTTAACGATG TATGGCCAGA AG - #TATTTTCT3060- ACTAATAAAG ATAAAGATAG TCTATCTTAT CTACAAGATA TGAAAGAAGA TA - #ATCATTTA3120- GTAGTAGCTA CTAATATGGA AAGAAATGTA TACAAAAACG TGGAAGCTTT TA - #TATTAAAT3180- AGCATATTAC TAGAAGATTT AAAATCTAGA CTTAGTATAA CAAAACAGTT AA - #ATGCCAAT3240- ATCGATTCTA TATTTCATCA TAACAGTAGT ACATTAATCA GTGATATACT GA - #AACGATCT3300- ACAGACTCAA CTATGCAAGG AATAAGCAAT ATGCCAATTA TGTCTAATAT TT - #TAACTTTA3360- GAACTAAAAC GTTCTACCAA TACTAAAAAT AGGATACGTG ATAGGCTGTT AA - #AAGCTGCA3420- ATAAATAGTA AGGATGTAGA AGAAATACTT TGTTCTATAC CTTCGGAGGA AA - #GAACTTTA3480# 3521 ATCA AACTTGTATT TATGAAGGTA C- (2) INFORMATION FOR SEQ ID NO:65:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 2160 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:- AAGACTAATT TGTAAACCAT CTTACTCAAA ATATGTAACA ATAGTACGAT GC - #AATGAGTA 60- AGACAATAGG AAATCTATCT TATATACACA TAATTATTCT ATCAATTTTA CC - #AATTAGTT 120- AGTGTAATGT TATAAAAACT AATTAATCAC TCGAGCCCCC TCGAAGCTTC TT - #TATTCTAT 180- ACTTAAAAAG TGAAAATAAA TACAAAGGTT CTTGAGGGTT GTGTTAAATT GA - #AAGCGAGA 240- AATAATCATA AATTATTTCA TTATCGCGAT ATCCGTTAAG TTTGTATCGT AA - #TGGAGTCG 300- CGCGGTCGCC GTTGTCCCGA AATGATATCC GTACTGGGTC CCATTTCGGG GC - #ACGTGCTG 360- AAAGCCGTGT TTAGTCGCGG CGACACGCCG GTGCTGCCGC ACGAGACGCG AC - #TCCTGCAG 420- ACGGGTATCC ACGTGCGCGT GAGCCAGCCC TCGCTGATCC TGGTGTCGCA GT - #ACACGCCC 480- GACTCGACGC CATGCCACCG CGGCGACAAT CAGCTGCAGG TGCAGCACAC GT - #ACTTTACG 540- GGCAGCGAGG TGGAGAACGT GTCGGTCAAC GTGCACAACC CCACGGGCCG GA - #GCATCTGC 600- CCCAGCCAAG AGCCCATGTC GATCTATGTG TACGCGCTGC CGCTCAAGAT GC - #TGAACATC 660- CCCAGCATCA ACGTGCACCA CTACCCGTCG GCGGCCGAGC GCAAACACCG AC - #ACCTGCCC 720- GTAGCTGACG CTGTGATTCA CGCGTCGGGC AAGCAGATGT GGCAGGCGCG TC - #TCACGGTC 780- TCGGGACTGG CCTGGACGCG TCAGCAGAAC CAGTGGAAAG AGCCCGACGT CT - #ACTACACG 840- TCAGCGTTCG TGTTTCCCAC CAAGGACGTG GCACTGCGGC ACGTGGTGTG CG - #CGCACGAG 900- CTGGTTTGCT CCATGGAGAA CACGCGCGCA ACCAAGATGC AGGTGATAGG TG - #ACCAGTAC 960- GTCAAGGTGT ACCTGGAGTC CTTCTGCGAG GACGTGCCCT CCGGCAAGCT CT - #TTATGCAC1020- GTCACGCTGG GCTCTGACGT GGAAGAGGAC CTGACGATGA CCCGCAACCC GC - #AACCCTTC1080- ATGCGCCCCC ACGAGCGCAA CGGCTTTACG GTGTTGTGTC CCAAAAATAT GA - #TAATCAAA1140- CCGGGCAAGA TCTCGCACAT CATGCTGGAT GTGGCTTTTA CCTCACACGA GC - #ATTTTGGG1200- CTGCTGTGTC CCAAGAGCAT CCCGGGCCTG AGCATCTCAG GTAACCTATT GA - #TGAACGGG1260- CAGCAGATCT TCCTGGAGGT GCAAGCGATA CGCGAGACCG TGGAACTGCG TC - #AGTACGAT1320- CCCGTGGCTG CGCTCTTCTT TTTCGATATC GACTTGCTGC TGCAGCGCGG GC - #CTCAGTAC1380- AGCGAACACC CCACCTTCAC CAGCCAGTAT CGCATCCAGG GCAAGCTTGA GT - #ACCGACAC1440- ACCTGGGACC GGCACGACGA GGGTGCCGCC CAGGGCGACG ACGACGTCTG GA - #CCAGCGGA1500- TCGGACTCCG ACGAGGAACT CGTAACCACC GAGCGCAAGA CGCCCCGCGT TA - #CCGGCGGC1560- GGCGCCATGG CGGGCGCCTC CACTTCCGCG GGCCGCAAAC GCAAATCAGC AT - #CCTCGGCG1620- ACGGCGTGCA CGGCGGGCGT TATGACACGC GGCCGCCTTA AGGCCGAGTC CA - #CCGTCGCG1680- CCCGAAGAGG ACACCGACGA GGATTCCGAC AACGAAATCC ACAATCCGGC CG - #TGTTCACC1740- TGGCCGCCCT GGCAGGCCGG CATCCTGGCC CGCAACCTGG TGCCCATGGT GG - #CTACGGTT1800- CAGGGTCAGA ATCTGAAGTA CCAGGAGTTC TTCTGGGACG CCAACGACAT CT - #ACCGCATC1860- TTCGCCGAAT TGGAAGGCGT ATGGCAGCCC GCTGCGCAAC CCAAACGTCG CC - #GCCACCGG1920- CAAGACGCCT TGCCCGGGCC ATGCATCGCC TCGACGCCCA AAAAGCACCG AG - #GTTGATTT1980- TTATGGATCC TCGCGACTGC AGGGTACCTG AGTAGCTAAT TTTTAAACAA AA - #ATGTGGGA2040- GAATCTAATT AGTTTTTCTT TACACAATTG ACGTACATGA GTCTGAGTTC CT - #TGTTTTTG2100- CTAATTATTT CATCCAATTT ATTATTCTTG ACGATATCGA GATCTTTTGT AT - #AGGAGTCA2160- (2) INFORMATION FOR SEQ ID NO:66:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 3141 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:- ATGAGTTTGC AGTTTATCGG TCTACAGCGG CGCGATGTGG TGGCCCTGGT CA - #ACTTTCTG 60- CGCCATCTCA CGCAAAAGCC CGACGTGGAT CTCGAGGCAC ACCCCAAGAT CC - #TGAAAAAA 120- TGTGGCGAAA AACGCCTGCA CCGGCGTACG GTGCTGTTCA ACGAGCTCAT GC - #TTTGGTTG 180- GGATACTACC GCGAGCTGCG TTTCCACAAC CCCGACCTCT CCTCGGTTCT CG - #AGGAGTTC 240- GAGGTGCGTT GCGCGGCCGT GGCGCGTCGC GGCTACACTT ACCCGTTCGG TG - #ATCGTGGT 300- AAGGCGCGTG ACCACCTGGC TGTGCTAGAC CGTACCGAAT TCGATACGGA CG - #TACGCCAC 360- GATGCTGAGA TTGTGGAGCG CGCGCTCGTA AGCGCGGTCA TTCTGGCCAA GA - #TGTCGGTG 420- CGCGAGACGC TGGTCACAGC CATCGGCCAG ACGGAACCCA TCGCTTTTGT GC - #ACCTCAAG 480- GATACGGAGG TGCAGCGCAT TGAAGAAAAC CTGGAGGGTG TGCGCCGTAA CA - #TGTTCTGC 540- GTGAAACCGC TCGACCTTAA CCTGGACCGG CACGCCAACA CGGCGCTGGT CA - #ACGCCGTC 600- AACAAGCTCG TGTACACGGG CCGTCTCATC ATGAACGTGC GCAGGTCTTG GG - #AGGAGCTG 660- GAGCGCAAAT GTCTGGCGCG CATTCAGGAG CGCTGCAAGC TGCTGGTCAA GG - #AGCTGCGC 720- ATGTGCCTTT CCTTTGATTC CAACTACTGT CGCAATATCC TCAAACACGC CG - #TGGAAAAC 780- GGTGACTCGG CCGACACGCT GCTGGAGCTG CTCATCGAGG ACTTTGACAT CT - #ACGTGGAC 840- AGCTTCCCGC AGTCGGCGCA CACCTTTTTG GGCGCGCGCC CGCCGTCGTT GG - #AGTTTGAC 900- GATGACGCCA ATCTCCTCTC GCTCGGCGGC GGTTCAGCCT TCTCGTCGGT AC - #CCAAGAAA 960- CATGTCCCCA CGCAGCCGCT GGACGGCTGG AGCTGGATCG CCAGTCCCTG GA - #AGGGACAC1020- AAACCGTTCC GCTTCGAGGC CCATGGTTCT CTGGCACCGG CCGCCGACGC CC - #ACGCCGCC1080- CGTTCGGCGC GCGTCGGCTA TTACGACGAA GAGGAAAAGC GTCGCGAGCG GC - #AGAAACGG1140- GTGGACGACG AGGTGGTGCA GCGTGAGAAA CAGCAGCTGA AGGCTTGGGA GG - #AGAGGCAG1200- CAGAACCTGC AGCAACGTCA GCAGCAACCG CCGCCCCCGA CACGTAAACC GG - #GCGCCTCC1260- CGGAGGCTCT TTGGCTCCAG TGCCGATGAG GACGACGACG ATGATGATGA CG - #AGAAAAAC1320- ATCTTTACGC CCATCAAGAA ACCGGGAACT AGCGGCAAGG GCGCCGCTAG TG - #GCAACGGT1380- GTTTCCAGCA TTTTCAGCGG CATGTTATCC TCGGGCAGTC AGAAACCGAC CA - #GCGGTCCC1440- TTGAACATCC CGCAGCAACA ACAGCGTCAC GCGGCTTTCA GTCTCGTCTC CC - #CGCAGGTA1500- ACCAAGGCCA GCCCGGGAAG GGTCCGTCGG GACAGCGCGT GGGACGTGAG GC - #CGCTCACG1560- GAGACAAGAG GGGATCTTTT CTCGGGCGAC GAGGATTCCG ACAGCTCGGA TG - #GCTATCCC1620- CCCAACCGTC AAGATCCGCG TTTCACCGAC ACGCTGGTGG ACATCACGGA TA - #CCGAGACG1680- AGCGCCAAAC CGCCCGTCAC CACCGCGTAC AAGTTCGAGC AACCGACGTT GA - #CGTTCGGC1740- GCCGGAGTTA ACGTCCCTGC TGGCGCCGGC GCTGCCATCC TCACGCCGAC GC - #CTGTCAAT1800- CCTTCCACGG CCCCCGCTCC GGCCCCGACA CCTACCTTCG CGGGTACCCA AA - #CCCCGGTC1860- AACGGTAACT CGCCCTGGGC TCCGACGGCG CCGTTGCCCG GGGATATGAA CC - #CCGCCAAC1920- TGGCCGCGCG AACGCGCGTG GGCCCTCAAG AATCCTCACC TGGCTTACAA TC - #CCTTCAGG1980- ATGCCTACGA CTTCCACGAC TTCTCAAAAC AACGTGTCCA CCACCCCTCG GA - #GGCCGTCG2040- ACTCCACGCG CCGCGGTGAC ACAAACAGCG TCTCAGAACG CCGCTGATGA GG - #TTTGGGCT2100- TTAAGGGACC AAACTGCAGA GTCACCGGTC GAAGACAGCG AGGAGGAAGA CG - #ACGACTCC2160- TCGGACACCG GCTCCGTCGT CAGCCTGGGA CACACAACAC CGTCGTCCGA TT - #ACAACGAC2220- GTCATTTCGC CTCCCAGTCA GACGCCCGAG CAGTCGACGC CGTCCAGAAT AC - #GTAAAGCT2280- AAGTTATCGT CTCCAATGAC GACGACATCC ACGAGCCAGA AACCGGTGCT GG - #GCAAGCGA2340- GTCGCGACGC CGCACGCGTC CGCCCGAGCG CAGACGGTGA CGTCGACACC GG - #TTCAGGGA2400- AGGGTAGAGA AACAGGTATC GGGCACGCCG TCGACGGTAC CCGCCACGCT GT - #TGCAACCT2460- CAACCGGCTT CGTCTAAAAC AACGTCATCA AGGAACGTGA CTTCTGGCGC GA - #GAACCTCT2520- TCCGCTTCGG CTCGACAGCC GTCAGCCTCG GCGTCCGTTT TGTCGCCCAC GG - #AGGATGAT2580- GTCGTGTCCC CCGTCACGTC GCCGCTGTCC ATGCTTTCGT CAGCCTCTCC GT - #CCCCGGCC2640- AAGAGTGCCC CTCCGTCTCC GGTGAAAGGT CGGGGCAGCC GCGTCGGTGT TC - #CTTCTTTG2700- AAACCTACTT TGGGCGGCAA GGCGGTGGTA GGTCGACCGC CCTCGGTCCC CG - #TGAGCGGT2760- AGCGCGCCGG GTCGCCTGTC CGGCACCAGC CGGGCCGCCT CGACCACGCC GA - #CGTATCCC2820- GCGGTAACCA CCGTTTACCC ACCGTCGTCT ACGGCCAAAA GCAGCGTATC GA - #ATGCGCCG2880- CCTGTGGCCT CCCCCTCCAT CCTGAAACCG GGGGCGAGCG CGGCTTTGCA AT - #CACGCCGC2940- TCGACGGGGA CCGCCGCCGT AGGTTCCCCC GTCAAGAGCA CGACGGGCAT GA - #AAACGGTG3000- GCTTTCGACC TATCGTCGCC CCAGAAGAGC GGTACGGGGC CGCAACCGGG TT - #CTGCCGGC3060- ATGGGGGGCG CCAAAACGCC GTCGGACGCC GTGCAGAACA TCCTCCAAAA GA - #TCGAGAAG3120# 3141TA G- (2) INFORMATION FOR SEQ ID NO:67:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 4075 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:- AAGCTTGCGG CCGCTCATTA GACAAGCGAA TGAGGGACGA AAACGTGGAG GA - #GGTATTAA 60- GTTTGGAGAA ATGGAGAGAG ACTGTTTAAT AGCGCATGGC GCAGCCAATA CT - #ATTACAGA 120- AGTTTTGAAA GATTCGGAAG AAGATTATCA AGATGTGTAT GTTTGTGAAA AT - #TGTGGAGA 180- CATAGCAGCA CAAATCAAGG GTATTAATAC ATGTCTTAGA TGTTCAAAAC TT - #AATCTCTC 240- TCCTCTCTTA ACAAAAATTG ATACCACGCA CGTATCTAAA GTATTTCTTA CT - #CAAATGAA 300- CGCCAGAGGC GTAAAAGTCA AATTAGATTT CGAACGAAGG CCTCCTTCGT TT - #TATAAACC 360- ATTAGATAAA GTTGATCTCA AGCCGTCTTT TCTGGTGTAA TAAAAATTAA TT - #AATTACTC 420- GAGCCCCTAG CAATAAAAAC TATTCCTCCG TGTTCTTAAT CTTCTCGATC TT - #TTGGAGGA 480- TGTTCTGCAC GGCGTCCGAC GGCGTTTTGG CGCCCCCCAT GCCGGCAGAA CC - #CGGTTGCG 540- GCCCCGTACC GCTCTTCTGG GGCGACGATA GGTCGAAAGC CACCGTTTTC AT - #GCCCGTCG 600- TGCTCTTGAC GGGGGAACCT ACGGCGGCGG TCCCCGTCGA GCGGCGTGAT TG - #CAAAGCCG 660- CGCTCGCCCC CGGTTTCAGG ATGGAGGGGG AGGCCACAGG CGGCGCATTC GA - #TACGCTGC 720- TTTTGGCCGT AGACGACGGT GGGTAAACGG TGGTTACCGC GGGATACGTC GG - #CGTGGTCG 780- AGGCGGCCCG GCTGGTGCCG GACAGGCGAC CCGGCGCGCT ACCGCTCACG GG - #TACCGAGG 840- GCGGTCGACC TACCACCGCC TTGCCGCCCA AAGTAGGTTT CAAAGAAGGA AC - #ACCGACGC 900- GGCTGCCCCG ACCTTTCACC GGAGACGGAG GGGCACTCTT GGCCGGGGAC GG - #AGAGGCTG 960- ACGAAAGCAT GGACAGCGGC GACGTGACGG GGGACACGAC ATCATCCTCC GT - #GGGCGACA1020- AAACGGACGC CGAGGCTGAC GGCTGTCGAG CCGAAGCGGA AGAGGTTCTC GC - #GCCAGAAG1080- TCACGTTCCT TGATGACGTT GTTTTAGACG AAGCCGGTTG AGGTTGCAAC AG - #CGTGGCGG1140- GTACCGTCGA CGGCGTGCCC GATACCTGTT TCTCTACCCT TCCCTGAACC GG - #TGTCGACG1200- TCACCGTCTG CGCTCGGGCG GACGCGTGCG GCGTCGCGAC TCGCTTGCCC AG - #CACCGGTT1260- TCTGGCTCGT GGATGTCGTC GTCATTGGAG ACGATAACTT AGCTTTACGT AT - #TCTGGACG1320- GCGTCGACTG CTCGGGCGTC TGACTGGGAG GCGAAATGAC GTCGTTGTAA TC - #GGACGACG1380- GTGTTGTGTG TCCCAGGCTG ACGACGGAGC CGGTGTCCGA GGAGTCGTCG TC - #TTCCTCCT1440- CGCTGTCTTC GACCGGTGAC TCTGCAGTTT GGTCCCTTAA AGCCCAAACC TC - #ATCAGCGG1500- CGTTCTGAGA CGCTGTTTGT GTCACCGCGG CGCGTGGAGT CGACGGCCTC CG - #AGGGGTGG1560- TGGACACGTT GTTTTGAGAA GTCGTGGAAG TCGTAGGCAT CCTGAAGGGA TT - #GTAAGCCA1620- GGTGAGGATT CTTGAGGGCC CACGCGCGTT CGCGCGGCCA GTTGGCGGGG TT - #CATATCCC1680- CGGGCAACGG CGCCGTCGGA GCCCAGGGCG AGTTACCGTT GACCGGGGTT TG - #GGTACCCG1740- CGAAGGTAGG TGTCGGGGCC GGAGCGGGGG CCGTGGAAGG ATTGACAGGC GT - #CGGCGTGA1800- GGATGGCAGC GCCGGCGCCA GCAGGGACGT TAACTCCGGC GCCGAACGTC AA - #CGTCGGTT1860- GCTCGAACTT GTACGCGGTG GTGACGGGCG GTTTGGCGCT CGTCTCGGTA TC - #CGTGATGT1920- CCACCAGCGT GTCGGTGAAA CGCGGATCTT GACGGTTGGG GGGATAGCCA TC - #CGAGCTGT1980- CGGAATCCTC GTCGCCCGAG AAAAGATCCC CTCTTGTCTC CGTGAGCGGC CT - #CACGTCCC2040- ACGCGCTGTC CCGACGGACC CTTCCCGGGC TGGCCTTGGT TACCTGCGGG GA - #GACGAGAC2100- TGAAAGCCGC GTGACGCTGT TGTTGCTGCG GGATGTTCAA GGGACCGCTG GT - #CGGTTTCT2160- GACTGCCCGA GGATAACATG CCGCTGAAAA TGCTGGAAAC ACCGTTGCCA CT - #AGCGGCGC2220- CCTTGCCGCT AGTTCCCGGT TTCTTGATGG GCGTAAAGAT GTTTTTCTCG TC - #ATCATCAT2280- CGTCGTCGTC CTCATCGGCA CTGGAGCCAA AGAGCCTCCG GGAGGCGCCC GG - #TTTACGTG2340- TCGGGGGCGG CGGTTGCTGC TGACGTTGCT GCAGGTTCTG CTGCCTCTCC TC - #CCAAGCCT2400- TCAGCTGCTG TTTCTCACGC TGCACCACCT CGTCGTCCAC CCGTTTCTGC CG - #CTCGCGAC2460- GCTTTTCCTC TTCGTCGTAA TAGCCGACGC GCGCCGAACG GGCGGCGTGG GC - #GTCGGCGG2520- CCGGTGCCAG AGAACCATGG GCCTCGAAGC GGAACGGTTT GTGTCCCTTC CA - #GGGACTGG2580- CGATCCAGCT CCAGCCGTCC AGCGGCTGCG TGGGGACATG TTTCTTGGGT AC - #CGACGAGA2640- AGGCTGAACC GCCGCCGAGC GAGAGGAGAT TGGCGTCATC GTCAAACTCC AA - #CGACGGCG2700- GGCGCGCGCC CAAAAAGGTG TGCGCCGACT GCGGGAAGCT GTCCACGTAG AT - #GTCAAAGT2760- CCTCGATGAG CAGCTCCAGC AGCGTGTCGG CCGAGTCACC GTTTTCCACG GC - #GTGTTTGA2820- GGATATTGCG ACAGTAGTTG GAATCAAAGG AAAGGCACAT GCGCAGCTCC TT - #GACCAGCA2880- GCTTGCAGCG CTCCTGAATG CGCGCCAGAC ATTTGCGCTC CAGCTCCTCC CA - #AGACCTGC2940- GCACGTTCAT GATGAGACGG CCCGTGTACA CGAGCTTGTT GACGGCGTTG AC - #CAGCGCCG3000- TGTTGGCGTG CCGGTCCAGG TTAAGGTCGA GCGGTTTCAC GCAGAACATG TT - #ACGGCGCA3060- CACCCTCCAG GTTTTCTTCA ATGCGCTGCA CCTCCGTATC CTTGAGGTGC AC - #AAAAGCGA3120- GTGGGTTCCG TCTGGCCGAT GGCTGTGACC AGCGTCTCGC GCACCGACAT CT - #TGGCCAGA3180- ATGACCGCGC TTACGAGCGC GCGCTCCACA ATCTCAGCAT CGTGGCGTAC GT - #CCGTATCG3240- AATTCGGTAC GGTCTAGCAC AGCCAGGTGG TCACGCGCCT TACCACGATC AC - #CGAACGGG3300- TAAGTGTAGC CGCGACGCGC CACGGCCGCG CAACGCACCT CGAACTCCTC GA - #GAACCGAG3360- GAGAGGTCGG GGTTGTGGAA ACGCAGCTCG CGGTAGTATC CCAACCAAAG CA - #TGAGCTCG3420- TTGAACAGCA CCGTAGCCGG TGCAGGCGTT TTTCGCCACA TTTTTTCAGG AT - #CTTGGGGT3480- GTGCCTCGAG ATCCACGTCG GGCTTTTGCG TGAGATGGCG CAGAAAGTTG AC - #CAGGGCCA3540- CCACATCGCG CCGCTGTAGA CCGATAAACT GCAAACTCAT TTTATATTGT AA - #TTATATAT3600- TTTCAATTTT GAAATCCCAA AATATTATCA TATCTTCCCA ATAAAGCTAG GG - #GAGATCTA3660- ATTTAATTTA ATTTATATAA CTTATTTTTT GAATATACTT TTAATTAACA AA - #AGAGTTAA3720- GTTACTCATA TGGACGCCGT CCAGTCTGAA CATCAATCTT TTTAGCCAGA GA - #TATCATAG3780- CCGCTCTTAG AGTTTCAGCG TGATTTTCCA ACCTAAATAG AACTTCATCG TT - #GCGTTTAC3840- AACACTTTTC TATTTGTTCA AACTTTGTTG TTACATTAGT AATCTTTTTT TC - #CAAATTAG3900- TTAGCCGTTG TTTGAGAGTT TCCTCATTGT CGTCTTCATC GGCTTTAACA AT - #TGCTTCGC3960- GTTTAGCCTC CTGGCTGTTC TTATCAGCCT TTGTAGAAAA AAATTCAGTT GC - #TGGAATTG4020- CAAGATCGTC ATCTCCGGGG AAAAGAGTTC CGTCCATTTA AAGCCGCGGG AA - #TTC4075- (2) INFORMATION FOR SEQ ID NO:68:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 4909 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:- GAGCTCGCGG CCGCCTATCA AAAGTCTTAA TGAGTTAGGT GTAGATAGTA TA - #GATATTAC 60- TACAAAGGTA TTCATATTTC CTATCAATTC TAAAGTAGAT GATATTAATA AC - #TCAAAGAT 120- GATGATAGTA GATAATAGAT ACGCTCATAT AATGACTGCA AATTTGGACG GT - #TCACATTT 180- TAATCATCAC GCGTTCATAA GTTTCAACTG CATAGATCAA AATCTCACTA AA - #AAGATAGC 240- CGATGTATTT GAGAGAGATT GGACATCTAA CTACGCTAAA GAAATTACAG TT - #ATAAATAA 300- TACATAATGG ATTTTGTTAT CATCAGTTAT ATTTAACATA AGTACAATAA AA - #AGTATTAA 360- ATAAAAATAC TTACTTACGA AAAAATGACT AATTAGCTAT AAAAACCCGG GG - #GATCCTTA 420- ATTAATTAGT TATTAGACAA GGTGAAAACG AAACTATTTG TAGCTTAATT AA - #TTAGCTGC 480- AGGGCTGCAG GAATTCTAGC AATAAAAACT ATTCCTCCGT GTTCTTAATC TT - #CTCGATCT 540- TTTGGAGGAT GTTCTGCACG GCGTCCGACG GCGTTTTGGC GCCCCCCATG CC - #GGCAGAAC 600- CCGGTTGCGG CCCCGTACCG CTCTTCTGGG GCGACGATAG GTCGAAAGCC AC - #CGTTTTCA 660- TGCCCGTCGT GCTCTTGACG GGGGAACCTA CGGCGGCGGT CCCCGTCGAG CG - #GCGTGATT 720- GCAAAGCCGC GCTCGCCCCC GGTTTCAGGA TGGAGGGGGA GGCCACAGGC GG - #CGCATTCG 780- ATACGCTGCT TTTGGCCGTA GACGACGGTG GGTAAACGGT GGTTACCGCG GG - #ATACGTCG 840- GCGTGGTCGA GGCGGCCCGG CTGGTGCCGG ACAGGCGACC CGGCGCGCTA CC - #GCTCACGG 900- GTACCGAGGG CGGTCGACCT ACCACCGCCT TGCCGCCCAA AGTAGGTTTC AA - #AGAAGGAA 960- CACCGACGCG GCTGCCCCGA CCTTTCACCG GAGACGGAGG GGCACTCTTG GC - #CGGGGACG1020- GAGAGGCTGA CGAAAGCATG GACAGCGGCG ACGTGACGGG GGACACGACA TC - #ATCCTCCG1080- TGGGCGACAA AACGGACGCC GAGGCTGACG GCTGTCGAGC CGAAGCGGAA GA - #GGTTCTCG1140- CGCCAGAAGT CACGTTCCTT GATGACGTTG TTTTAGACGA AGCCGGTTGA GG - #TTGCAACA1200- GCGTGGCGGG TACCGTCGAC GGCGTGCCCG ATACCTGTTT CTCTACCCTT CC - #CTGAACCG1260- GTGTCGACGT CACCGTCTGC GCTCGGGCGG ACGCGTGCGG CGTCGCGACT CG - #CTTGCCCA1320- GCACCGGTTT CTGGCTCGTG GATGTCGTCG TCATTGGAGA CGATAACTTA GC - #TTTACGTA1380- TTCTGGACGG CGTCGACTGC TCGGGCGTCT GACTGGGAGG CGAAATGACG TC - #GTTGTAAT1440- CGGACGACGG TGTTGTGTGT CCCAGGCTGA CGACGGAGCC GGTGTCCGAG GA - #GTCGTCGT1500- CTTCCTCCTC GCTGTCTTCG ACCGGTGACT CTGCAGTTTG GTCCCTTAAA GC - #CCAAACCT1560- CATCAGCGGC GTTCTGAGAC GCTGTTTGTG TCACCGCGGC GCGTGGAGTC GA - #CGGCCTCC1620- GAGGGGTGGT GGACACGTTG TTTTGAGAAG TCGTGGAAGT CGTAGGCATC CT - #GAAGGGAT1680- TGTAAGCCAG GTGAGGATTC TTGAGGGCCC ACGCGCGTTC GCGCGGCCAG TT - #GGCGGGGT1740- TCATATCCCC GGGCAACGGC GCCGTCGGAG CCCAGGGCGA GTTACCGTTG AC - #CGGGGTTT1800- GGGTACCCGC GAAGGTAGGT GTCGGGGCCG GAGCGGGGGC CGTGGAAGGA TT - #GACAGGCG1860- TCGGCGTGAG GATGGCAGCG CCGGCGCCAG CAGGGACGTT AACTCCGGCG CC - #GAACGTCA1920- ACGTCGGTTG CTCGAACTTG TACGCGGTGG TGACGGGCGG TTTGGCGCTC GT - #CTCGGTAT1980- CCGTGATGTC CACCAGCGTG TCGGTGAAAC GCGGATCTTG ACGGTTGGGG GG - #ATAGCCAT2040- CCGAGCTGTC GGAATCCTCG TCGCCCGAGA AAAGATCCCC TCTTGTCTCC GT - #GAGCGGCC2100- TCACGTCCCA CGCGCTGTCC CGACGGACCC TTCCCGGGCT GGCCTTGGTT AC - #CTGCGGGG2160- AGACGAGACT GAAAGCCGCG TGACGCTGTT GTTGCTGCGG GATGTTCAAG GG - #ACCGCTGG2220- TCGGTTTCTG ACTGCCCGAG GATAACATGC CGCTGAAAAT GCTGGAAACA CC - #GTTGCCAC2280- TAGCGGCGCC CTTGCCGCTA GTTCCCGGTT TCTTGATGGG CGTAAAGATG TT - #TTTCTCGT2340- CATCATCATC GTCGTCGTCC TCATCGGCAC TGGAGCCAAA GAGCCTCCGG GA - #GGCGCCCG2400- GTTTACGTGT CGGGGGCGGC GGTTGCTGCT GACGTTGCTG CAGGTTCTGC TG - #CCTCTCCT2460- CCCAAGCCTT CAGCTGCTGT TTCTCACGCT GCACCACCTC GTCGTCCACC CG - #TTTCTGCC2520- GCTCGCGACG CTTTTCCTCT TCGTCGTAAT AGCCGACGCG CGCCGAACGG GC - #GGCGTGGG2580- CGTCGGCGGC CGGTGCCAGA GAACCATGGG CCTCGAAGCG GAACGGTTTG TG - #TCCCTTCC2640- AGGGACTGGC GATCCAGCTC CAGCCGTCCA GCGGCTGCGT GGGGACATGT TT - #CTTGGGTA2700- CCGACGAGAA GGCTGAACCG CCGCCGAGCG AGAGGAGATT GGCGTCATCG TC - #AAACTCCA2760- ACGACGGCGG GCGCGCGCCC AAAAAGGTGT GCGCCGACTG CGGGAAGCTG TC - #CACGTAGA2820- TGTCAAAGTC CTCGATGAGC AGCTCCAGCA GCGTGTCGGC CGAGTCACCG TT - #TTCCACGG2880- CGTGTTTGAG GATATTGCGA CAGTAGTTGG AATCAAAGGA AAGGCACATG CG - #CAGCTCCT2940- TGACCAGCAG CTTGCAGCGC TCCTGAATGC GCGCCAGACA TTTGCGCTCC AG - #CTCCTCCC3000- AAGACCTGCG CACGTTCATG ATGAGACGGC CCGTGTACAC GAGCTTGTTG AC - #GGCGTTGA3060- CCAGCGCCGT GTTGGCGTGC CGGTCCAGGT TAAGGTCGAG CGGTTTCACG CA - #GAACATGT3120- TACGGCGCAC ACCCTCCAGG TTTTCTTCAA TGCGCTGCAC CTCCGTATCC TT - #GAGGTGCA3180- CAAAAGCGAT GGGTTCCGTC TGGCCGATGG CTGTGACCAG CGTCTCGCGC AC - #CGACATCT3240- TGGCCAGAAT GACCGCGCTT ACGAGCGCGC GCTCCACAAT CTCAGCATCG TG - #GCGTACGT3300- CCGTATCGAA TTCGGTACGG TCTAGCACAG CCAGGTGGTC ACGCGCCTTA CC - #ACGATCAC3360- CGAACGGGTA AGTGTAGCCG CGACGCGCCA CGGCCGCGCA ACGCACCTCG AA - #CTCCTCGA3420- GAACCGAGGA GAGGTCGGGG TTGTGGAAAC GCAGCTCGCG GTAGTATCCC AA - #CCAAAGCA3480- TGAGCTCGTT GAACAGCACC GTACGCCGGT GCAGGCGTTT TTCGCCACAT TT - #TTTCAGGA3540- TCTTGGGGTG TGCCTCGAGA TCCACGTCGG GCTTTTGCGT GAGATGGCGC AG - #AAAGTTGA3600- CCAGGGCCAC CACATCGCGC CGCTGTAGAC CGATAAACTG CAAACTCATT TT - #ATATTGTA3660- ATTATATATT TTCAATTTTG AAATCCCAAA ATATTATCAT ATCTTCCCAA TA - #AAGCTAGA3720- TTCTTTTTAT TGATTAACTA GTCAAATGAG TATATATAAT TGAAAAAGTA AA - #ATATAAAT3780- CATATAATAA TGAAACGAAA TATCAGTAAT AGACAGGAAC TGGCAGATTC TT - #CTTCTAAT3840- GAAGTAAGTA CTGCTAAATC TCCAAAATTA GATAAAAATG ATACAGCAAA TA - #CAGCTTCA3900- TTCAACGAAT TACCTTTTAA TTTTTTCAGA CACACCTTAT TACAAACTAA CT - #AAGTCAGA3960- TGATGAGAAA GTAAATATAA ATTTAACTTA TGGGTATAAT ATAATAAAGA TT - #CATGATAT4020- TAATAATTTA CTTAACGATG TTAATAGACT TATTCCATCA ACCCCTTCAA AC - #CTTTCTGG4080- ATATTATAAA ATACCAGTTA ATGATATTAA AATAGATTGT TTAAGAGATG TA - #AATAATTA4140- TTTGGAGGTA AAGGATATAA AATTAGTCTA TCTTTCACAT GGAAATGAAT TA - #CCTAATAT4200- TAATAATTAT GATAGGAATT TTTTAGGATT TACAGCTGTT ATATGTATCA AC - #AATACAGG4260- CAGATCTATG GTTATGGTAA AACACTGTAA CGGGAAGCAG CATTCTATGG TA - #ACTGGCCT4320- ATGTTTAATA GCCAGATCAT TTTACTCTAT AAACATTTTA CCACAAATAA TA - #GGATCCTC4380- TAGATATTTA ATATTATATC TAACAACAAC AAAAAAATTT AACGATGTAT GG - #CCAGAAGT4440- ATTTTCTACT AATAAAGATA AAGATAGTCT ATCTTATCTA CAAGATATGA AA - #GAAGATAA4500- TCATTTAGTA GTAGCTACTA ATATGGAAAG AAATGTATAC AAAAACGTGG AA - #GCTTTTAT4560- ATTAAATAGC ATATTACTAG AAGATTTAAA ATCTAGACTT AGTATAACAA AA - #CAGTTAAA4620- TGCCAATATC GATTCTATAT TTCATCATAA CAGTAGTACA TTAATCAGTG AT - #ATACTGAA4680- ACGATCTACA GACTCAACTA TGCAAGGAAT AAGCAATATG CCAATTATGT CT - #AATATTTT4740- AACTTTAGAA CTAAAACGTT CTACCAATAC TAAAAATAGG ATACGTGATA GG - #CTGTTAAA4800- AGCTGCAATA AATAGTAAGG ATGTAGAAGA AATACTTTGT TCTATACCTT CG - #GAGGAAAG4860# 4909TAAGT TTAATCAAAC TTGTATTTAT GAAGGTACC- (2) INFORMATION FOR SEQ ID NO:69:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 3567 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:- AAGACTAATT TGTAAACCAT CTTACTCAAA ATATGTAACA ATAGTACGAT GC - #AATGAGTA 60- AGACAATAGG AAATCTATCT TATATACACA TAATTATTCT ATCAATTTTA CC - #AATTAGTT 120- AGTGTAATGT TATAAAAACT AATTAATCAC TCGAGCCCCT AGCAATAAAA AC - #TATTCCTC 180- CGTGTTCTTA ATCTTCTCGA TCTTTTGGAG GATGTTCTGC ACGGCGTCCG AC - #GGCGTTTT 240- GGCGCCCCCC ATGCCGGCAG AACCCGGTTG CGGCCCCGTA CCGCTCTTCT GG - #GGCGACGA 300- TAGGTCGAAA GCCACCGTTT TCATGCCCGT CGTGCTCTTG ACGGGGGAAC CT - #ACGGCGGC 360- GGTCCCCGTC GAGCGGCGTG ATTGCAAAGC CGCGCTCGCC CCCGGTTTCA GG - #ATGGAGGG 420- GGAGGCCACA GGCGGCGCAT TCGATACGCT GCTTTTGGCC GTAGACGACG GT - #GGGTAAAC 480- GGTGGTTACC GCGGGATACG TCGGCGTGGT CGAGGCGGCC CGGCTGGTGC CG - #GACAGGCG 540- ACCCGGCGCG CTACCGCTCA CGGGTACCGA GGGCGGTCGA CCTACCACCG CC - #TTGCCGCC 600- CAAAGTAGGT TTCAAAGAAG GAACACCGAC GCGGCTGCCC CGACCTTTCA CC - #GGAGACGG 660- AGGGGCACTC TTGGCCGGGG ACGGAGAGGC TGACGAAAGC ATGGACAGCG GC - #GACGTGAC 720- GGGGGACACG ACATCATCCT CCGTGGGCGA CAAAACGGAC GCCGAGGCTG AC - #GGCTGTCG 780- AGCCGAAGCG GAAGAGGTTC TTGCGCCAGA AGTCACGTTC CTTGATGACG TT - #GTTTTAGA 840- CGAAGCCGGT TGAGGTTGCA ACAGCGTGGC GGGTACCGTC GACGGCGTGC CC - #GATACCTG 900- TTTCTCTACC CTTCCCTGAA CCGGTGTCGA CGTCACCGTC TGCGCTCGGG CG - #GACGCGTG 960- CGGCGTCGCG ACTCGCTTGC CCAGCACCGG TTTCTGGCTC GTGGATGTCG TC - #GTCATTGG1020- AGACGATAAC TTAGCTTTAC GTATTCTGGA CGGCGTCGAC TGCTCGGGCG TC - #TGACTGGG1080- AGGCGAAATG ACGTCGTTGT AATCGGACGA CGGTGTTGTG TGTCCCAGGC TG - #ACGACGGA1140- GCCGGTGTCC GAGGAGTCGT CGTCTTCCTC CTCGCTGTCT TCGACCGGTG AC - #TCTGCAGT1200- TTGGTCCCTT AAAGCCCAAA CCTCATCAGC GGCGTTCTGA GACGCTGTTT GT - #GTCACCGC1260- GGCGCGTGGA GTCGACGGCC TCCGAGGGGT GGTGGACACG TTGTTTTGAG AA - #GTCGTGGA1320- AGTCGTAGGC ATCCTGAAGG GATTGTAAGC CAGGTGAGGA TTCTTGAGGG CC - #CACGCGCG1380- TTCGCGCGGC CAGTTGGCGG GGTTCATATC CCCGGGCAAC GGCGCCGTCG GA - #GCCCAGGG1440- CGAGTTACCG TTGACCGGGG TTTGGGTACC CGCGAAGGTA GGTGTCGGGG CC - #GGAGCGGG1500- GGCCGTGGAA GGATTGACAG GCGTCGGCGT GAGGATGGCA GCGCCGGCGC CA - #GCAGGGAC1560- GTTAACTCCG GCGCCGAACG TCAACGTCGG TTGCTCGAAC TTGTACGCGG TG - #GTGACGGG1620- CGGTTTGGCG CTCGTCTCGG TATCCGTGAT GTCCACCAGC GTGTCGGTGA AA - #CGCGGATC1680- TTGACGGTTG GGGGGATAGC CATCCGAGCT GTCGGAATCC TCGTCGCCCG AG - #AAAAGATC1740- CCCTCTTGTC TCCGTGAGCG GCCTCACGTC CCACGCGCTG TCCCGACGGA CC - #CTTCCCGG1800- GCTGGCCTTG GTTACCTGCG GGGAGACGAG ACTGAAAGCC GCGTGACGCT GT - #TGTTGCTG1860- CGGGATGTTC AAGGGACCGC TGGTCGGTTT CTGACTGCCC GAGGATAACA TG - #CCGCTGAA1920- AATGCTGGAA ACACCGTTGC CACTAGCGGC GCCCTTGCCG CTAGTTCCCG GT - #TTCTTGAT1980- GGGCGTAAAG ATGTTTTTCT CGTCATCATC ATCGTCGTCG TCCTCATCGG CA - #CTGGAGCC2040- AAAGAGCCTC CGGGAGGCGC CCGGTTTACG TGTCGGGGGC GGCGGTTGCT GC - #TGACGTTG2100- CTGCAGGTTC TGCTGCCTCT CCTCCCAAGC CTTCAGCTGC TGTTTCTCAC GC - #TGCACCAC2160- CTCGTCGTCC ACCCGTTTCT GCCGCTCGCG ACGCTTTTCC TCTTCGTCGT AA - #TAGCCGAC2220- GCGCGCCGAA CGGGCGGCGT GGGCGTCGGC GGCCGGTGCC AGAGAACCAT GG - #GCCTCGAA2280- GCGGAACGGT TTGTGTCCCT TCCAGGGACT GGCGATCCAG CTCCAGCCGT CC - #AGCGGCTG2340- CGTGGGGACA TGTTTCTTGG GTACCGACGA GAAGGCTGAA CCGCCGCCGA GC - #GAGAGGAG2400- ATTGGCGTCA TCGTCAAACT CCAACGACGG CGGGCGCGCG CCCAAAAAGG TG - #TGCGCCGA2460- CTGCGGGAAG CTGTCCACGT AGATGTCAAA GTCCTCGATG AGCAGCTCCA GC - #AGCGTGTC2520- GGCCGAGTCA CCGTTTTCCA CGGCGTGTTT GAGGATATTG CGACAGTAGT TG - #GAATCAAA2580- GGAAAGGCAC ATGCGCAGCT CCTTGACCAG CAGCTTGCAG CGCTCCTGAA TG - #CGCGCCAG2640- ACATTTGCGC TCCAGCTCCT CCCAAGACCT GCGCACGTTC ATGATGAGAC GG - #CCCGTGTA2700- CACGAGCTTG TTGACGGCGT TGACCAGCGC CGTGTTGGCG TGCCGGTCCA GG - #TTAAGGTC2760- GAGCGGTTTC ACGCAGAACA TGTTACGGCG CACACCCTCC AGGTTTTCTT CA - #ATGCGCTG2820- CACCTCCGTA TCCTTGAGGT GCACAAAAGC GATGGGTTCC GTCTGGCCGA TG - #GCTGTGAC2880- CAGCGTCTCG CGCACCGACA TCTTGGCCAG AATGACCGCG CTTACGAGCG CG - #CGCTCCAC2940- AATCTCAGCA TCGTGGCGTA CGTCCGTATC GAATTCGGTA CGGTCTAGCA CA - #GCCAGGTG3000- GTCACGCGCC TTACCACGAT CACCGAACGG GTAAGTGTAG CCGCGACGCG CC - #ACGGCCGC3060- GCAACGCACC TCGAACTCCT CGAGAACCGA GGAGAGGTCG GGGTTGTGGA AA - #CGCAGCTC3120- GCGGTAGTAT CCCAACCAAA GCATGAGCTC GTTGAACAGC ACCGTACGCC GG - #TGCAGGCG3180- TTTTTCGCCA CATTTTTTCA GGATCTTGGG GTGTGCCTCG AGATCCACGT CG - #GGCTTTTG3240- CGTGAGATGG CGCAGAAAGT TGACCAGGGC CACCACATCG CGCCGCTGTA GA - #CCGATAAA3300- CTGCAAACTC ATTTTATATT GTAATTATAT ATTTTCAATT TTGAAATCCC AA - #AATATTAT3360- CATATCTTCC CAATAAAGCT AGGGGGAATT CGGATCCTCG CGACTGCAGG GT - #ACCTGAGT3420- AGCTAATTTT TAAACAAAAA TGTGGGAGAA TCTAATTAGT TTTTCTTTAC AC - #AATTGACG3480- TACATGAGTC TGAGTTCCTT GTTTTTGCTA ATTATTTCAT CCAATTTATT AT - #TCTTGACG3540# 3567 TATA GGAGTCA- (2) INFORMATION FOR SEQ ID NO:70:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 4893 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:- CTGCAGGTCG ACGGATCTGA GAATGGATGA TTCTCCAGCC GAAACATATT CT - #ACCATGGC 60- TCCGTTTAAT TTGTTGATGA AGATGGATTC ATCCTTAAAT GTTTTCTCTG TA - #ATAGTTTC 120- CACCGAAAGA CTATGCAAAG AATTTGGAAT GCGTTCCTTG TGCTTAATGT TT - #CCATAGAC 180- GGCTTCTAGA AGTTGATACA ACATAGGACT AGCCGCGGTA ACTTTTATTT TT - #AGAAAGTA 240- TCCATCGCTT CTATCTTGTT TAGATTTATT TTTATAAAGT TTAGTCTCTC CT - #TCCAACAT 300- AATAAAAGTG GAAGTCATTT GACTAGATAA ACTATCAGTA AGTTTTATAG AG - #ATAGACGA 360- ACAATTAGCG TATTGAGAAG CATTTAGTGT AACGTATTCG ATACATTTTG CA - #TTAGATTT 420- ACTAATCGAT TTTGCATACT CTATAACACC CGCACAAGTC TGTAGAGAAT CG - #CTAGATGC 480- AGTAGGTCTT GGTGAAGTTT CAACTCTCTT CTTGATTACC TTACTCATGA TT - #AAACCTAA 540- ATAATTGTAC TTTGTAATAT AATGATATAT ATTTTCACTT TATCTCATTT GA - #GAATAAAA 600- AGATCACAAA AATTAACTAA TCAGGATCTC GAGATAAAAA TCAGCATGTC TT - #GAGCATGC 660- GGTAGAGCAG ATAGATGCCG ATGATGGCCG ATAGCGCGTA GACGGACATC AT - #GAGGAGAC 720- GACTGTCGGT AGCGTCCACG ACGACGTCAG TTACTTCTAG GACCGTACCG TT - #TTTCAAAA 780- GCATGAGGTA GTGAGTTCGC GGAGATGAGA CCACCACTTC GTTGTAGGGA TC - #CAGGGCGA 840- AAAGGACGTC GTCCGAGTCG TGCATGTACA TGATGTTGAT GACGCCTTGC GT - #GTCGTCGT 900- ATTCTAGTAG GGCGCTTTGG CAAAAGGCGC AGTTTTCTAG GGAAATGTTG AG - #CGCCGCTG 960- TGATGCTGTG TGTGGTATGC ATGTTGCGCG TCAGTTCGCA TTTAGTTTGA CT - #GTCCGTCT1020- GGGTGATGAT GAGGCTCTGG CCTACGACGG TGGTGGAGAC AGGGTAGGAG AT - #ACCTTTGA1080- TCAGGTACTG GTTTGTTACG ACATAACTGA CGTGTTCGGA GACGGTCAGC GC - #GGAGAAGG1140- ATTCGCCGAG CGGCAGACAA AACAGGTCGG GGAAGGTTTC TAGCGTGCTT GG - #TTGCATGG1200- TAGATAGGAT GGAGAGGGCG GCGGGAACGG TAGTGGGGAC GGTGGCATCG GG - #GAAGAGAC1260- GTGTGAGGCG TTCGAGCGAG TGATCGCGTC GCCCGCTACT GGAACAGGGT GT - #GTACAGGT1320- CGCTGAGGTA TTCGTGGTGC GGATGAGCTA GCAACTGCGT AAAGTGTGAT AG - #CTCGGCTA1380- ATGAACAGAG GCCCGTTTCT ACGATGAAGA TTTCGCGTCT CTCCGTCGTA TG - #TACTAGCA1440- TGGAGTGGAC GAGGCTGCCC ATGAGGTAGA GTTCTTGACG CGCGAAGGCT GA - #AAGAAAAG1500- AGGCCAGGTG CGTTTTGTGT AGTTTTAGGG CAAAGTCGGC GATCTGTCGT AG - #TGCCCACT1560- GGGGGATGAG ATGTTGCTGA TTCTGTTTAG AGAGTATGTA GACCAGGCGT AC - #GAGGCTGG1620- TGATGTCGGT GATCTGATTC GGTGTCCAAA GGGCTCGTTT GGCCAGGTCC AC - #GGCCGTGG1680- GATACAGCAG CAACGTGGTG CGTGGTGGTG TTTGTGAGAG GCAGGTGATC AT - #AAATTCTT1740- GTATTTGTAA GAGTGCGGCC TGGCGGTCTA GGGCCCGTGG GACGGAGACT TG - #GGCGCCGG1800- CCTCTTCTTG TCGGGCTGCT GCGAACAGTG CTAATGCGTA GGCGAAGGCC AT - #TTCTACCG1860- TGCGGCGGTC CAGCATCTGA CATCGACCGC TTTTGAGTAC ATCCACGGCG TA - #ACGGTGAA1920- AGCTGTTACG TAGTAGTGCG CTGAGGTCCA GGTAGTTGAA GTCAAGTGCG GC - #GTCAAGAA1980- AGTCCGGGTC TTTGAGATAA GAGTGACGGT TCAGTTGATC TTTCTTAACT AG - #CACCAGGA2040- GCTCGTGTTT TTCAGTTTGT CGTAGTATAA AGTTGTCGCG TTGATAGGGC GC - #TTTAAAGA2100- GTACGCGTGG AAGATGGCCG AAGATAAGCA GCATGGGTGT GTCGTCGTCT AT - #GGACACCG2160- TAACTACGAA GAAGTCCTCG GTCAGTGTTA TTTTAACGTA ACGTAGTTCG TC - #GATGAGGT2220- AAAAGCCTTG GTGCAAACAA GGTGTGACGG TGCTGAATAG TAGATCGTGT CC - #ATCAAAGA2280- GGATACAGGT CTGGTTAAAG TGTGGTCGGT GTAGTCCTGA GGTGGTATGT GA - #TTCTGTCC2340- AGCCGTGTGG AGTGGTTTGC GGTGGCATCC AAACGTGAGG TATTGACAGG TC - #AATGGGTG2400- GTGGCACAGT GGTGGGCTGT TCACCTAGGC TGTCCTGTGC CTTTAGCTGC TG - #CGAAAAAG2460- ATCGGTAGCT GGCCAGGTCT TTGGATACCA GCGCGTAAGT GTTAAGTCTC TG - #TTGGTATC2520- TTTCCAGGGT TTCGGTCAGA TCTACCTGGT TCAGAAACTG CTCCGCCAGA GG - #ACCCGCAA2580- AAAGACATCG AGGCATATGG AATACATAGT ATTGATTATA GCTTTGGAAA AA - #GTTGAAAC2640- TGATGGCGTT TTCCCTGACG ACCGTGCTGT TACGGAGGCT GCTATTGTAG GT - #ACACTGGG2700- TGGTGTTTTC ACGCAGGAAG CGGATGGGTC TCCCGTAGGT GTTGAGCAGT AG - #GTGAAACG2760- CTTTGTCCAG CGGTTCGGAT ATGGCTTCTG CGCCATATCG TGACGAAAGT AG - #GTGGCTGA2820- GGAGACAGAC GGCGAGGACG ATGAGGTAGG AGGGGAGCCC GGGCCGCATT TT - #ATATTGTA2880- ATTATATATT TTCAATTTTG AAATCCCAAA ATATTATCAT ATTCTTCCCA AT - #AAACTCGA2940- GATCCTTCTT TATTCTATAC TTAAAAAGTG AAAATAAATA CAAAGGTTCT TG - #AGGGTTGT3000- GTTAAATTGA AAGCGAGAAA TAATCATAAA TTATTTCATT ATCGCGATAT CC - #GTTAAGTT3060- TGTATCGTAA TGAAACAGAT TAAGGTTCGA GTGGACATGG TGCGGCATAG AA - #TCAAGGAG3120- CACATGCTGA AAAAATATAC CCAGACGGAA GAGAAATTCA CTGGCGCCTT TA - #ATATGATG3180- GGAGGATGTT TGCAGAATGC CTTAGATATC TTAGATAAGG TTCATGAGCC TT - #TCGAGGAG3240- ATGAAGTGTA TTGGGCTAAC TATGCAGAGC ATGTATGAGA ACTACATTGT AC - #CTGAGGAT3300- AAGCGGGAGA TGTGGATGGC TTGTATTAAG GAGCTGCATG ATGTGAGCAA GG - #GCGCCGCT3360- AACAAGTTGG GGGGTGCACT GCAGGCTAAG GCCCGTGCTA AAAAGGATGA AC - #TTAGGAGA3420- AAGATGATGT ATATGTGCTA CAGGAATATA GAGTTCTTTA CCAAGAACTC AG - #CCTTCCCT3480- AAGACCACCA ATGGCTGCAG TCAGGCCATG GCGGCACTGC AGAACTTGCC TC - #AGTGCTCC3540- CCTGATGAGA TTATGGCTTA TGCCCAGAAA ATATTTAAGA TTTTGGATGA GG - #AGAGAGAC3600- AAGGTGCTCA CGCACATTGA TCACATATTT ATGGATATCC TCACTACATG TG - #TGGAAACA3660- ATGTGTAATG AGTACAAGGT CACTAGTGAC GCTTGTATGA TGACCATGTA CG - #GGGGCATC3720- TCTCTCTTAA GTGAGTTCTG TCGGGTGCTG TGCTGCTATG TCTTAGAGGA GA - #CTAGTGTG3780- ATGCTGGCCA AGCGGCCTCT GATAACCAAG CCTGAGGTTA TCAGTGTAAT GA - #AGCGCCGC3840- ATTGAGGAGA TCTGCATGAA GGTCTTTGCC CAGTACATTC TGGGGGCCGA TC - #CTCTGAGA3900- GTCTGCTCTC CTAGTGTGGA TGACCTACGG GCCATCGCCG AGGAGTCAGA TG - #AGGAAGAG3960- GCTATTGTAG CCTACACTTT GGCCACCGCT GGTGTCAGCT CCTCTGATTC TC - #TGGTGTCA4020- CCCCCAGAGT CCCCTGTACC CGCGACTATC CCTCTGTCCT CAGTAATTGT GG - #CTGAGAAC4080- AGTGATCAGG AAGAAAGTGA GCAGAGTGAT GAGGAAGAGG AGGAGGGTGC TC - #AGGAGGAG4140- CGGGAGGACA CTGTGTCTGT CAAGTCTGAG CCAGTGTCTG AGATAGAGGA AG - #TTGCCCCA4200- GAGGAAGAGG AGGATGGTGC TGAGGAACCC ACCGCCTCTG GAGGTAAGAG TA - #CCCACCCT4260- ATGGTGACTA GAAGCAAGGC TGACCAGTAA TTTTTATCTC GAGCCCGGGA GA - #TCTTAGCT4320- AACTGATTTT TCTGGGAAAA AAATTATTTA ACTTTTCATT AATAGGGATT TG - #ACGTATGT4380- AGCGTACAAA ATTATCGTTC CTGGTATATA GATAAAGAGT CCTATATATT TG - #AAAATCGT4440- TACGGCTCGA TTAAACTTTA ATGATTGCAT AGTGAATATA TCATTAGGAT TT - #AACTCCTT4500- GACTATCATG GCGGCGCCAG AAATTACCAT CAAAAGCATT AATACAGTTA TG - #CCGATCGC4560- AGTTAGAACG GTTATAGCAT CCACCATTTA TATCTAAAAA TTAGATCAAA GA - #ATATGTGA4620- CAAAGTCCTA GTTGTATACT GAGAATTGAC GAAACAATGT TTCTTACATA TT - #TTTTTCTT4680- ATTAGTAACT GACTTAATAG TAGGAACTGG AAAGCTAGAC TTGATTATTC TA - #TAAGTATA4740- GATACCCTTC CAGATAATGT TCTCTTTGAT AAAAGTTCCA GAAAATGTAG AA - #TTTTTTAA4800- AAAGTTATCT TTTGCTATTA CCAAGATTGT GTTTAGACGC TTATTATTAA TA - #TGAGTAAT4860# 4893 CTAG ATATGGGGAA TTC- (2) INFORMATION FOR SEQ ID NO:71:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 6749 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:- GAGCTCGCGG CCGCCTATCA AAAGTCTTAA TGAGTTAGGT GTAGATAGTA TA - #GATATTAC 60- TACAAAGGTA TTCATATTTC CTATCAATTC TAAAGTACAT GATATTAATA AC - #TCAAAGAT 120- GATGATAGTA GATAATAGAT ACGCTCATAT AATGACTGCA AATTTGGACG GT - #TCACATTT 180- TAATCATCAC GCGTTCATAA GTTTCAACTG CATAGATCAA AATCTCACTA AA - #AAGATAGC 240- CGATGTATTT GAGAGAGATT GGACATCTAA CTACGCTAAA GAAATTACAG TT - #ATAAATAA 300- TACATAATGG ATTTTGTTAT CATCAGTTAT ATTTAACATA AGTACAATAA AA - #AGTATTAA 360- ATAAAAATAC TTACTTACGA AAAAATGACT AATTAGCTAT AAAAACCCAA CA - #AAAACTAA 420- TCAGCTATCG GGGTTAATTA ATTAGTTATT AGACAAGGTG AAAACGAAAC TA - #TTTGTAGC 480- TTAATTAATT AGAGCTTCTT TATTCTATAC TTAAAAAGTG AAAATAAATA CA - #AAGGTTCT 540- TGAGGGTTGT GTTAAATTGA AAGCGAGAAA TAATCATAAA TTATTTCATT AT - #GGCGATAT 600- CCGTTAAGTT TGTATCGTAA TGGAGTCGCG CGGTCGCCGT TGTCCCGAAA TG - #ATATCCGT 660- ACTGGGTCCC ATTTCGGGGC ACGTGCTGAA AGCCGTGTTT AGTCGCGGCG AC - #ACGCCGGT 720- GCTGCCGCAC GAGACGCGAC TCCTGCAGAC GGGTATCCAC GTGCGCGTGA GC - #CAGCCCTC 780- GCTGATCCTG GTGTCGCAGT ACACGCCCGA CTCGACGCCA TGCCACCGCG GC - #GACAATCA 840- GCTGCAGGTG CAGCACACGT ACTTTACGGG CAGCGAGGTG GAGAACGTGT CG - #GTCAACGT 900- GCACAACCCC ACGGGCCGGA GCATCTGCCC CAGCCAAGAG CCCATGTCGA TC - #TATGTGTA 960- GCGCGCTGCC GCTCAAGATG CTGAACATCC CCAGCATCAA CGTGCACCAC TA - #CCCGTCGG1020- CGGCCGAGCG CAAACACCGA CACCTGCCCG TAGCTGACGC TGTGATTCAC GC - #GTCGGGCA1080- AGCAGATGTG GCAGGCGCGT CTCACGGTCT CGGGACTGGC CTGGACGCGT CA - #GCAGAACC1140- AGTGGAAAGA GCCCGACGTC TACTACACGT CAGCGTTCGT GTTTCCCACC AA - #GGACGTGG1200- CACTGCGGCA CGTGGTGTGC GCGCACGAGC TGGTTTGCTC CATGGAGAAC AC - #GCGCGCAA1260- CCAAGATGCA GGTGATAGGT GACCAGTACG TCAAGGTGTA CCTGGAGTCC TT - #CTGCGAGG1320- ACGTGCCCTC CGGCAAGCTC TTTATGCACG TCACGCTGGG CTCTGACGTG GA - #AGAGGACC1380- TGACGATGAC CCGCAACCCG CAACCCTTCA TGCGCCCCCA CGAGCGCAAC GG - #CTTTACGG1440- TGTTGTGTCC CAAAAATATG ATAATCAAAC CGGGCAAGAT CTCGCACATC AT - #GCTGGATG1500- TGGCTTTTAC CTCACACGAG CATTTTGGGC TGCTGTGTCC CAAGAGCATC CC - #GGGCCTGA1560- GCATCTCAGG TAACCTATTG ATGAACGGGC AGCAGATCTT CCTGGAGGTG CA - #AGCGATAC1620- GCGAGACCGT GGAACTGCGT CAGTACGATC CCGTGGCTGC GCTCTTCTTT TT - #CGATATCG1680- AGCTTGCTGC TGCAGCGCGG GCCTCAGTAC AGCGAACACC CCACCTTCAC CA - #GCCAGTAT1740- CGCATCCAGG GCAAGCTTGA GTACCGACAC ACCTGGGACC GGCACGACGA GG - #GTGCCGCC1800- CAGGGCGACG ACGACGTCTG GACCAGCGGA TCGGACTCCG ACGAGGAACT CG - #TAACCACC1860- GAGGCGCAAG ACGCCCCGCG TTACCGGCGG CGGCGCCATG GCGGGCGCCT CC - #ACTTCCGC1920- GGGCCGCAAA CGCAAATCAG CATCCTCGGC GACGGCGTGC ACGGCGGGCG TT - #ATGACACG1980- CGGCCGCCTT AAGGCCGAGT CCACCGTCGC GCCCGAAGAG GACACCGACG AG - #GATTCCGA2040- CAACGAAATC CACAATCCGG CCGTGTTCAC CTGGCCGCCC TGGCAGGCCG GC - #ATCCTGGC2100- CCGCAACCTG GTGCCCATGG TGGCTACGGT TCAGGGTCAG AATCTGAAGT AC - #CAGGAGTT2160- CTTCTGGGAC GCCAACGACA TCTACCGCAT CTTCGCCGAA TTGGAAGGCG TA - #TGGCAGCC2220- CGCTGCGCAA CCCAAACGTC GCCGCCACCG GCAAGACGCC TTGCCCGGGC CA - #TGCATCGC2280- CTCGACGCCC AAAAAGCACC GAGGTTGATT TTTATGGATC CGGTACCCTC GA - #GGAATTCT2340- AGCAATAAAA ACTATTCCTC CGTGTTCTTA ATCTTCTCGA TCTTTTGGAG GA - #TGTTCTGC2400- ACGGCGTCCG ACGGCGTTTT GGCGCCCCCC ATGCCGGCAG AACCCGGTTG CG - #GCCCCGTA2460- CCGCTCTTCT GGGGCGACGA TAGGTCGAAA GCCACCGTTT TCATGCCCGT CG - #TGCTCTTG2520- ACGGGGGAAC CTACGGCGGC GGTCCCCGTC GAGCGGCGTG ATTGCAAAGC CG - #CGCTCGCC2580- CCCGGTTTCA GGATGGAGGG GGAGGCCACA GGCGGCGCAT TCGATACGCT GC - #TTTTGGCC2640- GTAGACGACG GTGGGTAAAC GGTGGTTACC GCGGGATACG TCGGCGTGGT CG - #AGGCGGCC2700- CGGCTGGTGC CGGACAGGCG ACCCGGCGCG CTACCGCTCA CGGGTACCGA GG - #GCGGTCGA2760- CCTACCACCG CCTTGCCGCC CAAAGTAGGT TTCAAAGAAG GAACACCGAC GC - #GGCTGCCC2820- CGACCTTTCA CCGGAGACGG AGGGGCACTC TTGGCCGGGG ACGGAGAGGC TG - #ACGAAAGC2880- ATGGACAGCG GCGACGTGAC GGGGGACACG ACATCATCCT CCGTGGGCGA CA - #AAACGGAC2940- GCCGAGGCTG ACGGCTGTCG AGCCGAAGCG GAAGAGGTTC TCGCGCCAGA AG - #TCACGTTC3000- CTTGATGACG TTGTTTTAGA CGAAGCCGGT TGAGGTTGCA ACAGCGTGGC GG - #GTACCGTC3060- GACGGCGTGC CCGATACCTG TTTCTCTACC CTTCCCTGAA CCGGTGTCGA CG - #TCACCGTC3120- TGCGCTCGGG CGGACGCGTG CGGCGTCGCG ACTCGCTTGC CCAGCACCGG TT - #TCTGGCTC3180- GTGGATGTCG TCGTCATTGG AGACGATAAC TTAGCTTTAC GTATTCTGGA CG - #GCGTCGAC3240- TGCTCGGGCG TCTGACTGGG AGGCGAAATG ACGTCGTTGT AATCGGACGA CG - #GTGTTGTG3300- TGTCCCAGGC TGACGACGGA GCCGGTGTCC GAGGAGTCGT CGTCTTCCTC CT - #CGCTGTCT3360- TCGACCGGTG ACTCTGCAGT TTGGTCCCTT AAAGCCCAAA CCTCATCAGC GG - #CGTTCTGA3420- GACGCTGTTT GTGTCACCGC GGCGCGTGGA GTCGACGGCC TCCGAGGGGT GG - #TGGACACG3480- TTGTTTTGAG AAGTCGTGGA AGTCGTAGGC ATCCTGAAGG GATTGTAAGC CA - #GGTGAGGA3540- TTCTTGAGGG CCCACGCGCG TTCGCGCGGC CAGTTGGCGG GGTTCATATC CC - #CGGGCAAC3600- GGCGCCGTCG GAGCCCAGGG CGAGTTACCG TTGACCGGGG TTTGGGTACC CG - #CGAAGGTA3660- GGTGTCGGGG CCGGAGCGGG GGCCGTGGAA GGATTGACAG GCGTCGGCGT GA - #GGATGGCA3720- GCGCCGGCGC CAGCAGGGAC GTTAACTCCG GCGCCGAACG TCAACGTCGG TT - #GCTCGAAC3780- TTGTACGCGG TGGTGACGGG CGGTTTGGCG CTCGTCTCGG TATCCGTGAT GT - #CCACCAGC3840- GTGTCGGTGA AACGCGGATC TTGACGGTTG GGGGGATAGC CATCCGAGCT GT - #CGGAATCC3900- TCGTCGCCCG AGAAAAGATC CCCTCTTGTC TCCGTGAGCG GCCTCACGTC CC - #ACGCGCTG3960- TCCCGACGGA CCCTTCCCGG GCTGGCCTTG GTTACCTGCG GGGAGACGAG AC - #TGAAAGCC4020- GCGTGACGCT GTTGTTGCTG CGGGATGTTC AAGGGACCGC TGGTCGGTTT CT - #GACTGCCC4080- GAGGATAACA TGCCGCTGAA AATGCTGGAA ACACCGTTGC CACTAGCGGC GC - #CCTTGCCG4140- CTAGTTCCCG GTTTCTTGAT GGGCGTAAAG ATGTTTTTCT CGTCATCATC AT - #CGTCGTCG4200- TCCTCATCGG CACTGGAGCC AAAGAGCCTC CGGGAGGCGC CCGGTTTACG TG - #TCGGGGGC4260- GGCGGTTGCT GCTGACGTTG CTGCAGGTTC TGCTGCCTCT CCTCCCAAGC CT - #TCAGCTGC4320- TGTTTCTCAC GCTGCACCAC CTCGTCGTCC ACCCGTTTCT GCCGCTCGCG AC - #GCTTTTCC4380- TCTTCGTCGT AATAGCCGAC GCGCGCCGAA CGGGCGGCGT GGGCGTCGGC GG - #CCGGTGCC4440- AGAGAACCAT GGGCCTCGAA GCGGAACGGT TTGTGTCCCT TCCAGGGACT GG - #CGATCCAG4500- CTCCAGCCGT CCAGCGGCTG CGTGGGGACA TGTTTCTTGG GTACCGACGA GA - #AGGCTGAA4560- CCGCCGCCGA GCGAGAGGAG ATTGGCGTCA TCGTCAAACT CCAACGACGG CG - #GGCGCGCG4620- CCCAAAAAGG TGTGCGCCGA CTGCGGGAAG CTGTCCACGT AGATGTCAAA GT - #CCTCGATG4680- AGCAGCTCCA GCAGCGTGTC GGCCGAGTCA CCGTTTTCCA CGGCGTGTTT GA - #GGATATTG4740- CGACAGTAGT TGGAATCAAA GGAAAGGCAC ATGCGCAGCT CCTTGACCAG CA - #GCTTGCAG4800- CGCTCCTGAA TGCGCGCCAG ACATTTGCGC TCCAGCTCCT CCCAAGACCT GC - #GCACGTTC4860- ATGATGAGAC GGCCCGTGTA CACGAGCTTG TTGACGGCGT TGACCAGCGC CG - #TGTTGGCG4920- TGCCGGTCCA GGTTAAGGTC GAGCGGTTTC ACGCAGAACA TGTTACGGCG CA - #CACCCTCC4980- AGGTTTTCTT CAATGCGCTG CACCTCCGTA TCCTTGAGGT GCACAAAAGC GA - #TGGGTTCC5040- GTCTGGCCGA TGGCTGTGAC CAGCGTCTCG CGCACCGACA TCTTGGCCAG AA - #TGACCGCG5100- CTTACGAGCG CGCGCTCCAC AATCTCACCA TCGTGGCGTA CGTCCGTATC GA - #ATTCGGTA5160- CGGTCTAGCA CAGCCAGGTG GTCACGCGCC TTACCACGAT CACCGAACGG GT - #AAGTGTAG5220- CCGCGACGCG CCACGGCCGC GCAACGCACC TCGAACTCCT CGGAACCGAG GA - #GAGGTCGG5280- GGTTGTGGAA ACGCAGCTCG CGGTAGTATC CCAACCAAAG CATGAGCTCG TT - #GAACAGCA5340- CCGTACGCCG GTGCAGGCGT TTTTCGCCAC ATTTTTTCAG GATCTTGGGG TG - #TGCCTCGA5400- GATCCACGTC GGGCTTTTGC GTGAGATGGC GCAGAAAGTT GACCAGGGCC AC - #CACATCGC5460- GCCGCTGTAG ACCGATAAAC TGCAAACTCA TTTTATATTG TAATTATATA TT - #TTCAATTT5520- TGAAATCCCA AAATATTATC ATATCTTCCC AATAAAGCTA GAATTCTTTT TA - #TTGATTAA5580- CTAGTCAAAT GAGTATATAT AATTGAAAAA GTAAAATATA AATCATATAA TA - #ATGAAACG5640- AAATATCAGT AATAGACAGG AACTGGCAGA TTCTTCTTCT AATGAAGTAA GT - #ACTGCTAA5700- ATCTCCAAAA TTAGATAAAA ATGATACACC AAATACAGCT TCATTCAACG AA - #TTACCTTT5760- TAATTTTTTC AGACACACCT TATTACAAAC TAACTAAGTC AGATGATGAG AA - #AGTAAATA5820- TAAATTTAAC TATGGGTATA ATATAATAAA GATTCATGAT ATTAATAATT TA - #CTTAACGA5880- TGTTAATAGA CTTATTCCAT CAACCCCTTC AAACCTTTCT GGATATTATA AA - #ATACCAGT5940- AATGATATTA AAATAGATTG TTTAAGAGAT GTAAATAATT ATTTGGAGGT AA - #AGGATATA6000- AAATTAGTCT ATCTTTCACA TGGAAATGAA TTACCTAATA TTAATAATTA TG - #ATAGGAAT6060- TTTTTAGGAT TTACAGCTGT TATATGTATC AACAATACAG GCAGATCTAT GG - #TTATGGTA6120- AAACACTGTA ACGGGAAGCA GCATTCTATG GTAACTGGCC TATGTTTAAT AG - #CCAGATCA6180- TTTTACTCTA TAAACATTTT ACCACAAATA ATAGGATCCT CTAGATATTT AA - #TATTATAT6240- CTAACAACAA CAAAAAAATT TAACGATGTA TGGCCAGAAG TATTTTCTAC TA - #ATAAAGAT6300- AAAGATAGTC TATCTTATCT ACAAGATATG AAAGAAGATA ATCATTTAGT AG - #TAGCTACT6360- AATATGGAAA GAAATGTATA CAAAAACGTG GAAGCTTTTA TATTAAATAG CA - #TATTACTA6420- GAAGATTTAA AATCTAGACT TAGTATAACA AAACAGTTAA ATGCCAATAT CG - #ATTCTATA6480- TTTCATCATA ACAGTAGTAC ATTAATCAGT GATATACTGA AACGATCTAC AG - #ACTCAACT6540- ATGCAAGGAA TAAGCAATAT GCCAATTATG TCTAATATTT TAACTTTAGA AC - #TAAAACGT6600- TCTACCAATA CTAAAAATAG GATACGTGAT AGGCTGTTAA AAGCTGCAAT AA - #ATAGTAAG6660- GATGTAGAAG AAATACTTTG TTCTATACCT TCGGAGGAAA GAACTTTAGA AC - #AACTTAAG6720# 6749 TTTA TGAAGGTAC- (2) INFORMATION FOR SEQ ID NO:72:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 837 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:- ATGTGCCGCC GCCCGGATTG CGGCTTCTCT TTCTCACCTG GACCGGTGGC AC - #TGCTGTGG 60- TGTTGCCTTC TGCTGCCCAT CGTTTCCTCA GCCACCGTCA GCGTCGCTCC TA - #CCGTCGCC 120- GAGAAAGTTC CCGCGGAGTG CCCCGAACTA ACGCGTCGAT GCCTGTTGGG TG - #AGGTGTTT 180- CAGGGTGACA AGTATGAAAG TTGGCTGCGC CCGTTGGTGA ATGTTACCAG AC - #GCGATGGC 240- CCGCTATCGC AACTTATTCG TTACCGTCCC GTTACGCCGG AGGCCGCCAA CT - #CCGTGCTG 300- TTGGACGATG CTTTCCTGGA CACTCTGGCC CTGCTGTACA ACAATCCGGA TC - #AATTGCGG 360- GCCTTGCTGA CGCTGTTGAG CTCGGACACA GCGCCGCGCT GGATGACGGT GA - #TGCGCGGT 420- TACAGCGAGT GCGGCGATGG CTCGCCGGCC GTGTACACGT GCGTGGACGA CC - #TGTGCCGC 480- GGCTACGACC TCACGCGACT GTCATACGGG CGCAGCATCT TCACGGAACA CG - #TGTTAGGC 540- TTCGAGCTGG TGCCACCGTC TCTCTTTAAC GTGGTGGTGG CCATACGCAA CG - #AAGCCACG 600- CGTACCAACC GCGCCGTGCG TCTGCCCGTG AGCACCGCTG CCGCGCCCGA GG - #GCATCACG 660- CTCTTTTACG GCCTGTACAA CGCAGTGAAG GAATTCTGCC TGCGTCACCA GC - #TGGACCCG 720- CCGCTGCTAC GCCACCTAGA TAAATACTAC GCCGGACTGC CGCCCGAGCT GA - #AGCAGACG 780- CGCGTCAACC TGCCGGCTCA CTCGCGCTAT GGCCCTCAAG CAGTGGATGC TC - #GCTAA 837- (2) INFORMATION FOR SEQ ID NO:73:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 5234 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:- AAGCTTTTGC GATCAATAAA TGGATCACAA CCAGTATCTC TTAACGATGT TC - #TTCGCAGA 60- TGATGATTCA TTTTTTAAGT ATTTGGCTAG TCAAGATGAT GAATCTTCAT TA - #TCTGATAT 120- ATTGCAAATC ACTCAATATC TAGACTTTCT GTTATTATTA TTGATCCAAT CA - #AAAAATAA 180- ATTAGAAGCC GTGGGTCATT GTTATGAATC TCTTTCAGAG GAATACAGAC AA - #TTGACAAA 240- ATTCACAGAC TCTCAAGATT TTAAAAAACT GTTTAACAAG GTCCCTATTG TT - #ACAGATGG 300- AAGGGTCAAA CTTAATAAAG GATATTTGTT CGACTTTGTG ATTAGTTTGA TG - #CGATTCAA 360- AAAAGAATCC TCTCTAGCTA CCACCGCAAT AGATCCTATT AGATACATAG AT - #CCTCGTCG 420- CGATATCGCA TTTTCTAACG TGATGGATAT ATTAAAGTCG AATAAAGTGA AC - #AATAATTA 480- ATTCTTTATT GTCATCATGT AATTAACTAG CTACCCGGGA GATCTCTCGA GC - #TGCAGAAG 540- CTTATAAAAA TCACAAGTCT CTGTCACTTT TTTTGTCTAG TTTTTTTTTC TC - #CTCTTGGT 600- TCAGACGTTC TCTTCTTCGT CGGAGTCTTT CAAGTGTCGG TAGCCGTTTT TG - #CGGTGTCG 660- CAGTCGGTCT AGCAGGTTGG GCTTCTGTCC CTTGTCCTGC GTGCCAGTCT GT - #CCGTCCAA 720- AGAATCTGTA CCGTTCTCGT GCGCTCGCTG CTCTGCGTCC AGACGGACCA GG - #GCCAGAAG 780- CATCTGGTAA GCCTGCTCGT TGGTGTAAGG CGGAGCCGCC GTGGATGCAT CA - #GACGACGG 840- TGGTCCCGGT CCTTTGCGAC CAGAATTATA AACACTTTCC TCGTAGGAAG GC - #GGAGCCTG 900- TAACGACGTG TCTTTGGTGT TGCCCGACGT CACGGTGGTC CCGTCGGCGG AC - #ACCAGATA 960- GGGAAAGAGG TTCTGCAGCG GCTGCATGCA GAGACGCCGC TGTCGAGTAT AG - #ATCAAATA1020- AATGATAATG ACGACGGCTA TGGCCACGAG GATGATGGTG AAGGCTCCGA AG - #GGGTTTTT1080- GAGGAAGGTG GCAACGCCTT CGACCACGGA GGCCACCGCG CCACCCACGG CC - #CCAATGGC1140- TACGCCAACG GCCTTTCCCG CGGCGCCCAG GCCGCTCATG AGGTCGTCCA GA - #CCCTTGAG1200- GTAGGGCGGC AGCGGGTCGA CTACCTTGTC CTCCACGTAC TTTACCCGCT GC - #TTATACGA1260- ATTGAACTCG CGCATGATCT CCTCGAGATC AAAAACGTTG CTGGAACGCA AT - #TCTTTCTG1320- CGAGTAAAGT TCCAGTACCC TGAAGTCGGT GTTTTCCAGC GGGTCGATGT CT - #AGGGCGAT1380- CATGCTGTCG ACGGTGGAGA TGCTGCTGAG GTCAATCATG CGTTTGAAGA GG - #TAGTCCAC1440- GTACTCGTAG GCCGAGTTGC CGGCGATGAA GATCTTGAGG CTGGGAAGCT GA - #CATTCCTC1500- AGTGCGGTGG TTGCCCAACA GGATTTCGTT ATCCTCGCCC AGTTGACCGT AC - #TGCACGTA1560- CGAGCTGTTG GCGAAATTAA AGATGACCAC TGGTCGTGAG TAGCAGCGTC CT - #GGCGATTC1620- CTTCACATTC ATATCACGCA GCACCTTGAC GCTGGTTTGG TTAATGGTCA CG - #CAGCTGGC1680- CAGACCCAGG ACATCACCCA TGAAACGCGC GGCAATCGGT TTGTTGTAGA TG - #GCCGAGAG1740- AATAGCTGAC GGGTTGATCT TGCTAAGTTC CTTGAAGACC TCTAGGGTGC GC - #CGTTGATC1800- CACACACCAG GCTTCTGCGA TTTCGGCCAG CGCCCGGTTG ATGTAACCGC GC - #AACGTGTC1860- ATAGGTGAAC TGCAGCTGGG CGTAGACCAG ATTGTGCACC GACTCCATGT TG - #GATAAATG1920- AGTTGCATTG TTGCCATCTG TACTTCTTTT GGTTCTATTA TGAGTAAGAT TC - #AGACTGGA1980- GCGGTTGGCC AAACGTTCGA GTTCCACCAG AGATTTTTGC TTGATACCTT GC - #CAGAACAC2040- CACCAAACCA CCAGTGGTTT CAAAGACGGA CACGTTTCCA TATTTTTCAT AT - #GTTTGATT2100- GTATGAAGTA TTGAAAATCT GCTGTAACTT ATTTATGGCC TCATCACGTA CA - #CAGTCCAG2160- CGCAGAGTCG GACATGTTCA CCTCTTGCTT CTTAGATAAG AAAGTGGCGG TC - #ATTTTGGC2220- AGAAGAAAAG TGATACGAGT CCTCGGCTTC GGAACGAATG GTGCGTTCCG AG - #GCTTCCCA2280- GAAAGTGAGT TGACAAGTAA CATTCTTCTC GTCCTGTATA TCCCAGGAGA TC - #ACTGAGTC2340- CGCACGTTCA AGAAAAGCCA CCAACCTGTG GGTCTCTAAC GCAGAATTCG GT - #CTTTCAAA2400- GTCGGAGACG ATAGTGTAGT TCGGAAAAAT GAAAAACTTG TCGGCGTTTT CT - #CCAAAATA2460- GCTGGCATTG CGATTAGTTC CGTTGTAGAA AGGAGAAATG TCAACCACAT CA - #CCCGTGGA2520- AGTTGCGAAA AAATGATAGG GATACTTGGA GCGCGCAGTA GTGATGGTCA CC - #ATACAATT2580- CAGATTACAG GTCTCACGAT AGAGCCAGGT GCTGCCGCGG CTGTGCCATT GA - #TCCTTGAC2640- CGTCACGTAA CGGGTACTGT GGGTGTTGGA ATAATCGTCG GGCATTAATT GC - #ATGGTTTT2700- GTTTTCATAG CTGTCCCTAT GATAAGCCAC GAAAACCGTG CCTGCTATAA CG - #CGGCTGTA2760- GGAACTGTAG CACTGACTGT GACTGTTGAT ATGATGAATC TCCCACATAG GA - #GGCGCCAC2820- GTATTCCGTG TTGCTGCCCA GCAGATAAGT GGTGTGGATG TAAGCGTAGC TA - #CGACGAAA2880- CGTCAAAACC TTCTGGTAGA CTCGTACCTT AAAGGTGTGC GCGACGATGT TG - #CGTTTGTA2940- GACCACCATG ATGCCCTCGT CCAGGTCTTC ATTGATGGGC TTCATCGAGG TG - #CAGACGAT3000- ATTACGTTCA AAGCGAATAA GATCCGTACC CTGTGCCATA GAACACACGC GA - #TAGGGGTA3060- CTTGGTGGTG TTGACCCCCA CCACATCTCC GTACTTGAGG GTAGTGTTGT AG - #ATGGTCTC3120- GTTAACACCA TGGCTGACCG TTTGGGAAGA AGTTACGCGT TGAGAGACTG AA - #CCGGATCG3180- AGAATGAGCA GCAGACGTCG TATGAGAGGA ATGGTGACTG TGAGTAGCAG AA - #GTTCCACG3240- AGTAGAAGAT GAGGAAACCG CAGCACCCAG ACAGACGATA CACAAGTTAA CG - #CAGACTAC3300- CAGGCACCAG ATCCTGGATT CCATTACGAT ACAAACTTAA CGGATATCGC GA - #TAATGAAA3360- TAATTTATGA TTATTTCTCG CTTTCAATTT AACACAACCC TCAAGAACCT TT - #GTATTTAT3420- TTTCACTTTT AAGTATAGAA TAAAGAAGCT TGCATGCCAC GCGTCTCGAG GG - #CCCCTGCA3480- GGTCGACTCT AGAGGATCCT TCTTTATTCT ATACTTAAAA AGTGAAAATA AA - #TACAAAGG3540- TTCTTGAGGG TTGTGTTAAA TTGAAAGCGA GAAATAATCA TAAATTATTT CA - #TTATCGCG3600- ATATCCGTTA AGTTTGTATC GTAATGTGCC GCCGCCCGGA TTGCGGCTTC TC - #TTTCTCAC3660- CTGGACCGGT GGCACTGCTG TGGTGTTGCC TTCTGCTGCC CATCGTTTCC TC - #AGCCACCG3720- TCAGCGTCGC TCCTACCGTC GCCGAGAAAG TTCCCGCGGA GTGCCCCGAA CT - #AACGCGTC3780- GATGCCTGTT GGGTGAGGTG TTTCAGGGTG ACAAGTATGA AAGTTGGCTG CG - #CCCGTTGG3840- TGAATGTTAC CAGACGCGAT GGCCCGCTAT CGCAACTTAT TCGTTACCGT CC - #CGTTACGC3900- CGGAGGCCGC CAACTCCGTG CTGTTGGACG ATGCTTTCCT GGACACTCTG GC - #CCTGCTGT3960- ACAACAATCC GGATCAATTG CGGGCCTTGC TGACGCTGTT GAGCTCGGAC AC - #AGCGCCGC4020- GCTGGATGAC GGTGATGCGC GGTTACAGCG AGTGCGGCGA TGGCTCGCCG GC - #CGTGTACA4080- CGTGCGTGGA CGACCTGTGC CGCGGCTACG ACCTCACGCG ACTGTCATAC GG - #GCGCAGCA4140- TCTTCACGGA ACACGTGTTA GGCTTCGAGC TGGTGCCACC GTCTCTCTTT AA - #CGTGGTGG4200- TGGCCATACG CAACGAAGCC ACGCGTACCA ACCGCGCCGT GCGTCTGCCC GT - #GAGCACCG4260- CTGCCGCGCC CGAGGGCATC ACGCTCTTTT ACGGCCTGTA CAACGCAGTG AA - #GGAATTCT4320- GCCTGCGTCA CCAGCTGGAC CCGCCGCTGC TACGCCACCT AGATAAATAC TA - #CGCCGGAC4380- TGCCGCCCGA GCTGAAGCAG ACGCGCGTCA ACCTGCCGGC TCACTCGCGC TA - #TGGCCCTC4440- AAGCAGTGGA TGCTCGCTAA TTTTTATAGA TCCTGATCCT TTTTCTGGGT AA - #GTAATACG4500- TCAAGGAGAA AACGAAACGA TCTGTAGTTA GCGGCCGCCT AATTAACTAA TA - #TTATATTT4560- TTTATCTAAA AAACTAAAAA TAAACATTGA TTAAATTTTA ATATAATACT TA - #AAAATGGA4620- TGTTGTGTCG TTAGATAAAC CGTTTATGTA TTTTGAGGAA ATTGATAATG AG - #TTAGATTA4680- CGAACCAGAA AGTGCAAATG AGGTCGCAAA AAAACTGCCG TATCAAGGAC AG - #TTAAAACT4740- ATTACTAGGA GAATTATTTT TTCTTAGTAA GTTACAGCGA CACGGTATAT TA - #GATGGTGC4800- CACCGTAGTG TATATAGGAT CGGCTCCTGG TACACATATA CGTTATTTGA GA - #GATCATTT4860- CTATAATTTA GGAATGATTA TCAAATGGAT GCTAATTGAC GGACGCCATC AT - #GATCCTAT4920- TTTAAATGGA TTGCGTGATG TGACTCTAGT GACTCGGTTC GTTGATGAGG AA - #TATCTACG4980- ATCCATCAAA AAACAACTGC ATCCTTCTAA GATTATTTTA ATTTCTGATG TG - #AGATCCAA5040- ACGAGGAGGA AATGAACCTA GTACGGCGGA TTTACTAAGT AATTACGCTC TA - #CAAAATGT5100- CATGATTAGT ATTTTAAACC CCGTGGCGTC TAGTCTTAAA TGGAGATGCC CG - #TTTCCAGA5160- TCAATGGATC AAGGACTTTT ATATCCCACA CGGTAATAAA ATGTTACAAC CT - #TTTGCTCC5220# 5234- (2) INFORMATION FOR SEQ ID NO:74:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 56 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:- GCCTCATCGC TGCTGGATAT CCGTTAAGTT TGTATCGTAA TGGAATCCAG GA - #TCTG 56- (2) INFORMATION FOR SEQ ID NO:75:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 40 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:# 40 TTTT ATAAGCTTCG TAAGCTGTCA- (2) INFORMATION FOR SEQ ID NO:76:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 55 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:- AGCTTCTTTA TTCTATACTT AAAAAGTGAA AATAAATACA AAGGTTCTTG AG - #GGT 55- (2) INFORMATION FOR SEQ ID NO:77:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 73 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:- TGTGTTAAAT TGAAAGCGAG AAATAATCAT AAATTATTTC ATTATCGCGA TA - #TCCGTTAA 60# 73- (2) INFORMATION FOR SEQ ID NO:78:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 56 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:- TTATTAGTAT TTAATAAAGT AATAGCGCTA TAGGCAATTC AAACATAGCA TG - #AGCT 56- (2) INFORMATION FOR SEQ ID NO:79:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 72 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:- AGAAATAAGA TATGAATTTT TCACTTTTAT TTATGTTTCC AAGAACTCCC AA - #CACAATTT 60# 72- (2) INFORMATION FOR SEQ ID NO:80:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 14 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:# 14- (2) INFORMATION FOR SEQ ID NO:81:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 22 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:# 22CTG CA- (2) INFORMATION FOR SEQ ID NO:82:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 29 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:# 29 TATT TTATTTCAG- (2) INFORMATION FOR SEQ ID NO:83:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 61 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:- TATCTGAATT CCTGCAGCCC GGGTTTTTAT AGCTAATTAG TCAAATGTGA GT - #TAATATTA 60# 61- (2) INFORMATION FOR SEQ ID NO:84:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 66 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:- TCGCTGAATT CGATATCAAG CTTATCGATT TTTATGACTA GTTAATCAAA TA - #AAAAGCAT 60# 66- (2) INFORMATION FOR SEQ ID NO:85:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 30 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:85:# 30 CATC AGTATCTAAC- (2) INFORMATION FOR SEQ ID NO:86:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 37 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:86:# 37 CAGA TATTTGTTAG CTTCTGC- (2) INFORMATION FOR SEQ ID NO:87:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 33 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:# 33 CCTA CCTACTACCT ACG- (2) INFORMATION FOR SEQ ID NO:88:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 29 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:# 29 GACA ATAACATAG- (2) INFORMATION FOR SEQ ID NO:89:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 30 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:# 30 TACT GGGTTACAAC- (2) INFORMATION FOR SEQ ID NO:90:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 17 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:# 17 C- (2) INFORMATION FOR SEQ ID NO:91:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 15 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:91:# 15- (2) INFORMATION FOR SEQ ID NO:92:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 39 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:92:# 39 TTAA TTAGTTATTA GACAAGGTG- (2) INFORMATION FOR SEQ ID NO:93:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 41 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:93:# 41 ACGA TACAAACTTA AGCGGATATC G- (2) INFORMATION FOR SEQ ID NO:94:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 45 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:94:#45 GCCG CTCATTAGAC AAGCGAATGA GGGAC- (2) INFORMATION FOR SEQ ID NO:95:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 62 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:95:- AGATCTCCCG GGCTCGAGTA ATTAATTAAT TTTTATTACA CCAGAAAAGA CG - #GCTTGAGA 60# 62- (2) INFORMATION FOR SEQ ID NO:96:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 64 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:96:- TAATTACTCG AGCCCGGGAG ATCTAATTTA ATTTAATTTA TATAACTCAT TT - #TTTGAATA 60# 64- (2) INFORMATION FOR SEQ ID NO:97:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 46 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:97:# 46GCT TTAAATGGAC GGAACTCTTT TCCCCC- (2) INFORMATION FOR SEQ ID NO:98:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 62 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:98:- GATCTTTTGT TAACAAAAAC TAATCAGCTA TCGCGAATCG ATTCCCGGGG GA - #TCCGGTAC 60# 62- (2) INFORMATION FOR SEQ ID NO:99:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 62 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:99:- TCGAGGGTAC CGGATCCCCC GGGAATCGAT TCGCGATAGC TGATTAGTTT TT - #GTTAACAA 60# 62- (2) INFORMATION FOR SEQ ID NO:100:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 46 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:100:# 46GCG GCGTCTCTGC ATGCAGCCGC TGCAGA- (2) INFORMATION FOR SEQ ID NO:101:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 46 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:101:# 46CAT GCAGAGACGC CGCTGTCGAG TCCATG- (2) INFORMATION FOR SEQ ID NO:102:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 33 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:102:# 33 CACC TATGACACGT TGC- (2) INFORMATION FOR SEQ ID NO:103:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 37 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:103:# 37 TCCA GACCCTTGAG GTAGGGC- (2) INFORMATION FOR SEQ ID NO:104:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 48 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:104:# 48CTGG ACGACACTCG ACAGCGGCGT CTCTGCAT- (2) INFORMATION FOR SEQ ID NO:105:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 12 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:105:# 12- (2) INFORMATION FOR SEQ ID NO:106:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 12 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:106:# 12- (2) INFORMATION FOR SEQ ID NO:107:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 20 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:107:# 20 GCGT- (2) INFORMATION FOR SEQ ID NO:108:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 25 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:108:# 25 GTTG TAGAT- (2) INFORMATION FOR SEQ ID NO:109:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 20 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:109:# 20 CGGC- (2) INFORMATION FOR SEQ ID NO:110:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 39 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:110:# 39 TAAG ATCTACAGAT GGCAACAAT- (2) INFORMATION FOR SEQ ID NO:111:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 33 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:111:# 33 CAGG CCTCCCCTCC TAC- (2) INFORMATION FOR SEQ ID NO:112:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 29 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:112:# 29 GTCT TGAGCATGC- (2) INFORMATION FOR SEQ ID NO:113:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 29 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:113:# 29 TTTT ATCTCGAGA- (2) INFORMATION FOR SEQ ID NO:114:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 37 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:114:# 37 AATC AGCATGTCTT GAGCATG- (2) INFORMATION FOR SEQ ID NO:115:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 46 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:115:# 46GGA AGAATATGAT AATATTTTGG GATTTC- (2) INFORMATION FOR SEQ ID NO:116:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 42 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:116:# 42 AATT ACAATATAAA ATGCGGCCCG GG- (2) INFORMATION FOR SEQ ID NO:117:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 34 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:117:# 34 TTTA TATTGTAATT ATAT- (2) INFORMATION FOR SEQ ID NO:118:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 54 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:118:- ATTTTCAATT TTGAAATCCC AAAATATTAT CATATTCTTC CCAATAAACT CG - #AG 54- (2) INFORMATION FOR SEQ ID NO:119:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 35 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:119:# 35 TCCC CTCCTACCTC ATCGT- (2) INFORMATION FOR SEQ ID NO:120:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 34 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:120:# 34 TAAG TCTCTGTTGG TATC- (2) INFORMATION FOR SEQ ID NO:121:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 66 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:121:- AGAAAAATCA GTTAGCTAAG ATCTCCCGGG CTCGAGGGTA CCGGATCCTG AT - #TAGTTAAT 60# 66- (2) INFORMATION FOR SEQ ID NO:122:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 70 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:122:- GATCACAAAA ATTAACTAAT CAGGATCCGG TACCCTCGAG CCCGGGAGAT CT - #TAGCTAAC 60# 70- (2) INFORMATION FOR SEQ ID NO:123:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 35 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:123:# 35 TGTT AAATGTTATA CTTTG- (2) INFORMATION FOR SEQ ID NO:124:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 28 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:124:# 28 GTAC CACTTCAG- (2) INFORMATION FOR SEQ ID NO:125:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 44 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:125:# 44 CTTA TAAAGATCTA AAATGCATAA TTTC- (2) INFORMATION FOR SEQ ID NO:126:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 35 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:126:# 35 TCTA AACTAGGAAT AGATG- (2) INFORMATION FOR SEQ ID NO:127:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 82 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:127:- GTACGTGACT AATTAGCTAT AAAAAGGATC CGGTACCCTC GAGTCTAGAA TC - #GATCCCGG 60# 82ATC AC- (2) INFORMATION FOR SEQ ID NO:128:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 82 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:128:- GGCCGTGATT AACTAGTCAT AAAAACCCGG GATCGATTCT AGACTCGAGG GT - #ACCGGATC 60# 82GTC AC- (2) INFORMATION FOR SEQ ID NO:129:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 70 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:129:- GATCTTAATT AATTAGTCAT CAGGCAGGGC GAGAACGAGA CTATCTGCTC GT - #TAATTAAT 60# 70- (2) INFORMATION FOR SEQ ID NO:130:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 70 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:130:- GATCCGTCGA CCTAATTAAT TAACGAGCAG ATAGTCTCGT TCTCGCCCTG CC - #TGATGACT 60# 70- (2) INFORMATION FOR SEQ ID NO:131:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 12 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:131:# 12- (2) INFORMATION FOR SEQ ID NO:132:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 78 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:132:- ATAAAAATTA GCTACTCAGG TACCCTGCAG TCGCGAGGAT CCGAATTCCC CG - #GGCTCGAG 60# 78 AT- (2) INFORMATION FOR SEQ ID NO:133:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 78 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:133:- ATAAAAACTA ATTAATCACT CGAGCCCGGG GAATTCGGAT CCTCGCGACT GC - #AGGGTACC 60# 78 AT- (2) INFORMATION FOR SEQ ID NO:134:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 35 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:134:# 35 TACT GGTCAGCCTT GCTTC- (2) INFORMATION FOR SEQ ID NO:135:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 42 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:135:# 42 TCGT AATGGAGTCC TCTGCCAAGA GA- (2) INFORMATION FOR SEQ ID NO:136:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 44 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:136:# 44 ATCC GTTAAGTTTG TATCGTAATG GAGT- (2) INFORMATION FOR SEQ ID NO:137:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 30 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:137:# 30 TCCT TCCTCAACAT- (2) INFORMATION FOR SEQ ID NO:138:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 29 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:138:# 29 AGTG TAATGAAGC- (2) INFORMATION FOR SEQ ID NO:139:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 46 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:139:# 46AAA AATTACTGGT CAGCCTTGCT TCTAGT- (2) INFORMATION FOR SEQ ID NO:140:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 43 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:140:# 43 TGTA TCGTAATCTG CAGCCCGGGG GGG- (2) INFORMATION FOR SEQ ID NO:141:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 44 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:141:# 44 GATT ACGATACAAA CTTAACGGAT ATCG- (2) INFORMATION FOR SEQ ID NO:142:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 60 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:142:- CGCGAATTCT CGCGATATCC GTTAAGTTTG TATCGTAATG AAACAGATTA AG - #GTTCGAGT 60- (2) INFORMATION FOR SEQ ID NO:143:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 27 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:143:# 27 ATGG CCTGACT- (2) INFORMATION FOR SEQ ID NO:144:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 39 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:144:# 39 TTAA TTAGTCATCA GGCAGGGCG- (2) INFORMATION FOR SEQ ID NO:145:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 40 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:145:# 40 ACGA TACAAACTTA ACGGATATCG- (2) INFORMATION FOR SEQ ID NO:146:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 27 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:146:# 27 TTCT ATACTTA- (2) INFORMATION FOR SEQ ID NO:147:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 72 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:147:- AATTCTCGCG ATATCCGTTA AGTTTGTATC GTAATGACGA CGTTCCTGCA GA - #CTATGTTG 60# 72- (2) INFORMATION FOR SEQ ID NO:148:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 68 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:148:- AACCTCCTTC CTCAACATAG TCTGCAGGAA CGTCGTCATT ACGATACAAA CT - #TAACGGAT 60# 68- (2) INFORMATION FOR SEQ ID NO:149:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 39 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:149:# 39 ACGA TTGTTCATGA TGGCAAGAT- (2) INFORMATION FOR SEQ ID NO:150:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 68 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:150:- CCCGGGGGAT CCCTCGAGGG TACCAAGCTT AATTAATTAA ATATTAGTAT AA - #AAAGTGAT 60# 68- (2) INFORMATION FOR SEQ ID NO:151:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 77 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:151:- AAGCTTGGTA CCCTCGAGGG ATCCCCCGGG TAGCTAGCTA ATTTTTCTTT TA - #CGTATTAT 60# 77 C- (2) INFORMATION FOR SEQ ID NO:152:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 39 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:152:# 39 GTAT TTTTAAAACT TCTAACACC- (2) INFORMATION FOR SEQ ID NO:153:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 62 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:153:- GATTATCGCG ATATCCGTTA AGTTTGTATC GTAATGGCAT CCGTACTGGG TC - #CCATTTCG 60# 62- (2) INFORMATION FOR SEQ ID NO:154:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 47 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:154:# 47CATA AAAATCAACC TCGGTGCTTT TTGGGCG- (2) INFORMATION FOR SEQ ID NO:155:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 29 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:155:# 29 TCAG TCGCCTACA- (2) INFORMATION FOR SEQ ID NO:156:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 29 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:156:# 29 AAAA AGAAGAGCG- (2) INFORMATION FOR SEQ ID NO:157:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 61 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:157:- GATTATCGCG ATATCCGTTA AGTTTGTATC GTAATGGAGT CGCGCGGTCG CC - #GTTGTCCC 60# 61- (2) INFORMATION FOR SEQ ID NO:158:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 17 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:158:# 17 C- (2) INFORMATION FOR SEQ ID NO:159:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 42 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:159:# 42 CCGC CTATCAAAAG TCTTAATGAG TT- (2) INFORMATION FOR SEQ ID NO:160:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 72 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:160:- GAATTCCTCG AGCTGCAGCC CGGGTTTTTA TAGCTAATTA GTCATTTTTT CG - #TAAGTAAG 60# 72- (2) INFORMATION FOR SEQ ID NO:161:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 72 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:161:- CCCGGGCTGC AGCTCGAGGA ATTCTTTTTA TTGATTAACT AGTCAAATGA GT - #ATATATAA 60# 72- (2) INFORMATION FOR SEQ ID NO:162:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 45 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:162:#45 TAAA TACAAGTTTG ATTAAACTTA AGTTG- (2) INFORMATION FOR SEQ ID NO:163:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 26 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:163:# 26 GAGA AAAGCC- (2) INFORMATION FOR SEQ ID NO:164:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 32 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:164:# 32 GAAG GGATTGTAAG CC- (2) INFORMATION FOR SEQ ID NO:165:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 28 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:165:# 28 AGTC TCGTCTCC- (2) INFORMATION FOR SEQ ID NO:166:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 30 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:166:# 30 TGCC CGCGGACAAC- (2) INFORMATION FOR SEQ ID NO:167:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 99 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:167:- TTCGAATTCG CTAGCTTTAT TGGGAAGAAT ATGATAATAT TTTGGGATTT CA - #AAATTGAA 60# 99 ATAA AATGAGTTTG CAGTTTATC- (2) INFORMATION FOR SEQ ID NO:168:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 28 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:168:# 28 GTTG AACAGCAC- (2) INFORMATION FOR SEQ ID NO:169:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 44 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:169:# 44 ATAA AAACTATTCC TCCGTGTTCT TAAT- (2) INFORMATION FOR SEQ ID NO:170:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 28 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:170:# 28 AGCT AAGTTATC- (2) INFORMATION FOR SEQ ID NO:171:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 30 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:171:# 30 GCCG CCCGGATTGC- (2) INFORMATION FOR SEQ ID NO:172:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 33 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:172:# 33 ATCC ACTGCTTGAG GGC- (2) INFORMATION FOR SEQ ID NO:173:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 54 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:173:- TCCAAGCTTA GATCTATAAA AATTAGCGAG CATCCACTGC TTGAGGGCCA TA - #GC 54- (2) INFORMATION FOR SEQ ID NO:174:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 32 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:174:# 32 GCTG TTGAGCTCGG AC- (2) INFORMATION FOR SEQ ID NO:175:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 58 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:175:- CGCGAATTCT CGCGATATCC GTTAAGTTTG TATCGTAATG TGCCGCCGCC CG - #GATTGC 58- (2) INFORMATION FOR SEQ ID NO:176:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 34 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:176:# 34 GCGG CGCTGTGTCC GAGC- (2) INFORMATION FOR SEQ ID NO:177:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 6749 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:177:- GAGCTCGCGG CCGCCTATCA AAAGTCTTAA TGAGTTAGGT GTAGATAGTA TA - #GATATTAC 60- TACAAAGGTA TTCATATTTC CTATCAATTC TAAAGTAGAT GATATTAATA AC - #TCAAAGAT 120- GATGATAGTA GATAATAGAT ACGCTCATAT AATGACTGCA AATTTGGACG GT - #TCACATTT 180- TAATCATCAC GCGTTCATAA GTTTCAACTG CATAGATCAA AATCTCACTA AA - #AAGATAGC 240- CGATGTATTT GAGAGAGATT GGACATCTAA CTACGCTAAA GAAATTACAG TT - #ATAAATAA 300- TACATAATGG ATTTTGTTAT CATCAGTTAT ATTTAACATA AGTACAATAA AA - #AGTATTAA 360- ATAAAAATAC TTACTTACGA AAAAATGACT AATTAGCTAT AAAAACCCAA CA - #AAAACTAA 420- TCAGCTATCG GGGTTAATTA ATTAGTTATT AGACAAGGTG AAAACGAAAC TA - #TTTGTAGC 480- TTAATTAATT AGAGCTTCTT TATTCTATAC TTAAAAAGTG AAAATAAATA CA - #AAGGTTCT 540- TGAGGGTTGT GTTAAATTGA AAGCGAGAAA TAATCATAAA TTATTTCATT AT - #GGCGATAT 600- CCGTTAAGTT TGTATCGTAA TGGAGTCGCG CGGTCGCCGT TGTCCCGAAA TG - #ATATCCGT 660- ACTGGGTCCC ATTTCGGGGC ACGTGCTGAA AGCCGTGTTT AGTCGCGGCG AC - #ACGCCGGT 720- GCTGCCGCAC GAGACGCGAC TCCTGCAGAC GGGTATCCAC GTGCGCGTGA GC - #CAGCCCTC 780- GCTGATCCTG GTGTCGCAGT ACACGCCCGA CTCGACGCCA TGCCACCGCG GC - #GACAATCA 840- GCTGCAGGTG CAGCACACGT ACTTTACGGG CAGCGAGGTG GAGAACGTGT CG - #GTCAACGT 900- GCACAACCCC ACGGGCCGGA GCATCTGCCC CAGCCAAGAG CCCATGTCGA TC - #TATGTGTA 960- CGCGCTGCCG CTCAAGATGC TGAACATCCC CAGCATCAAC GTGCACCACT AC - #CCGTCGGC1020- GGCCGAGCGC AAACACCGAC ACCTGCCCGT AGCTGACGCT GTGATTCACG CG - #TCGGGCAA1080- GCAGATGTGG CAGGCGCGTC TCACGGTCTC GGGACTGGCC TGGACGCGTC AG - #CAGAACCA1140- GTGGAAAGAG CCCGACGTCT ACTACACGTC AGCGTTCGTG TTTCCCACCA AG - #GACGTGGC1200- ACTGCGGCAC GTGGTGTGCG CGCACGAGCT GGTTTGCTCC ATGGAGAACA CG - #CGCGCAAC1260- CAAGATGCAG GTGATAGGTG ACCAGTACGT CAAGGTGTAC CTGGAGTCCT TC - #TGCGAGGA1320- CGTGCCCTCC GGCAAGCTCT TTATGCACGT CACGCTGGGC TCTGACGTGG AA - #GAGGACCT1380- GACGATGACC CGCAACCCGC AACCCTTCAT GCGCCCCCAC GAGCGCAACG GC - #TTTACGGT1440- GTTGTGTCCC AAAAATATGA TAATCAAACC GGGCAAGATC TCGCACATCA TG - #CTGGATGT1500- GGCTTTTACC TCACACGAGC ATTTTGGGCT GCTGTGTCCC AAGAGCATCC CG - #GGCCTGAG1560- CATCTCAGGT AACCTATTGA TGAACGGGCA GCAGATCTTC CTGGAGGTGC AA - #GCGATACG1620- CGAGACCGTG GAACTGCGTC AGTACGATCC CGTGGCTGCG CTCTTCTTTT TC - #GATATCGA1680- CTTGCTGCTG CAGCGCGGGC CTCAGTACAG CGAACACCCC ACCTTCACCA GC - #CAGTATCG1740- CATCCAGGGC AAGCTTGAGT ACCGACACAC CTGGGACCGG CACGACGAGG GT - #GCCGCCCA1800- GGGCGACGAC GACGTCTGGA CCAGCGGATC GGACTCCGAC GAGGAACTCG TA - #ACCACCGA1860- GCGCAAGACG CCCCGCGTTA CCGGCGGCGG CGCCATGGCG GGCGCCTCCA CT - #TCCGCGGG1920- CCGCAAACGC AAATCAGCAT CCTCGGCGAC GGCGTGCACG GCGGGCGTTA TG - #ACACGCGG1980- CCGCCTTAAG GCCGAGTCCA CCGTCGCGCC CGAAGAGGAC ACCGACGAGG AT - #TCCGACAA2040- CGAAATCCAC AATCCGGCCG TGTTCACCTG GCCGCCCTGG CAGGCCGGCA TC - #CTGGCCCG2100- CAACCTGGTG CCCATGGTGG CTACGGTTCA GGGTCAGAAT CTGAAGTACC AG - #GAGTTCTT2160- CTGGGACGCC AACGACATCT ACCGCATCTT CGCCGAATTG GAAGGCGTAT GG - #CAGCCCGC2220- TGCGCAACCC AAACGTCGCC GCCACCGGCA AGACGCCTTG CCCGGGCCAT GC - #ATCGCCTC2280- GACGCCCAAA AAGCACCGAG GTTGATTTTT ATGGATCCGG TACCCTCGAG GA - #ATTCTAGC2340- TTTATTGGGA AGATATGATA ATATTTTGGG ATTTCAAAAT TGAAAATATA TA - #ATTACAAT2400- ATAAAATGAG TTTGCAGTTT ATCGGTCTAC AGCGGCGCGA TGTGGTGGCC CT - #GGTCAACT2460- TTCTGCGCCA TCTCACGCAA AAGCCCGACG TGGATCTCGA GGCACACCCC AA - #GATCCTGA2520- AAAAATGTGG CGAAAAACGC CTGCACCGGC GTACGGTGCT GTTCAACGAG CT - #CATGCTTT2580- GGTTGGGATA CTACCGCGAG CTGCGTTTCC ACAACCCCGA CCTCTCCTCG GT - #TCTCGAGG2640- AGTTCGAGGT GCGTTGCGCG GCCGTGGCGC GTCGCGGCTA CACTTACCCG TT - #CGGTGATC2700- GTGGTAAGGC GCGTGACCAC CTGGCTGTGC TAGACCGTAC CGAATTCGAT AC - #GGACGTAC2760- GCCACGATGC TGAGATTGTG GAGCGCGCGC TCGTAAGCGC GGTCATTCTG GC - #CAAGATGT2820- CGGTGCGCGA GACGCTGGTC ACAGCCATCG GCCAGACGGA ACCCATCGCT TT - #TGTGCACC2880- TCAAGGATAC GGAGGTGCAG CGCATTGAAG AAAACCTGGA GGGTGTGCGC CG - #TAACATGT2940- TCTGCGTGAA ACCGCTCGAC CTTAACCTGG ACCGGCACGC CAACACGGCG CT - #GGTCAACG3000- CCGTCAACAA GCTCGTGTAC ACGGGCCGTC TCATCATGAA CGTGCGCAGG TC - #TTGGGAGG3060- AGCTGGAGCG CAAATGTCTG GCGCGCATTC AGGAGCGCTG CAAGCTGCTG GT - #CAAGGAGC3120- TGCGCATGTG CCTTTCCTTT GATTCCAACT ACTGTCGCAA TATCCTCAAA CA - #CGCCGTGG3180- AAAACGGTGA CTCGGCCGAC ACGCTGCTGG AGCTGCTCAT CGAGGACTTT GA - #CATCTACG3240- TGGACAGCTT CCCGCAGTCG GCGCACACCT TTTTGGGCGC GCGCCCGCCG TC - #GTTGGAGT3300- TTGACGATGA CGCCAATCTC CTCTCGCTCG GCGGCGGTTC AGCCTTCTCG TC - #GGTACCCA3360- AGAAACATGT CCCCACGCAG CCGCTGGACG GCTGGAGCTG GATCGCCAGT CC - #CTGGAAGG3420- GACACAAACC GTTCCGCTTC GAGGCCCATG GTTCTCTGGC ACCGGCCGCC GA - #CGCCCACG3480- CCGCCCGTTC GGCGCGCGTC GGCTATTACG ACGAAGAGGA AAAGCGTCGC GA - #GCGGCAGA3540- AACGGGTGGA CGACGAGGTG GTGCAGCGTG AGAAACAGCA GCTGAAGGCT TG - #GGAGGAGA3600- GGCAGCAGAA CCTGCAGCAA CGTCAGCAGC AACCGCCGCC CCCGACACGT AA - #ACCGGGCG3660- CCTCCCGGAG GCTCTTTGGC TCCAGTGCCG ATGAGGACGA CGACGATGAT GA - #TGACGAGA3720- AAAACATCTT TACGCCCATC AAGAAACCGG GAACTAGCGG CAAGGGCGCC GC - #TAGTGGCA3780- ACGGTGTTTC CAGCATTTTC AGCGGCATGT TATCCTCGGG CAGTCAGAAA CC - #GACCAGCG3840- GTCCCTTGAA CATCCCGCAG CAACAACAGC GTCACGCGGC TTTCAGTCTC GT - #CTCCCCGC3900- AGGTAACCAA GGCCAGCCCG GGAAGGGTCC GTCGGGACAG CGCGTGGGAC GT - #GAGGCCGC3960- TCACGGAGAC AAGAGGGGAT CTTTTCTCGG GCGACGAGGA TTCCGACAGC TC - #GGATGGCT4020- ATCCCCCCAA CCGTCAAGAT CCGCGTTTCA CCGACACGCT GGTGGACATC AC - #GGATACCG4080- AGACGAGCGC CAAACCGCCC GTCACCACCG CGTACAAGTT CGAGCAACCG AC - #GTTGACGT4140- TCGGCGCCGG AGTTAACGTC CCTGCTGGCG CCGGCGCTGC CATCCTCACG CC - #GACGCCTG4200- TCAATCCTTC CACGGCCCCC GCTCCGGCCC CGACACCTAC CTTCGCGGGT AC - #CCAAACCC4260- CGGTCAACGG TAACTCGCCC TGGGCTCCGA CGGCGCCGTT GCCCGGGGAT AT - #GAACCCCG4320- CCAACTGGCC GCGCGAACGC GCGTGGGCCC TCAAGAATCC TCACCTGGCT TA - #CAATCCCT4380- TCAGGATGCC TACGACTTCC ACGACTTCTC AAAACAACGT GTCCACCACC CC - #TCGGAGGC4440- CGTCGACTCC ACGCGCCGCG GTGACACAAA CAGCGTCTCA GAACGCCGCT GA - #TGAGGTTT4500- GGGCTTTAAG GGACCAAACT GCAGAGTCAC CGGTCGAAGA CAGCGAGGAG GA - #AGACGACG4560- ACTCCTCGGA CACCGGCTCC GTCGTCAGCC TGGGACACAC AACACCGTCG TC - #CGATTACA4620- ACGACGTCAT TTCGCCTCCC AGTCAGACGC CCGAGCAGTC GACGCCGTCC AG - #AATACGTA4680- AAGCTAAGTT ATCGTCTCCA ATGACGACGA CATCCACGAG CCAGAAACCG GT - #GCTGGGCA4740- AGCGAGTCGC GACGCCGCAC GCGTCCGCCC GAGCGCAGAC GGTGACGTCG AC - #ACCGGTTC4800- AGGGAAGGGT AGAGAAACAG GTATCGGGCA CGCCGTCGAC GGTACCCGCC AC - #GCTGTTGC4860- AACCTCAACC GGCTTCGTCT AAAACAACGT CATCAAGGAA CGTGACTTCT GG - #CGCGAGAA4920- CCTCTTCCGC TTCGGCTCGA CAGCCGTCAG CCTCGGCGTC CGTTTTGTCG CC - #CACGGAGG4980- ATGATGTCGT GTCCCCCGTC ACGTCGCCGC TGTCCATGCT TTCGTCAGCC TC - #TCCGTCCC5040- CGGCCAAGAG TGCCCCTCCG TCTCCGGTGA AAGGTCGGGG CAGCCGCGTC GG - #TGTTCCTT5100- CTTTGAAACC TACTTTGGGC GGCAAGGCGG TGGTAGGTCG ACCGCCCTCG GT - #ACCCGTGA5160- GCGGTAGCGC GCCGGGTCGC CTGTCCGGCA CCAGCCGGGC CGCCTCGACC AC - #GCCGACGT5220- ATCCCGCGGT AACCACCGTT TACCCACCGT CGTCTACGGC CAAAAGCAGC GT - #ATCGAATG5280- CGCCGCCTGT GGCCTCCCCC TCCATCCTGA AACCGGGGGC GAGCGCGGCT TT - #GCAATCAC5340- GCCGCTCGAC GGGGACCGCC GCCGTAGGTT CCCCCGTCAA GAGCACGACG GG - #CATGAAAA5400- CGGTGGCTTT CGACCTATCG TCGCCCCAGA AGAGCGGTAC GGGGCCGCAA CC - #GGGTTCTG5460- CCGGCATGGG GGGCGCCAAA ACGCCGTCGG ACGCCGTGCA GAACATCCTC CA - #AAAGATCG5520- AGAAGATTAA GAACACGGAG GAATAGTTTT TATTGCTAGA ATTCTTTTTA TT - #GATTAACT5580- AGTCAAATGA GTATATATAA TTGAAAAAGT AAAATATAAA TCATATAATA AT - #GAAACGAA5640- ATATCAGTAA TAGACAGGAA CTGGCAGATT CTTCTTCTAA TGAAGTAAGT AC - #TGCTAAAT5700- CTCCAAAATT AGATAAAAAT GATACAGCAA ATACAGCTTC ATTCAACGAA TT - #ACCTTTTA5760- ATTTTTTCAG ACACACCTTA TTACAAACTA ACTAAGTCAG ATGATGAGAA AG - #TAAATATA5820- AATTTAACTT ATGGGTATAA TATAATAAAG ATTCATGATA TTAATAATTT AC - #TTAACGAT5880- GTTAATAGAC TTATTCCATC AACCCCTTCA AACCTTTCTG GATATTATAA AA - #TACCAGTT5940- AATGATATTA AAATAGATTG TTTAAGAGAT GTAAATAATT ATTTGGAGGT AA - #AGGATATA6000- AAATTAGTCT ATCTTTCACA TGGAAATGAA TTACCTAATA TTAATAATTA TG - #ATAGGAAT6060- TTTTTAGGAT TTACAGCTGT TATATGTATC AACAATACAG GCAGATCTAT GG - #TTATGGTA6120- AAACACTGTA ACGGGAAGCA GCATTCTATG GTAACTGGCC TATGTTTAAT AG - #CCAGATCA6180- TTTTACTCTA TAAACATTTT ACCACAAATA ATAGGATCCT CTAGATATTT AA - #TATTATAT6240- CTAACAACAA CAAAAAAATT TAACGATGTA TGGCCAGAAG TATTTTCTAC TA - #ATAAAGAT6300- AAAGATAGTC TATCTTATCT ACAAGATATG AAAGAAGATA ATCATTTAGT AG - #TAGCTACT6360- AATATGGAAA GAAATGTATA CAAAAACGTG GAAGCTTTTA TATTAAATAG CA - #TATTACTA6420- GAAGATTTAA AATCTAGACT TAGTATAACA AAACAGTTAA ATGCCAATAT CG - #ATTCTATA6480- TTTCATCATA ACAGTAGTAC ATTAATCAGT GATATACTGA AACGATCTAC AG - #ACTCAACT6540- ATGCAAGGAA TAAGCAATAT GCCAATTATG TCTAATATTT TAACTTTAGA AC - #TAAAACGT6600- TCTACCAATA CTAAAAATAG GATACGTGAT AGGCTGTTAA AAGCTGCAAT AA - #ATAGTAAG6660- GATGTAGAAG AAATACTTTG TTCTATACCT TCGGAGGAAA GAACTTTAGA AC - #AACTTAAG6720# 6749 TTTA TGAAGGTAC- (2) INFORMATION FOR SEQ ID NO:178:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 5798 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:178:- TCTAGAACTA GTGGATCTTC TGGTAATGAC AAATTAAACT GTTTAGCGTA TA - #TTATATAC 60- TCGTATAAAA AATCATGATC TATATTCTTA ATAGCTTTTA GAAGGTTCAT AT - #CGTAGAAA 120- TAAACATAAG TTCCTTTCAT CACTCTACCT ACACGACCTT TACGTTGCGT CA - #TCATAGAT 180- TTTGATATAA ACATCTGAAC ACCACCAAAA GGTCTAGGTA CGTATACTCT AC - #CGGTATCG 240- TATACGTGAG TCGCTGTACG TATAGTAATA CTAGATTCCA AATAAGGGGT AG - #ATACTAGA 300- ATACAAGGTC TTTCTCTATT AGGTCGTTGA ACATCTTGTA GGATTTCTGC TA - #TATTTTTT 360- AATTTTCCAT GTATTACTAT AAAATCAATA TTCTTATTCT TAGATTCTAA GT - #ACTCTTTA 420- TACTTAATAC ATTCTGATAC AGAAGGTAAG AATAAAATAC CACACATTCC AT - #TATCTGGC 480- TTACACCACA ATAAAGTAGA CGATATATTC TTTCTCTCAT TATCAAAATA AA - #CTCTCTTA 540- TCCGGAGAAT ACCTATTTTT TACGTATATT TCTTTTATGG AGTAAAGAAC TG - #GTCCTTCT 600- ATATGGTAAA ATTCAACATC AGGAAGAAAT TCCATTAGTC TATCTTTATC AT - #CTTCTAGA 660- GTGGCAGACA TCAATACTAG CGAATGAATG CTATCTATAT TTTTTCTTAG AA - #CGGCTATC 720- ATAATATCGG CTATCCTATC ATGTTCATGT ATTTCATCTA TTATGACTAT AT - #TATACTTT 780- GATAGAGAGT AACTAGTCAG TTTATTAGTA GAAAGTACTA TACCTTGAAA TC - #CTTTTTTG 840- GTTTTTTCTG TATGTCCTCC GTATTTAAGT TCTACAGGAG AACCTTCGAA CT - #GTGAAAAT 900- CCCAACGATT GTAAAAAATT ATTTCCGTTG CTCTTTACCA AAGTCACCCT AG - #GAAGAGAT 960- AAAACTATAG GTTTGGGTAT AAAATCTAGC CTTATCCTGT CTATATCATC CC - #ATCCTCCG1020- AATAAATAGT TATACCACAT TATTACTTTT GGTAACTGAG ATGTTTTACC TA - #TGCCTGTA1080- CTACCGGTAA CTACTATCTG TTTCCTCTTC TTTAACATAT CAAAGATATG AA - #CCTGTGTT1140- GTTAAACTAA GGGATTTGAA CGATATGATA GCGAAAGGAT TTGGATTATT GA - #GTATTCCT1200- ATAGAATTCT TAATGGGTAC CTTCTTATTG GAAGAGAAAA TAGACAGATG AT - #TTCCAGCT1260- ACTAGTAATC CTCTTTTATC GTCAAGCGTT ATATCAGATA CATGATTATA AC - #CGATACAT1320- TTTACGTAAC TATAGCATTC AAACGTTATA AATCTATCGT TACCTATATA GT - #ATACCTGT1380- TTACTGTAGT TGATACTGAC GGGTATTATA TCTATAAGTT TACTAACAGG TA - #TTTTAGCG1440- GGTATTGAAT TAGTAGTTTC TATATTCAGC ATATAAGTAT CGTCCTTTAA GC - #AGATAAAT1500- ACTTTATTCC ACCTATGTTT TATTATAGGA AATACAGAAT GAGAAAAAAA TA - #ACGTATCT1560- TTATTATGAT ATTCTTCTAA TTCTTTTTGG GTATACTTAC TTGGGAATAT AT - #CGTACATA1620- TTAGGGAAAG CGTATATCGA AAATAGCTCG TTAGTGGCCA TAGTTCCTAC AG - #TATGTATA1680- TTTAGTTAGT AATAAATGGA TAGATACACA GAACTAGTTA TTAATAAAAT AC - #CAGAATTA1740- GGATTCGTTA ACTTGCTTTC TCATATCTAT CAAACAGTTG GGTTATCCTA CG - #ATATAGAT1800- GTATCAAAAT TCAAAACTAA TTGCAATGGT TACGTCGTAG AGAGATTTGA TA - #ACTCAGAA1860- ACAGTTGGCA AAGTGTCCTG CGTGCCTATA TCTATACTGT TAGAATTGGT AG - #ACAGAAAA1920- ATATTATCTA AACCAGATAC GTCTAAAACA GAAATAGAGA TTAAAGAAGA TT - #TAGTAAAC1980- GAATTAATTG AAAATACCAA TAGTTTCGAA GATATAATGA CTATACCTAC CA - #GTATCCCT2040- ATGAGATATT TTTTTAAACC GGTACTAAGA GAAAAAGTAT CTAAAGCTGT AG - #ATTTTTCC2100- AGAATGGATA TTAAGGGAGA TGATATTAGC AAAATGGGAA TAAAACACGG AG - #AAAAAAGT2160- AATAATATAT CTAATATTAA GATTGTACCA GAAAAAGATG CCTGGATGAC TA - #ATACTAGT2220- ATTCAGCAAT TAATAGGACC TATGTCGTAC GGAACAGAAG TTAGCTATAT AG - #GTCAATTT2280- AACTTTAATT TTATTAACAC ATATCCTGTA TACGAAAAAT CTGCAGCCCT TA - #ACAGAAGT2340- CCAGAACTTT TTAAGATTAA AGATAGAATT AAAGGATTAC GTACAAGATT TG - #TTATGTTC2400- GGTTTCTGTT ATATGTTCCA TTGGAAATGT TTGATATATG ATAGAGAAAA CG - #ATTTTGTA2460- TGTTTCTATG ATTCAGGAGG ATCTAATCCA AATGACTTTG ATCACTATGA TA - #ATTTTTTC2520- TACTATAGTC ATTCGAGAGG ATTCAATAGA AATTCTAAGA GGTCATCTAG CT - #TATCTAAT2580- GAAAATGCAG ATATAGATAT TCTGTTCAAC TTTTTCGTGG ATAATTACGA AG - #TTACTTCA2640- GGATGTATAA ACGTAGAAGT CAATCAGCTG ATGGAATCAG AATGTGGTAT GT - #TTACTTGT2700- TTGTTTATGA CTATGTGCTG TCTCCATCCT CCTAAAGGAT TTAAAGGGAT AA - #GAAAGACA2760- TATACCTATT TTAAGTTTTT AGCCGATAAA AAAATGACTA TGCTAAAGTC TA - #TACTTTTC2820- AACGCTGACA AGATGGAATT TAAAGTGAAA GAATCAAGCA GTAAAGGCAT AC - #AAGAATAT2880- AAAAAAATGG AAGAGTGGTG TGGTAAAACT ATAAACATTT TAGCTGATAA AA - #TAACAACA2940- CGTGTAAATA GTATAATAGA GTAGTAAAAT GGATAATTTT ATAAAGCAGA TA - #TCGTCAAA3000- GATAGTAAAA CCTATAGCAG AATTAGAACC TCCAGATTCT AAAGTACAAT AT - #TATTACAT3060- GACTATATCG TTTAATTTTC CTGACTTATA TTATTGTAAT AAAAATTTAT TT - #GCGAAACC3120- CGATAATACT TTGCTAGATG TTTCTAAGTC TTTGCTTACT TTAAACTCAT TT - #CCGTATGA3180- AAACTTTGTG ATAAATGATT TACTAAGAAC TATTAGGCGT TACTGTCACG TA - #TATGATGT3240- CTATTTTTTA CCCGTAGGGT GGTTTGTAGG AAAAGAAGAT GTATTACCCA AT - #TACCAAGT3300- ATCGATAAAA ATAATAAGAA GTACTAATCA AGAAGTAATA GAAAACATTA TT - #AGGAATTA3360- TTTATCACGA CACGGTATTT ATGGAGATAA CCTATCTATA GAAACAGACC GA - #TTAAACGA3420- AGTATCTATA AACAGACATT CTATTGTAGG AGCTAGACAG TTAGCACCTA TA - #TGCGTTGT3480- TTCTTTTTAT CCTTTCGACC CTGAAAATAA AATACTTTTC GTTATATATG TA - #GGTAGATA3540- CAAAGACAGA CATTGCGGTG TATCTTATGT AGTTGATAGA GAGGATATGT AT - #AAAGTAAT3600- TAACAGAATA TATTCTTACG TAGTTTGTAT TTATCTAGTT TCCGATGATA TG - #GTCACGTT3660- TCATACTACT CCTCTAGCTA ATCACAGTAA AAAATTAATA CCGTTACCCA TA - #AATCATTG3720- CAATACCTTA TGCGAGATAG TTCACGACTT TGAGTTTTTA AGATTTGAGC AA - #TCCACTAT3780- GCCAATACCC GTTTTCACTC CTTTTATTCC TAAACAGCTA GTTAATATAA TC - #AACTTACC3840- TGATGATATA CCTATTACTT GTGCATCAAT AAACAGATTA GAATATGTTA CA - #CATATAGA3900- TGATAAAAAA TTAAAAAGAG TACTGATTAT CGTAAAGGAT AAATTTCTTA GA - #AATACTAT3960- TCTTCACGGT ACATTTAAAA AAAGGAATAT AGTCAGAAAC AGGAAATATA CT - #TTCACTAT4020- AACATGGTCT AATTTCGAAT GTCCGACGTT AGGAGACGTT AAGTCTTCTT CA - #CCTAATAC4080- CTGTAATAGA GTAGTTTTAG ACGGTAGTAG ATACGTTACA AAAACCTTTA AT - #GATACAAT4140- ATAAATGGAA CTAACTAGAG AAACGCTGAT ATTTGTAGGC ATTACTGTAC TA - #GTAGTAGT4200- AATGATCATA TCTGGTTTCT CACTAATATT GCGATTGATA CCTGGTGTAT AT - #TCATCAGT4260- TATTAGATCG TCGTTCGTAG GAGGGAAAAT ATTAAGATTT ATGGAGGTAT TC - #TCTACTGT4320- TATGTTTATA CCATCATTAG TAATACTTTA TACAGCATAT ATAAGGAAAT CT - #AAAGTGAA4380- AAATAACTAA ATATTATAGT ATTTGTAATA AATGGCTACT GGAGAGATTC GT - #CTTATTAT4440- AGGGCCTATG TTTTCAGGTA AAACAACAGA ATTAGTTAGA TTAATAAGAA GA - #TTTATGAT4500- ATCGGGACGT AAATGTATAA TAATAAAACA TTGTAGTGAT TCCCGTTATA CC - #GAAGGAGA4560- TTTAGAAGCT ATATATACTC ATGATAAAAT TTCGATGGAA GCACTATCGT GT - #AGCAAATT4620- ATTACCTTTA ATACCTAAAA TTGATAACTT TGAAGTAATA GGTATAGACG AA - #GGACAGTT4680- TTTTGAAGAT ATAGTAGAAT TTAGTGAGAT TATGGCTAAT AAGGGTAAAA CT - #GTAATCAT4740- AGCGGCTTTA AATGGAGATT TCAAACGACA ATTATTTGGA AACATATTTA AA - #CTATTATC4800- TTTATCAGAA TCAGTTACTA GTTTAACTGC TATTTGTGCA GTTTGTAAAA AC - #GAAGCATC4860- TTTTTCTAAG CGCATGACTG ATGATAAAGA TGTAAAAGTT ATAGGAGGTA AA - #GAAATGTA4920- TACTGCTGTT TGTAGAAAAT GCTTTTTATG AGTCTAATAT ACGTACTAAA TA - #CTTGTACG4980- TACAACTATG TTAGAATAAT TTGCTTAGTA TAGTATATAA ACAAGTATGT AA - #AAAATAAA5040- ATTGATATAA AAGTAGTCTT CTATTCCGAA CAATAACTAT ACAAAATGGA TT - #TAGATATT5100- AAATCTTGCA GAAGTATTTA CAAAATATGG GATAAATATC ATTTTATGAC AG - #GGTATAAA5160- TATAAAAATG ATAAACAGAG ATTTAAAATT ACAATTTACT GTAAATGTGA TT - #GTTCTATC5220- AAAGAATATC CTTATAGATT TGTTACTGAG AAACTGCTTT TAATGTATAT TA - #TTAATAAG5280- TTTAGAGGAA AGTATCTAAT CAAAATTAGG ATAGAACCCA TAGTTAAAAA TT - #AAATCATA5340- TATCAATACA TGTCAGTTTT TTATCGAAAA ATGGATTTAT AAATAAAATG AA - #AAATAACT5400- TGAATGAAGG AAAAAATAAC CATGAGTAAA AAACCAGTAA AGACGGTCCA GC - #GTAGACGT5460- GGAAACGATG AGGATAATAA GTTTACTTGT ATCCAAGCGC TAGAACATGC AA - #AAAGCTTA5520- TGTACTAAAA ATAATAAAAT AGTTAAATCT GTTAAACTAT CACAATCTCT CT - #TTAAGTCA5580- TCTAACAATA TTTCTGTGAT ATTAGAACCA GAATATAAAG ACAAATTAGT GA - #CTCCTCTT5640- ATTATTGTAG AAGGTGAAGG AAAAATATAC CATAATAAGA ATGATAGTTT TA - #ATCGTGAA5700- GAACCGTATT TTCTAAAAAT ACGACCTACG TTAATGAATC CTATATTATA TC - #AGATTATG5760# 5798 ATCC CCCGGGCTGC AGGAATTC- (2) INFORMATION FOR SEQ ID NO:179:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 20 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:179:# 20 CATG- (2) INFORMATION FOR SEQ ID NO:180:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 70 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:180:- TATGAATTCC TCGAGGGATC CAGGCCTTTT TTATTGACTA GTTAATCAGT CT - #AATATACG 60# 70- (2) INFORMATION FOR SEQ ID NO:181:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 20 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:181:# 20 GACG- (2) INFORMATION FOR SEQ ID NO:182:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 66 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:182:- TTAGAATTCT CGCGACCCGG GTTTTTATAG CTAATTAGTA CTTATTACAA AT - #ACTATAAT 60# 66- (2) INFORMATION FOR SEQ ID NO:183:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 35 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:183:# 35 CCTC GAGGGTACCG CATGC- (2) INFORMATION FOR SEQ ID NO:184:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 31 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:184:# 31 AGGG ATCCGTCGAC G- (2) INFORMATION FOR SEQ ID NO:185:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 52 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:185:- CCGAAGCTTC TCGAGATAAA AATCAACGAC TGTCGGTAGC GTCCACGACG AC - # 52- (2) INFORMATION FOR SEQ ID NO:186:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 16 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:186:# 16- (2) INFORMATION FOR SEQ ID NO:187:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 5062 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:187:- AAGCTTGCGG CCGCTCATTA GACAAGCGAA TGAGGGACGA AAACGTGGAG GA - #GGTATTAA 60- GTTTGGAGAA ATGGAGAGAG ACTGTTTAAT AGCGCATGGC GCAGCCAATA CT - #ATTACAGA 120- AGTTTTGAAA GATTCGGAAG AAGATTATCA AGATGTGTAT GTTTGTGAAA AT - #TGTGGAGA 180- CATAGCAGCA CAAATCAAGG GTATTAATAC ATGTCTTAGA TGTTCAAAAC TT - #AATCTCTC 240- TCCTCTCTTA ACAAAAATTG ATACCACGCA CGTATCTAAA GTATTTCTTA CT - #CAAATGAA 300- CGCCAGAGGC GTAAAAGTCA AATTAGATTT CGAACGAAGG CCTCCTTCGT TT - #TATAAACC 360- ATTAGATAAA GTTGATCTCA AGCCGTCTTT TCTGGTGTAA TAAAAATTAA TT - #AATTACTC 420- GAGATAAAAA TCAACGACTG TCGGTAGCGT CCACGACGAC GTCAGTTACT TC - #TAGGACCG 480- TACCGTTTTT CAAAAGCATG AGGTAGTGAG TTCGCGGAGA TGAGACCACC AC - #TTCGTTGT 540- AGGGATCCAG GGCGAAAAGG ACGTCGTCCG AGTCGTGCAT GTACATGATG TT - #GATGACGC 600- CTTGCGTGTC GTCGTATTCT AGTAGGGCGC TTTGGCAAAA GGCGCAGTTT TC - #TAGGGAAA 660- TGTTGAGCGC CGCTGTGATG CTGTGTGTGG TATGCATGTT GCGCGTCAGT TC - #GCATTTAG 720- TTTGACTGTC CGTCTGGGTG ATGATGAGGC TCTGGCCTAC GACGGTGGTG GA - #GACAGGGT 780- AGGAGATACC TTTGATCAGG TACTGGTTTG TTACGACATA ACTGACGTGT TC - #GGAGACGG 840- TCAGCGCGGA GAAGGATTCG CCGAGCGGCA GACAAAACAG GTCGGGGAAG GT - #TTCTAGCG 900- TGCTTGGTTG CATGGTAGAT AGGATGGAGA GGGCGGCGGG AACGGTAGTG GG - #GACGGTGG 960- CATCGGGGAA GAGACGTGTG AGGCGTTCGA GCGAGTGATC GCGTCGCCCG CT - #ACTGGAAC1020- AGGGTGTGTA CAGGTCGCTG AGGTATTCGT GGTGCGGATG AGCTAGCAAC TG - #CGTAAAGT1080- GTGATAGCTC GGCTAATGAA CAGAGGCCCG TTTCTACGAT GAAGATTTCG CG - #TCTCTCCG1140- TCGTATGTAC TAGCATGGAG TGGACGAGGC TGCCCATGAG GTAGAGTTCT TG - #ACGCGCGA1200- AGGCTGAAAG AAAAGAGGCC AGGTGCGTTT TGTGTAGTTT TAGGGCAAAG TC - #GGCGATCT1260- GTCGTAGTGC CCACTGGGGG ATGAGATGTT GCTGATTCTG TTTAGAGAGT AT - #GTAGACCA1320- GGCGTACGAG GCTGGTGATG TCGGTGATCT GATTCGGTGT CCAAAGGGCT CG - #TTTGGCCA1380- GGTCCACGGC CGTGGGATAC AGCAGCAACG TGGTGCGTGG TGGTGTTTGT GA - #GAGGCAGG1440- TGATCATAAA TTCTTGTATT TGTAAGAGTG CGGCCTGGCG GTCTAGGGCC CG - #TGGGACGG1500- AGACTTGGGC GCCGGCCTCT TCTTGTCGGG CTGCTGCGAA CAGTGCTAAT GC - #GTAGGCGA1560- AGGCCATTTC TACCGTGCGG CGGTCCAGCA TCTGACATCG ACCGCTTTTG AG - #TACATCCA1620- CGGCGTAACG GTGAAAGCTG TTACGTAGTA GTGCGCTGAG GTCCAGGTAG TT - #GAAGTCAA1680- GTGCGGCGTC AAGAAAGTCC GGGTCTTTGA GATAAGAGTG ACGGTTCAGT TG - #ATCTTTCT1740- TAACTAGCAC CAGGAGCTCG TGTTTTTCAG TTTGTCGTAG TATAAAGTTG TC - #GCGTTGAT1800- AGGGCGCTTT AAAGAGTACG CGTGGAAGAT GGCCGAAGAT AAGCAGCATG GG - #TGTGTCGT1860- CGTCTATGGA CACCGTAACT ACGAAGAAGT CCTCGGTCAG TGTTATTTTA AC - #GTAACGTA1920- GTTCGTCGAT GAGGTAAAAG CCTTGGTGCA AACAAGGTGT GACGGTGCTG AA - #TAGTAGAT1980- CGTGTCCATC AAAGAGGATA CAGGTCTGGT TAAAGTGTGG TCGGTGTAGT CC - #TGAGGTGG2040- TATGTGATTC TGTCCAGCCG TGTGGAGTGG TTTGCGGTGG CATCCAAACG TG - #AGGTATTG2100- ACAGGTCAAT GGGTGGTGGC ACAGTGGTGG GCTGTTCACC TAGGCTGTCC TG - #TGCCTTTA2160- GCTGCTGCGA AAAAGATCGG TAGCTGGCCA GGTCTTTGGA TACCAGCGCG TA - #AGTGTTAA2220- GTCTCTGTTG GTATCTTTCC AGGGTTTCGG TCAGATCTAC CTGGTTCAGA AA - #CTGCTCCG2280- CCAGAGGACC CGCAAAAAGA CATCGAGGCA TATGGAATAC ATAGTATTGA TT - #ATAGCTTT2340- GGAAAAAGTT GAAACTGATG GCGTTTTCCC TGACGACCGT GCTGTTACGG AG - #GCTGCTAT2400- TGTAGGTACA CTGGGTGGTG TTTTCACGCA GGAAGCGGAT GGGTCTCCCG TA - #GGTGTTGA2460- GCAGTAGGTG AAACGCTTTG TCCAGCGGTT CGGATATGGC TTCTGCGCCA TA - #TCGTGACG2520- AAAGTAGGTG GCTGAGGAGA CAGACGGCGA GGACGATGAG GTAGGAGGGG AG - #CCCGGGCC2580- GCATTTTATA TTGTAATTAT ATATTTTCAA TTTTGAAATC CCAAAATATT AT - #CATATTCT2640- TCCCAATAAA CTCGAGGGTA CCGGATCCTT CTTTATTCTA TACTTAAAAA GT - #GAAAATAA2700- ATACAAAGGT TCTTGAGGGT TGTGTTAAAT TGAAAGCGAG AAATAATCAT AA - #ATTATTTC2760- ATTATCGCGA TATCCGTTAA GTTTGTATCG TAATGTGCCG CCGCCCGGAT TG - #CGGCTTCT2820- CTTTCTCACC TGGACCGGTG GCACTGCTGT GGTGTTGCCT TCTGCTGCCC AT - #CGTTTCCT2880- CAGCCACCGT CAGCGTCGCT CCTACCGTCG CCGAGAAAGT TCCCGCGGAG TG - #CCCCGAAC2940- TAACGCGTCG ATGCCTGTTG GGTGAGGTGT TTCAGGGTGA CAAGTATGAA AG - #TTGGCTGC3000- GCCCGTTGGT GAATGTTACC AGACGCGATG GCCCGCTATC GCAACTTATT CG - #TTACCGTC3060- CCGTTACGCC GGAGGCCGCC AACTCCGTGC TGTTGGACGA TGCTTTCCTG GA - #CACTCTGG3120- CCCTGCTGTA CAACAATCCG GATCAATTGC GGGCCTTGCT GACGCTGTTG AG - #CTCGGACA3180- CAGCGCCGCG CTGGATGACG GTGATGCGCG GTTACAGCGA GTGCGGCGAT GG - #CTCGCCGG3240- CCGTGTACAC GTGCGTGGAC GACCTGTGCC GCGGCTACGA CCTCACGCGA CT - #GTCATACG3300- GGCGCAGCAT CTTCACGGAA CACGTGTTAG GCTTCGAGCT GGTGCCACCG TC - #TCTCTTTA3360- ACGTGGTGGT GGCCATACGC AACGAAGCCA CGCGTACCAA CCGCGCCGTG CG - #TCTGCCCG3420- TGAGCACCGC TGCCGCGCCC GAGGGCATCA CGCTCTTTTA CGGCCTGTAC AA - #CGCAGTGA3480- AGGAATTCTG CCTGCGTCAC CAGCTGGACC CGCCGCTGCT ACGCCACCTA GA - #TAAATACT3540- ACGCCGGACT GCCGCCCGAG CTGAAGCAGA CGCGCGTCAA CCTGCCGGCT CA - #CTCGCGCT3600- ATGGCCCTCA AGCAGTGGAT GCTCGCTAAT TTTTATAGAT CCCCCGGGAA TC - #GATTCGCG3660- ATAGCTGATT AGTTTTTGTT AACAAAAATG TGGGAGAATC TAATTAGTTT TT - #CTTTACAC3720- AATTGACGTA CATGAGTCTG AGTTCCTTGT TTTTGCTAAT TATTTCATCC AA - #TTTATTAT3780- TCTTGACGAT ATCGAGATCT TTTGTATAGG AGTCAGACTT GTATTCAACA TG - #CTTTTCTA3840- TAATCATCTT AGTTATTTCG GCATCATCCA ATAGTACATT TTCCAGATTA AC - #AGAGTAGA3900- TATTAATGTC GTATTTGAAC AGAGCCTGTA ACATCTCAAT GTCTTTATTA TC - #TATAGCCA3960- ATTTAATGTC CGGAATGAAG AGAAGGGAAT TATTGGTGTT TGTCGACGTC AT - #ATAGTCGA4020- GCAAGAGAAT CATCATATCC ACGTGTCCAT TTTTTATAGT GGTGTGAATA CA - #ACTAAGGA4080- GAATAGCCAG ATCAAAAGTA GATGGTATTT CTGAAAGAAA GTATGATACA AT - #ACTTACAT4140- CATTAAGCAT GACGGCATGA TAAAATGAAG TTTTCCATCC AGTTTTCCCA TA - #GAACATCA4200- GTCTCCAATT TTTCTTAAAC AGTTTCACCG TTTGCATGTT ACCACTATCA AC - #CGCATAAT4260- ACAATGCGGT GTTTCCTTTG TCATCAAATT GTGAATCATC CATTCCACTG AA - #TAGCAAAA4320- TCTTTACTAT TTTGGTATCT TCTAATGTGG CTGCCTGATG TAATGGAAAT TC - #ATTCTCTA4380- GAAGATTTTT CAATGCTCCA GCGTTCAACA ACGTACATAC TAGACGCACG TT - #ATTATCAG4440- CTATTGCATA ATACAAGGCA CTATGTCCAT GGACATCCGC CTTAAATGTA TC - #TTTACTAG4500- AGAGAAAGCT TTTCAGCTGC TTAGACTTCC AAGTATTAAT TCGTGACAGA TC - #CATGTCTG4560- AAACGAGACG CTAATTAGTG TATATTTTTT CATTTTTTAT AATTTTGTCA TA - #TTGCACCA4620- GAATTAATAA TATCTCTAAT AGATCTAATT TAATTTAATT TATATAACTT AT - #TTTTTGAA4680- TATACTTTTA ATTAACAAAA GAGTTAAGTT ACTCATATGG ACGCCGTCCA GT - #CTGAACAT4740- CAATCTTTTT AGCCAGAGAT ATCATAGCCG CTCTTAGAGT TTCAGCGTGA TT - #TTCCAACC4800- TAAATAGAAC TTCATCGTTG CGTTTACAAC ACTTTTCTAT TTGTTCAAAC TT - #TGTTGTTA4860- CATTAGTAAT CTTTTTTTCC AAATTAGTTA GCCGTTGTTT GAGAGTTTCC TC - #ATTGTCGT4920- CTTCATCGGC TTTAACAATT GCTTCGCGTT TAGCCTCCTG GCTGTTCTTA TC - #AGCCTTTG4980- TAGAAAAAAA TTCAGTTGCT GGAATTGCAA GATCGTCATC TCCGGGGAAA AG - #AGTTCCGT5040# 5062AAT TC- (2) INFORMATION FOR SEQ ID NO:188:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 2151 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:188:- ATGCGGCCAG GCCTCCCCTC CTACCTCATC GTCCTCGCCG TCTGTCTCCT CA - #GCCACCTA 60- CTTTCGTCAC GATATGGCGC AGAAGCCATA TCCGAACCGC TGGACAAAGC GT - #TTCACCTA 120- CTGCTCAACA CCTACGGGAG ACCCATCCGC TTCCTGCGTG AAAACACCAC CC - #AGTGTACC 180- TACAATAGCA GCCTCCGTAA CAGCACGGTC GTCAGGGAAA ACGCCATCAG TT - #TCAACTTT 240- TTCCAAAGCT ATAATCAATA CTATGTATTC CATATGCCTC GATGTCTTTT TG - #CGGGTCCT 300- CTGGCGGAGC AGTTTCTGAA CCAGGTAGAT CTGACCGAAA CCCTGGAAAG AT - #ACCAACAG 360- AGACTTAACA CTTACGCGCT GGTATCCAAA GACCTGGCCA GCTACCGATC TT - #TTTCGCAG 420- CAGCTAAAGG CACAGGACAG CCTAGGTGAA CAGCCCACCA CTGTGCCACC AC - #CCATTGAC 480- CTGTCAATAC CTCACGTTTG GATGCCACCG CAAACCACTC CACACGGCTG GA - #CAGAATCA 540- CATACCACCT CAGGACTACA CCGACCACAC TTTAACCAGA CCTGTATCCT CT - #TTGATGGA 600- CACGATCTAC TATTCAGCAC CGTCACACCT TGTTTGCACC AAGGCTTTTA CC - #TCATCGAC 660- GAACTACGTT ACGTTAAAAT AACACTGACC GAGGACTTCT TCGTAGTTAC GG - #TGTCCATA 720- GACGACGACA CACCCATGCT GCTTATCTTC GGCCATCTTC CACGCGTACT CT - #TTAAAGCG 780- CCCTATCAAC GCGACAACTT TATACTACGA CAAACTGAAA AACACGAGCT CC - #TGGTGCTA 840- GTTAAGAAAG ATCAACTGAA CCGTCACTCT TATCTCAAAG ACCCGGACTT TC - #TTGACGCC 900- GCACTTGACT TCAACTACCT GGACCTCAGC GCACTACTAC GTAACAGCTT TC - #ACCGTTAC 960- GCCGTGGATG TACTCAAAAG CGGTCGATGT CAGATGCTGG ACCGCCGCAC GG - #TAGAAATG1020- GCCTTCGCCT ACGCATTAGC ACTGTTCGCA GCAGCCCGAC AAGAAGAGGC CG - #GCGCCCAA1080- GTCTCCGTCC CACGGGCCCT AGACCGCCAG GCCGCACTCT TACAAATACA AG - #AATTTATG1140- ATCACCTGCC TCTCACAAAC ACCACCACGC ACCACGTTGC TGCTGTATCC CA - #CGGCCGTG1200- GACCTGGCCA AACGAGCCCT TTGGACACCG AATCAGATCA CCGACATCAC CA - #GCCTCGTA1260- CGCCTGGTCT ACATACTCTC TAAACAGAAT CAGCAACATC TCATCCCCCA GT - #GGGCACTA1320- CGACAGATCG CCGACTTTGC CCTAAAACTA CACAAAACGC ACCTGGCCTC TT - #TTCTTTCA1380- GCCTTCGCGC GTCAAGAACT CTACCTCATG GGCAGCCTCG TCCACTCCAT GC - #TAGTACAT1440- ACGACGGAGA GACGCGAAAT CTTCATCGTA GAAACGGGCC TCTGTTCATT AG - #CCGAGCTA1500- TCACACTTTA CGCAGTTGCT AGCTCATCCG CACCACGAAT ACCTCAGCGA CC - #TGTACACA1560- CCCTGTTCCA GTAGCGGGCG ACGCGATCAC TCGCTCGAAC GCCTCACACG TC - #TCTTCCCC1620- GATGCCACCG TCCCCACTAC CGTTCCCGCC GCCCTCTCCA TCCTATCTAC CA - #TGCAACCA1680- AGCACGCTAG AAACCTTCCC CGACCTGTTT TGTCTGCCGC TCGGCGAATC CT - #TCTCCGCG1740- CTGACCGTCT CCGAACACGT CAGTTATGTC GTAACAAACC AGTACCTGAT CA - #AAGGTATC1800- TCCTACCCTG TCTCCACCAC CGTCGTAGGC CAGAGCCTCA TCATCACCCA GA - #CGGACAGT1860- CAAACTAAAT GCGAACTGAC GCGCAACATG CATACCACAC ACAGCATCAC AG - #CGGCGCTC1920- AACATTTCCC TAGAAAACTG CGCCTTTTGC CAAAGCGCCC TACTAGAATA CG - #ACGACACG1980- CAAGGCGTCA TCAACATCAT GTACATGCAC GACTCGGACG ACGTCCTTTT CG - #CCCTGGAT2040- CCCTACAACG AAGTGGTGGT CTCATCTCCG CGAACTCACT ACCTCATGCT TT - #TGAAAAAC2100# 2151AAGTAAC TGACGTCGTC GTGGACGCTA CCGACAGTCG T- (2) INFORMATION FOR SEQ ID NO:189:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 3962 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:189:- GCCCTTAACA GAAGTCCAGA ACTTTTTAAG ATTAAAGATA GAATTAAAGG AT - #TACGTACA 60- AGATTTGTTA TGTTCGGTTT CTGTTATATG TTCCATTGGA AATGTTTGAT AT - #ATGATAGA 120- GAAAACGATT TTGTATGTTT CTATGATTCA GGAGGATCTA ATCCAAATGA CT - #TTGATCAC 180- TATGATAATT TTTTCTACTA TAGTCATTCG AGAGGATTCA ATAGAAATTC TA - #AGAGGTCA 240- TCTAGCTTAT CTAATGAAAA TGCAGATATA GATATTCTGT TCAACTTTTT CG - #TGGATAAT 300- TACGAAGTTA CTTCAGGATG TATAAACGTA GAAGTCAATC AGCTGATGGA AT - #CAGAATGT 360- GGTATGTTTA CTTGTTTGTT TATGACTATG TGCTGTCTCC ATCCTCCTAA AG - #GATTTAAA 420- GGGATAAGAA AGACATATAC CTATTTTAAG TTTTTAGCCG ATAAAAAAAT GA - #CTATGCTA 480- AAGTCTATAC TTTTCAACGC TGACAAGATG GAATTTAAAG TGAAAGAATC AA - #GCAGTAAA 540- GGCATACAAG AATATAAAAA AATGGAAGAG TGGTGTGGTA AAACTATAAA CA - #TTTTAGCT 600- GATAAAATAA CAACACGTGT AAATAGTATA ATAGAGTAGT AAAATGGATA AT - #TTTATAAA 660- GCAGATATCG TCAAAGATAG TAAAACCTAT AGCAGAATTA GAACCTCCAG AT - #TCTAAAGT 720- ACAATATTAT TACATGACTA TATCGTTTAA TTTTCCTGAC TTATATTATT GT - #AATAAAAA 780- TTTATTTGCG AAACCCGATA ATACTTTGCT AGATGTTTCT AAGTCTTTGC TT - #ACTTTAAA 840- CTCATTTCCG TATGAAAACT TTGTGATAAA TGATTTACTA AGAACTATTA GG - #CGTTACTG 900- TCACGTATAT GATGTCTATT TTTTACCCGT AGGTGGTTTG TAGGAAAAGA AG - #ATGTATTA 960- CCCAATTACC AAGTATCGAT AAAAATAATA AGAAGTACTA ATCAAGAAGT AA - #TAGAAAAC1020- ATTATTAGGA ATTATTTATC ACGACACGGT ATTTATGGAG ATAACCTATC TA - #TAGAAACA1080- GACCGATTAA ACGAAGTATC TATAAACAGA CATTCTATTG TAGGAGCTAG AC - #AGTTAGCA1140- CCTATATGCG TTGTTTCTTT TTATCCTTTC GACCCTGAAA ATAAAATACT TT - #TCGTTATA1200- TATGTAGGTA GATACAAAGA CAGACATTGC GGTGTATCTT ATGTAGTTGA TA - #GAGAGGAT1260- ATGTATAAAG TAATTAACAG AATATATTCT TACGTAGTTT GTATTTATCT AG - #TTTCCGAT1320- GATATGGTCA CGTTTCATAC TACTCCTCTA GCTAATCACA GTAAAAAATT AA - #TACCGTTA1380- CCCATAAATC ATTGCAATAC CTTATGCGAG ATAGTTCACG ACTTTGAGTT TT - #TGAGATTT1440- GAGCAATCCA CTATGCCAAT ACCCGTTTTC ACTCCTTTTA TTCCTAAACA GC - #TAGTTAAT1500- ATAATCAACT TACCTGATGA TATACCTATT ACTTGTGCAT CAATAAACAG AT - #TAGAATAT1560- GTTACACATA TAGATGATAA AAAATTAAAA AGAGTACTGA TTATCGTAAA GG - #ATAAATTT1620- CTTAGAAATA CTATTCTTCA CGGTACATTT AAAAAAAGGA ATATAGTCAG AA - #ACAGGAAA1680- TATACTTTCA CTATAACATG GTCTAATTTC GAATGTCCGA CGTTAGGAGA CG - #TTAAGTCT1740- TCTTCACCTA ATACCTGTAA TAGAGTAGTT TTAGACGGTA GTAGATACGT TA - #CAAAAACC1800- TTTAATGATA CAATATAAAT GGAACTAACT AGAGAAACGC TGATATTTGT AG - #GCATTACT1860- GTACTAGTAG TAGTAATGAT CATATCTGGT TTCTCACTAA TATTGCGATT GA - #TACCTGGT1920- GTATATTCAT CAGTTATTAG ATCGTCGTTC GTAGGAGGGA AAATATTAAG AT - #TTATGGAG1980- GTATTCTCTA CTGTTATGTT TATACCATCA TTAGTAATAC TTTATACAGC AT - #ATATAAGG2040- AAATCTAAAG TGAAAAATAA CTAAATATTA TAGTATTTGT AATAAGTACT AA - #TTAGCTAT2100- AAAAACCCGG GTCGCGAGAA TTCGTCGACG GATCCTTCTT TATTCTATAC TT - #AAAAAGTG2160- AAAATAAATA CAAAGGTTCT TGAGGGTTGT GTTAAATTGA AAGCGAGAAA TA - #ATCATAAA2220- TTATTTCATT ATCGCGATAT CCGTTAAGTT TGTATCGTAA TGTGCCGCCG CC - #CGGATTGC2280- GGCTTCTCTT TCTCACCTGG ACCGGTGGCA CTGCTGTGGT GTTGCCTTCT GC - #TGCCCATC2340- GTTTCCTCAG CCACCGTCAG CGTCGCTCCT ACCGTCGCCG AGAAAGTTCC CG - #CGGAGTGC2400- CCCGAACTAA CGCGTCGATG CCTGTTGGGT GAGGTGTTTC AGGGTGACAA GT - #ATGAAAGT2460- TGGCTGCGCC CGTTGGTGAA TGTTACCAGA CGCGATGGCC CGCTATCGCA AC - #TTATTCGT2520- TACCGTCCCG TTACGCCGGA GGCCGCCAAC TCCGTGCTGT TGGACGATGC TT - #TCCTGGAC2580- ACTCTGGCCC TGCTGTACAA CAATCCGGAT CAATTGCGGG CCTTGCTGAC GC - #TGTTGAGC2640- TCGGACACAG CGCCGCGCTG GATGACGGTG ATGCGCGGTT ACAGCGAGTG CG - #GCGATGGC2700- TCGCCGGCCG TGTACACGTG CGTGGACGAC CTGTGCCGCG GCTACGACCT CA - #CGCGACTG2760- TCATACGGGC GCAGCATCTT CACGGAACAC GTGTTAGGCT TCGAGCTGGT GC - #CACCGTCT2820- CTCTTTAACG TGGTGGTGGC CATACGCAAC GAAGCCACGC GTACCAACCG CG - #CCGTGCGT2880- CTGCCCGTGA GCACCGCTGC CGCGCCCGAG GGCATCACGC TCTTTTACGG CC - #TGTACAAC2940- GCAGTGAAGG AATTCTGCCT GCGTCACCAG CTGGACCCGC CGCTGCTACG CC - #ACCTAGAT3000- AAATACTACG CCGGACTGCC GCCCGAGCTG AAGCAGACGC GCGTCAACCT GC - #CGGCTCAC3060- TCGCGCTATG GCCCTCAAGC AGTGGATGCT CGCTAATTTT TATAGATCCC TC - #GAGGGTAC3120- CGCATGCCCT TTTTATTGAC TAGTTAATCA GTCTAATATA CGTACTAAAT AC - #TTGTACGT3180- ACAACTATGT TAGAATAATT TGCTTAGTAT AGTATATAAA CAAGTATGTA AA - #AAATAAAA3240- TTGATATAAA AGTAGTCTTC TATTCCGAAC AATAACTATA CAAAATGGAT TT - #AGATATTA3300- AATCTTGCAG AAGTATTTAC AAAATATGGG ATAAATATCA TTTTATGACA GG - #GTATAAAT3360- ATAAAAATGA TAAACAGAGA TTTAAAATTA CAATTTACTG TAAATGTGAT TG - #TTCTATCA3420- AAGAATATCC TTATAGATTT GTTACTGAGA AACTGCTTTT AATGTATATT AT - #TAATAAGT3480- TTAGAGGAAA GTATCTAATC AAAATTAGGA TAGAACCCAT AGTTAAAAAT TA - #AATCATAT3540- ATCAATACAT GTCAGTTTTT TATCGAAAAA TGGATTTATA AATAAAATGA AA - #AATAACTT3600- GAATGAAGGA AAAAATAACC ATGAGTAAAA AACCAGTAAA GACGGTCCAG CG - #TAGACGTG3660- GAAACGATGA GGATAATAAG TTTACTTGTA TCCAAGCGCT AGAACATGCA AA - #AAGCTTAT3720- GTACTAAAAA TAATAAAATA GTTAAATCTG TTAAACTATC ACAATCTCTC TT - #TAAGTCAT3780- CTAACAATAT TTCTGTGATA TTAGAACCAG AATATAAAGA CAAATTAGTG AC - #TCCTCTTA3840- TTATTGTAGA AGGTGAAGGA AAAATATACC ATAATAAGAA TGATAGTTTT AA - #TCGTGAAG3900- AACCGTATTT TCTAAAAATA CGACCTACGT TAATGAATCC TATATTATAT CA - #GATTATGG3960# 3962- (2) INFORMATION FOR SEQ ID NO:190:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 5302 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:190:- GCCCTTAACA GAAGTCCAGA ACTTTTTAAG ATTAAAGATA GAATTAAAGG AT - #TACGTACA 60- AGATTTGTTA TGTTCGGTTT CTGTTATATG TTCCATTGGA AATGTTTGAT AT - #ATGATAGA 120- GAAAACGATT TTGTATGTTT CTATGATTCA GGAGGATCTA ATCCAAATGA CT - #TTGATCAC 180- TATGATAATT TTTTCTACTA TAGTCATTCG AGAGGATTCA ATAGAAATTC TA - #AGAGGTCA 240- TCTAGCTTAT CTAATGAAAA TGCAGATATA GATATTCTGT TCAACTTTTT CG - #TGGATAAT 300- TACGAAGTTA CTTCAGGATG TATAAACGTA GAAGTCAATC AGCTGATGGA AT - #CAGAATGT 360- GGTATGTTTA CTTGTTTGTT TATGACTATG TGCTGTCTCC ATCCTCCTAA AG - #GATTTAAA 420- GGGATAAGAA AGACATATAC CTATTTTAAG TTTTTAGCCG ATAAAAAAAT GA - #CTATGCTA 480- AAGTCTATAC TTTTCAACGC TGACAAGATG GAATTTAAAG TGAAAGAATC AA - #GCAGTAAA 540- GGCATACAAG AATATAAAAA AATGGAAGAG TGGTGTGGTA AAACTATAAA CA - #TTTTAGCT 600- GATAAAATAA CAACACGTGT AAATAGTATA ATAGAGTAGT AAAATGGATA AT - #TTTATAAA 660- GCAGATATCG TCAAAGATAG TAAAACCTAT AGCAGAATTA GAACCTCCAG AT - #TCTAAAGT 720- ACAATATTAT TACATGACTA TATCGTTTAA TTTTCCTGAC TTATATTATT GT - #AATAAAAA 780- TTTATTTGCG AAACCCGATA ATACTTTGCT AGATGTTTCT AAGTCTTTGC TT - #ACTTTAAA 840- CTCATTTCCG TATGAAAACT TTGTGATAAA TGATTTACTA AGAACTATTA GG - #CGTTACTG 900- TCACGTATAT GATGTCTATT TTTTACCCGT AGGTGGTTTG TAGGAAAAGA AG - #ATGTATTA 960- CCCAATTACC AAGTATCGAT AAAAATAATA AGAAGTACTA ATCAAGAAGT AA - #TAGAAAAC1020- ATTATTAGGA ATTATTTATC ACGACACGGT ATTTATGGAG ATAACCTATC TA - #TAGAAACA1080- GACCGATTAA ACGAAGTATC TATAAACAGA CATTCTATTG TAGGAGCTAG AC - #AGTTAGCA1140- CCTATATGCG TTGTTTCTTT TTATCCTTTC GACCCTGAAA ATAAAATACT TT - #TCGTTATA1200- TATGTAGGTA GATACAAAGA CAGACATTGC GGTGTATCTT ATGTAGTTGA TA - #GAGAGGAT1260- ATGTATAAAG TAATTAACAG AATATATTCT TACGTAGTTT GTATTTATCT AG - #TTTCCGAT1320- GATATGGTCA CGTTTCATAC TACTCCTCTA GCTAATCACA GTAAAAAATT AA - #TACCGTTA1380- CCCATAAATC ATTGCAATAC CTTATGCGAG ATAGTTCACG ACTTTGAGTT TT - #TGAGATTT1440- GAGCAATCCA CTATGCCAAT ACCCGTTTTC ACTCCTTTTA TTCCTAAACA GC - #TAGTTAAT1500- ATAATCAACT TACCTGATGA TATACCTATT ACTTGTGCAT CAATAAACAG AT - #TAGAATAT1560- GTTACACATA TAGATGATAA AAAATTAAAA AGAGTACTGA TTATCGTAAA GG - #ATAAATTT1620- CTTAGAAATA CTATTCTTCA CGGTACATTT AAAAAAAGGA ATATAGTCAG AA - #ACAGGAAA1680- TATACTTTCA CTATAACATG GTCTAATTTC GAATGTCCGA CGTTAGGAGA CG - #TTAAGTCT1740- TCTTCACCTA ATACCTGTAA TAGAGTAGTT TTAGACGGTA GTAGATACGT TA - #CAAAAACC1800- TTTAATGATA CAATATAAAT GGAACTAACT AGAGAAACGC TGATATTTGT AG - #GCATTACT1860- GTACTAGTAG TAGTAATGAT CATATCTGGT TTCTCACTAA TATTGCGATT GA - #TACCTGGT1920- GTATATTCAT CAGTTATTAG ATCGTCGTTC GTAGGAGGGA AAATATTAAG AT - #TTATGGAG1980- GTATTCTCTA CTGTTATGTT TATACCATCA TTAGTAATAC TTTATACAGC AT - #ATATAAGG2040- AAATCTAAAG TGAAAAATAA CTAAATATTA TAGTATTTGT AATAAGTACT AA - #TTAGCTAT2100- AAAAACCCGG GCTCGAGATA AAAATTACTG GTCAGCCTTG CTTCTAGTCA CC - #ATAGGGTG2160- GGTACTCTTA CCTCCAGAGG CGGTGGGTTC CTCAGCACCA TCCTCCTCTT CC - #TCTGGGGC2220- AACTTCCTCT ATCTCAGACA CTGGCTCAGA CTTGACAGAC ACAGTGTCCT CC - #CGCTCCTC2280- CTGAGCACCC TCCTCCTCTT CCTCATCACT CTGCTCACTT TCTTCCTGAT CA - #CTGTTCTC2340- AGCCACAATT ACTGAGGACA GAGGGATAGT CGCGGGTACA GGGGACTCTG GG - #GGTGACAC2400- CAGAGAATCA GAGGAGCTGA CACCAGCGGT GGCCAAAGTG TAGGCTACAA TA - #GCCTCTTC2460- CTCATCTGAC TCCTCGGCGA TGGCCCGTAG GTCATCCACA CTAGGAGAGC AG - #ACTCTCAG2520- AGGATCGGCC CCCAGAATGT ACTGGGCAAA GACCTTCATG CAGATCTCCT CA - #ATGCGGCG2580- CTTCATTACA CTGATAACCT CAGGCTTGGT TATCAGAGGC CGCTTGGCCA GC - #ATCACACT2640- AGTCTCCTCT AAGACATAGC AGCACAGCAC CCGACAGAAC TCACTTAAGA GA - #GAGATGCC2700- CCCGTACATG GTCATCATAC AAGCGTCACT AGTGACCTTG TACTCATTAC AC - #ATTGTTTC2760- CACACATGTA GTGAGGATAT CCATAAATAT GTGATCAATG TGCGTGAGCA CC - #TTGTCTCT2820- CTCCTCATCC AAAATCTTAA ATATTTTCTG GGCATAAGCC ATAATCTCAT CA - #GGGGAGCA2880- CTGAGGCAAG TTCTGCAGTG CCGCCATGGC CTGACTGCAG CCATTGGTGG TC - #TTAGGGAA2940- GGCTGAGTTC TTGGTAAAGA ACTCTATATT CCTGTAGCAC ATATACATCA TC - #TTTCTCCT3000- AAGTTCATCC TTTTTAGCAC GGGCCTTAGC CTGCAGTGCA CCCCCCAACT TG - #TTAGCGGC3060- GCCCTTGCTC ACATCATGCA GCTCCTTAAT ACAAGCCATC CACATCTCCC GC - #TTATCCTC3120- AGGTACAATG TAGTTCTCAT ACATGCTCTG CATAGTTAGC CCAATACACT TC - #ATCTCCTC3180- GAAAGGCTCA TGAACCTTAT CTAAGATATC TAAGGCATTC TGCAAACATC CT - #CCCATCAT3240- ATTAAAGGCG CCAGTGAATT TCTCTTCCGT CTGGGTATAT TTTTTCAGCA TG - #TGCTCCTT3300- GATTCTATGC CGCACCATGT CCACTCGAAC CTTAATCTGT TTCATTACGA TA - #CAAACTTA3360- ACGGATATCG CGATAATGAA ATAATTTATG ATTATTTCTC GCTTTCAATT TA - #ACACAACC3420- CTCAAGAACC TTTGTATTTA TTTTCACTTT TTAAGTATAG AATAAAGAAG GA - #TCCTTCTT3480- TATTCTATAC TTAAAAAGTG AAAATAAATA CAAAGGTTCT TGAGGGTTGT GT - #TAAATTGA3540- AAGCGAGAAA TAATCATAAA TTATTTCATT ATCGCGATAT CCGTTAAGTT TG - #TATCGTAA3600- TGTGCCGCCG CCCGGATTGC GGCTTCTCTT TCTCACCTGG ACCGGTGGCA CT - #GCTGTGGT3660- GTTGCCTTCT GCTGCCCATC GTTTCCTCAG CCACCGTCAG CGTCGCTCCT AC - #CGTCGCCG3720- AGAAAGTTCC CGCGGAGTGC CCCGAACTAA CGCGTCGATG CCTGTTGGGT GA - #GGTGTTTC3780- AGGGTGACAA GTATGAAAGT TGGCTGCGCC CGTTGGTGAA TGTTACCAGA CG - #CGATGGCC3840- CGCTATCGCA ACTTATTCGT TACCGTCCCG TTACGCCGGA GGCCGCCAAC TC - #CGTGCTGT3900- TGGACGATGC TTTCCTGGAC ACTCTGGCCC TGCTGTACAA CAATCCGGAT CA - #ATTGCGGG3960- CCTTGCTGAC GCTGTTGAGC TCGGACACAG CGCCGCGCTG GATGACGGTG AT - #GCGCGGTT4020- ACAGCGAGTG CGGCGATGGC TCGCCGGCCG TGTACACGTG CGTGGACGAC CT - #GTGCCGCG4080- GCTACGACCT CACGCGACTG TCATACGGGC GCAGCATCTT CACGGAACAC GT - #GTTAGGCT4140- TCGAGCTGGT GCCACCGTCT CTCTTTAACG TGGTGGTGGC CATACGCAAC GA - #AGCCACGC4200- GTACCAACCG CGCCGTGCGT CTGCCCGTGA GCACCGCTGC CGCGCCCGAG GG - #CATCACGC4260- TCTTTTACGG CCTGTACAAC GCAGTGAAGG AATTCTGCCT GCGTCACCAG CT - #GGACCCGC4320- CGCTGCTACG CCACCTAGAT AAATACTACG CCGGACTGCC GCCCGAGCTG AA - #GCAGACGC4380- GCGTCAACCT GCCGGCTCAC TCGCGCTATG GCCCTCAAGC AGTGGATGCT CG - #CTAATTTT4440- TATAGATCCC TCGAGGGTAC CGCATGCCCT TTTTATTGAC TAGTTAATCA GT - #CTAATATA4500- CGTACTAAAT ACTTGTACGT ACAACTATGT TAGAATAATT TGCTTAGTAT AG - #TATATAAA4560- CAAGTATGTA AAAAATAAAA TTGATATAAA AGTAGTCTTC TATTCCGAAC AA - #TAACTATA4620- CAAAATGGAT TTAGATATTA AATCTTGCAG AAGTATTTAC AAAATATGGG AT - #AAATATCA4680- TTTTATGACA GGGTATAAAT ATAAAAATGA TAAACAGAGA TTTAAAATTA CA - #ATTTACTG4740- TAAATGTGAT TGTTCTATCA AAGAATATCC TTATAGATTT GTTACTGAGA AA - #CTGCTTTT4800- AATGTATATT ATTAATAAGT TTAGAGGAAA GTATCTAATC AAAATTAGGA TA - #GAACCCAT4860- AGTTAAAAAT TAAATCATAT ATCAATACAT GTCAGTTTTT TATCGAAAAA TG - #GATTTATA4920- AATAAAATGA AAAATAACTT GAATGAAGGA AAAAATAACC ATGAGTAAAA AA - #CCAGTAAA4980- GACGGTCCAG CGTAGACGTG GAAACGATGA GGATAATAAG TTTACTTGTA TC - #CAAGCGCT5040- AGAACATGCA AAAAGCTTAT GTACTAAAAA TAATAAAATA GTTAAATCTG TT - #AAACTATC5100- ACAATCTCTC TTTAAGTCAT CTAACAATAT TTCTGTGATA TTAGAACCAG AA - #TATAAAGA5160- CAAATTAGTG ACTCCTCTTA TTATTGTAGA AGGTGAAGGA AAAATATACC AT - #AATAAGAA5220- TGATAGTTTT AATCGTGAAG AACCGTATTT TCTAAAAATA CGACCTACGT TA - #ATGAATCC5280# 5302TGG AA__________________________________________________________________________

	Number	Date	Country
Parent	502834	Apr 1990
Parent	622135	Jun 1984

	Number	Date
Parent	471014	Jun 1995
Parent	105483	Aug 1993
Parent	713967	Jun 1991
Parent	666056	Mar 1991
Parent	124668	Sep 1993
Parent	394488	Aug 1989
Parent	339004	Apr 1989
Parent	446824	Dec 1982
Parent	334456	Dec 1987

Recombinant poxvirus-cytomegalovirus, compositions and uses

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

US Classifications

Field of Search

US

International Classifications

Abstract

Description

Claims

RELATED APPLICATIONS

US Referenced Citations (1)

Non-Patent Literature Citations (4)

Related Publications (1)

Divisions (2)

Continuations (1)

Continuation in Parts (9)

Entry
Gehrz et al, 1992, Antivival Rej., vol. 17, pp. 115-131.
Tartaglia et al, 1992, Virology, vol. 188, pp. 217-232.
Perkus et al, 1985, Science, vol. 229, pp. 981-984.
Qadri et al, 1992, J. Gen. Virology, vol. 73, pp. 2913-2921.